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INTRODUCTION
Patellofemoral pain (PFP) is a common knee complaint, also referred to as ’anterior knee 
pain’, ’patellar dysfunction’, ’chondromalacia patellae’, or ’retropatellar chondropathy’. 
PFP is particularly prevalent among physically active young individuals.1 PFP is char-
acterized by retropatellar pain (behind the kneecap) or peripatellar pain (around the 
kneecap) (Figure 1), specifically during knee loading activities, like running, cycling, 
squatting, stair climbing, and/or during prolonged sitting with the knees flexed in 90 
degrees. Other symptoms can be crepitus and a feeling of giving way.2-4 On average, a 
general practitioner diagnoses five to six new cases per 1000 registered patients yearly, 
whereas the incidence reaches up to 22 new cases per 1000 patients per year in highly 
active populations.5-8 In fact, of all patients with a new running injury in sports medicine 
practices 17% is diagnosed with PFP and the annual prevalence in elite cyclists is 36%.9,10 
The diagnosis PFP is made per exclusionem of other specific knee pathologies, such as 
Hoffa syndrome, Osgood Schlatter syndrome, patellar tendinitis, intra-articular pathol-
ogy (including osteoarthritis), plica syndromes, and traumatic injuries (such as injured 
ligaments, meniscal tears, and patellar luxation). Sensitivity and specificity of physical 
tests, such as the Clarke compression test, are disputable.11,12
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Figure 1. Knee joint anatomy
10 Chapter 1
Exercise therapy
The majority of people with PFP are treated conservatively with knee orthoses13, foot 
orthoses14, patellar taping15, exercise therapy16, or a combination of these. In the past, 
exercise therapy focused solely on quadriceps muscle strengthening, since less knee 
extension strength was found to be associated with PFP17 and lower knee extension 
peak torque was identified as a possible risk factor for PFP.18 More recently, focus has 
shifted to the whole chain of movement and hip muscle dysfunction was identified as 
a possible contributor to PFP.19-21 This thesis comprises a Cochrane review (Chapter II) 
assessing the effects of exercise therapy in PFP including multiple comparisons, such as 
quadriceps focused exercise therapy versus a control strategy (no treatment, placebo or 
waiting list controls), hip exercise versus quadriceps exercises alone, or a combination of 
quadriceps and hip exercises.
Pathogenesis
Despite the application of a variety of treatment modalities, a substantial group of pa-
tients has persistent complaints.13,15,22-25 PFP is no self-limiting disorder as was thought in 
the past, but can have a debilitating effect, due to the common recurrence of symptoms, 
tendency to chronicity, and its impact on physical activity levels.26-30 Previously, research 
emphasis was primarily placed on mechanical and neuromuscular deficits. However, it 
is still unknown where the pain originates. The pathogenesis, which is the biological 
mechanism that leads to the diseased state, of PFP is considered to be multifactorial, 
but still largely unknown.
In the beginning of this century, Dye introduced quite a new view on the pathogenesis 
of PFP by focusing on tissue homeostasis, which is the internal steady state within a de-
fined tissue of an organism.31 Dye proposed that certain high loading conditions of the 
patellofemoral joint can induce a symptomatic loss of tissue homeostasis, which, once 
initiated, may persist indefinitely.31 Some of the proposed pathophysiologic mecha-
nisms for knee pain in literature are structural joint tissue abnormalities, inflammation, 
increased intraosseous hydrostatic pressure, and patellar bone ischemia.7,32-49 Nowadays, 
it is possible to study these mechanisms in depth with innovative MRI techniques. Two 
of these mechanisms will be discussed in more detail in the following paragraphs.
Structural joint tissue abnormalities
Around 1960 it was believed that PFP was caused by chondromalacia and subsequently 
patients underwent arthroscopy with shaving of the patellar cartilage. Between 1970 
and 1990, arthroscopic studies clarified that PFP is not necessarily related to cartilage 
defects, which was confirmed in 1999 by the study of Kannus et al. with the use of mag-
netic resonance imaging (MRI)7,27,50,51 To date evidence on the association between PFP 
and retropatellar cartilage damage is not conclusive and ‘retropatellar chondropathy’ 
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is still widely used as synonym for PFP. With current-day MRI with high spatial resolu-
tion it is nowadays possible to detect even minor cartilage defects, such as signal ab-
normalities, fraying or fissuring, and hypertrophy, which could potentially have been 
undetected with prior imaging techniques. Furthermore, other abnormalities, such as 
patellar retinaculum, synovial plicae, Hoffa’s fat pad and subchondral bone marrow, 
have long been mentioned in literature as possible sources of pain, but have not yet 
been systematically investigated in a PFP population with MRI.7,32-34,52 Therefore, chapter 
III focuses on the association between PFP and structural joint tissue abnormalities of 
the patellofemoral joint on MRI.
Chapter IV takes it one step further by focusing on the association between PFP and 
patellofemoral cartilage composition. PFP has been suggested as a precursor of patel-
lofemoral osteoarthritis (OA)53,54 and changes in cartilage composition are known to 
precede changes in cartilage morphology in OA.55 So, if cartilage changes are expected 
in PFP, which typically involves a young patient population without morphologic car-
tilage defects, this would be changes in cartilage composition. Structural components 
of cartilage are essential for cartilage structure and its mechanical behavior. The latter 
depends on the interaction of these structural components and water.56 Hypothetically, 
in case of an altered cartilage composition, pain receptors of the subchondral endplate 
may be exposed to stress that normally would be absorbed by healthy cartilage.57 
Nowadays, cartilage composition can be measured with quantitative MRI techniques 
such as delayed gadolinium enhanced MRI of cartilage (dGEMRIC), T1ρ and T2 mapping. 
These techniques estimate the amount and network integrity of structural components 
of cartilage, like collagen and glycosaminoglycans.58
Patellar bone ischemia
An increasing body of research suggests that vascular problems leading to an increased 
intraosseous pressure or bone ischemia might play a role in PFP.35-39 This might be es-
pecially important in patients with PFP during prolonged sitting, since Naslund et al. 
measured a reduced pulsatile blood flow in the patella during knee flexion.59 Quantita-
tive analysis of blood perfusion is nowadays possible with dynamic contrast-enhanced 
magnetic resonance imaging (DCE-MRI). DCE-MRI measures the amount of contrast 
taken up in a preselected volume over a time period, as a measure of blood perfusion.60 
Due to the relatively poor vascularization of bone compared to other tissues, DCE-MRI 
of bone poses important challenges, and only a few studies used a quantitative ap-
proach.61-65 To our knowledge, DCE-MRI has neither been applied in the patellar bone 
nor in patients with PFP previously. Therefore, chapter V describes the development of 
a method to apply DCE-MRI in patellar bone. Subsequently, chapter VI describes the 
association between blood perfusion of the patellar bone and PFP.
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Altered pain perception
Next to this structural approach, an altered pain perception has also been proposed as 
possible mechanism contributing to PFP. Pain is normally present when a nociceptor, 
a pain receptor, is stimulated. If an altered pain perception exists, there is no longer 
a nociceptive stimulus present or only a small stimulus, which cannot account for the 
amount of pain felt. Previous studies by Jensen et al. indicated that aberrations of the 
nervous system leading to an altered pain perception might play a role in chronic patel-
lar PFP.66,67 More recently, two studies demonstrated the presence of pressure hyperal-
gesia, an increased response to a pain provoking mechanical stimulus, in a population 
of adult females with PFP.68,69 Pressure hyperalgesia can be assessed with the pressure 
pain threshold (PPT); this is the amount of mechanical pressure needed to induce pain. 
The PPT can be tested with a handheld dynamometer with algometry tip. Chapter VII 
focuses on the inter-rater reliability of handheld dynamometry testing of the pressure 
pain threshold, while chapter VIII describes the association between PFP and pain per-
ception.
In summary
The aims of this thesis are to assess the effects of exercise therapy in patients with PFP 
and to contribute to a better understanding of the pathogenesis of PFP. Figure 2 sum-
marizes the hypothetic pathophysiologic mechanisms of patellofemoral pain. The white 
boxes depict the mechanisms, which will be discussed in this thesis.
Patellofemoral 
pain 
Structural joint 
tissue 
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Inflammation 
Increased 
intraossesous 
pressure 
Altered pain 
perception 
Patellar bone 
ischemia 
Figure 2. Hypothetic pathophysiologic mechanisms of patellofemoral pain
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ABSTRACT
Background
Patellofemoral pain syndrome (PFPS) is a common knee problem, which particularly af-
fects adolescents and young adults. PFPS, which is characterised by retropatellar (behind 
the kneecap) or peripatellar (around the kneecap) pain, is often referred to as anterior 
knee pain. The pain mostly occurs when load is put on the knee extensor mechanism 
when climbing stairs, squatting, running, cycling or sitting with flexed knees. Exercise 
therapy is often prescribed for this condition.
Objectives
To assess the effects (benefits and harms) of exercise therapy aimed at reducing knee 
pain and improving knee function for people with patellofemoral pain syndrome.
Search methods
We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register 
(May 2014), the Cochrane Central Register of Controlled Trials (2014, Issue 4), MEDLINE 
(1946 to May 2014), EMBASE (1980 to 2014 Week 20), PEDro (to June 2014), CINAHL 
(1982 to May 2014) and AMED (1985 to May 2014), trial registers (to June 2014) and 
conference abstracts.
Selection criteria
Randomised and quasi-randomised trials evaluating the effect of exercise therapy on 
pain, function and recovery in adolescents and adults with patellofemoral pain syn-
drome. We included comparisons of exercise therapy versus control (e.g. no treatment) 
or versus another non-surgical therapy; or of different exercises or exercise programmes.
Data collection and analysis
Two review authors independently selected trials based on pre-defined inclusion criteria, 
extracted data and assessed risk of bias. Where appropriate, we pooled data using either 
fixed-effect or random-effects methods. We selected the following seven outcomes for 
summarising the available evidence: pain during activity (short-term: ≤ 3 months); usual 
pain (short-term); pain during activity (long-term: > 3 months); usual pain (long-term); 
functional ability (short-term); functional ability (long-term); and recovery (long-term).
main results
In total, 31 heterogeneous trials including 1690 participants with patellofemoral pain 
are included in this review. There was considerable between-study variation in pa-
tient characteristics (e.g. activity level) and diagnostic criteria for study inclusion (e.g. 
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minimum duration of symptoms) and exercise therapy. Eight trials, six of which were 
quasi-randomised, were at high risk of selection bias. We assessed most trials as being 
at high risk of performance bias and detection bias, which resulted from lack of blind-
ing. The included studies, some of which contributed to more than one comparison, 
provided evidence for the following comparisons: exercise therapy versus control (10 
trials); exercise therapy versus other conservative interventions (e.g. taping; eight trials 
evaluating different interventions); and different exercises or exercise programmes. The 
latter group comprised: supervised versus home exercises (two trials); closed kinetic 
chain (KC) versus open KC exercises (four trials); variants of closed KC exercises (two 
trials making different comparisons); other comparisons of other types of KC or miscel-
laneous exercises (five trials evaluating different interventions); hip and knee versus 
knee exercises (seven trials); hip versus knee exercises (two studies); and high- versus 
low-intensity exercises (one study). There were no trials testing exercise medium (land 
versus water) or duration of exercises. Where available, the evidence for each of seven 
main outcomes for all comparisons was of very low quality, generally due to serious 
flaws in design and small numbers of participants. This means that we are very unsure 
about the estimates. The evidence for the two largest comparisons is summarised here.
Exercise versus control. Pooled data from five studies (375 participants) for pain during 
activity (short-term) favoured exercise therapy: mean difference (MD) -1.46, 95%con-
fidence interval (CI) -2.39 to -0.54. The CI included the minimal clinically important 
difference (MCID) of 1.3 (scale 0 to 10), indicating the possibility of a clinically important 
reduction in pain. The same finding applied for usual pain (short-term; two studies, 41 
participants), pain during activity (long-term; two studies, 180 participants) and usual 
pain (long-term; one study, 94 participants). Pooled data from seven studies (483 par-
ticipants) for functional ability (short-term) also favoured exercise therapy; standardised 
mean difference (SMD) 1.10, 95% CI 0.58 to 1.63. Re-expressed in terms of the Anterior 
Knee Pain Score (AKPS; 0 to 100), this result (estimated MD 12.21 higher, 95% CI 6.44 to 
18.09 higher) included the MCID of 10.0, indicating the possibility of a clinically impor-
tant improvement in function. The same finding applied for functional ability (long-term; 
three studies, 274 participants). Pooled data (two studies, 166 participants) indicated 
that, based on the ’recovery’ of 250 per 1000 in the control group, 88 more (95% CI 2 
fewer to 210 more) participants per 1000 recovered in the long term (12 months) as a 
result of exercise therapy.
Hip plus knee versus knee exercises. Pooled data from three studies (104 participants) 
for pain during activity (short-term) favoured hip and knee exercise: MD -2.20, 95% CI 
-3.80 to -0.60; the CI included a clinically important effect. The same applied for usual 
pain (short-term; two studies, 46 participants). One study (49 participants) found a clini-
cally important reduction in pain during activity (long-term) for hip and knee exercise. 
Although tending to favour hip and knee exercises, the evidence for functional ability 
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(short-term; four studies, 174 participants; and long-term; two studies, 78 participants) 
and recovery (one study, 29 participants) did not show that either approach was superior.
Authors’ conclusions
This review has found very low quality but consistent evidence that exercise therapy for 
PFPS may result in clinically important reduction in pain and improvement in functional 
ability, as well as enhancing long-term recovery. However, there is insufficient evidence 
to determine the best form of exercise therapy and it is unknown whether this result 
would apply to all people with PFPS. There is some very low quality evidence that hip 
plus knee exercises may be more effective in reducing pain than knee exercise alone. 
Further randomised trials are warranted but in order to optimise research effort and 
engender the large multicentre randomised trials that are required to inform practice, 
these should be preceded by research that aims to identify priority questions and at-
tain agreement and, where practical, standardisation regarding diagnostic criteria and 
measurement of outcome.
BACkGROUND
Description of the condition
Patellofemoral pain syndrome (PFPS) is a common knee problem, which particularly 
affects adolescents and young adults.1 Synonyms for patellofemoral pain syndrome are 
’anterior knee pain syndrome’, ’patellar dysfunction’, ’chondromalacia patellae’ or 
’chondropathy’. Its incidence varies from 22 new cases per 1000 persons/year in highly 
active populations to five to six new cases per 1000 in general practice.2 3 PFPS is char-
acterised by retropatellar pain (behind the kneecap) or peripatellar pain (around the 
kneecap), mostly occurring when load is put on the knee extensor mechanism such 
as when climbing stairs, squatting, running, cycling or sitting with flexed knees.4 5 The 
diagnosis is based on these symptoms after excluding other distinct knee pathologies, 
which potentially cause anterior knee pain, such as Hoffa’s syndrome, Osgood Schlat-
ter syndrome, Sinding-Larsen-Johansson syndrome, iliotibial band friction syndrome, 
tendinitis, neuromas, intra-articular pathology including osteoarthritis, rheumatoid 
arthritis, traumatic injuries (such as injured ligaments, meniscal tears, patellar fractures 
and patellar luxation), plica syndromes and more rarely occurring pathologies. Physical 
tests, for example the Clarke’s compression test, are used to diagnose PFPS, but the sen-
sitivity and specificity of these tests are debated.6 7 Several factors have been implicated 
in the aetiology of PFPS. These include local factors (contribution of patellofemoral joint 
mechanics and surrounding tissues to patellofemoral pain), distal factors (contribution 
of foot and ankle mechanics) and proximal factors (contribution of hip, pelvis and trunk 
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mechanics).4 However, the aetiology of the condition is still unclear, as is the origin of 
the pain. Other factors that have recently been described as factors associated with 
PFPS are a lower knee extension strength, a lower hip extension strength and decreased 
flexibility of the lower extremity muscles.5
Description of the intervention
The majority of people with PFPS are treated conservatively (non-surgically). Physically-
based conservative interventions include knee orthoses, foot orthoses8, patellar taping9 
and exercise therapy. Most exercise therapy programmes for PFPS have focused on 
strengthening the quadriceps muscles, which was seen as the most promising conser-
vative treatment method for patellofemoral pain syndrome.10-12 More recently, studies 
have focused on hip muscle dysfunction as a possible contributor to patellofemoral 
pain.13-15 Exercise therapy comprises a broad range of possible variations and accompa-
nying terms. Activity of the quadriceps muscles – and other muscles involved in knee 
function - can either be concentric, eccentric or isometric. During concentric activities 
the muscles shorten, whereas during eccentric activities the muscles lengthen in an ac-
tively controlled manner. During isometric activity the muscle length remains the same. 
Exercises can either be static or dynamic. Exercises are referred to as static if the position 
of the knee does not change. If the position of the knee does change, the exercise is 
called dynamic. In cases where the lower leg moves at a predetermined, constant speed, 
which requires an isokinetic dynamometer to control the velocity, the dynamic exercise 
is also called isokinetic. Exercises where the foot is in contact with a fixed surface are 
referred to ’closed kinetic chain exercises’, as opposed to ’open kinetic chain’ exercises 
where the foot is not in contact with a fixed surface. Thus, exercises can be arranged in 
three ways: the type of muscle activity (concentric, eccentric, isotonic), joint movement 
(dynamic versus static) and the presence of reaction forces caused by contact of the foot 
with a fixed surface (closed versus open kinetic chain).16 17 Combinations of the above 
apply to every type of exercise, and the terminology used for exercise programmes 
reflects the emphasis intended by the therapist or researcher. Emphasis during exercise 
therapy may be put on the co-ordinated contraction of the medial and lateral parts of 
the quadriceps muscle, and also on the co-ordinated contraction of hip adductor, hip 
abductor and gluteal muscles.18 In addition, there are other differences such as in the 
delivery of exercise, for example, supervised exercise versus home exercise; or in the 
duration or intensity of exercise.
How the intervention might work
A recent published review on factors associated with PFPS concluded that people with 
PFPS have lower knee extension strength, lower hip extension strength and decreased 
flexibility of the lower extremity muscles compared with people without PFPS.5 Exercise 
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programmes that comprise static and dynamic muscular exercises for both quadriceps 
and hip muscles aim to improve the strength of these muscles and consequently reduce 
pain by decreasing the load on the patellofemoral joint and improve function by nor-
malising the kinematics.
Why it is important to do this review
Patellofemoral pain syndrome (PFPS) is a common knee problem, particularly affect-
ing adolescents and young adults and exercise therapy to strengthen the quadriceps 
is often prescribed. However, the aetiology of the condition, including the structures 
causing the pain, and treatment methods are all debated and consensus has not been 
reached so far. This review updates and supercedes a former Cochrane review.10
OBjECTIVES
To assess the effects (benefits and harms) of exercise therapy aimed at reducing knee 
pain and improving knee function for people with patellofemoral pain syndrome.
mETHODS
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised (using a method of allocating participants to a 
treatment or control condition by a method that is not strictly random, e.g. by hospital 
number) controlled clinical trials that evaluate exercise therapy for patellofemoral pain 
syndrome.
Types of participants
Adolescents and adults with patellofemoral pain (or a synonym of this) as defined by 
trial authors. We excluded studies focusing on other named knee pathologies such as 
Hoffa’s syndrome, Osgood Schlatter syndrome, Sinding-Larsen-Johansson syndrome, 
iliotibial band friction syndrome, tendinitis, neuromas, intra-articular pathology includ-
ing osteoarthritis, rheumatoid arthritis, traumatic injuries (such as injured ligaments, 
meniscal tears, patellar fractures and patellar luxation), plica syndromes and more rarely 
occurring pathologies.12 19
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Types of interventions
We included studies evaluating exercise therapy for patellofemoral pain syndrome. Exer-
cises could be applied on their own or in combination with other non-surgical interven-
tions, provided the same other intervention was applied to the whole population in the 
comparison. Exercises could be performed at home or under supervision of a therapist.
Comparisons
1. Exercise therapy versus control (no treatment, placebo or waiting list controls). This 
also includes ’exercise therapy + another intervention (e.g. taping) versus the other 
intervention alone (e.g. taping)’
2. Exercise therapy versus different conservative interventions (e.g. taping)
 i)  Exercise therapy versus unimodal conservative interventions
 ii)  Exercise therapy versus multimodal conservative interventions
3. Comparisons of different exercises or exercise therapy programmes:
 i)  Delivery of exercises or exercise programmes (e.g. supervised versus home 
exercise; group versus individual supervision)
 ii)  Medium of exercises or exercise programmes (water versus land-based exer-
cise)
 iii)  Types of exercises or exercise programmes (e.g. closed versus open kinetic 
chain exercises; dynamic versus static)
 iv)  Target of exercises or exercise programmes (strengthening of hip or abdominal 
muscles versus quadriceps muscles)
 v)  Duration of exercises or exercise programmes (e.g. long duration (more than 
three months) versus shorter duration (three months or less))
 vi)  Intensity of exercises or exercise programmes (e.g. high-intensity (several times 
per week) versus low-intensity (once weekly))
We defined the intervention group for comparisons of different exercises as the most 
novel, intensive or resource-dependent intervention. For instance, the intervention was 
supervised exercise and the control was home exercise in the first comparison (3a). We 
also gave consideration to consistency in the choice of control groups. For comparison 
3c, types of exercises, we implemented a secondary categorisation based on the type of 
kinetic chain involved. These were closed versus open kinetic chain exercises; variants 
of closed kinetic chain exercise; and open, mixed or unspecified kinetic chain exercises 
subgrouped by type of muscle action (isometric, isotonic (concentric or eccentric) or 
isokinetic). We presented separately any exceptions that did not fit in. In terms of the ’ex-
ercise therapy’ group, combined interventions or treatment packages including exercise 
were not tested in this review, with the exception of exercises provided with instructions 
or advice, where exercise was the predominant intervention.
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Types of outcome measures
Primary outcomes
1. Knee pain measured by validated self reporting methods (visual analogue scale (VAS), 
numerical rating scale (NRS) or McGill Pain questionnaire).20 If multiple pain scales were 
reported in one study, we only included pain in daily life (usual pain, worst pain and pain 
at activities (e.g. sports, pain during descending stairs)21 in the analyses. We selected 
pain at descending for pooling on ’pain at activities’ as this outcome measure was pres-
ent in most studies eligible for pooling of pain at activity.
Secondary outcomes
1. Functional ability (i.e. knee function in activities of daily living) measured by ques-
tionnaires focusing on knee function (such as Functional Index Questionnaire (FIQ)22, 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)23, Ku-
jala Patellofemoral Function Scale or Anterior Knee Pain Score (AKPS)24 and Lysholm 
scale25). If multiple scales for functional ability were measured including the AKPS, 
we used the latter for pooling.
2. Functional performance tests, including squatting and hopping on one leg.26
3. Subjective perception of recovery. Recovery from patellofemoral pain syndrome is 
an outcome measure inconsistently reported in studies and different methods are 
used to describe recovery. In this review, we gave preference to ’number of patients 
no longer troubled by symptoms’ or ’perceived recovery’ measured on a Likert scale.27
4. Adverse events: we considered knee swelling or substantially increasing pain levels 
as a direct effect of treatment.
Based on Crossely et al.21, we chose the following minimal clinically important differ-
ences for pain and function: 1.3 points on a VAS (0 to 10) for pain during activity; 2.0 
points on a VAS (0 to 10) for usual and worst pain; 10 points for the AKPS (0 to 100) and 
2 points for the FIQ (0 to 16).
Changes in knee function measured on impairment level only (e.g. range of motion, 
muscle strength) do not directly represent changes in the symptoms of patellofemoral 
pain or the resulting disability, and we therefore did not consider them clinically relevant 
outcome measures in this review.28 29
Timing of outcome measurement
We considered outcomes measured within three months after the baseline measure-
ment short-term outcomes of exercise therapy, and we considered measurements more 
than three months after the baseline measurement long-term outcomes. If multiple 
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short-term outcomes were measured in one trial, we used the time point closest to three 
months for pooling.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register 
(23 May 2014), the Cochrane Central Register of Controlled Trials (2014, Issue 4), MED-
LINE (1946 to May Week 2 2014), MEDLINE In-Process & Other Non-Indexed Citations 
(22 May 2014), EMBASE (1980 to 2014 Week 20), PEDro - The Physiotherapy Evidence 
Database (to 26 June 2014), CINAHL (1982 to 23 May 2014) and AMED (1985 to May 
2014). We also searched the World Health Organization (WHO) International Clinical Tri-
als Registry Platform and Current Controlled Trials for ongoing and recently completed 
trials (30 June 2014). In MEDLINE (Ovid Online), we combined a subject-specific strategy 
with the sensitivity-maximising version of the Cochrane Highly Sensitive Search Strategy 
for identifying randomised trials.30 Search strategies for MEDLINE, the Cochrane Central 
Register of Controlled Trials, EMBASE, CINAHL and AMED are shown in Appendix 1. We 
did not apply any language restrictions.
Searching other resources
We checked reference lists of included studies and other relevant articles, including a 
previous Cochrane review10, for additional trials. We contacted institutions and experts 
in the field in order to identify unpublished studies. We searched conference abstracts 
from the International Patellofemoral Pain Research Retreat.4
Data collection and analysis
The intended methodology for data collection and analysis was described in our pub-
lished protocol31, which was based on the Cochrane handbook for systematic reviews of 
interventions.32
Selection of studies
Two review authors (RAH and NEL) selected potentially eligible articles by reviewing the 
title and abstract of each citation. After obtaining full articles, both authors indepen-
dently performed study selection. In cases of disagreement, we reached a consensus 
through discussion.
Data extraction and management
Two review authors (RAH and NEL) independently extracted the data within included 
trials using a piloted data collection form. We resolved any disagreements by consensus. 
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Where data were missing or incompletely reported, we contacted authors of trials. 
Where pooling was possible, and if necessary, we converted pain scores (VAS, NRS) to a 
0 to 10 scale and function scores to a 0 to 100 scale.
Assessment of risk of bias in included studies
Two review authors (RAH and NEL) independently assessed the risk of bias of the in-
cluded trials using The Cochrane Collaboration’s ’Risk of bias’ tool.32 We assessed the 
following domains: random sequence generation; allocation concealment; blinding of 
participants and personnel; blinding of outcome assessment; incomplete outcome data; 
selective reporting; and other bias. Other sources of bias included bias from major imbal-
ance in baseline characteristics and performance bias such as from lack of comparability 
in clinicians’ experience with the interventions under test, differences in care other than 
the interventions under test or compliance with the intervention. We explicitly judged 
each of these criteria using: low risk of bias; high risk of bias; and unclear risk of bias 
(where ’unclear’ relates to a lack of information or uncertainty over the potential for 
bias). Disagreements between review authors regarding the risk of bias for domains 
were resolved by consensus.
Measures of treatment effect
We calculated risk ratios with 95% confidence intervals for dichotomous outcomes. We 
calculated mean differences with 95% confidence intervals for continuous outcomes 
as appropriate. When two or more studies presented their data derived from the same 
instrument of evaluation (with the same units of measurement), we pooled data as a 
mean difference (MD). Conversely, we used the standardised mean difference (SMD) 
when primary studies express the same variables through clearly different instruments 
(and different units of measurement). In case of pooling of different units of measure-
ments, we scaled values to 0 to 10 (lower is better) for pain and 0 to 100 (higher is better) 
for functional ability. In order to re-express SMDs in VAS (0 to 10) and AKPS (0 to 100), we 
multiplied SMDs and 95% CIs by an estimate (the median of all control and intervention 
standard deviations (SDs)) of the SD of VAS or AKPS respectively.
Unit of analysis issues
The unit of randomisation in the studies likely to be included in this review is usually 
the individual participant. Exceptionally, as in the case of trials including people with 
bilateral complaints, data for trials could be evaluated for knees, instead of individual 
patients. Where such unit of analysis issues arose and appropriate corrections had 
not been made, we proposed to present data for such trials only where the disparity 
between the units of analysis and randomisation was small. Where data were pooled, 
we aimed to perform a sensitivity analysis to examine the effects of pooling these incor-
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rectly analysed trials with the other correctly analysed trials. However, all the outcome 
measures, except functional performance, presented their outcome data based on the 
individual participant. For functional performance, studies including participants with 
bilateral complaints used the most painful side for analysis. So, no unit of analysis issues 
occurred. For multi-comparison studies, we attempted to combine data where two or 
more of the groups tested interventions in the same category. When combining was not 
appropriate but the data presented for the difference comparisons were presented in 
the same analysis, we divided the number of participants in the shared comparison (e.g. 
halved where this intervention appears twice) in order to avoid the ’double-counting’ of 
participants for the ’shared comparison’ in the meta-analyses. For cross-over trials, we 
proposed to present data collected prior to the cross-over of the intervention, but there 
were no cross-over trials included.
Dealing with missing data
We contacted trial authors where further details of methodology or data were required 
for trial inclusion. Where possible we performed intention-to-treat analyses to include 
all people randomised. However, where dropouts were identified, we used the actual 
numbers of participants contributing data at the relevant outcome assessment. We were 
alert to the potential mislabelling or non-identification of standard errors and standard 
deviations (SDs). Unless missing standard deviations could be derived from confidence 
intervals or standard errors, we planned to consider whether it was appropriate to esti-
mate values based on comparable data included in this review in order to present these 
in the analyses. We imputed no data in the review. Should we impute data in future, we 
will make clear for which trials imputed data have been used (e.g. footnotes in the forest 
plots). Should data have been presented as the median (inter-quartile range), we would 
not have transformed these to achieve normality or to estimate the mean and SD.
Assessment of heterogeneity
We assessed heterogeneity by visual inspection of the forest plot (analysis) along with 
consideration of the Chi² test for heterogeneity and the I² statistic.32 We considered het-
erogeneity statistically significant if the I² statistic was 70% or more or the P value < 0.1 
for the Chi² test. We also examined studies for methodological and clinical heterogene-
ity, particularly if significant statistical heterogeneity was identified.
Assessment of reporting biases
For future updates of the review, we will explore the possibility of publication bias using 
a funnel plot if there are data from at least 10 trials available for pooling.32
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Data synthesis
When considered appropriate, we pooled results of comparable groups of trials using 
both fixed-effect and random-effects models. The choice of the model to report was 
guided by a careful consideration of the extent of heterogeneity and whether it could be 
explained, in addition to other factors such as the number and size of studies that were 
included. The fixed-effect model was the standard. We used a random-effects model in 
case of statistically significant heterogeneity.
Subgroup analysis and investigation of heterogeneity
Where data permitted, we proposed to perform the following subgroup analyses:
• Gender
• Duration of complaints (acute (less than three months) versus chronic)
• Sport participation (athletes and/or military recruits versus the general population)
We intended to inspect the overlap of confidence intervals and perform the test for 
subgroup differences available in RevMan to test whether subgroups were statistically 
significantly different from one another. However, subgroup analysis to determine the 
effects of gender, duration of complaints and sports participation on the outcomes of 
interest was not possible due to the small number of participants in the studies and the 
inconsistent reporting of baseline characteristics.
Sensitivity analysis
Where appropriate, we performed sensitivity analyses investigating the effects of risks 
of bias by excluding trials with high or unclear risk of bias (such as selection bias for trials 
with lack of allocation concealment and lack of random sequence generation) and trials 
reported in abstracts only. We explored the effects of using different models (fixed-effect 
versus random-effects) for pooling data where there was substantial heterogeneity and 
retained the more conservative result (random-effects) but also explored the effects on 
the results of removing single trials (outliers) in analyses where there were three trials or 
more. We did not need to perform sensitivity analyses to explore the effects of included 
trials with imputed data (e.g. SDs) for this version of the review.
’Summary of findings’ tables
Where there were sufficient data, we summarised the results for the main comparisons 
described in the Types of interventions in ’Summary of findings’ tables (Appendix 2). We 
used the GRADE approach for systematic reviews33-36 to assess the quality of evidence 
related to seven outcomes (pain during activity (short-term; ≤ 3 months); usual pain 
(short-term); pain during activity (long-term; > 3months); usual pain (long-term); func-
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tional ability (short-term); functional ability (long-term); recovery (long-term); see Types 
of outcome measures) (Higgins32; see section 12.2).
RESULTS
Description of studies
See Characteristics of included studies; Characteristics of excluded studies; Character-
istics of studies awaiting classification; Characteristics of ongoing studies; Available 
online: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010387.pub2/full
Results of the search
We found 1398 records from the following databases: Cochrane Bone, Joint and Muscle 
Trauma Group Specialised Register (49 records); Cochrane Central Register of Controlled 
Trials (135), MEDLINE (326 records), EMBASE (491 records), AMED (178 records), CINAHL 
(146 records), PEDro (11 records), the WHO International Clinical Trials Registry Platform 
(42) and Current Controlled Trials (20). Furthermore, we identified 13 potentially eligible 
studies from the previous review of Heintjes et al.10
The search identified 107 potentially eligible studies of which 60 were clearly not 
eligible upon the retrieval of full-text articles. Of those remaining, 31 studies (two with 
data published in two reports) were included in the review. We excluded 12 studies and 
there is one ongoing study. One study is reported in Turkish and has been placed in 
Characteristics of studies awaiting classification pending translation.37
A flow diagram summarising the study selection process is shown in Figure 1.
Included studies
Full details of the trials can be found in the Characteristics of included studies (online 
available). A summary of key patient characteristics is presented in Table 1; and in the 
text below.
Design
We included 25 randomised controlled trials17 27 29 38-60 and six quasi randomized trials.61-66 
We extracted data for one comparison from 21 trials and for two comparisons from 10 
trials.29 39 43 46 50-53 57 65
Sample sizes
In total, 1690 participants from 31 trials were included in this review. The number of 
participants in the intervention groups in the individual studies ranged from six58 to 6527.
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Recruitment setting
Participants were recruited from the following settings: orthopaedic clinics39 40 42 43 49-52 57 60 66, 
general practices27 43 50 52 60 65, physiotherapy practices38 44 53 54 62, chiropractic practices58, 
rehabilitation services46 47, athletic trainer practices45, sports medicine practices27, rheu-
matology department43, department of community health48, institute of sports48, poster 
advertisements in public places58, screening of all female students at the physiotherapy 
clinic affiliated to the rehabilitation faculty55, or via bulletin board posters and word of 
mouth52 (see Table 1). Seven trials recruited from more than one setting.27 43 48 50 52 58 60 
Seven trials did not report their recruitment setting.17 29 41 56 61 63 64 Trials were undertaken 
in 18 different countries (Australia (two trials); Belgium (one); Brazil (four); Canada (two); 
Egypt (two); Germany (one); Iran (four); Israel (one); Norway (one); Saudi Arabia (one); 
Figure 1. Study flow diagram
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Spain (one); Sweden (one); Switzerland (one); Taiwan (one); the Netherlands (one); 
Turkey (one); UK (three); and USA (three) (see Table 1).
Participants
All participants were diagnosed with patellofemoral pain syndrome based on clinical 
symptoms and, occasionally, radiological examination (Table 2).
Exceptionally, in Abrahams et al.39, malalignment also had to be diagnosed by X-ray. 
The trials varied quite markedly in their inclusion criteria, such as the explicit men-
tion of a minimum duration of symptoms and, if mentioned, the minimum required; 
this ranged from three weeks52 to eight months.39 Five trials provided no details 
of pain provoking activities or pain provoking functional or clinical tests used for 
determining eligibility (see Table 2).29 39 43 49 56 62 Trials consisted of populations with 
different levels of activity. Six trials reported that they included a less active popula-
tion46 47 53 57 63 64 and four trials an active population.44 56 61 65 18 trials included both male 
and female participants.17 27 29 38 39 43 48 50 52-54 56-58 60 61 64 65 Ten studies involved only female 
participants41 42 44-47 49 55 63 66 and one included only male participants.51 Two studies did 
not report the number of females and males.40 62 The age of participants ranged from 10 
to 65
 years. The mean age of the participants reported in 28 trials ranged from 18 to 40.9 years. 
The mean body mass index (BMI), only reported in 15 trials, ranged from 21.5 to 26.9 (see 
Table 1). The duration of complaints ranged from four weeks54 to nine years.66 Eleven tri-
als included both participants with unilateral- or bilateral complaints.17 27 43 45 48 50 52 55 60 64 66 
Seven trials included only participants with unilateral complaints38 39 42 46 47 65 and one 
trial included only patients with bilateral complaints.63 The remaining 13 studies did 
not mention the proportion of unilateral and bilateral complaints. A total of six trials 
excluded participants who had prior exercise therapy.27 43 51 52 60 63
Interventions
A range of exercise therapy interventions were evaluated in the included trials. We 
distinguished three comparisons:
1. Exercise therapy versus control (no treatment, placebo or waiting list controls)
2. Exercise therapy versus different conservative interventions:
 i) Exercise therapy versus unimodal conservative interventions
 ii) Exercise therapy versus multimodal conservative interventions
3. Different types of exercise therapy
 i)  Delivery of exercises or exercise programmes (e.g. supervised versus home 
exercise; group versus individual supervision)
 ii)  Medium of exercises or exercise programmes (water versus land-based exer-
cise)
36 Chapter 2
 iii)  Types of exercises or exercise programmes (with the primary categorisation 
being by the type of kinetic chain involved)
 iv)  Target of exercises or exercise programmes (strengthening of hip and knee 
muscles versus knee muscles)
 v)  Duration of exercises or exercise programmes (e.g. long duration (more than 
three months) versus shorter duration (three months or less))
 vi)  Intensity of exercises or exercise programmes (e.g. high-intensity (several times 
per week) versus low-intensity (once weekly)
The intervention period ranged from three weeks41 to four months53 and participants 
exercised on average three times per week.
Exercise therapy versus control (no treatment, placebo or waiting list)
For further details, see Appendix 2.
Ten trials compared exercise therapy with a control strategy (no treatment, placebo or 
waiting list controls).27 39 43 46 51-53 57 58 65 Clark et al.43 compared exercise therapy and edu-
cation versus education alone. Abrahams et al.39 compared both a traditional exercise 
protocol and an exercise protocol with thigh adduction and tibia medial rotation during 
eccentric squat with waiting list. This study was not pooled due to clinical heterogeneity 
(participants in this study had to be diagnosed with malalignment and PFPS). Taylor et 
al.58 compared exercise and patella mobilisation/manipulation with patella mobilisation/
manipulation alone. A supervised exercise programme and a home exercise programme 
were both compared with a control intervention (information leaflet) by Loudon et al.65 
Lun et al.52 compared a home exercise programme with brace versus brace alone. Her-
rington et al.51 compared both weightbearing exercises (CKC) and non weightbearing 
exercises (OKC) with a control group without treatment. Knee exercises and knee and 
hip exercises were both compared with no intervention by Song et al.57 Van Linschoten 
et al.27 compared exercise therapy with usual care (’wait and see policy’). Moyano et al.53 
compared classic stretching and quadriceps exercises with education and propriocep-
tive neuromuscular facilitation stretching (including aerobic exercise) with education. 
Finally, Fukuda et al.46 compared both a knee exercise group and a knee and hip exercise 
group with a group that received no treatment.
Exercise therapy versus different conservative treatments
For further details, see Appendix 2.
Exercise therapy versus unimodal conservative interventions
Four trials compared exercise therapy with different unimodal conservative interven-
tions.29 43 52 63 Gobelet et al.29 compared both an isokinetic exercise programme and an 
isometric exercise programme with a muscle electrostimulation group. In Clark et al.43, 
Exercise therapy for patellofemoral pain (Review) 37
Ta
bl
e 
2.
 S
um
m
ar
y 
of
 d
ia
gn
os
tic
 in
cl
us
io
n 
cr
ite
ria
In
cl
us
io
n 
cr
ite
ri
on
Sy
m
pt
om
Sy
m
pt
om
 d
ur
at
io
n
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
ac
tiv
iti
es
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
te
st
s
Pa
in
 p
ro
vo
ki
ng
 c
lin
ic
al
 te
st
s
O
th
er
 c
lin
ic
al
 
te
st
s
Im
ag
in
g 
te
st
s
A
bd
 E
lh
af
z 
20
11
D
iff
us
e,
 u
ni
la
te
ra
l 
an
te
rio
r k
ne
e 
pa
in
At
 le
as
t 8
 w
ee
ks
Ex
ac
er
ba
te
d 
by
 a
ct
iv
ity
Ex
ac
er
ba
te
d 
by
 is
om
et
ric
 
qu
ad
ric
ep
s c
on
tr
ac
tio
n
A
br
ah
am
s 2
00
3
U
ni
la
te
ra
l P
FP
S;
 
re
tr
op
at
el
la
r o
r 
an
te
rio
r k
ne
e 
pa
in
8-
18
 m
on
th
s
Pa
in
 o
n 
sq
ua
tt
in
g
Po
sit
iv
e 
di
re
ct
 p
at
el
lo
fe
m
or
al
 
gr
in
d 
te
st
M
al
al
ig
nm
en
t a
s 
di
ag
no
se
d 
by
 X
-ra
y
Av
ra
ha
m
 2
00
7
An
te
rio
r k
ne
e 
pa
in
Pa
in
 re
la
te
d 
to
 p
ro
lo
ng
ed
 
sit
tin
g,
 c
lim
bi
ng
 st
ai
rs
, a
nd
 
de
sc
en
di
ng
 st
ai
rs
Po
sit
iv
e 
sig
n 
in
 p
at
el
lo
fe
m
or
al
 
gl
id
in
g 
te
st
; n
eg
at
iv
e 
M
cM
ur
ra
y 
te
st
Fu
ll 
kn
ee
 ra
ng
e 
of
 
m
ot
io
n
N
o 
re
le
va
nt
 
pa
te
llo
fe
m
or
al
 
de
ge
ne
ra
tiv
e 
ch
an
ge
s 
on
 im
ag
in
g
Ba
kh
tia
ry
 2
00
8
Ch
on
dr
om
al
ac
ia
 
pa
te
lla
e
Pa
in
 d
ur
in
g 
cl
im
bi
ng
 u
p 
an
d 
do
w
n 
st
ai
rs
 a
nd
 p
ai
n 
af
te
r s
itt
in
g 
fo
r a
 lo
ng
 
tim
e 
w
ith
 th
e 
kn
ee
 fl
ex
ed
 
an
d 
pr
ob
le
m
 w
ith
 k
ne
e 
ex
te
ns
io
n 
af
te
r s
itt
in
g 
fo
r 
a 
lo
ng
 ti
m
e 
w
ith
 th
e 
kn
ee
 
fle
xe
d 
an
d 
gi
vi
ng
 a
w
ay
 
du
rin
g 
w
al
ki
ng
Po
sit
iv
e 
Cl
ar
k 
te
st
Ba
lc
i 2
00
9
Pa
te
llo
fe
m
or
al
 
pa
in
At
 le
as
t 2
 m
on
th
s
Be
tw
ee
n 
at
 le
as
t 2
 a
ct
iv
iti
es
 
lik
e 
lo
ng
tim
e 
sit
tin
g,
 
st
ai
r/
slo
pe
 c
lim
bi
ng
 a
nd
 
de
sc
en
di
ng
, c
ro
uc
hi
ng
, 
ru
nn
in
g,
 b
ou
nc
in
g 
an
d 
ju
m
pi
ng
Cl
ar
k 
20
00
An
te
rio
r k
ne
e 
pa
in
> 
3 
m
on
th
s
38 Chapter 2
Ta
bl
e 
2.
 S
um
m
ar
y 
of
 d
ia
gn
os
tic
 in
cl
us
io
n 
cr
ite
ria
 (c
on
tin
ue
d)
In
cl
us
io
n 
cr
ite
ri
on
Sy
m
pt
om
Sy
m
pt
om
 d
ur
at
io
n
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
ac
tiv
iti
es
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
te
st
s
Pa
in
 p
ro
vo
ki
ng
 c
lin
ic
al
 te
st
s
O
th
er
 c
lin
ic
al
 
te
st
s
Im
ag
in
g 
te
st
s
Co
lo
n 
19
88
Pa
te
llo
fe
m
or
al
 
ch
on
dr
os
is
2 
ou
t o
f t
he
 fo
llo
w
in
g 
6 
cr
ite
ria
: p
er
sis
te
nt
 a
ch
in
g 
in
 th
e 
kn
ee
s w
hi
le
 a
t r
es
t, 
pa
in
 in
 th
e 
kn
ee
s a
fte
r 
sit
tin
g 
w
ith
 th
e 
kn
ee
s i
n 
a 
fle
xe
d 
po
sit
io
n 
fo
r m
or
e 
th
an
 1
0 
to
 2
0 
m
in
ut
es
, 
oc
cu
rr
en
ce
 o
r e
xa
gg
er
at
io
n 
of
 p
ai
n 
on
 w
al
ki
ng
 u
p 
or
 
do
w
n 
st
ai
rs
, c
re
pi
ta
tio
n 
in
 
th
e 
kn
ee
s w
ith
 m
ov
em
en
t, 
sn
ap
pi
ng
 se
ns
at
io
ns
 in
 th
e 
kn
ee
s u
po
n 
ex
te
ns
io
n 
or
 
fle
xi
on
, l
oc
ki
ng
 o
f t
he
 k
ne
es
, 
in
ab
ili
ty
 to
 sq
ua
t d
ow
n 
w
ith
ou
t p
ai
n
Cr
ep
ita
tio
n 
an
d 
co
m
pr
es
sio
n 
sig
n 
du
rin
g 
ph
ys
ic
al
 
ex
am
in
at
io
n
D
e 
m
ar
ch
e 
20
14
An
te
rio
r o
r 
re
tr
op
at
el
la
r 
kn
ee
 p
ai
n 
of
 3
 o
r 
gr
ea
te
r o
n 
th
e 
10
 
cm
 V
AS
 sc
al
e
M
in
im
um
 o
f 8
 w
ee
ks
Pa
in
 d
ur
in
g 
at
 le
as
t 3
 o
f 
th
e 
fo
llo
w
in
g 
ac
tiv
iti
es
: 
as
ce
nd
in
g/
 d
es
ce
nd
in
g 
st
ai
rs
, s
qu
at
tin
g,
 ru
nn
in
g,
 
kn
ee
lin
g,
 ju
m
pi
ng
, a
nd
 
pr
ol
on
ge
d 
sit
tin
g
D
ol
ak
 2
01
1
An
te
rio
r- 
or
 
re
tr
op
at
el
la
r k
ne
e
M
or
e 
th
an
 1
 m
on
th
Pa
in
 d
ur
in
g 
at
 le
as
t 2
 o
f t
he
 
ac
tiv
iti
es
 o
f s
ta
ir 
cl
im
bi
ng
, 
ho
pp
in
g,
 ru
nn
in
g,
 sq
ua
tt
in
g,
 
kn
ee
lin
g,
 a
nd
 p
ro
lo
ng
ed
 
sit
tin
g
Pa
in
 w
ith
 c
om
pr
es
sio
n 
of
 th
e 
pa
te
lla
: p
ai
n 
on
 p
al
pa
tio
n 
of
 
pa
te
lla
r f
ac
et
s
Eb
ur
ne
 1
99
6
An
te
rio
r k
ne
e 
pa
in
Exercise therapy for patellofemoral pain (Review) 39
Ta
bl
e 
2.
 S
um
m
ar
y 
of
 d
ia
gn
os
tic
 in
cl
us
io
n 
cr
ite
ria
 (c
on
tin
ue
d)
In
cl
us
io
n 
cr
ite
ri
on
Sy
m
pt
om
Sy
m
pt
om
 d
ur
at
io
n
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
ac
tiv
iti
es
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
te
st
s
Pa
in
 p
ro
vo
ki
ng
 c
lin
ic
al
 te
st
s
O
th
er
 c
lin
ic
al
 
te
st
s
Im
ag
in
g 
te
st
s
Fu
ku
da
 2
01
0
An
te
rio
r k
ne
e 
pa
in
At
 le
as
t t
he
 p
as
t 3
 
m
on
th
s
Pa
in
 in
 2
 o
r m
or
e:
 a
sc
en
di
ng
 
an
d 
de
sc
en
di
ng
 st
ai
rs
, 
sq
ua
tt
in
g,
 k
ne
el
in
g,
 
ju
m
pi
ng
, l
on
g 
sit
tin
g,
 
iso
m
et
ric
 k
ne
e 
ex
te
ns
io
n 
co
nt
ra
ct
io
n 
at
 6
0°
 o
f 
kn
ee
 fl
ex
io
n,
 a
nd
 p
ai
n 
on
 
pa
lp
at
io
n 
of
 th
e 
m
ed
ia
l a
nd
/
or
 la
te
ra
l f
ac
et
 o
f t
he
 p
at
el
la
Pa
in
 o
n 
pa
lp
at
io
n 
of
 th
e 
m
ed
ia
l a
nd
/o
r l
at
er
al
 fa
ce
t o
f 
th
e 
pa
te
lla
Fu
ku
da
 2
01
2
An
te
rio
r k
ne
e 
pa
in
At
 le
as
t t
he
 p
as
t 3
 
m
on
th
s
Pa
in
 in
 2
 o
r m
or
e:
 a
sc
en
di
ng
 
an
d 
de
sc
en
di
ng
 st
ai
rs
, 
sq
ua
tt
in
g,
 k
ne
el
in
g,
 
ju
m
pi
ng
, l
on
g 
sit
tin
g,
 
iso
m
et
ric
 k
ne
e 
ex
te
ns
io
n 
co
nt
ra
ct
io
n 
at
 6
0°
 o
f 
kn
ee
 fl
ex
io
n,
 a
nd
 p
ai
n 
on
 
pa
lp
at
io
n 
of
 th
e 
m
ed
ia
l a
nd
/
or
 la
te
ra
l f
ac
et
 o
f t
he
 p
at
el
la
Pa
in
 o
n 
pa
lp
at
io
n 
of
 th
e 
m
ed
ia
l a
nd
/o
r l
at
er
al
 fa
ce
t o
f 
th
e 
pa
te
lla
40 Chapter 2
Ta
bl
e 
2.
 S
um
m
ar
y 
of
 d
ia
gn
os
tic
 in
cl
us
io
n 
cr
ite
ria
 (c
on
tin
ue
d)
In
cl
us
io
n 
cr
ite
ri
on
Sy
m
pt
om
Sy
m
pt
om
 d
ur
at
io
n
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
ac
tiv
iti
es
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
te
st
s
Pa
in
 p
ro
vo
ki
ng
 c
lin
ic
al
 te
st
s
O
th
er
 c
lin
ic
al
 
te
st
s
Im
ag
in
g 
te
st
s
G
aff
ne
y 
19
92
Pa
te
llo
fe
m
or
al
 
kn
ee
 p
ai
n,
 u
su
al
ly
 
re
tr
op
at
el
la
r o
r 
m
ed
ia
lly
Pa
in
 d
ur
in
g 
1 
of
 th
e 
fo
llo
w
in
g 
ac
tiv
iti
es
: 
as
ce
nd
in
g 
or
 d
es
ce
nd
in
g 
st
ai
rs
, s
qu
at
tin
g 
or
 ri
sin
g 
fro
m
 a
 sq
ua
t, 
or
 si
tt
in
g 
w
ith
 
th
e 
kn
ee
 b
en
t a
t 9
0 
de
gr
ee
s.
N
o 
sig
n 
of
 li
ga
m
en
t d
am
ag
e 
as
 d
et
er
m
in
ed
 b
y 
va
lg
us
 a
nd
 
va
ru
s s
tr
es
s t
es
ts
, L
ac
hm
an
’s 
te
st
 a
nd
 th
e 
an
te
rio
r d
ra
w
er
 
of
 th
e 
kn
ee
 in
 n
eu
tr
al
, i
nt
er
na
l 
an
d 
ex
te
rn
al
 ro
ta
tio
n 
no
 si
gn
 
of
 m
en
isc
al
 in
vo
lv
em
en
t a
s 
de
te
rm
in
ed
 b
y 
th
e 
M
cM
ur
ra
y 
an
d 
St
ei
nm
an
n 
te
st
; n
o 
in
vo
lv
em
en
t o
f s
tr
uc
tu
re
s 
ar
ou
nd
 th
e 
pa
te
lla
; P
at
ie
nt
s 
w
ho
 h
ad
 te
nd
er
ne
ss
 a
ro
un
d 
th
e 
pa
te
lla
 e
ith
er
 o
n 
its
 
m
ar
gi
ns
 o
r c
ho
nd
ra
l s
ur
fa
ce
 
w
er
e 
in
cl
ud
ed
G
ob
el
et
 1
99
2
Re
tr
o-
pa
te
lla
r 
ch
on
dr
op
at
hy
W
ith
ou
t r
ad
io
lo
gi
ca
l 
le
sio
n;
 w
ith
 o
r w
ith
ou
t 
W
yb
er
g 
dy
sp
la
sia
 
1 
or
 2
H
af
ez
 2
01
2
Ch
on
dr
om
al
ac
ia
 
pa
te
lla
e
Exercise therapy for patellofemoral pain (Review) 41
Ta
bl
e 
2.
 S
um
m
ar
y 
of
 d
ia
gn
os
tic
 in
cl
us
io
n 
cr
ite
ria
 (c
on
tin
ue
d)
In
cl
us
io
n 
cr
ite
ri
on
Sy
m
pt
om
Sy
m
pt
om
 d
ur
at
io
n
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
ac
tiv
iti
es
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
te
st
s
Pa
in
 p
ro
vo
ki
ng
 c
lin
ic
al
 te
st
s
O
th
er
 c
lin
ic
al
 
te
st
s
Im
ag
in
g 
te
st
s
H
ar
ri
so
n 
19
99
D
ia
gn
os
ed
 w
ith
 
PF
PS
2 
of
 th
e 
fo
llo
w
in
g 
cr
ite
ria
: 
pa
te
lla
r p
ai
n 
w
ith
 m
an
ua
l 
co
m
pr
es
sio
n 
of
 th
e 
pa
te
lla
 
ag
ai
ns
t t
he
 fe
m
ur
, p
at
el
la
r 
te
nd
er
ne
ss
 w
ith
 p
al
pa
tio
n 
of
 th
e 
po
st
er
io
r-m
ed
ia
l a
nd
 
po
st
er
o-
la
te
ra
l b
or
de
rs
 o
f 
th
e 
pa
te
lla
, p
at
el
la
r p
ai
n 
du
rin
g 
re
sis
te
d 
dy
na
m
ic
 k
ne
e 
ex
te
ns
io
ns
, o
r p
at
el
la
r p
ai
n 
w
ith
 m
an
ua
l c
om
pr
es
sio
n 
of
 th
e 
pa
te
lla
 a
ga
in
st
 th
e 
fe
m
ur
 d
ur
in
g 
iso
m
et
ric
 k
ne
e 
ex
te
ns
or
 c
on
tr
ac
tio
n 
(C
la
rk
e’s
 
co
m
pr
es
sio
n 
te
st
)
H
er
ri
ng
to
n 
20
07
An
te
rio
r k
ne
e 
pa
in
At
 le
as
t 1
 m
on
th
An
te
rio
r o
r r
et
ro
pa
te
lla
r 
kn
ee
 p
ai
n 
on
 a
t l
ea
st
 2
 o
f 
th
e 
fo
llo
w
in
g 
ac
tiv
iti
es
: 
pr
ol
on
ge
d 
sit
tin
g,
 c
lim
bi
ng
 
st
ai
rs
, s
qu
at
tin
g,
 ru
nn
in
g,
 
kn
ee
lin
g,
 a
nd
 h
op
pi
ng
/
ju
m
pi
ng
Av
er
ag
e 
pa
in
 le
ve
l o
f 3
 o
r 
m
or
e 
on
 a
 1
0-
cm
 v
isu
al
 
an
al
og
ue
 sc
al
e 
du
rin
g 
st
ep
pi
ng
 u
p 
an
d 
do
w
n 
a 
25
-c
m
 h
ei
gh
t
Pr
es
en
ce
 o
f 2
 o
f t
he
 fo
llo
w
in
g 
cl
in
ic
al
 c
rit
er
ia
 o
n 
as
se
ss
m
en
t: 
pa
in
 d
ur
in
g 
ap
pr
eh
en
sio
n 
te
st
, p
ai
n 
du
rin
g 
th
e 
pa
te
lla
r c
om
pr
es
sio
n 
te
st
, 
an
d 
cr
ep
ita
tio
n 
du
rin
g 
th
e 
co
m
pr
es
sio
n 
te
st
kh
ay
am
ba
sh
i 2
01
2
D
ia
gn
os
is 
of
 
bi
la
te
ra
l P
FP
 b
as
ed
 
on
 th
e 
lo
ca
tio
n 
of
 sy
m
pt
om
s 
(p
er
ip
at
el
la
r a
nd
/
or
 re
tr
op
at
el
la
r
At
 le
as
t 6
 m
on
th
s
Pa
in
 w
ith
 a
ct
iv
iti
es
 
co
m
m
on
ly
 a
ss
oc
ia
tio
n 
w
ith
 
th
is 
co
nd
iti
on
, s
uc
h 
as
 st
ai
r 
de
sc
en
t, 
sq
ua
tt
in
g,
 k
ne
el
in
g,
 
an
d 
pr
ol
on
ge
d 
sit
tin
g
42 Chapter 2
Ta
bl
e 
2.
 S
um
m
ar
y 
of
 d
ia
gn
os
tic
 in
cl
us
io
n 
cr
ite
ria
 (c
on
tin
ue
d)
In
cl
us
io
n 
cr
ite
ri
on
Sy
m
pt
om
Sy
m
pt
om
 d
ur
at
io
n
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
ac
tiv
iti
es
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
te
st
s
Pa
in
 p
ro
vo
ki
ng
 c
lin
ic
al
 te
st
s
O
th
er
 c
lin
ic
al
 
te
st
s
Im
ag
in
g 
te
st
s
kh
ay
am
ba
sh
i 2
01
4
D
ia
gn
os
is 
of
 
PF
P 
ba
se
d 
on
 
th
e 
lo
ca
tio
n 
of
 sy
m
pt
om
s 
(p
er
ip
at
el
la
r a
nd
/
or
 re
tr
op
at
el
la
r
At
 le
as
t 6
 m
on
th
s
Pa
in
 w
ith
 a
ct
iv
iti
es
 
co
m
m
on
ly
 a
ss
oc
ia
tio
n 
w
ith
 
th
is 
co
nd
iti
on
, s
uc
h 
as
 st
ai
r 
de
sc
en
t, 
sq
ua
tt
in
g,
 k
ne
el
in
g,
 
an
d 
pr
ol
on
ge
d 
sit
tin
g
Lo
ud
on
 2
00
4
D
ia
gn
os
is 
of
 
un
ila
te
ra
l P
FP
S 
ba
se
d 
on
 p
ai
n 
ar
ou
nd
 o
r u
nd
er
 
th
e 
pa
te
lla
At
 le
as
t a
 2
-m
on
th
 
du
ra
tio
n
3 
of
 th
e 
4 
cr
ite
ria
: p
ai
n 
in
 th
e 
pa
te
llo
fe
m
or
al
 jo
in
t d
ur
in
g 
or
 a
fte
r a
ct
iv
ity
, s
itt
in
g,
 st
ai
r 
cl
im
bi
ng
, s
qu
at
tin
g
Lu
n 
20
05
At
ra
um
at
ic
 
un
ila
te
ra
l a
nd
/
or
 b
ila
te
ra
l 
pe
rip
at
el
la
r o
r 
re
tr
op
at
el
la
r k
ne
e 
pa
in
Pa
in
 fo
r a
t l
ea
st
 
3 
w
ee
ks
 b
ut
 n
o 
gr
ea
te
r t
ha
n 
2 
ye
ar
s
Pa
te
llo
fe
m
or
al
 k
ne
e 
pa
in
 
w
ith
 a
nd
/o
r a
fte
r a
ct
iv
ity
; 
in
ac
tiv
ity
 p
at
el
lo
fe
m
or
al
 
pa
in
 a
nd
/o
r s
tiff
ne
ss
, 
es
pe
ci
al
ly
 w
ith
 si
tt
in
g 
w
ith
 
kn
ee
s i
n 
a 
fle
xe
d 
po
sit
io
n
Pe
rip
at
el
la
r t
en
de
rn
es
s 
±m
ild
 in
fe
rio
r p
at
el
la
r p
ol
e 
te
nd
er
ne
ss
m
oy
an
o 
20
13
D
ia
gn
os
is 
of
 P
FP
Pa
in
 h
ist
or
y 
m
or
e 
th
an
 si
x 
m
on
th
s
Po
sit
iv
e 
te
st
s: 
pa
te
llo
fe
m
or
al
 
gr
in
di
ng
 te
st
 a
nd
 
pa
te
llo
fe
m
or
al
 c
om
pr
es
sio
n 
te
st
N
ak
ag
aw
a 
20
08
An
te
rio
r o
r 
re
tr
op
at
el
la
r k
ne
e 
pa
in
Pa
in
 p
er
sis
te
nt
 fo
r a
t 
le
as
t 4
 w
ee
ks
Pa
in
 d
ur
in
g 
at
 le
as
t 3
 o
f 
th
e 
fo
llo
w
in
g 
ac
tiv
iti
es
: 
as
ce
nd
in
g/
de
sc
en
di
ng
 
st
ai
rs
, s
qu
at
tin
g,
 ru
nn
in
g,
 
kn
ee
lin
g,
 h
op
pi
ng
/ju
m
pi
ng
 
an
d 
pr
ol
on
ge
d 
sit
tin
g
Pa
in
 o
n 
st
ep
pi
ng
 d
ow
n 
fro
m
 
a 
25
-c
m
 st
ep
, o
r d
ur
in
g 
a 
do
ub
le
-le
gg
ed
 sq
ua
t
Pa
in
 o
n 
pa
lp
at
io
n 
of
 th
e 
pa
te
lla
r f
ac
et
s
Exercise therapy for patellofemoral pain (Review) 43
Ta
bl
e 
2.
 S
um
m
ar
y 
of
 d
ia
gn
os
tic
 in
cl
us
io
n 
cr
ite
ria
 (c
on
tin
ue
d)
In
cl
us
io
n 
cr
ite
ri
on
Sy
m
pt
om
Sy
m
pt
om
 d
ur
at
io
n
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
ac
tiv
iti
es
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
te
st
s
Pa
in
 p
ro
vo
ki
ng
 c
lin
ic
al
 te
st
s
O
th
er
 c
lin
ic
al
 
te
st
s
Im
ag
in
g 
te
st
s
Ra
ze
gh
i 2
01
0
Re
tr
o-
 o
r 
pe
rip
at
el
la
r p
ai
n
In
sid
io
us
 o
ns
et
 
of
 p
ai
n 
w
ith
ou
t a
 
hi
st
or
y 
of
 tr
au
m
a 
pe
rs
ist
in
g 
fo
r a
t l
ea
st
 
4 
w
ee
ks
Pa
in
 fr
om
 a
t l
ea
st
 2
 o
f 
th
e 
fo
llo
w
in
g 
ac
tiv
iti
es
: 
sq
ua
tt
in
g,
 p
ro
lo
ng
ed
 si
tt
in
g,
 
st
ai
r c
lim
bi
ng
, r
un
ni
ng
, 
kn
ee
lin
g
Pa
in
 d
ur
in
g 
pa
te
lla
r 
co
m
pr
es
sio
n 
te
st
, p
at
el
la
r 
gr
in
d 
te
st
 o
r m
ed
ia
l/
la
te
ra
l p
at
el
la
r f
ac
et
 
te
nd
er
ne
ss
; n
eg
at
iv
e 
pa
te
lla
r 
ap
pr
eh
en
sio
n 
sig
n
Sc
hn
ei
de
r 2
00
1
U
ni
la
te
ra
l 
re
tr
op
at
el
la
r p
ai
n
M
or
e 
th
an
 6
 m
on
th
s
So
ng
 2
00
9
An
te
rio
r o
r 
re
tr
op
at
el
la
r k
ne
e 
pa
in
Fo
r m
or
e 
th
an
 1
 
m
on
th
Pa
in
 a
fte
r p
er
fo
rm
in
g 
at
 
le
as
t 2
 o
f t
he
 fo
llo
w
in
g 
ac
tiv
iti
es
: p
ro
lo
ng
ed
 si
tt
in
g,
 
st
ai
r c
lim
bi
ng
, s
qu
at
tin
g,
 
ru
nn
in
g,
 k
ne
el
in
g,
 h
op
pi
ng
 
an
d 
ju
m
pi
ng
, a
nd
 d
ee
p 
kn
ee
 fl
ex
in
g
2 
of
 th
e 
fo
llo
w
in
g 
po
sit
iv
e 
sig
ns
 o
f a
nt
er
io
r k
ne
e 
pa
in
 
du
rin
g 
th
e 
in
iti
al
 p
hy
sic
al
 
ex
am
in
at
io
n:
 p
at
el
la
r 
cr
ep
itu
s, 
pa
in
 fo
llo
w
in
g 
iso
m
et
ric
 q
ua
dr
ic
ep
s f
em
or
is
 
m
us
cl
e 
co
nt
ra
ct
io
n 
ag
ai
ns
t 
su
pr
ap
at
el
la
r r
es
ist
an
ce
 
w
ith
 th
e 
kn
ee
 in
 sl
ig
ht
 
fle
xi
on
 (C
la
rk
e’s
 si
gn
), 
pa
in
 
fo
llo
w
in
g 
co
m
pr
es
sio
n 
of
 th
e 
pa
te
lla
 a
ga
in
st
 th
e 
fe
m
or
al
 
co
nd
yl
es
 w
ith
 th
e 
kn
ee
 in
 fu
ll 
ex
te
ns
io
n 
(p
at
el
la
r g
rin
d 
te
st
), 
te
nd
er
ne
ss
 u
po
n 
pa
lp
at
io
n 
of
 th
e 
po
st
er
io
r s
ur
fa
ce
 o
f 
th
e 
pa
te
lla
 o
r s
ur
ro
un
di
ng
 
st
ru
ct
ur
es
, a
nd
 p
ai
n 
fo
llo
w
in
g 
re
sis
te
d 
kn
ee
 e
xt
en
sio
n
44 Chapter 2
Ta
bl
e 
2.
 S
um
m
ar
y 
of
 d
ia
gn
os
tic
 in
cl
us
io
n 
cr
ite
ria
 (c
on
tin
ue
d)
In
cl
us
io
n 
cr
ite
ri
on
Sy
m
pt
om
Sy
m
pt
om
 d
ur
at
io
n
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
ac
tiv
iti
es
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
te
st
s
Pa
in
 p
ro
vo
ki
ng
 c
lin
ic
al
 te
st
s
O
th
er
 c
lin
ic
al
 
te
st
s
Im
ag
in
g 
te
st
s
Ta
yl
or
 2
00
3
Lo
ca
lis
ed
 p
er
i o
r 
re
tr
op
at
el
la
r p
ai
n 
or
ig
in
at
in
g 
fro
m
 
th
e 
pe
rip
at
el
la
r 
tis
su
e 
or
 th
e 
pa
te
llo
fe
m
or
al
 
jo
in
t
At
 le
as
t 1
 m
on
th
Pa
in
 d
ur
in
g 
2 
of
 th
e 
fo
llo
w
in
g:
 sq
ua
tt
in
g,
 
ru
nn
in
g,
 a
sc
en
di
ng
 a
nd
/o
r 
de
sc
en
di
ng
 st
ai
rs
, i
so
m
et
ric
 
qu
ad
ric
ep
s f
em
or
is 
m
us
cl
e 
co
nt
ra
ct
io
n 
or
 a
fte
r s
itt
in
g 
fo
r a
 p
ro
lo
ng
ed
 p
er
io
d 
of
 
tim
e 
w
ith
 th
e 
kn
ee
 fl
ex
ed
Th
om
ee
 1
99
7
Pa
in
 fr
om
 th
e 
pa
te
llo
fe
m
or
al
 
jo
in
t
Fo
r a
 m
in
im
um
 o
f 6
 
m
on
th
s
3 
of
 th
e 
fo
llo
w
in
g 
4 
in
cl
us
io
n 
cr
ite
ria
 w
er
e 
fu
lfi
lle
d:
 p
ai
n 
fro
m
 th
e 
pa
te
llo
fe
m
or
al
 
jo
in
t d
ur
in
g 
or
 a
fte
r a
ct
iv
ity
, 
du
rin
g 
or
 a
fte
r s
itt
in
g,
 
du
rin
g 
st
ai
r c
lim
bi
ng
, d
ur
in
g 
sq
ua
tt
in
g
Va
n 
Li
ns
ch
ot
en
 
20
09
Pa
in
 >
 2
 m
on
th
s a
nd
 
< 
2 
ye
ar
At
 le
as
t 3
 o
f t
he
 fo
llo
w
in
g 
sy
m
pt
om
s: 
pa
in
 w
he
n 
w
al
ki
ng
 u
p 
or
 d
ow
n 
st
ai
rs
; 
pa
in
 w
he
n 
sq
ua
tt
in
g;
 p
ai
n 
w
he
n 
ru
nn
in
g;
 p
ai
n 
w
he
n 
cy
cl
in
g;
 p
ai
n 
w
he
n 
sit
tin
g 
w
ith
 k
ne
es
 fl
ex
ed
 fo
r a
 
pr
ol
on
ge
d 
pe
rio
d 
of
 ti
m
e;
 
gr
in
di
ng
 o
f t
he
 p
at
el
la
A 
po
sit
iv
e 
cl
in
ic
al
 p
at
el
la
r 
te
st
 (s
uc
h 
as
 C
la
rk
e’s
 te
st
 o
r 
pa
te
lla
r f
em
or
al
 g
rin
di
ng
 te
st
)
Exercise therapy for patellofemoral pain (Review) 45
Ta
bl
e 
2.
 S
um
m
ar
y 
of
 d
ia
gn
os
tic
 in
cl
us
io
n 
cr
ite
ria
 (c
on
tin
ue
d)
In
cl
us
io
n 
cr
ite
ri
on
Sy
m
pt
om
Sy
m
pt
om
 d
ur
at
io
n
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
ac
tiv
iti
es
Pa
in
 p
ro
vo
ki
ng
 fu
nc
tio
na
l 
te
st
s
Pa
in
 p
ro
vo
ki
ng
 c
lin
ic
al
 te
st
s
O
th
er
 c
lin
ic
al
 
te
st
s
Im
ag
in
g 
te
st
s
W
itv
ro
uw
 2
00
0
An
te
rio
r k
ne
e 
pa
in
Fo
r m
or
e 
th
an
 6
 
w
ee
ks
2 
of
 th
e 
fo
llo
w
in
g 
cr
ite
ria
 o
n 
in
iti
al
 a
ss
es
sm
en
t: 
pa
in
 o
n 
di
re
ct
 c
om
pr
es
sio
n 
of
 th
e 
pa
te
lla
 a
ga
in
st
 th
e 
fe
m
or
al
 
co
nd
yl
es
 w
ith
 th
e 
kn
ee
 in
 
fu
ll 
ex
te
ns
io
n,
 te
nd
er
ne
ss
 
on
 p
al
pa
tio
n 
of
 th
e 
po
st
er
io
r 
su
rf
ac
e 
of
 th
e 
pa
te
lla
, p
ai
n 
on
 
re
sis
te
d 
kn
ee
 e
xt
en
sio
n,
 a
nd
 
pa
in
 w
ith
 is
om
et
ric
 q
ua
dr
ic
ep
s 
m
us
cl
e 
co
nt
ra
ct
io
n 
ag
ai
ns
t 
su
pr
ap
at
el
la
r r
es
ist
an
ce
 w
ith
 
th
e 
kn
ee
 in
 sl
ig
ht
 fl
ex
io
n
O
st
er
as
a 
20
12
An
te
rio
r o
r 
re
tr
op
at
el
la
r p
ai
n
Fo
r m
or
e 
th
an
 2
 
m
on
th
s
An
te
rio
r o
r r
et
ro
pa
te
lla
r 
pa
in
 fr
om
 a
t l
ea
st
 tw
o 
of
 
th
e 
fo
llo
w
in
g 
ac
tiv
iti
es
 –
 
pr
ol
on
ge
d 
sit
tin
g,
 c
lim
bi
ng
 
st
ai
rs
, s
qu
at
tin
g,
 ru
nn
in
g,
 
kn
ee
lin
g 
an
d 
ho
pp
in
g/
ju
m
pi
ng
Pa
in
 o
n 
pa
lp
at
io
n 
of
 th
e 
pa
te
lla
r f
ac
et
s o
r p
os
iti
ve
 
ph
ys
ic
al
 te
st
s o
n 
gr
in
di
ng
 o
f 
th
e 
pa
te
lla
, C
la
rk
e’s
 te
st
 o
r 
pa
te
lla
r c
re
pi
tu
s
PF
P:
 p
at
el
lo
fe
m
or
al
 p
ai
n,
 P
FP
S:
 p
at
el
lo
fe
m
or
al
 p
ai
n 
sy
nd
ro
m
e,
 V
A
S:
 v
is
ua
l a
na
lo
gu
e 
sc
al
e
46 Chapter 2
the data comparing exercise therapy versus tape were used. In Lun et al.52, data from a 
structured home exercise programme were compared with a brace group. Khayambashi 
et al.63 compared hip exercises with 1000 mg of Omega-3 and 400 mg of calcium daily.
Exercise therapy versus multimodal conservative interventions
Four trials compared exercise therapy with different multimodal conservative inter-
ventions including exercises.48 50 56 62 Harrison et al.50 compared both a supervised 
exercise programme and a home exercise programme versus a vastus medialis-specific 
supervised exercise programme including taping. Eburne and Bannister.62 compared 
isometric quadriceps exercise versus the multimodal McConnell regimen comprising 
different types of exercises and taping. Gaffney et al.48 compared concentric exercises 
versus a multimodal intervention comprising excentric exercises and taping. Schneider 
et al.56 compared physiotherapeutic exercises based on proprioceptive neuromuscular 
facilitation versus a special knee resistance-controlled knee splint combined with a 
special exercise programme.
Different exercises or exercise programmes
For further details, see Appendix 2.
Delivery of exercises or exercise programmes
Two studies compared supervised exercise programmes with home exercise pro-
grammes (Harrison 1999; Loudon 2004).50 65 Harrison et al.50 compared a supervised 
exercise programme with a home exercise programme. Loudon et al.65 compared a 
supervised exercise programme and additional home exercises with home exercises 
and five physiotherapy sessions. A supervised exercise programme was regarded as the 
intervention group.
Medium of exercises or exercise programmes
There were no trials eligible for this comparison.
Types of exercise or exercise programmes
Eleven studies compared types of exercises or exercise programmes with each oth-
er.17 29 38 39 41 42 49 51 53 61 66 Of these, four studies compared closed kinetic chain exercises with 
open kinetic chain exercises.17 38 41 51 Closed kinetic chain (CKC) exercise was regarded as 
the intervention group. Two studies tested variants of closed kinetic chain exercises.39 42 
The first listed CKC variant was regarded as the intervention group. Abrahams et al.39 
compared an exercise protocol with thigh adduction and tibia medial rotation during 
eccentric squat versus a traditional exercise protocol. This study was not pooled due to 
clinical heterogeneity (participants also had to be diagnosed with malalignment). Balci 
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et al.42 compared closed kinetic chain exercises with internally rotated hip versus closed 
kinetic chain exercises with externally rotated hip. Four studies studied open, mixed or 
unspecified kinetic chain exercises subgrouped by type of muscle action.29 49 61 66 The first 
listed kinetic chain exercise group was regarded as the intervention group. Hafez et al.49 
compared eccentric exercises versus concentric exercises. One study compared eccentric 
exercises versus isometric exercises.66 One study compared isokinetic exercises versus 
isometric exercises.29 One study compared combined isotonic and isometric exercises 
(pogo stick) versus isometric exercises.61 One study, which is presented separately in 
Effects of interventions, compared proprioceptive neuromuscular facilitation stretching 
and aerobic exercise with classic stretching and quadriceps exercises.53
Target of exercise or exercise programmes
Nine trials compared different targets of exercises or exercises programmes with each 
other.40 44-47 54 55 57 64 Seven trials compared exercises for the knee and hip with exercises 
for the knee.40 44 46 47 54 55 57 Two trials compared exercises for the knee with exercises for 
the hip.45 64 Since studies investigated similar exercises (i.e. quadriceps exercises or knee 
exercises) but named them differently, we defined them all as knee exercises. An exercise 
programme including hip exercises was regarded as the intervention group.
Duration of exercises or exercise programmes
There were no trials eligible for this comparison.
Intensity of exercises of exercise programmes
Østerås et al.60 was the only trial that compared high-dose, high repetition medical 
exercise therapy (MET) with low-dose, low repetition exercises. The high-intensity group 
was regarded as the intervention group.
Outcomes
Pain was measured by a visual analogue scale (VAS) or numerical (pain) rating scale (N(P)
RS), the McGill pain score20 and as number of patients experiencing pain. A higher score 
on VAS, N(P)RS or McGill means worse pain. Pain was scored in various ways: during 
activity, usual, worst, at rest, after exposure, least, one hour after sport activity, following 
30 minutes of sitting with knees flexed, experienced at four different positions of the 
knee, during isometric knee extension, during triple jump test, during walking, ascend-
ing stairs, during running, during jumping, during sports, during squatting, during pro-
longed sitting, during the night and during isokinetic test. If multiple pain scales were 
reported only pain in daily life (usual pain), worst pain and pain at activities (e.g. sports, 
pain during descending stairs) are presented in Effects of interventions. We selected pain 
at descending for pooling on ’pain at activities’ as this outcome measure was present in 
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most studies eligible for pooling of pain at activity. Functional ability was scored with 
the Anterior Knee Pain Scale (AKPS)24, (Modified) Functional Index Questionnaire ((M)
FIQ)22 67, Arpège function scale, Lower Extremity Function Scale (LEFS)68, (modified) func-
tion scale69, patient specific function score, patellofemoral scale, Bessette and Hunter 
score70, WOMAC Osteoarthritis Index 23, Patellofemoral Joint Evaluation Scale71, Lysholm 
score25) and dichotomously as the number of patients improved in function. If multiple 
scales for functional ability were measured including the AKPS, we used the latter for 
pooling. A higher score means better function, except for WOMAC. For consistency, we 
have inverted the WOMAC scale, in order that a higher score means better function. 
Functional performance was scored with, for example, the single leg triple hop test, step 
(down) test, single-limb hop test, bilateral and unilateral squat, anteromedial lunge, 
step-down dips, leg press, balance and reach and vertical jump test. Studies includ-
ing participants with bilateral complaints used the most painful side for analysis; thus 
avoiding unit of analysis issues. Recovery was measured with eight different measures: a 
Likert scale27, number of patients no longer troubled by symptoms43, number of patients 
with more than 50% improved on pain scale61, improvement percentage62, patients’ 
impression of change (ordinal scale of three)50, subjective success (yes or no)48, number 
of patients participating in sports with or without pain66, and the global rating of change 
on a 15-point scale.44 Four trials reported adverse events.45 58 61 63 Two trials reported that 
they actively recorded adverse events.45 61 Most trials measured the outcomes post-
intervention; however, a few studies reported on a longer term follow-up period ranging 
from five months44 to a maximum of five years.16
Excluded studies
We discussed and excluded 12 potentially eligible studies after consensus28 72-82 see 
the Characteristics of excluded studies (online available). Two studies were neither 
randomised nor quasi-randomised.75 77 Two trials also included patients with osteoar-
thritis74 81 and Roush et al76 also included participants with patellofemoral osteoarthritis, 
plica syndrome, patellar tendinitis, quadriceps tendinitis and Osgood-Schlatter’s disease. 
Dursun et al.28 studied the effect of electromyographic (EMG) feedback rather than our 
interventions of interest; and the other trials studied a combination of interventions and 
we were unable to extract the effect of exercise alone.72 73 78-80 82
Ongoing studies
There is one ongoing study that investigates the effect of lumbo pelvic stabilisation 
training in women with patellofemoral pain.83 This study includes women from 18 to 30 
years with patellofemoral pain. The women allocated to the experimental group carry 
out strengthening exercises for the lumbo-pelvic muscles as well as functional training 
to correct any dynamic lower limb misalignment. The control group receives a conven-
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tional treatment focusing on quadriceps strengthening and stretching of the lower limb 
muscles. Both groups perform the activities three times a week for eight consecutive 
weeks.
Studies awaiting classification
Erel and Ozakn.37 is reported in Turkish and is awaiting classification pending translation.
Risk of bias in included studies
We explicitly judged all criteria using: low risk of bias; high risk of bias; and unclear risk of 
bias (where ’unclear’ relates to a lack of information or uncertainty over the potential for 
bias). Full details of the risk of bias for the 31 trials are provided in Figure 2 and Figure 3.
Allocation
Random sequence generation was applied in 16 out of 31 trials and was mainly done 
by computer-generated lists.17 27 41 43-47 50-54 57 58 60 Six trials were quasi randomized.61-66 
Allocation of the participants was concealed in 12 out of 31 trials mainly by using 
sealed and opaque envelopes.17 27 41 44 46 47 51 53 54 57 58 60 Eight trials were at high risk of 
allocation bias43 45 61-66, because of matching, because the randomization was done by 
the physiotherapist/investigator or because allocation concealment was highly unlikely 
in quasi-randomised trials. In the remaining 11 trials the process of allocation was not 
specified or unclear.
Blinding
Blinding of personnel was impractical due to the nature of the intervention, and while 
standardisation of interactions between personnel and patients (i.e. use of standardised 
scripts) would have been possible, none of the included studies took this approach. Five 
studies attempted to address performance bias by means of blinding the patients. Abd 
Elhafz et al.38 stated that patients were unaware about the number of groups, randomisa-
tion technique or interventions for each group. De Marche et al.44 and Nakagawa et al.54 
reported that patients were blinded to group allocation. In Khayambashi et al.63, partici-
pants were aware of an alternative treatment group in the study but had no knowledge 
of intervention details. In Taylor et al.58, participants were aware that they were receiving 
what was believed to be ’real’ treatments, but were not aware of which treatment was 
considered better by those delivering the treatments or collecting data. As the success 
of these measures was uncertain, we rated all as unclear for performance bias. We rated 
the other studies as high risk on this criterion. The risk of detection bias is inevitably high 
for studies where patients who have not been blinded to interventions self report on 
outcomes; but we rated the risk as unclear in four of the five studies when patient blind-
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Figure 2. ‘Risk of bias’ summary: review 
authors’ judgement about each risk of bias 
item for each included study
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ing had been attempted.38 54 58 63 We rated the other study reporting patient blinding at 
high risk because assessor blinding was not done for functional performance.44
Incomplete outcome data
We judged incomplete outcome data on three items. We considered a dropout rate 
greater than 20% in the short-term or greater than 30% on follow-up at 12 months or 
longer, cross-over or dropout due to adverse events to be high risk criteria if no reliable 
intention-to-treat analysis was carried out. We rated 15 trials low risk since they reported 
no cross-overs and low dropout rates.17 27 38 44 46 47 51 53-55 57 58 60 64 66 We rated six trials high 
risk as they reported a high dropout rate, cross-overs or dropouts due to adverse events 
and did not report an intention-to treat-analysis.29 40 50 52 61 62 Avraham et al.40 reported 
29% dropout in the short-term and no intention-to-treat analysis. In Colón et al.61, a pa-
tient dropped out due to increased pain after the intervention, and no intention-to-treat 
analysis was reported. Eburne and Bannister.62 reported 29% dropout in the short-term 
and no intention-to-treat analysis. Gobelet et al.29 reported 22% dropout, not equally 
distributed among groups: 12 patients stopped because of ineffectiveness of treatment 
and no intention-to-treat analysis was reported. Harrison et al.50 reported a 33% dropout 
in the short-term, 48% dropout at 12 months and no intention-to-treat analysis. Lun et 
al.52 reported that two participants crossed over to another treatment group before three 
months. These were considered to be withdrawals from the study and no intention-to-
treat analysis was reported. We rated one trial high risk because they reported an 18% 
dropout rate in the short-term, a withdrawal by the investigators for increased pain and 
an unreliable imputation method.45 They carried out the last available measure moved 
forward method, which is generally considered conservative, but there are more reliable 
methods such as multiple imputation.84 We rated the remaining nine trials unclear as no 
further details were reported.
Figure 3. ‘Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as percent-
age across all included studies
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Selective reporting
None of the trials, except Van Linschoten et al.27, published a study protocol. We con-
sidered any outcomes of pain and functional ability to be expected outcomes and they 
had to be reported at all time points in order to get a low risk rating. One study did not 
report any of these expected outcomes and we therefore rated it high risk.61 Khayam-
bashi et al.63 did not provide long-term (six months) results on pain or functional ability 
for the comparator group and we also rated it high risk. We rated eight studies unclear 
risk.29 38 39 41 54 55 62 66 Two studies did not report pain data29 39 and six studies did not report 
functional ability data.38 41 54 55 62 66 The remaining 21 trials did report pain and functional 
ability data at all time points listed in their methods and we therefore rated them low 
risk.
Other potential sources of bias
We judged all studies on four potential other sources of bias: difference in baseline 
characteristics, comparability in clinician’s experience with the interventions under test, 
differences in care other than the interventions and compliance with therapy. We rated 
a total of 17 trials low risk. Twelve trials reported no significant statistical difference in 
demographic variables and outcome variables.17 41 43 46 47 51 53 54 57 60 63 64 Five trials reported 
no statistical significant difference in demographic variables, but did not statistically test 
the difference in outcome variables.27 39 45 50 52 Their outcome values seemed similar and 
therefore we also rated them low risk. We rated six trials high risk since demographics or 
outcome variables were statistically different or did not seem to be similar.42 44 48 56 62 65 In 
Balci et al.42, the groups differed in height. BMI was not statistically tested, but the differ-
ence between groups was 2.3 points. Gaffney et al.48 reported a significant difference in 
BMI attributed to the fact that there were slightly more females and some 11 to 13 years 
old in the concentric group. Eburne and Bannister.62 reported a significant difference 
between groups for age. The duration of complaints between groups in the study of 
De Marche et al.44 seemed to be rather different with a remarkably higher duration of 
complaints in the stabilisation group. The VAS in the physiotherapy group was higher 
compared with the other two groups in the study of Loudon et al.65 In Schneider et al.56, 
there was a difference in VAS at rest across groups. Hafez et al.49 did report comparable 
baseline outcome data, but did not report demographics and we rated it unclear. The 
remaining seven trials did not report on demographics or outcome variables and we 
therefore rated them unclear. Only Fukuda et al.46 47 and Witvrouw et al.17 reported that 
the therapists were trained and we therefore rated them low risk. We rated Eburne and 
Bannister.62 high risk as there were two changes of therapist in the McConnell and three 
in the isometric quadriceps group. The remaining trials did not report comparability of 
clinician’s experience with the interventions under test. We rated three studies low risk 
as they reported on co-interventions and the comparability across groups in individual 
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studies. Abrahams et al.39 excluded participants who started a co-intervention. Van 
Linschoten et al.27 reported that other interventions, like the use of bandages or braces, 
insoles or ice application, or consumption of medication other than simple analgesics, 
were allowed in both groups (despite from exercise therapy in the control group) and 
equally used. Witvrouw et al.17 reported that no medication was prescribed as part of 
their treatment. No brace or tape was used by any patient in this study. We rated the re-
maining trials unclear. Compliance was adequately reported in eight trials and we rated 
these low risk.17 Gaffney et al.48 reported a self reported compliance of 86% in eccentric 
and 88% in concentric programmes. Fukuda et al.46 47 excluded patients if they missed 
treatment sessions. In Khayambashi et al.64, all participants were required to complete 
at least 19 out of the 24 treatment sessions (= 80%) to remain in the study. In addition, 
if a patient missed three consecutive treatment sessions, their participation in the study 
was terminated. All participants completed the required number of treatment sessions. 
Loudon et al.65 asked participants to keep a diary and excluded those who did not com-
plete 90% of the exercise programme. Lun et al.52 asked participants to document in a 
journal when the exercises were done and/or when the brace or sleeve was worn. These 
journals were submitted to the second research assistant on a monthly basis. Overall, 
the compliance was very good and similar among all treatment groups. Song et al.57 
reported that all exercise intervention participants except one attended all scheduled 
exercise sessions. One participant in the knee exercises only group completed only half 
of the intervention and subsequently dropped out of the study due to work commit-
ments. Witvrouw et al17 reported that every patient followed the exercise programme for 
the required period of five weeks. Four trials reported a method for aiding compliance 
but did not report the actual compliance at the end of the intervention.27 41 43 45 The 
remaining nine trials did not report on compliance.
Effects of interventions
See: Summary of findings for the main comparison (Appendix 2). Exercise therapy 
compared with a control strategy (no treatment, placebo or waiting list controls) for 
patellofemoral pain syndrome; Summary of findings 2 (Appendix 2) Supervised exer-
cises compared with home exercises for patellofemoral pain syndrome; Summary of 
findings 3(Appendix 2) Closed kinetic chain exercises compared with open kinetic chain 
exercises for patellofemoral pain syndrome; Summary of findings 4(Appendix 2) Target 
of exercise: hip + knee versus knee exercises for treating patellofemoral pain syndrome; 
Summary of findings 5(Appendix 2) Target of exercise: hip versus knee exercises for treat-
ing patellofemoral pain syndrome; Summary of findings 6(Appendix 2) High-intensity 
versus low intensity exercise programmes for patellofemoral pain syndrome.
54 Chapter 2
Exercise therapy versus control (no treatment, placebo or waiting list controls)
Ten studies compared exercise therapy with a control strategy (no treatment, placebo or 
waiting list controls).27 39 43 46 51-53 57 58 65 In the analyses, these are subgrouped according 
to the main characteristic of exercise therapy. Although, with the exception of Abra-
hams et al.39, we have pooled the results of these heterogeneous studies, the pooled 
result should be taken as illustrative, especially where the heterogeneity is statistically 
significant. We presented Abrahams et al.39 in a separate analysis (malalignment group) 
because of clear clinical heterogeneity since participants also had to be diagnosed 
with malalignment. Where a trial tested two separate exercise interventions and one 
control group, we split the data in the control group so that the individual results of the 
each intervention could be presented while avoiding double counting of those in the 
control group.46 51 57 We extracted standard deviations for pain and function51 from error 
bars, which we interpreted to be standard deviations (SDs), in graphs presented in the 
publications of this trial.
Knee pain in the short term
During activity (0 to 10 scale; higher scores mean worse pain)
Pooled data from five studies27 43 46 51 52 (375 participants) showed a mean difference (MD) 
of -1.46 favouring exercise therapy, 95% confidence interval (CI) -2.39 to -0.54, P value = 
0.002, random-effects model used due to statistical heterogeneity (P value = 0.0003; I² 
= 74%); very low quality evidence due to risk of bias, imprecision and inconsistency; see 
Analysis 1.1. The results were homogeneous (P value = 0.55 and I2 = 0%) upon removal 
of Herrington et al.51, but with a reduced effect size (MD -0.76, 95% CI -1.26 to -0.25, P 
value = 0.003).
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ANALYSIS 1.1 Exercise therapy versus control, outcome: 1.1 Sum: pain during activity continuous short-
term
usual pain (0 to 10 scale; higher scores mean worse pain)
Pooled data from two studies58 65 (41 participants) showed a standardised mean differ-
ence (SMD) of -0.93 favouring exercise therapy, 95% CI -1.60 to -0.25, P value = 0.007; 
very low quality evidence due to serious risk of bias and imprecision; see Analysis 1.2.
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ANALYSIS 1.2 Comparison I Exercise therapy versus control, outcome 2 Usual pain (short term)
Worst pain (0 to 10 scale; higher scores mean worse pain)
Pooled data from two studies57 58 (91 participants) resulted in a MD of -2.28 favouring 
exercise therapy, 95% CI -3.33 to -1.23, P value < 0.0001; low quality evidence due to risk 
of bias and imprecision; see Analysis 1.3.
ANALYSIS 1.3 Comparison I Exercise therapy versus control, outcome 3 Worst pain (short term)
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Knee pain in the long term
During activity (0 to 10 scale; higher scores mean worse pain)
Pooled data from two studies27 43 (180 participants) resulted in a MD of -1.07 favouring 
exercise therapy, 95% CI -1.93 to -0.21, P value = 0.01; very low quality evidence due to 
serious risk of bias and imprecision; see Analysis 1.4.
ANALYSIS 1.4 Comparison I Exercise therapy versus control, outcome 4 Pain during activity (short term)
usual pain (visual analogue scale (vas) 0 to 10; higher scores mean worse pain)
Pooled data from two exercise interventions tested by one study53 (94 participants) 
showed a MD of -4.32 favouring exercise therapy, 95% CI -7.75 to -0.89, P value < 0.00001; 
random-effects model used due to statistical heterogeneity (heterogeneity P value < 
0.00001, I² = 97%); very low quality evidence due to risk of bias and serious imprecision; 
see Analysis 1.5.
ANALYSIS 1.5 Comparison I Exercise therapy versus control, outcome 5 Usual pain (long term)
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Functional ability in the short term (0 to 100 scale; modified Functional Index 
Questionnaire (MFIQ) 0 to 16; higher scores mean better function)
Based on a 0 to 100 scale (higher scores mean better function), pooled data from seven 
studies27 43 46 51 52 57 65 (483 participants) showed a SMD of 1.10 favouring exercise therapy, 
95% CI 0.58 to 1.63, P value < 0.0001, random-effects model used due to statistical 
heterogeneity (P value < 0.00001, I² = 83%); very low quality evidence due to risk of bias 
and serious inconsistency; see Analysis 1.6. The results did not became homogeneous 
after excluding any single study.
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ANALYSIS 1.6 Comparison I Exercise therapy versus control, outcome 6 Functional ability (short term)
Based on the MFIQ (0 to 16), Abrahams et al.39 (78 participants) reported a MD of -1.90, 
favouring a control strategy, 95% CI -3.24 to -0.56, P value = 0.005; very low quality 
evidence due to risk of bias and serious imprecision; see Analysis 1.7.
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ANALYSIS 1.7 Comparison I Exercise therapy versus control, outcome 7 Functional ability (short term), all 
participants had malalignment
Functional ability in the long term (0 to 100 scale; patient specific function scale; higher 
scores mean better function)
Pooled data from three studies27 43 53 (274 participants) resulted in a SMD of 1.62, favour-
ing exercise therapy, 95% CI 0.31 to 2.94, P value = 0.02; random-effects model used due 
to statistical heterogeneity (heterogeneity P value < 0.00001, I² = 94%); very low quality 
evidence due to risk of bias, imprecision and inconsistency; see Analysis 1.8. The results 
were homogeneous (I² = 0%) upon removal of Moyano et al.53, but smaller in effect size 
(SMD0.27, 95%CI -0.02 to 0.56, P value = 0.07). Taylor et al.58 (12 participants) reported 
that there were no statistically significant differences between groups for patient spe-
cific function scale scores for three different activities.
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ANALYSIS 1.8 Comparison I Exercise therapy versus control, outcome 8 Functional ability (long term)
Functional performance in the short term (single-limb hop test; bilateral squat)
Fukuda et al.46 (64 participants) reported for the single-limb hop test a MD of 8.73 cm fa-
vouring exercise therapy, 95% CI -3.35 to 20.80, P value = 0.16; very low quality evidence 
due to risk of bias and serious imprecision; see Analysis 1.9.
ANALYSIS 1.9 Comparison I Exercise therapy versus control, outcome 9 Functional performance (short 
term), single leg hop test
Loudon et al.65 (29 participants) reported for the bilateral squat test (number completed 
in 30 seconds) a MD of 1.08 favouring exercise therapy, 95% CI -1.68 to 3.84, P value = 
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0.44; very low quality evidence due to serious risk of bias and serious imprecision; see 
Analysis 1.10.
Full data were not available for the four other functional performance tests, based on 
limb symmetry index, measured by Loudon et al.65 (29 participants): anteromedial lunge, 
step-down dip, leg press, and balance and reach.
ANALYSIS 1.10 Comparison I Exercise therapy versus control, outcome 10 Functional performance (short 
term), bilateral squat test
Recovery in the short term (number of participants no longer troubled by symptoms)
Van Linschoten et al.27 (122 participants) reported that 26/62 participants in the exercise 
group versus 21/60 participants in the tape group were no longer troubled by pain at 
three months; risk ratio (RR) 1.20 favouring exercise therapy, 95% CI 0.76 to 1.88, P value 
= 0.43; very low quality evidence due to risk of bias and serious imprecision; see Analysis 
1.11.
ANALYSIS 1.11 Comparison I Exercise therapy versus control, outcome 11 Recovery (short term)
Recovery in the long term (number of patients recovered and number of patients no 
longer troubled by symptoms)
Pooled data from two studies27 43 (166 participants) reported that 45/80 participants in 
the exercise group versus 35/86 participants in the tape group were no longer troubled 
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by pain at 12months;RR1.35 favouring exercise therapy, 95% CI 0.99 to 1.84, P value = 
0.06; very low quality evidence due to serious risk of bias and imprecision; see Analysis 
1.12.
ANALYSIS 1.12 Comparison I Exercise therapy versus control, outcome 12 Recovery (long term)
Adverse events
Taylor et al.58 reported no harmful side effects.
Exercise therapy versus different conservative treatments: exercise therapy versus 
unimodal conservative interventions
For convenience, the available data for five different comparisons, tested within four 
trials29 43 52 63, are presented together in Analyses 2.1 to 2.5 but without pooling. The five 
comparisons are presented in turn below. None of the four trials reported on functional 
performance or adverse events.
Hip exercises versus 1000 mg of Omega-3 and 400 mg of calcium
One study evaluated this comparison.63 It did not report on functional performance 
or aspects of recovery and did not provide long-term (six months) results on pain or 
functional ability for the comparator group.
Knee pain in the short term
During activity (vas 0 to 10; higher scores mean worse pain)
Khayambashi et al.63 (28 participants) reported a MD of -5.30 favouring hip exercises, 
95%CI -6.90 to -3.70, P value < 0.00001; very low quality evidence due to serious risk of 
bias and serous imprecision; see Analysis 2.1.
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Functional ability in the short term (WOMAC 0 to 96) (inverted score; higher scores mean 
better function)
Khayambashi et al.63 (28 participants) reported a MD of 49.20 favouring hip exercises, 
95%CI 38.49 to 59.91, P value < 0.00001; very low quality evidence due to serious risk of 
bias and serious imprecision; see Analysis 2.3.
Adverse events
Khayambashi et al.63 stated that no adverse effects were reported.
Home exercise programme versus brace
The one study making this comparison did not report on long-term outcome, functional 
performance, aspects of recovery or adverse events.52
Knee pain in the short term
During activity (vas 0 to 10; higher scores mean worse pain)
Lun et al.52 (66 participants) reported a MD of 0.20 favouring bracing, 95% CI -0.82 to 
1.22, P value = 0.70; very low quality evidence due to risk of bias and serious imprecision; 
see Analysis 2.1.
Functional ability in the short term (function scale 0 to 53; higher scores mean better 
function)
Lun et al.52 (66 participants) reported a MD of 2.00 favouring a home exercise programme, 
95% CI -1.88 to 5.88, P value = 0.31; very low quality evidence due to risk of bias and 
serious imprecision; see Analysis 2.3.
Exercise therapy versus tape
One study made this comparison.43 It did not report on functional performance or 
adverse events.
Knee pain in the short term
During activity (vas 0 to 200; higher scores mean worse pain)
Clark et al.43 (34 participants) reported a MD of -27.80 favouring exercise therapy, 95%CI 
-54.29 to -1.31, P value = 0.04; very low quality evidence due to serious risk of bias and 
serious imprecision; see Analysis 2.1.
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ANALYSIS 2.1 Comparison 2 Exercise therapy versus unimodal conservative interventions, Outcome 1 pain 
during activity (short term)
Knee pain in the long term
During activity (vas 0 to 200; higher scores mean worse pain)
Clark et al.43 (24 participants) reported a MD of -39.50 favouring exercise therapy, 95% 
CI -82.69 to 3.69, P value = 0.07; very low quality evidence due to serious risk of bias and 
serious imprecision; see Analysis 2.2.
ANALYSIS 2.2 Comparison 2 Exercise therapy versus unimodal conservative interventions, Outcome 2 pain 
during activity (long term)
Functional ability in the short term (WOMAC 0 to 96) (inverted score; higher scores mean 
better function)
Clark et al.43 (34 participants) reported a MD of 10.90 favouring exercise therapy, 95% 
CI 1.70 to 20.10, P value = 0.02; very low quality evidence due to serious risk of bias and 
serious imprecision; see Analysis 2.3.
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ANALYSIS 2.3 Comparison 2 Exercise therapy versus unimodal conservative interventions, Outcome 3 
Functional ability in the short term (short term)
Functional ability in the long term (WOMAC 0 to 96) (inverted scores; higher scores mean 
better function)
Clark et al.43 (24 participants) reported a MD of 12.00 favouring exercise therapy, 95% CI 
-3.78 to 27.78, P value = 0.14; very low quality evidence due to serious risk of bias and 
serious imprecision; see Analysis 2.4.
ANALYSIS 2.4 Comparison 2 Exercise therapy versus unimodal conservative interventions, Outcome 4 
Functional ability (long term)
Recovery (number of participants no longer troubled by symptoms)
Clark et al.43 reported that 5/12 participants in the exercise group versus 3/12 partici-
pants in the tape group were no longer troubled by pain at 12 months; RR 1.6 favouring 
exercise therapy, 95% CI 0.51 to 5.46, P value = 0.40; very low quality evidence due to 
serious risk of bias and serious imprecision; see Analysis 2.5.
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ANALYSIS 2.5 Comparison 2 Exercise therapy versus unimodal conservative interventions, Outcome 5 Re-
covery (long term)
Isometric exercises versus muscle electrostimulation
The one study making this comparison did not report on long-term outcome, knee pain 
(during activity, usual or worse), functional performance, aspects of recovery or adverse 
events.29
Functional ability in the short term (Arpège function scale 0 to 18; higher scores mean 
better function)
Gobelet et al.29 (54 participants) reported a MD of 0.70 favouring isometric exercises, 
95%CI -0.63 to 2.03, P value = 0.30; very low quality evidence due to serious risk of bias 
and serious imprecision; see Analysis 2.3.
Isokinetic exercises versus muscle electrostimulation
The one study making this comparison did not report on long-term outcome, knee pain 
(during activity, usual or worse), functional performance, aspects of recovery or adverse 
events.29
Functional ability in the short term (Arpège function scale 0 to 18; higher scores mean 
better function)
Gobelet et al.29 (68 participants) reported a MD of 1.10 favouring isokinetic exercises, 
95%CI -0.18 to 2.38, P value = 0.09; very low quality evidence due to serious risk of bias 
and serious imprecision; see Analysis 2.3
Exercise therapy versus different conservative treatments: exercise therapy versus 
multimodal conservative interventions
For convenience, the available data for five different comparisons, tested within four 
trials48 50 56 62, are presented together in Analyses 3.1 to 3.5 but without pooling. The five 
comparisons are presented in turn below. None of the four trials reported on functional 
performance. Only Eburne and Bannister.62 reported on adverse events but did not 
report on denominators. Harrison et al.50 presented functional ability via a Functional 
Index Questionnaire (FIQ) modified score and a non-validated patellofemoral scale. 
Therefore the FIQ is presented.
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Isometric quadriceps exercises versus McConnell regimen including exercises and tape
One study made this comparison.62 It did not report on long-term outcome, knee pain 
during activity, usual pain or worse pain, functional ability or functional performance.
Knee pain in the short term
pain experienced at four different positions of the knee
Eburne and Bannister.62 (53 participants) reported that a positive McConnell critical 
test (pain experienced at four different positions of the knee) was “abolished” in 25% of 
participants in the isometric exercises group and 30% in the McConnell regimen group; 
very low quality evidence due to serious risk of bias and imprecision.
Recovery in the short term
Eburne and Bannister.62 concluded that there was improvement in 50% of each group; 
very low quality evidence due to serious risk of bias, indirectness and imprecision.
Adverse events
Eburne and Bannister.62 (75 participants) did not report the numbers assigned. However 
one participant was withdrawn from the trial for surgery (group not stated) and “three 
due to severe allergy to the strapping” (presumably in the McConnell regimen group); 
very low quality evidence due to serious risk of bias and imprecision.
Supervised exercise programme versus vastus medius specific exercise programme plus 
taping
The one study making this comparison did not report on adverse events.50
Knee pain in the short term
usual pain (vas 0 to 10; higher scores mean worse pain)
Harrison et al.50 (40 participants) reported a MD of -0.01 favouring supervised exercise, 
95% CI -1.08 to 1.06, P value = 0.99; very low quality evidence due to risk of bias and 
serious imprecision; see Analysis 3.1.
Worst pain (vas 0 to 10; higher scores mean worse pain)
Harrison et al.50 (40 participants) reported a MD of -0.53 favouring supervised exercise, 
95% CI -2.09 to 1.03, P value = 0.50; very low quality evidence due to risk of bias and 
serious imprecision; see Analysis 3.1.
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ANALYSIS 3.1 Comparison 3 Exercise therapy versus multimodal conservative interventions, Outcome 1 
Pain (short term)
Knee pain in the long term
usual pain (vas 0 to 10; higher scores mean worse pain)
Harrison et al.50 (31 participants) reported a MD of 0.24 favouring vastus medius specific 
supervised exercise plus tape, 95%CI -0.88 to 1.36, P value = 0.68; very low quality evi-
dence due to risk of bias and serious imprecision; see Analysis 3.2.
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Worst pain (vas 0 to 10; higher scores mean worse pain)
Harrison et al.50 (31 participants) reported a MD of 0.41 favouring vastus medius specific 
supervised exercise plus tape, 95%CI -1.61 to 2.43, P value = 0.69; very low quality evi-
dence due to risk of bias and serious imprecision; see Analysis 3.2.
ANALYSIS 3.2 Comparison 3 Exercise therapy versus multimodal conservative interventions, Outcome 2 
Pain (long term)
Functional ability in the short term (FIQ modified 0 to 16 scale; higher scores mean better 
function)
Harrison et al.50 (54 participants) presented the numbers of participants with scores split 
into four FIQ categories (0 to 4, 5 to 8, 9 to 12, 13 to 16). Although we present the data 
for those in the top (13 to 16, best function) category, the ordinal nature of the data and 
extent of the loss to follow-up in both groups raises serious questions as to the validity 
of these results (6/24 versus 17/28; RR 0.41 favouring a vastus medius specific exercise 
programme plus taping, 95% CI 0.19 to 0.88, P value = 0.02; very low quality evidence 
due to risk of bias, indirectness and serious imprecision; see Analysis 3.3.
ANALYSIS 3.3 Comparison 3 Exercise therapy versus multimodal conservative interventions, Outcome 3 
Functional ability (short term)
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Functional ability in the long term (FIQ modified 0 to 16 scale; higher scores mean better 
function)
As described above, Harrison et al.50 (33 participants) presented modified FIQ data split 
into four categories. The results for participants in the best function category (13 to 16) 
were: 11/13 versus 14/20; RR 1.21 favouring a supervised exercise programme, 95% CI 
0.84 to 1.75, P value = 0.31; very low quality evidence due to risk of bias, indirectness and 
serious imprecision; see Analysis 3.4.
ANALYSIS 3.4 Comparison 3 Exercise therapy versus multimodal conservative interventions, Outcome 4 
Functional ability (long term)
ANALYSIS 3.5 Comparison 3 Exercise therapy versus multimodal conservative interventions, Outcome 5 
Recovery (short term)
Functional performance in the short term (step test)
Harrison et al.50 (44 participants) performed a step test (time until pain) and reported a 
MD of 0.00 seconds favouring neither intervention, 95%CI -60.72 to 60.72, P value = 1.00; 
very low quality evidence due to risk of bias and serious imprecision; see Analysis 3.6.
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ANALYSIS 3.6 Comparison 3 Exercise therapy versus multimodal conservative interventions, Outcome 6 
Functional performance (short term)
Functional performance in the long term (step test)
Harrison et al.50 (34 participants) performed a step test (time until pain) and reported a 
MD of -5.00 seconds favouring a vastus medius specific exercise programme plus taping, 
95% CI -70.14 to 60.14, P value = 0.88; very low quality evidence due to risk of bias and 
serious imprecision; see Analysis 3.7.
ANALYSIS 3.7 Comparison 3 Exercise therapy versus multimodal conservative interventions, Outcome 7 
Functional performance (long term)
Recovery in the short term
Harrison et al.50 (54 participants) reported that 6/29 participants in the supervised 
exercise programme versus 17/25 participants in the vastus medius specific exercise 
programme plus taping reported significant improvement; RR 0.30 favouring the vastus 
medius specific exercise programme plus taping, 95% CI 0.14 to 0.65, P value = 0.002; 
very low quality evidence due to serious risk of bias, indirectness and imprecision; see 
Analysis 3.5.
Home exercise programme versus vastus medius specific exercise programme plus taping
The one study making this comparison did not report on adverse events.50
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Knee pain in the short term
usual pain (vas 0 to 10; higher scores mean worse pain)
Harrison et al.50 (42 participants) reported a MD of 0.55 favouring vastus medius specific 
supervised exercise plus tape, 95%CI -0.65 to 1.75, P value = 0.37; very low quality evi-
dence due to risk of bias and serious imprecision; see Analysis 3.1.
Worst pain (vas 0 to 10; higher scores mean worse pain)
Harrison et al.50 (42 participants) reported a MD of -0.31 favouring home exercise, 95% 
CI -1.96 to 1.34, P value = 0.71; very low quality evidence due to risk of bias and serious 
imprecision; see Analysis 3.1.
Knee pain in the long term
usual pain (vas 0 to 10; higher scores mean worse pain)
Harrison et al.50 (36 participants) reported a MD of 0.67 favouring vastus medius specific 
supervised exercise plus tape, 95%CI -0.58 to 1.92, P value = 0.29; very low quality evi-
dence due to risk of bias and serious imprecision; see Analysis 3.2.
Worst pain (vas 0 to 10; higher scores mean worse pain)
Harrison et al.50 (36 participants) reported a MD of 0.21 favouring vastus medius specific 
supervised exercise plus tape, 95%CI -1.76 to 2.18, P value 0.83; very low quality evi-
dence due to risk of bias and serious imprecision; see Analysis 3.2.
Functional ability in the short term (FIQ modified 0 to 16 scale; higher scores mean better 
function)
Harrison et al.50 (52 participants) presented the numbers of participants with scores split 
into four FIQ categories (0 to 4, 5 to 8, 9 to 12, 13 to 16). Although we present the data 
for those in the top (13 to 16, best function) category, the ordinal nature of the data 
and extent of the loss to follow-up in both groups raises serious questions as to the 
validity of these results (13/24 versus 17/28; RR 0.89 favouring the vastus medius specific 
exercise programme plus taping, 95% CI 0.56 to 1.43, P value = 0.64; very low quality 
evidence due to risk of bias, indirectness and serious imprecision; see Analysis 3.3.
Functional ability in the long term (FIQ modified 0 to 16 scale; higher scores mean better 
function)
As described above, Harrison et al.50 (39 participants) presented modified FIQ data 
split into four categories. The results for participants in the best function category (13 
to 16) were: 12/19 versus 14/20; RR 0.90 favouring the vastus medius specific exercise 
programme plus taping, 95%CI 0.58 to 1.41, P value = 0.65; very low quality evidence 
due to risk of bias, indirectness and serious imprecision; see Analysis 3.4.
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Functional performance in the short term (step test)
Harrison et al.50 (45 participants) performed a step test (time until pain) and reported 
a MD of -24.00 seconds favouring the vastus medius specific exercise programme plus 
taping, 95% CI -90.27 to 42.27, P value = 0.48; very low quality evidence due to risk of 
bias and serious imprecision; see Analysis 3.6.
Functional performance in the long term (step test)
Harrison et al.50 (31 participants) performed a step test (time until pain) and reported 
a MD of -54.00 seconds favouring the vastus medius specific exercise programme plus 
taping, 95% CI -120.88 to 12.88, P value = 0.11; very low quality evidence due to risk of 
bias and serious imprecision; see Analysis 3.7.
Recovery in the short term
Harrison et al.50 (54 participants) reported that 9/29 participants in the home exercise 
programme versus 17/25 participants in the vastus medius specific exercise programme 
plus taping reported significant improvement; RR 0.46 favouring the vastus medius 
specific exercise programme plus taping, 95% CI 0.25 to 0.84, P value = 0.001; very low 
quality evidence due to serious risk of bias, indirectness and imprecision; see Analysis 
3.5.
Concentric exercises versus eccentric exercises and tape
One study made this comparison.48 It did not report on long-term outcome, functional 
performance or adverse events.
Knee pain in the short term
Worst pain (vas 0 to 10; higher scores mean worse pain)
Gaffney et al.48 (60 participants) reported no significant between group difference in 
mean maximum pain values (concentric 2.64 versus eccentric 2.86); very low quality 
evidence due to serious risk of bias and imprecision.
Functional ability in the short term (number of patients improved)
Gaffney et al.48 (60 participants) reported that 15/32 in the concentric exercises and 
18/28 in the eccentric plus tape group had improved function; RR 0.73 favouring the 
eccentric plus tape group, 95% CI 0.46 to 1.16, P value = 0.18; very low quality evidence 
due to serious risk of bias and imprecision; see Analysis 3.3.
Recovery in the short term (participant-rated success)
Gaffney et al.48 (60 participants) reported that 24/32 in the concentric exercises and 
25/28 in the eccentric plus tape group rated their outcome as a success; RR 0.84 favour-
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ing the eccentric plus tape group, 95% CI 0.66 to 1.07, P value = 0.15; very low quality 
evidence due to serious risk of bias, indirectness and imprecision; see Analysis 3.3.
Physiotherapeutic exercises based on proprioceptive neuromuscular facilitation versus 
special knee splint combined with exercises
One study (40 participants) made this comparison.56 It did not report on long-term 
outcome, knee pain during activity, usual pain or worse pain, functional performance, 
aspects of recovery or adverse events.
Knee pain in the short term
pain at rest and pain after exposure (vas 0 to 10; higher scores mean worse pain)
Schneider et al.56 (40 participants) reported on knee pain at rest and “after exposure” 
to some muscle tests. Schneider et al.56 reported a MD of 0.80 favouring special knee 
splint and exercises for pain at rest, 95% CI -0.26 to 1.86, P value = 0.83; very low quality 
evidence due to serious risk of bias and serious imprecision; see Analysis 3.1
For pain after exposure, Schneider et al.56 reported a MD of 3.20 favouring special knee 
splint and exercises for pain at rest, 95% CI 2.38 to 4.02, P value < 0.00001; very low 
quality evidence due to serious risk of bias and serious imprecision; see Analysis 3.1.
Functional ability in the short term (Bessette and Hunter score: 0 to 100; higher scores 
mean better function)
Schneider et al.56 (40 participants) reported significant improvements in both groups 
from53 to 69 points in the physiotherapeutic exercises based on proprioceptive neu-
romuscular facilitation group and from 53 to 72 points in the group receiving a special 
knee splint combined with exercises. However, Schneider et al.56 did not report SDs for 
the Bessette and Hunter score; very low quality evidence due to serious risk of bias and 
lack of data.
Different modes of delivery of exercises or exercise programmes: Supervised versus home 
exercise programmes
Two studies compared supervised with home exercise programmes.50 65 Harrison et al.50 
reported functional ability using a modified FIQ and a non-validated patellofemoral 
scale; only the modified FIQ is presented below. Neither study reported on adverse 
events. We obtained missing standard deviations for pain and function for Loudon et 
al.65
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Knee pain in the short term
usual pain (vas 0 to 10; higher scores mean worse pain)
Pooled data from two studies50 65 (59 participants) showed a MD of -0.22 favouring a 
supervised exercise programme, 95%CI -1.22 to 0.77, P value = 0.66; very low quality 
evidence due to risk of bias and serious imprecision; see Analysis 4.1.
ANALYSIS 4.1 Comparison 4 Delivery of exercise: supervised versus home exercise program, Outcome 1 
Usual pain (short term)
Worst pain (vas 0 to 10; higher scores mean worse pain)
Harrison et al.50 (42 participants) reported a MD of -0.22 favouring a supervised exercise 
programme, 95% CI -1.88 to 1.44, P value = 0.79; very low quality evidence due to risk of 
bias and serious imprecision; see Analysis 4.2.
ANALYSIS 4.2 Comparison 4 Delivery of exercise: supervised versus home exercise program, Outcome 2 
Worst pain (short term)
Knee pain in the long term
usual pain (vas 0 to 10; higher scores mean worse pain)
Harrison et al.50 (31 participants) reported a MD of -0.43 favouring a supervised exercise 
programme, 95% CI -1.84 to 0.98, P value = 0.55; very low quality evidence due to risk of 
bias and serious imprecision; see Analysis 4.3.
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ANALYSIS 4.3 Comparison 4 Delivery of exercise: supervised versus home exercise program, Outcome 3 
Pain (long term)
Worst pain (vas 0 to 10; higher scores mean worse pain)
Harrison et al.50 (31 participants) reported a MD of 0.20 favouring a home exercise pro-
gramme, 95% CI -1.93 to 2.33, P value = 0.85; very low quality evidence due to risk of bias 
and serious imprecision; see Analysis 4.3.
Functional ability in the short term (Anterior Knee Pain Score (AKPS) 0 to 100; modified 
FIQ 0 to 16; higher scores mean better function)
Loudon et al.65 (18 participants) measured the AKPS (higher scores mean better func-
tion) and reported a MD of -2.30 favouring a home exercise programme, 95% CI -11.33 to 
6.73, P value = 0.62; very low quality evidence due to serious risk of bias and imprecision; 
see Analysis 4.4.
ANALYSIS 4.4 Comparison 4 Delivery of exercise: supervised versus home exercise program, Outcome 4 
Functional ability (short term)
Harrison et al.50 (48 participants) presented the numbers of participants with scores split 
into four FIQ categories (0 to 4, 5 to 8, 9 to 12, 13 to 16). Although we present the data 
for those in the top (13 to 16, best function) category, the ordinal nature of the data and 
extent of the loss to follow-up in both groups raises serious questions as to the validity 
of these results (6/24 versus 13/ 24); RR 0.46 favouring the home exercise group, 95% CI 
0.21 to 1.01, P value = 0.05; very low quality evidence due to risk of bias, indirectness and 
serious imprecision; see Analysis 4.5.
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ANALYSIS 4.5 Comparison 4 Delivery of exercise: supervised versus home exercise program, Outcome 5 
Functional ability (short and long term)
Functional ability in the long term (modified FIQ 0 to 16; higher scores mean better 
function)
As described above, Harrison et al.50 presented modified FIQ data split into four catego-
ries. They reported a significant improvement in function scores for both groups but 
for even fewer participants at 12 months follow-up. The results for participants in the 
best function category (13 to 16) were: 11/13 versus 12/19; RR 1.34, 95%CI 0.89 to 2.03, 
P value = 0.17; very low quality evidence due to risk of bias, indirectness and serious 
imprecision; see Analysis 4.5.
Functional performance in the short term (step test, bilateral squat)
Harrison et al.50 (46 participants) performed a step test (time until pain) and reported 
a MD of 47.00 seconds favouring a supervised exercise programme, 95% CI -19.04 to 
113.04, P value = 0.16; very low quality evidence due to risk of bias and serious impreci-
sion; see Analysis 4.6.
ANALYSIS 4.6 Comparison 4 Delivery of exercise: supervised versus home exercise program, Outcome 6 
Functional performance (short term)
Loudon et al.65 (18 participants) performed the bilateral squat test (number completed 
in 30 seconds) and reported a MD of -3.90 favouring a home exercise programme, 95% 
CI -7.27 to -0.53, P value = 0.02; very low quality evidence due to serious risk of bias and 
serious imprecision; see Analysis 4.6.
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Full data were not available for the four other functional performance tests, based on 
limb symmetry index, measured by Loudon et al.65 (18 participants): anteromedial lunge, 
step-down dip, leg press, and balance and reach.
Functional performance in the long term (step test: time until pain)
Harrison et al.50 (31 participants) reported a MD of 49.00 seconds favouring a supervised 
exercise programme, 95% CI -27.73 to 125.73 seconds, P value = 0.21; very low quality 
evidence due to risk of bias and serious imprecision; see Analysis 4.7.
ANALYSIS 4.7 Comparison 4 Delivery of exercise: supervised versus home exercise program, Outcome 7 
Functional performance (long term)
Recovery in the short term
Harrison et al.50 (58 participants) reported that 9/29 participants in the home exercise 
programme versus 6/29 participants in the supervised exercise programme reported 
signifi cant improvement; RR 0.67 favouring a home exercise programme, 95% CI 0.27 
to 1.63, P value = 0.37; very low quality evidence due to serious risk of bias, indirectness 
and imprecision; see Analysis 4.8.
ANALYSIS 4.8 Comparison 4 Delivery of exercise: supervised versus home exercise program, Outcome 8 
Recovery (short term)
Medium of exercises or exercise programmes
There were no trials evaluating this comparison, i.e. water- versus land-based exercise.
Diff erent types of exercise or exercise programmes
Eleven studies compared diff erent types of exercises or exercise pro-
grammes.17 29 38 39 41 42 49 51 53 61 66 We grouped the seven diff erent comparisons into three 
groups defi ned according to type of kinetic chain exercise: closed kinetic chain exercises 
versus open kinetic chain exercises; variants of closed kinetic chain exercises; and open, 
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mixed or unspecified kinetic chain exercises subgrouped by type of muscle action. For 
convenience, these are presented subgrouped in the same forest plots, but without 
overall pooling. A comparison of proprioceptive neuromuscular facilitation stretching 
and aerobic exercise versus classic stretching and quadriceps exercises is presented 
separately.53
Recovery was not reported in any study making these comparisons.
Closed kinetic chain exercises versus open kinetic chain exercises
Four studies compared closed kinetic chain exercises versus open kinetic chain exer-
cises.17 38 41 51 None of the four studies reported on aspects of recovery or adverse events. 
We extracted standard deviations for pain and function51 and function17 from error bars, 
which we interpreted to be SDs, in graphs presented in the publications of these two 
trials.
Knee pain in the short term
pain during activity (vas 0 to 10; higher scores mean worse pain)
Pooled data from two studies17 51; (90 participants) showed a MD of 0.03 favouring open 
kinetic chain exercises, 95% CI -0.63 to 0.70, P value = 0.92; very low quality evidence 
due to risk of bias, inconsistency and serious imprecision; see Analysis 5.1.
ANALYSIS 5.1 Comparison 5 Types of exercise: closed kinetic chain exercises versus open kinetic chain 
exercises, Outcome 1 Pain during activity (short term)
usual pain (vas 0 to 10; higher scores mean worse pain)
Pooled data from three studies17 38 41; (122 participants) showed a MD of 0.20 favour-
ing open kinetic chain exercises, 95% CI -0.37 to 0.76, P value =0.38; very low quality 
evidence due to risk of bias and serious imprecision; see Analysis 5.2.
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ANALYSIS 5.2 Comparison 5 Types of exercise: closed kinetic chain exercises versus open kinetic chain 
exercises, Outcome 2 Usual pain (short term)
Worst pain (vas 0 to 10; higher scores mean worse pain)
Witvrouw et al.17 (60 participants) reported a MD of -0.10 favouring closed kinetic chain 
exercises, 95% CI -1.21 to 1.01, P value = 0.86; very low quality evidence due to risk of 
bias and serious imprecision; see Analysis 5.3.
ANALYSIS 5.3 Comparison 5 Types of exercise: closed kinetic chain exercises versus open kinetic chain 
exercises, Outcome 3 Worst pain (short term)
Knee pain in the long term (five years follow-up)
pain during activity (vas 0 to 10; higher scores mean worse pain)
Witvrouw et al.17 (49 participants) showed a MD of 2.10 favouring open kinetic chain 
exercises, 95% CI 1.08 to 3.12, P value <0.0001; very low quality evidence due to risk of 
bias and serious imprecision; see Analysis 5.4.
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ANALYSIS 5.4 Comparison 5 Types of exercise: closed kinetic chain exercises versus open kinetic chain 
exercises, Outcome 4 Pain (long term)
usual pain (vas 0 to 10; higher scores mean worse pain)
Witvrouw et al.17 (49 participants) reported a MD of 0.80 favouring open kinetic chain 
exercises, 95% CI 0.07 to 1.53, P value 0.03; very low quality evidence due to risk of bias 
and serious imprecision; see Analysis 5.4.
Worst pain (vas 0 to 10; higher scores mean worse pain)
Witvrouw et al.17 (49 participants) reported a MD 1.90 favouring open kinetic chain 
exercises, 95% CI 0.61 to 3.19, P value 0.004; very low quality evidence due to risk of bias 
and serious imprecision; see Analysis 5.4.
Functional ability in the short term (AKPS 0 to 100; higher scores mean better function)
Pooled data from two studies17 51; (90 participants) showed a MD of -3.51 favouring open 
kinetic chain exercises, 95% CI -7.84 to 0.82, P value = 0.11; very low quality evidence 
due to risk of bias, imprecision and inconsistency; see Analysis 5.5.
ANALYSIS 5.5 Comparison 5 Types of exercise: closed kinetic chain exercises versus open kinetic chain 
exercises, Outcome 5 Functional ability (short term)
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Functional ability in the long term (AKPS 0 to 100; higher scores mean better function)
Data from Witvrouw et al.17 (49 participants) showed a MD of -8.30 favouring open ki-
netic chain exercises, 95% CI -12.95 to -3.65, P value = 0.0005; very low quality evidence 
due to risk of bias and serious imprecision; see Analysis 5.6.
ANALYSIS 5.6 Comparison 5 Types of exercise: closed kinetic chain exercises versus open kinetic chain 
exercises, Outcome 6 Functional ability (long term)
Functional performance in the short term (step-up, stepdown, unilateral squat)
Witvrouw et al.17 (60 participants) reported that 22/30 participants in each group were 
without symptoms during the step-up test; RR 1.00 favouring neither intervention, 
95%CI 0.32 to 3.14, P value = 1.00; very low quality evidence due to risk of bias and 
serious imprecision; see Analysis 5.7.
Witvrouw et al.17 (60 participants) reported that 23/30 participants in the closed kinetic 
chain exercise group and 20/30 participants in the open kinetic chain exercise group 
were without symptoms during the step-down test; RR of 1.15 favouring closed kinetic 
chain exercises, 95% CI 0.83 to 1.59, P value = 0.39; very low quality evidence due to risk 
of bias and serious imprecision; see Analysis 5.7
Witvrouw et al.17 (60 participants) reported that 17/30 participants in the closed kinetic 
chain exercise group and 16/30 participants in the open kinetic chain exercise group 
were without symptoms during the unilateral squat test; RR 1.06 favouring closed ki-
netic chain exercises, 95% CI 0.67 to 1.68, P value = 0.80; very low quality evidence due 
to risk of bias and serious imprecision; see Analysis 5.7.
Witvrouw et al.17 also reported there were no significant differences between treatment 
groups for the triple jump test but did not provide supporting data.
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ANALYSIS 5.7 Comparison 5 Types of exercise: closed kinetic chain exercises versus open kinetic chain 
exercises, Outcome 7 Functional performance(short term)
Functional performance in the long term (triple jump test (cm), step-up (N of patients 
without symptoms) and stepdown (N of patients without symptoms))
Witvrouw et al.17 (49 participants) reported that 20/25 participants in the closed kinetic 
chain exercise group and 17/24 participants in the open kinetic chain exercise group 
were without symptoms during the step-down test; RR 1.13, favouring closed kinetic 
chain exercises, 95% CI 0.82 to 1.56, P value = 0.46; very low quality evidence due to risk 
of bias and serious imprecision; see Analysis 5.8.
Witvrouw et al.17 (49 participants) reported that 20/25 participants in the closed kinetic 
chain exercise group and 22/24 participants in the open kinetic chain exercise group 
were without symptoms during the step-up test; RR 0.87, favouring open kinetic chain 
exercises, 95% CI 0.69 to 1.10, P value = 0.25; very low quality evidence due to risk of bias 
and serious imprecision; see Analysis 5.8.
Witvrouw et al.17 also reported that there were no signifi cant diff erences between treat-
ment groups for the triple jump test but did not provide supporting data.
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ANALYSIS 5.8 Comparison 5 Types of exercise: closed kinetic chain exercises versus open kinetic chain 
exercises, Outcome 8 Functional performance (long term)
Variants of closed kinetic chain exercises
Two studies tested variants of closed kinetic chain exercises. Abrahams et al.39 compared 
an exercise protocol with thigh adduction and tibiamedial rotation during eccentric 
squat versus a traditional exercise protocol. Balci et al.42 compared closed kinetic chain 
exercises with internally rotated hip versus closed kinetic chain exercises with exter-
nally rotated hip. For convenience, these two heterogeneous studies are presented 
subgrouped in the same forest plots, but without overall pooling. Neither trial reported 
on long-term outcomes, functional performance, aspects of recovery or adverse events.
Knee pain in the short term
This outcome was not reported in Abrahams et al.39
pain during activity (vas 0 to 10; higher scores mean worse pain)
Balci et al.42 (40 participants) showed a MD of -0.30 favouring closed kinetic chain ex-
ercises with internal hip rotation, 95% CI -1.46 to 0.86, P value = 0.61; very low quality 
evidence due to serious risk of bias and serious imprecision; see Analysis 6.1.
ANALYSIS 6.1 Comparison 6 Types of exercise: variants of closed kinetic chain exercises, Outcome 1 Pain 
during activity (short term)
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Functional ability in the short term (MFIQ 0 to 16, AKPS 0 to 100; higher scores mean 
better function)
Based on the MFIQ (0 to 16) score, Abrahams et al.39 (52 participants) reported a MD of 
-2.00 favouring the novel exercise protocol, 95% CI -3.39 to -0.61, P value = 0.005; very 
low quality evidence due to serious risk of bias and serious imprecision; see Analysis 6.2.
Based on the AKPS 0 to 100 score, Balci et al.42 (40 participants) showed a MD of 6.20 
favouring closed kinetic chain exercises with internal hip rotation, 95% CI 0.29 to 12.11, 
P value = 0.04; very low quality evidence due to serious risk of bias and serious impreci-
sion; see Analysis 6.2.
ANALYSIS 6.2 Comparison 6 Types of exercise: variants of closed kinetic chain exercises , Outcome 2 Func-
tional ability (short term)
Open, mixed or unspecifi ed kinetic chain exercises subgrouped by type of muscle action
The comparisons undertaken by four studies fell into this category. One study com-
pared eccentric exercises versus concentric exercises.49 One study compared eccentric 
exercises versus isometric exercises.66 One study compared isokinetic exercises versus 
isometric exercises.29 One study compared combined isotonic and isometric exercises 
(pogo stick) versus isometric exercises.61
Knee pain in the short term
This was not reported in Colón et al.61 or Gobelet et al.29
pain during activity (number of patients with pain)
Thomee et al.66 (40 participants) reported that 9/20 participants in the eccentric exercise 
group and 12/20 participants in the isometric exercise group had pain during jogging; 
RR of 0.75 favouring eccentric exercises, 95% CI 0.41 to 1.37, P value = 0.35; very low 
quality evidence due to serious risk of bias and serious imprecision; see Analysis 7.1.
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ANALYSIS 7.1 Comparison 7 Types of exercise: open, mixed or unspecifi ed kinetic chain exercises sub-
grouped by type of muscle action, Outcome 1 Pain during activity (short term)
usual pain (vas 0 to 10; higher scores mean worse pain)
Hafez et al.49 (40 participants) reported a MD of -1.30 favouring eccentric exercise, 95% 
CI -1.97 to -0.63, P value = 0.0002; very low quality evidence due to serious risk of bias 
and serious imprecision; see Analysis 7.2.
ANALYSIS 7.2 Comparison 7 Types of exercise: open, mixed or unspecifi ed kinetic chain exercises sub-
grouped by type of muscle action, Outcome 2 Usual pain continuous (short term)
Knee pain in the long term
This was not reported in Colón et al.61, Gobelet et al.29 or Hafez et al.49
pain during activity (number of patients with pain)
Thomee et al.66 (40 participants) reported that 4/20 participants in the eccentric exercise 
group and 6/20 participants in the isometric exercise group had pain during jogging; RR 
of 0.67 favouring eccentric exercises, 95% CI 0.22 to 2.01, P value = 0.47; very low quality 
evidence due to serious risk of bias and serious imprecision; see Analysis 7.3.
ANALYSIS 7.3 Comparison 7 Types of exercise: open, mixed or unspecifi ed kinetic chain exercises sub-
grouped by type of muscle action, Outcome 3 Pain during activity (long term)
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Functional ability in the short term (WOMAC 0 to 96 (inverted scores; higher scores mean 
better function), Arpège function scale 0 to 18; higher scores mean better function)
This was not reported in Colón et al.61 or Thomee et al.66 Based on the WOMAC (0 to 96) 
score, Hafez et al.49 (40 participants) reported a MD of 11.65 favouring eccentric exer-
cises, 95% CI 5.15 to 18.15, P value = 0.0004; very low quality evidence due to serious risk 
of bias and serious imprecision; see Analysis 7.4.
Based on the Arpège scale (0 to 18),Gobelet et al.29 (66 participants) reported a MD of 
0.40 favouring isometric exercises, 95% CI -0.80 to 1.60, P value = 0.51; very low quality 
evidence due to serious risk of bias and imprecision; see Analysis 7.4.
ANALYSIS 7.4 Comparison 7 Types of exercise: open, mixed or unspecifi ed kinetic chain exercises sub-
grouped by type of muscle action, Outcome 4 Functional ability (short term)
Functional ability in the long term
This was not reported in any of the four trials.
Functional performance in the short term (vertical jump test)
Only Thomee et al.66 reported on functional performance, using the vertical jump test; 
however, only the overall data for the trial population were provided.
Recovery in the short and long term
Colón et al.61 reported that 13/14 participants in the isotonic and isokinetic group versus 
9/11 participants in the isometric exercise group had 50% or higher pain relief at eight 
weeks follow-up; RR 1.13 favouring isotonic and isokinetic exercises, 95% CI 0.83 to 1.55, 
P value = 0.43; very low quality evidence due to serious risk of bias, indirectness and 
imprecision; see Analysis 7.5.
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ANALYSIS 7.5 Comparison 7 Types of exercise: open, mixed or unspecifi ed kinetic chain exercises sub-
grouped by type of muscle action, Outcome 5 Recovery (short term)
Thomee et al.66 (40 participants) reported that all participant except one (group not 
identifi ed) rated their knee function as excellent at 12 months; the exception rated her 
knee function as improved although still poor; very low quality evidence due to seri-
ous risk of bias, indirectness and imprecision. Two participants, one in each group, had 
chosen to undergo surgery at nine months.
Adverse events (number of patients with increased pain)
Colón et al.61 reported that 1/16 participants in the isotonic and isokinetic group versus 
0/11 participants in the isometric exercise group had an adverse event; RR 2.12 favour-
ing isometric exercises, 95% CI 0.09 to 47.68, P value = 0.64; very low quality evidence 
due to serious risk of bias and serious imprecision; see Analysis 7.6.
ANALYSIS 7.6 Comparison 7 Types of exercise: open, mixed or unspecifi ed kinetic chain exercises sub-
grouped by type of muscle action, Outcome 6 Adverse events
Proprioceptive neuromuscular facilitation stretching and aerobic exercise versus classic 
stretching and quadriceps exercises
The one study making this comparison (68 participants) reported on long-term (16 
weeks) pain and function only.53
Knee pain in the long term
usual pain (vas 0 to 10)
Moyano et al.53 reported a MD of -3.50, favouring proprioceptive neuromuscular facilita-
tion stretching and aerobic exercise, 95% CI -4.08 to -2.92, P value < 0.00001; very low 
quality evidence due to risk of bias and serious imprecision; see Analysis 8.1.
90 Chapter 2
ANALYSIS 8.1 Comparison 8 Types of exercise: open proprioceptive neuromuscular facilitation + aerobic 
exercise versus classic stretching + quadriceps exercises, Outcome 1 Usual pain (long term)
Functional ability in the long term (0 to 100 AKPS scale; higher scores mean better 
function)
Moyano et al.53 reported a MD of 17.01, favouring proprioceptive neuromuscular facilita-
tion stretching and aerobic exercise, 95% CI 11.85 to 22.17, P value < 0.00001; very low 
quality evidence due to risk of bias and serious imprecision; see Analysis 8.2.
ANALYSIS 8.2 Comparison 8 Types of exercise: open proprioceptive neuromuscular facilitation + aerobic 
exercise versus classic stretching + quadriceps exercises, Outcome 2 Functional ability (long term)
Target of exercises or exercise programmes: Knee and hip exercises versus knee exercises 
alone
Seven studies compared knee and hip exercises versus knee exercises alone.40 44 46 47 54 55 57 
Only De Marche et al.44 reported on aspects of recovery, which was assessed via a global 
rating of improvement (15-point scale). None of the trials reported on adverse events. 
Avraham et al.40, which provided very low quality evidence refl ecting very serious risk 
of bias and imprecision, only presented P values in a graph for the comparisons of three 
groups of which two were knee and hip exercises and one was knee exercises.
Knee pain in the short term
pain during activity (0 to 10 scale; higher scores mean worse pain)
Pooled data from three studies46 47 54 (104 participants) showed a MD of -2.02 favouring 
knee and hip exercises, 95%CI -3.80 to -0.60, P value = 0.007; very low quality evidence 
due to risk of bias, serious inconsistency and imprecision (signifi cant heterogeneity: P 
value = 0.004, I2 = 82%); see Analysis 9.1. The results were homogeneous (P value = 0.66 
and I2 = 0%) upon removal of Fukuda et al.47, but smaller in eff ect size (MD -1.37, 95% CI 
-2.40 to -0.33, P value = 0.010).
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ANALYSIS 9.1 Comparison 9 Target of exercise: hip + knee versus knee exercises , Outcome 1 Pain during 
activity (short term)
usual pain (vas 0 to 10; higher scores mean worse pain)
Pooled data from two studies54 55 (46 participants) showed a MD of -1.77 favouring knee 
and hip exercises, 95%CI -2.78 to -0.76, P value = 0.0006; very low quality evidence due 
to risk of bias and serious imprecision; see Analysis 9.2.
ANALYSIS 9.2 Comparison 9 Target of exercise: hip + knee versus knee exercises, Outcome 2 Usual pain 
(short term)
Avraham et al.40 (30 participants) reported that no signifi cant between-group diff er-
ences were found for pain (reported P value =0.11 and P value = 0.72, P values extracted 
from graph).
Worst pain (0 to 10 scale; higher scores mean worse pain)
Pooled data from three studies44 54 57 (98 participants) showed a MD of -0.79 favouring 
knee and hip exercises, 95% CI -1.66 to 0.09, P value = 0.08; very low quality evidence 
due to risk of bias, inconsistency and imprecision; see Analysis 9.3.
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ANALYSIS 9.3 Comparison 9 Target of exercise: hip + knee versus knee exercises, Outcome 3 Worst pain 
(short term)
Knee pain in the long term
pain during activity (numerical pain rating scale (nprs) 0 to 10; higher scores mean worse pain)
Fukuda et al.47 (49 participants) reported a MD of -3.90 favouring knee and hip exercises, 
95% CI -4.46 to -3.34, P value < 0.00001; very low quality evidence due to risk of bias and 
serious imprecision; see Analysis 9.4.
ANALYSIS 9.4 Comparison 9 Target of exercise: hip + knee versus knee exercises, Outcome 4 Pain (long 
term)
Worst pain (vas 0 to 10; higher scores mean worse pain)
De Marche et al.44 (29 participants) reported a MD of -1.60 favouring knee and hip exer-
cises, 95% CI -3.15 to -0.05, P value = 0.04; very low quality evidence due to risk of bias 
and serious imprecision; see Analysis 9.4.
Functional ability in the short term (0 to 100 scale; higher scores mean better function)
Pooled data from four studies44 46 47 57 (174 participants) showed a SMD of 0.61 favouring 
knee and hip exercises, 95% CI -0.39 to 1.61, P value = 0.23; very low quality evidence 
due to risk of bias, imprecision and serious inconsistency (signifi cant heterogeneity: P 
value < 0.00001, I2 = 90%); see Analysis 9.5. Upon removal of Fukuda et al.47, the results 
were homogeneous (P value = 0.33 and I² = 11%) with little diff erence between the two 
groups (SMD 0.06, 95% CI -0.32 to 0.43, P value = 0.76).
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Avraham et al.40 (20 participants) reported no signifi cant between group diff erences 
were found for function assessed using the patellofemoral joint evaluation scale (0 to 
100) (reported P value = 0.74 and P value = 0.70; P values extracted from graph).
ANALYSIS 9.5 Comparison 9 Target of exercise: hip + knee versus knee exercises, Outcome 5 Functional 
ability (short term)
Functional ability in the long term (0 to 100 scale; higher scores mean better function)
Pooled data from two studies44 47 (78 participants) showed a SMD of 1.49 favouring knee 
and hip exercises, 95% CI -0.17 to 3.15, P value = 0.08; very low quality evidence due to 
risk of bias, imprecision and serious inconsistency (signifi cant heterogeneity: P value = 
0.002, I² = 90%); see Analysis 9.6.
ANALYSIS 9.6 Comparison 9 Target of exercise: hip + knee versus knee exercises, Outcome 6 Functional 
ability (long term)
Functional performance in the short term (single-limb hop test)
Pooled data from two trials46 47 (90 participants) reporting the single-limb hop test 
showed a MD of 13.89 cm favouring knee and hip exercises, 95% CI 5.21 to 22.56, P value 
= 0.002; low quality evidence due to risk of bias and imprecision; see Analysis 9.7.
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ANALYSIS 9.7 Comparison 9 Target of exercise: hip + knee versus knee exercises, Outcome 7 Functional 
performance (short term)
Functional performance in the long term (single-leg triple hop test and single-limb hop test)
De Marche et al.44 (29 participants) reported for the single-leg triple hop test a MD of 
45.20 cm favouring knee and hip exercises, 95% CI 1.03 to 89.37, P value = 0.04; very low 
quality evidence due to risk of bias and serious imprecision; see Analysis 9.8.
Fukuda et al.47 (49 participants) reported for the single-limb hop test a MD of 16.70 
cm favouring knee and hip exercises, 95% CI 7.32 to 26.08, P value = 0.001; low quality 
evidence due to risk of bias and imprecision; see Analysis 9.8.
ANALYSIS 9.8 Comparison 9 Target of exercise: hip + knee versus knee exercises, Outcome 8 Functional 
performance (long term)
Recovery in the short and long term (number of participants at least moderately better)
De Marche et al.44 (30 participants in the short term, 29 participants in the long term) re-
ported on the number of participants who perceived themselves as at least moderately 
better in the short term (14/14 versus 12/16), RR 1.31 favouring hip and knee exercises, 
95% CI 0.97 to 1.78, P value = 0.07; very low quality evidence due to risk of bias, indirect-
ness and serious imprecision) and in the long term (12/13 versus 11/16), RR 1.34 favour-
ing hip and knee exercises, 95% CI 0.93 to 1.94, P value = 0.11; very low quality evidence 
due to risk of bias, indirectness and serious imprecision), see Analysis 9.9.
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ANALYSIS 9.9 Comparison 9 Target of exercise: hip + knee versus knee exercises, Outcome 9 Recovery 
(short and long term)
Target of exercises or exercise programmes: Hip exercises versus knee exercises
Two studies compared hip versus knee exercises.45 64 Dolak et al.45 did not report on long-
term outcome. Neither study reported on aspects of recovery.
Knee pain in the short term
During activity (vas 0 to 10; higher scores mean worse pain)
Khayambashi et al.642014 (36 participants) reported a MD of -1.16 favouring hip exer-
cises, 95% CI -2.41 to 0.09, P value = 0.07; very low quality evidence due to serious risk of 
bias and serious imprecision; see Analysis 10.1.
ANALYSIS 10.1 Comparison 10 Target of exercise: hip versus knee exercises, Outcome 1 Pain (short and 
long term)
Worst pain (vas 0 to 10; higher scores mean worse pain)
Dolak et al.45 (25 participants) reported a MD of -0.30 favouring hip exercises, 95% CI 
-2.19 to 1.59, P value = 0.76; very low quality evidence due to serious risk of bias and 
serious imprecision; see Analysis 10.1.
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Knee pain in the long term
During activity (vas 0 to 10; higher scores mean worse pain)
Khayambashi et al.64 (36 participants) reported a MD of -2.00 favouring hip exercises, 
95% CI -3.45 to -0.55, P value = 0.007; very low quality evidence due to serious risk of bias 
and serious imprecision; see Analysis 10.1.
Functional ability in the short term (0 to 100 scale; higher scores mean better function)
Pooled data from two studies45 64 (58 participants) showed a SMD of 0.85 favouring hip 
exercises, 95% CI 0.30 to 1.40, P value = 0.002, which was statistically heterogeneous (P 
value = 0.08; I2 = 68%); very low quality evidence due to serious risk of bias, imprecision 
and inconsistency; see Analysis 10.2.
ANALYSIS 10.2 Comparison 10 Target of exercise: hip versus knee exercises, Outcome 2 Functional ability 
(short term)
Functional ability in the long term (WOMAC 0 to 96, score inverted so that higher scores 
mean better function)
Khayambashi et al.64 (36 participants) reported a MD of 16.22 favouring hip exercises, 
95%CI 9.17 to 23.27, P value < 0.00001; very low quality evidence due to serious risk of 
bias and serious imprecision; see Analysis 10.3.
ANALYSIS 10.3 Comparison 10 Target of exercise: hip versus knee exercises , Outcome 3 Functional ability 
(long term)
Functional performance in the short term (step-down test (N of repetitions in 30 seconds))
Dolak et al.45 (27 participants) performed the step-down test (number of repetitions in 
30 seconds) and reported a MD of -1.00 favouring quadriceps exercises, 95% CI -5.18 
to 3.18, P value = 0.64; very low quality evidence due to serious risk of bias and serious 
imprecision; see Analysis 10.4.
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ANALYSIS 10.4 Comparison 10 Target of exercise: hip versus knee exercises, Outcome 4 Functional perfor-
mance (short term)
Adverse events
Dolak et al.45 (31 participants) reported that 0/17 participants in the hip exercise group 
versus 1/16 participants in the knee exercise group had an adverse event; RR of 0.31 
favouring hip exercises, 95% CI 0.01 to 7.21, P value = 0.47; very low quality evidence 
due to serious risk of bias and serious imprecision; see Analysis 10.5.
ANALYSIS 10.5 Comparison 10 Target of exercise: hip versus knee exercises, Outcome 5 Adverse events
Duration of exercises or exercise programmes
There were no trials testing duration of exercise therapy.
Intensity of exercises or exercise programmes: High- versus low-intensity exercise 
programme
One study compared high-dose, high-repetition medical exercise therapy (MET) with 
low-dose, low-repetition exercises.60 Østerås et al.60 did not report on aspects of recovery 
or adverse events.
Knee pain in the short term
usual pain (0 to 10 scale; higher scores mean worse pain)
Østerås et al.60 (40 participants) reported a MD of -1.90 favouring a high-intensity pro-
gramme, 95% CI -2.85 to -0.95, P value <0.0001; very low quality evidence due to risk of 
bias and serious imprecision; see Analysis 11.1.
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Knee pain in the long term
usual pain (0 to 10 scale; higher scores mean worse pain)
Østerås et al.60 (28 participants) reported a MD of -3.20 favouring a high-intensity pro-
gramme, 95% CI -4.05 to -2.35, P value <0.00001; very low quality evidence due to risk of 
bias and serious imprecision; see Analysis 11.1.
ANALYSIS 11.1 Comparison 11 Intensity of exercise: high- versus low-intensity exercise programme, Out-
come 1 Usual pain (short and long term)
Functional ability in the short term (FIQ 0 to 16 scale; higher scores mean better function)
Østerås et al.60 (40 participants) reported a MD of 3.70 favouring a high-intensity pro-
gramme, 95% CI 1.59 to 5.81, P value = 0.0006; very low quality evidence due to risk of 
bias and serious imprecision; see Analysis 11.2.
ANALYSIS 11.2 Comparison 11 Intensity of exercise: high- versus low-intensity exercise programme, Out-
come 2 Functional ability (short and long term)
Functional ability in the long term (FIQ 0 to 16 scale; higher scores mean better function)
Østerås et al.60 (28 participants) reported a MD of 3.90 favouring a high-intensity pro-
gramme, 95% CI 1.72 to 6.08, P value = 0.0005; very low quality evidence due to risk of 
bias and serious imprecision; see Analysis 11.2.
Functional performance in the short term (step-down test)
Østerås et al.60 (40 participants) performed the step-down test (number of repetitions 
in 30 seconds) and reported a MD 9.40 favouring a high-intensity programme, 95% CI 
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4.24 to 14.56, P value = 0.0004; very low quality evidence due to risk of bias and serious 
imprecision; see Analysis 11.3.
Functional performance in the long term (step-down test)
Østerås et al.60 (28 participants) performed the step-down test (number of repetitions 
in 30 seconds) and reported a MD of 15.10 favouring a high-intensity programme, 95% 
CI 10.21 to 19.99,P value < 0.00001; very low quality evidence due to risk of bias and 
serious imprecision; see Analysis 11.3.
ANALYSIS 11.3 Comparison 11 Intensity of exercise: high- versus low-intensity exercise programme, Out-
come 3 Functional performance (short and long term)
Subgroup analyses for patient characteristics
We did not perform subgroup analyses to determine the effects of patient characteristics 
(gender, duration of complaints and sports participation) on outcome. This reflected the 
lack of data and the inconsistent and incomplete reporting of baseline characteristics.
Sensitivity analysis excluding trials at high risk of selection bias
The results of pooled studies were robust when excluding trials with a high risk of bias 
of selection bias: Clark et al.43; Colón et al.61; Dolak et al.45; Eburne and Bannister.62; Khay-
ambashi et al.63 64 85; Loudon et al.65; and Thomee et al.66 (results not shown).
DISCUSSION
Summary of main results
This systematic review assessed the effects (benefits and harms) of exercise therapy 
aimed at reducing knee pain and improving knee function for people with patellofemo-
ral pain syndrome.
This review comprises 31 heterogeneous trials including 1690 participants with a diag-
nosis of patellofemoral pain syndrome. As well as variation in the patient characteristics 
and diagnostic criteria for study inclusion, the exercise interventions tested in the trials 
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varied considerably. We assessed the evidence as being very low quality (see Quality of 
the evidence (online available)).
We based our assessment of clinical relevance on the following minimal clinically 
important differences: 1.3 points on a visual analogue scale (VAS) for pain during activ-
ity; 2.0 points on a VAS for usual and worst pain; 10.0 points on the Anterior Knee Pain 
Score (AKPS) and 2.0 points on the modified Functional Index Questionnaire (FIQ) (0 to 
16)21; and 15.0 points for the Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC)86. In our summary of the main results for each comparison, we restrict 
our report to seven outcomes (pain during activity (short-term: ≤ 3 months); usual 
pain (short-term); pain during activity (long-term: > 3 months); usual pain (long-term); 
functional ability (short-term); functional ability (long-term); and recovery (long-term)).
Exercise therapy versus control (no treatment, placebo or health educational material)
Although 10 studies compared exercise therapy versus control, we do not discuss the 
findings from Abrahams et al.39 here because this trial also required participants to have 
patella malalignment and was thus presented separately in Effects of interventions.
All nine trials stipulated a minimum duration of symptoms; this ranged from three 
weeks to six months. We assessed the quality of the available evidence as being of very 
low quality for each outcome (see appendix 2 Summary of finding table for the main 
comparison).
Pooled data from five studies (375 participants) for pain during activity in the short 
term(four weeks to three months) favoured exercise therapy; the confidence interval, 
which did not cross the line of no effect, included the minimal clinically important differ-
ence pointing to the possibility of a clinically important effect. The same finding applied 
for pooled data from two studies (41 participants) for usual pain in the short term (four to 
eight weeks); for pooled data from two studies (180 participants) for pain during activity 
in the long term (12 months) and for data from a single study (94 participants) for usual 
pain in the long term(16 weeks). Pooled data from seven studies (483 participants) for 
functional ability in the short term (four weeks to three months) also favoured exercise 
therapy.
In order to interpret the standardised mean difference results, we converted these 
to AKPS; the resulting confidence interval, which did not cross the line of no effect, 
included the minimal clinically important difference pointing to the possibility of a clini-
cally important effect. The same finding applied to pooled data from three studies (274 
participants) for functional ability in the long term (16 weeks to 12 months). Pooled data 
from two studies (166 participants) indicated that, based on the recovery of 250 per 
1000 in the control group, 88 more (95%confidence interval (CI) 2 fewer to 210 more) 
participants per 1000 recovered in the long term(12 months) as a result of exercise 
therapy. It is important to note the very significant heterogeneity in the contributing 
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trials and in the results for pain during activity and functional ability in the short term. 
However, sensitivity analyses did retain the positive findings for both of these outcomes, 
although the effect sizes were reduced.
Exercise therapy versus different unimodal or multimodal conservative interventions
All comparisons in this category are represented by single trials only, with no pooling 
undertaken because of the heterogeneity in the control groups (other conservative 
intervention).
Exercise therapy versus different unimodal interventions
Four trials provided very low quality and incomplete evidence for five comparisons of 
exercise therapy versus different unimodal conservative interventions.
One study (28 less active female participants; bilateral symptoms of at least six months 
duration) comparing hip exercises versus 1000 mg of Omega-3 and 400 mg of calcium 
daily found a clinically important and highly statistically significant difference favouring 
the hip exercises group for pain during activity and functional ability in the short term 
(eight weeks).
One study (66 participants; symptoms of at least three weeks duration) comparing 
home exercises versus brace reporting on short-term( three months) results found 
slightly lower pain during activity in the brace group and better functional ability in 
the exercises group. However, the confidence interval for pain during activity crossed 
the line of no effect and did not include the minimal clinically important difference. The 
confidence interval for functional ability also crossed the line of no effect but may have 
included a clinically important effect for exercise as well as a non-clinically important 
effect for bracing.
One study (24 participants with symptoms of at least three months) comparing exercise 
therapy versus tape found lower pain during activity in the short term (three months) 
in the exercises group; the confidence interval, which did not cross the line of no effect, 
included a clinically important effect. A similar finding applied to pain during activity in 
the long term (12 months); however the confidence interval also crossed the line of no 
effect and a small but clinically irrelevant effect in favour of tape cannot be ruled out. The 
same pattern, in favour of exercise, applied to functional ability at short- and long-term 
follow-up. Slightly more participants in the exercise group had recovered by 12months; 
the confidence interval crossed the line of no effect and thus a result in favour of taping 
cannot be ruled out.
One study (54 participants) comparing isometric exercises versus muscle electrostimu-
lation found better functional ability in the short term(four weeks) in the exercise group; 
the confidence interval included a clinically important effect but also crossed the line 
of no effect and thus included a non-clinically important effect in favour of muscle 
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electrostimulation. The same observation applies to short-term functional ability results 
from the comparison of isokinetic exercises versus muscle electrostimulation made in 
the same trial (68 participants).
Exercise therapy versus multimodal conservative interventions
Four trials provided very low quality and incomplete evidence for five comparisons of 
exercise therapy versus different multimodal conservative interventions. One quasi-
randomised study (53 participants), which compared isometric quadriceps exercise 
versus the multimodal McConnell regimen comprising different types of exercises and 
taping, provided no usable quantitative data. It concluded that there was improve-
ment in 50%of each group in the short term (three months). It also reported that three 
participants withdrew because of “severe allergy to the strapping” (presumably in the 
McConnell regimen group).
One study, which compared a supervised exercise programme versus a vastus medialis-
specific supervised exercise programme including taping found no clinically important 
difference between the two groups in usual pain in the short term (three months; 40 
participants) or long term (12 months; 31 participants). In both cases the confidence in-
tervals crossed the line of no effect and did not include the minimal clinically important 
difference. This study found over twice as many participants in the multimodal group 
had best function in the short term (52 participants overall). Conversely, the result at 12 
months (33 participants) favoured the exercise group; however, the confidence intervals 
crossed the line of no effect.
The same study as above also compared a home exercise programme versus a vastus 
medialis-specific supervised exercise programme including taping. For usual pain and 
functional ability at both short (42 and 52 participants respectively) and long-term 
follow-up (36 and 39 participants respectively), the confidence intervals crossed the 
line of no effect and, for usual pain, did not include the minimal clinically important 
difference.
One study (60 participants), which compared concentric exercises versus a multimodal 
intervention comprising excentric exercises and taping, found better functional ability 
(expressed in terms of the number of participants with improved function) and recovery 
in the short term(eight weeks follow-up) in the multimodal group. In both cases, the 
confidence intervals crossed the line of no effect and thus a greater benefit from con-
centric exercises alone cannot be ruled out.
One study (40 active participants with symptoms for at least six months), which com-
pared physiotherapeutic exercises based on proprioceptive neuromuscular facilitation 
versus a special knee resistance-controlled knee splint combined with a special exercise 
programme, provided no data on the selected pain measures and incomplete data for 
functional ability at short-term (eight weeks) follow-up. It did not find a statistically or 
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clinically significant difference between the two groups in pain at rest or functional abil-
ity.
Different exercises or exercise programmes
Delivery of exercises or exercise programmes: supervised versus home exercise
Two trials, one of which stipulated a minimum duration of symptoms of two months, 
provided very low quality evidence for this comparison (see Summary of findings table 
(Appendix 2)). Pooled data (59 participants) for usual pain in the short term (eight weeks 
or three months) marginally favoured supervised exercises but the confidence interval 
crossed the line of no effect and did not include the minimal clinically important differ-
ence for usual pain. The same observation applied to data from one study (31 partici-
pants) for usual pain in the long term (12 months). One study (18 active participants) 
found functional ability in the short term (eight weeks) slightly favoured home exercise; 
however, although the confidence interval included the minimal clinically important 
difference, it also crossed the line of no effect. The other trial (31 participants) reported 
higher numbers of participants with best function in the home group in the short term 
(one month; 48 participants) but the converse in the long term (12 months). In both 
cases, the confidence intervals crossed the line of no effect and thus a benefit from 
supervised exercises in the short term and home exercises in the long term cannot be 
ruled out.
Types of exercises or exercise programmes: closed kinetic chain exercises versus open 
kinetic chain exercises
This comparison was tested in four trials; the three providing quantitative data stipulated 
a minimum duration of symptoms (four, six and eight weeks respectively). We assessed 
all evidence for this comparison as being of very low quality (see Summary of findings 
table (Appendix 2)). Recovery was not reported. Although pooled data from two studies 
(90 participants) for pain during activity in the short term (six weeks or three months) 
marginally favoured open kinetic exercises, the confidence interval crossed the line 
of no effect and did not include the minimal clinically important difference. The same 
observation applied to pooled data from three studies (122 participants) for usual pain 
in the short term (four weeks to three months). In the long term (five years), one study 
(49 participants) found less pain during activity and usual pain in the open kinetic chain 
group; the confidence interval included a clinically important effect for the first outcome 
but not the second.
Although pooled data from two studies (90 participants) for functional ability in the 
short term (six weeks or three months) marginally favoured open kinetic exercises, 
the confidence interval crossed the line of no effect and did not include the minimal 
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clinically important difference. In the long term (five years), one study (49 participants) 
found better function in the open kinetic chain group; the confidence interval included 
a clinically important effect. It is important to note that data for long-term effect were 
from one trial only and that data for functional ability were extracted from graphs for 
both trials reporting these data.
Types of exercises or exercise programmes: variants of closed kinetic chain exercises
Two trials provided very low quality and incomplete evidence for two different com-
parisons of variants of closed kinetic chain exercises. Neither trial reported on long-term 
outcomes or recovery.
One trial (52 participants with a minimum duration of symptoms of eight months 
plus patella malalignment) comparing an exercise protocol with thigh adduction and 
tibia medial rotation during eccentric squat versus a traditional exercise protocol found 
better functional ability in the short term (six weeks) in the first intervention group; 
the confidence interval, which did not cross the line of no effect, included a clinically 
important effect.
One trial (40 female participants with symptoms for at least two months) comparing 
closed kinetic chain exercises with internally rotated hip versus closed kinetic chain 
exercises with externally rotated hip reported less pain during activity in the short 
term (four weeks) in the internally rotated group; the confidence interval included a 
clinically important effect but also crossed the line of no effect and included a non-
clinically important effect in favour of the externally rotated group. This trial reported 
better functional ability in the short term in the internally rotated group; the confidence 
interval, which did not cross the line of no effect, included a clinically important effect.
Types of exercises or exercise programmes: open, mixed or unspecified kinetic chain 
exercises subgrouped by type of muscle action
Four trials provided very low quality and incomplete evidence for four different com-
parisons. One study (40 female participants) comparing eccentric exercises versus 
concentric exercises found lower usual pain in the short term (12 weeks) for eccentric 
exercises; however, the confidence interval, which did not cross the line of no effect, ex-
cluded a clinically important effect. This study found better WOMAC scores in the short 
term for eccentric exercises; in this case the confidence interval, which did not cross the 
line of no effect, included a clinically important effect.
One study (40 female participants; symptoms for a minimum of six months) comparing 
eccentric exercises versus isometric exercises reported slightly fewer participants in 
the eccentric exercise group had pain during activity (jogging) in the short term(three 
months) and long term (12 months); the confidence intervals crossed the line of no ef-
fect and thus included the potential for an effect in favour of isometric exercises. All 
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participants except one (group not identified) rated their knee function as excellent at 
12 months.
One study (66 participants) comparing isokinetic exercises versus isometric exercises 
found a small and clinically non-relevant between-group difference in favour of isomet-
ric exercises in functional ability in the short term (four weeks). The confidence interval 
crossed the line of no effect and thus included the possibility of a better but probably 
not clinically important result after isokinetic exercises.
One study comparing combined isotonic and isometric exercises (pogo stick) versus 
isometric exercises reported only on recovery (more in the first group reported 50%or 
higher pain relief at eight weeks; 25 active participants) and adverse events (one person 
in the first group had increased pain; 27 active participants). Although favouring isotonic 
and isokinetic exercises, the confidence interval for recovery crossed the line of no effect 
and thus also included the possibility of a better result after isometric exercises.
Types of exercises or exercise programmes: proprioceptive neuromuscular facilitation 
stretching and aerobic exercise versus classic stretching and quadriceps exercises
Very low quality evidence from one trial (68 less active participants with a minimum 
duration of pain of six months) that reported only on usual pain and functional ability in 
the long term (16 weeks) showed a strong clinically important effect on both outcomes 
in favour of proprioceptive neuromuscular facilitation stretching and aerobic exercise 
compared with classic stretching and quadriceps exercises. The confidence intervals for 
both outcomes were located beyond the minimal clinically important differences.
Target of exercises or exercise programmes: hip and knee exercises compared with knee 
exercises
This comparison was tested in seven trials; the six providing quantitative data stipulated 
a minimum duration of symptoms (one month (three studies), two months (one study), 
three months (two studies)) (see Summary of findings table (Appendix 2)). Very low 
quality evidence pooled from three studies (104 participants) showed lower pain during 
activity in the short term (four weeks to three months) in the hip and knee exercise group 
compared with the knee exercises group; the confidence interval, which did not cross 
the line of no effect, included a clinically important effect. Very low quality evidence 
pooled from two studies (46 participants) showed lower usual pain in the short term 
(four or six weeks) in the hip and knee exercise group; the confidence interval, which 
did not cross the line of no effect, included a clinically important effect. Very low qual-
ity evidence pooled from one study (49 less active female participants) showed lower 
pain during activity in the long term (12months) in the hip and knee exercise group 
compared with the knee exercise group; the confidence interval was located beyond 
the minimal clinically important difference of 1.3 points on a 0 to 10 scale. No study 
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reported on usual pain in the long term. Very low quality evidence for functional ability 
in both the short term (four weeks to three months; four studies, 174 participants) and 
long term (5 or 12 months; two studies, 78 participants) was in favour of hip and knee 
exercises. However, both confidence intervals crossed the line of no effect and while 
including a clinically important effect in favour of hip and knee exercises there was also 
the potential for a non-clinically important effect in favour of knee exercises. Very low 
quality evidence from one trial (29 active female participants) showed that long-term 
(five months) recovery was greater in the hip and knee exercises group; however, the 
confidence interval also included the possibility of better recovery in the knee exercises 
group.
Target of exercises or exercise programmes: hip exercises compared with knee exercises
This comparison was tested in two studies, both of which stipulated a minimum duration 
of symptoms (one and six months respectively). Neither trial reported on usual pain or 
recovery (see Summary of findings table (Appendix 2)). Very low quality evidence from 
one quasi randomized trial (36 less active participants) showed that hip exercises may 
reduce pain during activity to a greater extent compared with knee exercise in the short 
term (eight weeks) and long term (six months); the confidence intervals at both time 
points included a clinically important effect. The short-term result also included the po-
tential for a small clinically non-relevant difference in favour of knee exercises, whilst the 
confidence interval for the long-term result did not cross the line of no effect. Very low 
quality evidence from two studies (58 participants) showed that hip exercises may im-
prove functional ability in the short term (eight weeks or three months) compared with 
knee exercises; the confidence interval, which did not cross the line of no effect, included 
a clinically important effect. Very low quality evidence from one quasi-randomised trial 
(36 less active participants) showed that hip exercises may improve functional ability 
in the long term (six months) compared with knee exercises; the confidence interval, 
which did not cross the line of no effect, included a clinically important effect.
Intensity of exercises
There is very low quality evidence from one trial (40 participants with untreated patel-
lofemoral pain syndrome (PFPS) of over two months in duration) that a 12-week long 
high-intensity exercise programme is more effective than a 12-week long low-intensity 
exercise programme in reducing usual pain and improving functional ability in the short 
term (three months) and the long term (12 months) (see of findings table (Appendix 
2)).However, the confidence intervals for usual pain (short-term) and functional ability 
(short and long-term), which did not cross the line of no effect, included both a non-
clinically important effect and a clinically important effect. The confidence interval for 
Exercise therapy for patellofemoral pain (Review) 107
usual pain (long-term) was located beyond the minimal clinically important difference 
of 2.0 points on a 0 to 10 scale. Pain during activity and recovery were not reported.
Overall completeness and applicability of evidence
This multi-comparison review comprised 31 heterogeneous trials including 1690 
participants with a diagnosis of patellofemoral pain syndrome. The largest comparison 
(exercise versus control (no exercise)) was tested in 10 trials but the largest analysis in 
this review, which was for this comparison, included data from only 483 participants 
(Analysis 1.6). There were no trials testing the medium of exercise or duration of exer-
cises. Many other comparisons, notably those comparing exercise with other conserva-
tive interventions and different intensities of exercise were tested in small single trials 
only. The inclusion criteria of the included trials were diverse. In the majority of trials, 
the diagnosis of PFPS was based on a set of clinical criteria and most trials excluded 
other knee pathologies (see Table 2 (online available)). The clinical diagnosis was made 
by a variety of clinical practitioner disciplines and together with the absence of a gold 
standard diagnostic test, differences in examination and judgements of suitability for 
inclusion are inevitable. Nonetheless, we judged that it was very likely that there was 
sufficient similarity in the underlying condition (i.e. all had PFPS) in participants recruited 
into all trials to warrant pooling where data were available. A notable exception was 
Abrahams et al.39, since participants of this trial also had to be diagnosed with malalign-
ment. We presented data for this trial separately. Otherwise, we made the decision to 
pool data despite the heterogeneity in the characteristics of the trial populations. Most 
trials studied the general population, but some focused on specific populations, such as 
sedentary individuals46 47 63, and people who did not engage in regular sports activity53 57, 
compared with more active patients who participated in sports for at least 120 minutes/
week65 and recreational athletes44 56 61. Some studies included only males or females or 
people who had not undergone previous physiotherapy. The minimum duration of the 
compliant or symptoms was specified as an inclusion criterion in the majority of trials 
but varied from a few weeks to several months. This diversity in baseline characteristics 
of the trial participants hampers the applicability of the results but the main assumption 
that these trials were testing the effects of exercise for the same underlying condition is 
key to consideration of applicability. The variety of the exercises tested by different trials 
for the same comparison is shown by an inspection of Analysis 1.1, where six different 
types of exercise, tested in five trials, were compared with no treatment. The hetero-
geneity in the types of exercise together with the lack of or insufficient data available 
for direct comparisons of different types of exercise means that the interpretation of 
the applicability of the results should be levelled at generic exercise and not at specific 
types of exercise.
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Outcome measures
Although there was also considerable heterogeneity in outcome measurement, most 
trials reported scores for pain during activity, usual pain (pain in daily life) and worst 
pain. We selected ’pain during descending’ when pooling pain during activities because 
this again was frequently reported. Most studies reported functional ability with the 
Anterior Knee Pain Score (AKPS), (modified) FIQ or Lower Extremity Function Scale 
(LEFS). If multiple measures were reported, including the AKPS score, we used the latter 
for pooling as this score is reliable, valid and responsive when measuring the effect of 
therapy for PFPS.21 Some studies reported function with scores initially designed for 
other purposes, such as knee instability (Lysholm score) or osteoarthritis (WOMAC).
When assessing the quality of the evidence from these different measures of functional 
ability, whether presented alone or pooled in a meta-analysis, we did not downgrade 
the evidence for indirectness because all of these measures, when presented as continu-
ous outcomes, can be considered to be directly related to functional ability for people 
with PFPS. This is in contrast to recovery, which was assessed in different ways by the 
eight studies that reported on recovery. Notably, Van Linschoten et al.27 found the ef-
fects of exercise on pain and function scores were not reflected in the effect on self 
reported recovery between groups. Van Linschoten et al.27 commented on the difficul-
ties in “understanding what exactly comprises recovery from the patient’s point of view”. 
Furthermore, incomplete recovery might reflect the true nature of PFPS.87-89 Hence, 
self reported recovery can give additional insights on the natural course of PFPS or the 
effects of therapeutic interventions, since it cannot be fully understood by pain and 
function outcomes alone. Functional performance tests might also contribute in assess-
ing a patient’s ’recovery’, as the ultimate goal of rehabilitation is return to the highest 
functional level. These tests are widely used in other sport-related injuries26 and could 
be of use in patellofemoral pain research. However, standardisation is needed since the 
studies that performed these tests could not be pooled because they did not perform 
similar tests.
Applicability
The implications of pooling data from trials with different inclusion criteria and different 
exercise therapies, in particular for the comparison of exercise therapy versus control, 
means that only a general interpretation should be made in terms of the population 
(people diagnosed with PFPS) and the intervention (exercise therapy). This does not 
rule out that some subgroups of patients may benefit from a certain intervention while 
others may not90, nor that some exercise interventions may be more effective or, indeed, 
that some may not be effective. Direct comparisons of different exercise interventions 
should help inform this issue but, although several trials have compared different 
exercises, the current evidence is very poor quality and does not provide definitive an-
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swers. The studies on exercise therapy reflect the changing opinions through the years 
concerning preferred treatment strategy. For example, in the late 1970s and mid 1980s 
questions arose about the effect and possible side effects of open and closed kinetic 
chain exercises for PFPS. The very low quality evidence available in this review generally 
favoured open kinetic exercise but did not establish there being a clinically important 
difference between these two approaches. Around the turn of the 21st century there 
was increased interest in the delivery of exercises, in particular supervised versus home 
exercises. The very low quality evidence available on this comparison did not establish a 
difference between these two approaches. In the last decade, attention has shifted to hip 
exercises with or without knee exercises. Again there is only very low quality evidence 
to inform on the choice of hip plus knee versus knee only exercises or hip versus knee 
exercises. The available evidence tends to favour hip plus knee exercises or hip exercises 
with the potential for a clinically important effect on pain and function; but again is not 
definitive. Lastly, although one study provides evidence that a high-intensity exercise 
programme is more effective than a low intensity exercise programme for patients with 
untreated PFPS of over two months in duration60, such a finding needs verification by 
further research and in a more general population.
Besides exercise, many other interventions are used for PFPS. Only very poor quality 
and generally incomplete evidence from single trials was available for comparisons of 
exercise therapy versus different unimodal or multimodal conservative treatment strate-
gies. In terms of applicability, the focus should be on conservative treatment strategies 
in common use; the evidence base for such treatments, such as taping, also needs 
consideration.9
This review did not aim to investigate the additional value of other strategies when they 
are combined with exercise therapy.
Quality of the evidence
In the previous systematic review by Heintjes et al.10, the authors pointed to the need 
for higher quality in study methodology and reporting. This need continues as several 
of the newly included studies were at high or unclear risk of bias for multiple domains 
(Figure 2), including selection bias reflecting the use of quasi-randomisation methods 
in two recently published trials. We assessed most trials as being at high risk of perfor-
mance bias and detection bias; although blinding is generally impractical for exercise 
trials, some measures such as standardisation of interactions between personnel and 
patients can still be taken to reduce bias.
Overall, the quality of the evidence, expressed using GRADE terminology, varies be-
tween ’low quality’ (“Further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate”) and ’very low 
quality’ (“We are very uncertain about the estimate”). All the evidence for the outcomes 
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presented in our ’Summary of findings’ tables was very low quality. In our assessment of 
the quality of the evidence according to the GRADE guidelines, downgrading resulted 
from risk of bias (primarily relating to sequence generation, allocation concealment 
and assessor blinding), imprecision (wide confidence intervals and small sample size), 
inconsistency (significant heterogeneity) and indirectness (here this was used only for 
inadequate outcome measures). In some cases we downgraded our assessment of the 
quality of the evidence by two levels for serious risk of bias, serious imprecision and/
or serious inconsistency. In assessing imprecision, we planned to downgrade one level 
where there were fewer than 400 cases for continuous data or fewer than 300 cases for 
dichotomous data. More often, however, downgrading was based on an assessment of 
the spread of the 95% confidence interval or that the evidence was available solely from 
one small study, often with a large effect size. We did not downgrade for indirectness 
relating to patient characteristics because the results are ’direct’ when the focus is on 
patients with PFPS. We avoided the problem of indirectness associated with Abrahams 
et al.39, which focused on a different population by including only patients with a diag-
nosed malalignment, by not pooling this study with other studies comparing exercise 
versus a control strategy. Some studies focused on different predefined activity-based 
populations (less active or active) or included only males or females or patients without 
previous physiotherapy. Where studies included a more specific population, we took 
this into consideration by stating the specific population in the case of single studies 
and checking for heterogeneity in the case of pooled studies.
Potential biases in the review process
With some exceptions, as detailed in Differences between protocol and review (online 
available), we conducted this review in accordance with our previously published pro-
tocol31. Although the changes to the protocol were often prompted by our review of the 
evidence (for example, the division of the comparison ’exercise therapy versus different 
conservative interventions’ into two separate comparisons), we strived to avoid bias by 
establishing the new rules and methods prior to our interpretation of the evidence. Al-
though we conducted a comprehensive literature search and were systematic and over-
inclusive in our screening process, it is likely that we failed to identify some, particularly 
unpublished, small single-centre trials. It is not possible to determine the bias resulting 
from this but it is notable that we have found only one ongoing trial; another small trial 
awaits classification pending translation.
Agreements and disagreements with other studies or reviews
We have found four recently published systematic reviews investigating the effects 
of exercise therapy for PFPS.91-93 The scopes and inclusion criteria of all four reviews 
differed substantively from our review. For example, Bolgla and Boling91. and Frye et 
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al.93 also included cohort and case-control studies. Harvie et al.94 set out to examine 
the “parameters of exercise programs reported in primary research”, and thus excluded 
randomised controlled trials (RCTs) that did not show an effect of exercise therapy. Col-
lins et al.92 included RCTs comparing all types of non-surgical interventions, including 
acupuncture, electromyography and taping.
Checks of the RCTs included in the four reviews did not reveal any that were missing 
from our review. Moreover, our review includes more trials, which also reflects our more 
up-to-date search. All four reviews assessed the quality of their included studies with 
a quality scale. Frye et al.93 and Harvie et al.94 used the PEDro scale. Collins et al92 used 
a modified version of the PEDro scale, and Bolgla and Boling91 used the Strength of 
Recommended Taxonomy.95 However, the use of quality scales is not recommended, be-
cause these scales are inconsistent and unpredictable.32 Other choices, such as pooling 
and presentation of the results and transparency of the reporting (for instance, it was 
unclear which studies were pooled in Frye et al.93 also differed amongst the four reviews 
and with our review. Inspection of all four reviews mainly revealed the diversity in the 
approaches taken by the investigators and did not yield additional insights relating to 
exercise therapy.
AUTHORS’ CONCLUSION
Implications for practice
This review has found very low quality but consistent evidence that exercise therapy 
for patellofemoral pain syndrome (PFPS) may result in clinically important reduction in 
pain and improvement in functional ability, as well as enhancing long-term recovery. 
However, the best form of exercise therapy and whether this result would apply to all 
people with PFPS are unknown.
There is insufficient evidence to draw conclusions about the relative effects of exercise 
versus other conservative interventions, either unimodal (e.g. taping) or multimodal 
(combinations of interventions that may include different exercises to the exercise 
intervention).
The very low quality evidence for each comparison examined by the included trials was 
from small single trials only.
The very low quality evidence available for comparisons of different exercises was insuf-
ficient to draw conclusions on the relative effects of supervised versus home exercises; 
closed versus open kinetic chain exercises; different variants of closed kinetic chain 
exercises; other comparisons of other types of kinetic chain exercises; proprioceptive 
neuromuscular facilitation stretching and aerobic exercise versus classic stretching and 
quadriceps exercises; hip versus knee exercises; and high- versus low-intensity exercises.
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There is some very low quality evidence that hip plus knee exercises may be more ef-
fective in reducing pain than knee exercise alone, but the relative effect of these two 
exercise types on functional ability is uncertain.
There is a lack of evidence from randomised controlled trials on exercise medium (land 
versus water) and duration of exercises.
Implications for research
Further randomised trials, which conform to international standards in their design, con-
duct and reporting, are needed. However, to optimise research effort and underpin the 
large multicenter randomised trials that are required to inform practice, it is preferable 
to precede this with research that aims to identify priority questions and attain agree-
ment on these and, where practical, standardisation regarding diagnostic criteria and 
measurement of outcome. The selection of priority areas for research should take into 
account the current coverage of the evidence, current practice and differences in prac-
tice, and should involve consultation with patients as to their preferences and values. 
Achieving professional consensus on treatment uncertainties should facilitate sufficient 
centre recruitment into multicentre trials and also implementation of their findings.
Although the identification of priority topics requires input from others, we make a few 
suggestions drawing from the evidence in this review.
First, although we accept that the underpinning evidence for the effectiveness of 
exercise therapy, while consistent in effect direction, is of very poor quality, we sug-
gest that research should be directed at comparisons of different exercises rather than 
comparisons of exercise therapy versus control. In our perception, recent trends in clini-
cal practice for patellofemoral pain syndrome are moving towards protocols featuring 
combined knee and hip exercise programmes and high-intensity exercise programmes. 
Both trends are insufficiently evidenced and thus further evaluation by randomised tri-
als on these seems warranted.
Linked with this is the need to determine whether there are important differences in the 
effectiveness of exercise or different types of exercise in different patient populations. 
This points to the need for clear definitions of patient characteristics and pre-specified 
subgroups in trials, such as by pre-PFPS activity level, which can help to inform on po-
tential variation in the effects of exercise therapy.
In terms of outcomes, we suggest that consideration is given to standardising pain 
during a patient-nominated activity and, until a better instrument is developed, using 
the Anterior Knee Pain Score (AKPS)24 to assess functional ability in future studies. The 
natural course of patellofemoral pain syndrome varies considerably and more research 
is needed to identify the risk factors for prolonged pain and functional deficit, and the 
potential association with degenerative joint disease. As evidenced in this review, not all 
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patients show full recovery and thus the development of a validated outcome measure 
that captures patient-rated recovery seems warranted.
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APPENDIX
Appendix 1 Search strategies
Cochrane Central Register of Controlled Trials (Wiley Online Library)
#1 MeSH descriptor: [Patellofemoral Pain Syndrome] this term only (68)
#2 MeSH descriptor: [Patella] this term only (243)
#3 MeSH descriptor: [Knee Joint] explode all trees (2304)
#4 MeSH descriptor: [Knee] this term only (573)
#5 #2 or #3 or #4 (2957)
#6 MeSH descriptor: [Arthralgia] this term only (466)
#7 MeSH descriptor: [Pain] explode all trees (32936)
#8 #6 or #7 (32936)
#9 #5 and #8 (710)
#10 anterior knee pain:ti,ab,kw (353)
#11 (patell* or femoropatell* or femoro-patell* or retropatell*) near/2 (pain or syn-
drome or dysfunction):ti,ab,kw (284)
#12 ((lateral compression or lateral facet or lateral pressure or odd facet) near/2 
syndrome):ti,ab,kw (0)
#13 (chondromalac* or chondropath* or chondrosis) near/2 (knee* or patell* or 
femoropatell* or femoro-patell* or retropatell*):ti,ab,kw (31)
#14 MeSH descriptor: [Chondromalacia Patellae] this term only (5)
#15 #1 or #9 or #10 or #11 or #12 or #13 or #14 (1185)
#16 MeSH descriptor: [Exercise Therapy] explode all trees (7116)
#17 MeSH descriptor: [Exercise] explode all trees (13885)
#18 exercis* or strengthen* or stretch* or train* or physiotherapy or physical 
therap*:ti,ab,kw (70701)
#19 #16 or #17 or #18 (71833)
#20 #9 and #15 and #19 in Trials (148)
mEDLINE (Ovid Online)
1 Patellofemoral Pain Syndrome/ (453)
2 Patella/ or exp Knee Joint/ or Knee/ (56364)
3 Arthralgia/ or Pain/ (112939)
4 2 and 3 (3290)
5 anterior knee pain.tw. (1003)
6 ((patell* or femoropatell* or femoro-patell* or retropatell*) adj2 (pain or syn-
drome or dysfunction)).tw. (1766)
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7 ((lateral compression or lateral facet or lateral pressure or odd facet) adj2 syn-
drome).tw. (20)
8 ((chondromalac* or chondropath* or chondrosis) adj2 (knee*1 or patell* or femo-
ropatell* or femoro-patell* or retropatell*)).tw. (513)
9 Chondromalacia Patellae/ (59)
10 or/1,4-9 (5753)
11 exp Exercise Therapy/ or exp Exercise/ (140226)
12 (exercis* or strengthen* or stretch* or train* or physiotherapy or physical therap*).
tw. (595688)
13 or/11-12 (655179)
14 Randomized controlled trial.pt. (373732)
15 Controlled clinical trial.pt. (88369)
16 randomized.ab. (293610)
17 placebo.ab. (153908)
18 Drug therapy.fs. (1698370)
19 randomly.ab. (212608)
20 trial.ab. (304899)
21 groups.ab. (1353578)
22 or/14-21 (3335964)
23 exp Animals/ not Humans/ (3938734)
24 22 not 23 (2860785)
25 and/10,13,24 (343)
EmBASE (Ovid Online)
1 Patellofemoral Pain Syndrome/ (678)
2 Patella/ or Patellofamoral Joint/ (6639)
3 Arthralgia/ or Pain/ (229980)
4 2 and 3 (518)
5 Knee Pain/ (7720)
6 anterior knee pain.tw. (1178)
7 ((patell* or femoropatell* or femoro-patell* or retropatell*) adj2 (pain or syn-
drome or dysfunction)).tw. (2017)
8 ((lateral compression or lateral facet or lateral pressure or odd facet) adj2 syn-
drome).tw. (25)
9 ((chondromalac* or chondropath* or chondrosis) adj2 (knee*1 or patell* or femo-
ropatell* or femoro-patell* or retropatell*)).tw. (601)
10 Patella Chondromalacia/ (581)
11 or/1,4-10 (11083)
12 exp Exercise/ or exp Kinesiotherapy/ (228968)
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13 (exercis* or strengthen* or stretch* or train* or physiotherapy or physical therap*).
tw. (700876)
14 12 or 13 (777358)
15 exp Randomized Controlled Trial/ or exp Single Blind Procedure/ or expDouble 
Blind Procedure/ or Crossover Procedure/ (384984)
16 (random* or RCT or placebo or allocat* or crossover* or ’cross over’ or trial or 
(doubl* adj1 blind*) or (singl* adj1 blind*)).ti,ab. (1230960)
17 15 or 16 (1303210)
18 (exp Animal/ or Animal.hw. or Nonhuman/) not (exp Human/ or Human Cell/ or 
(human or humans).ti.) (5041638)
19 17 not 18 (1144157)
20 11 and 14 and 19 (471)
CINAHL (EBSCO)
S1 (MH “Patellofemoral Pain Syndrome”) (915)
S2 (MH “Patella”) OR (MH “Knee”) OR (MH “Knee Joint”) (15,082)
S3 (MH “Arthralgia”) and (MH “Pain”) (60)
S4 S2 AND S3 (10)
S5 TX anterior knee pain (436)
S6 TX ((patell* or femoropatell* or femoro-patell* or retropatell*) n2 (pain or syn-
drome or dysfunction)) (1,263)
S7 TX ((lateral compression or lateral facet or lateral pressure or odd facet) n2 syn-
drome) (7)
S8 TX ((chondromalac* or chondropath* or chondrosis) n2 (knee* or patell* or 
femoropatell* or femoro-patell* or retropatell*)) (107)
S9 (MH “Chondromalacia Patella”) (61)
S10 S1 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 (1,626)
S11 (MH “Therapeutic Exercise+”) and (MH “Exercise+”) (18,366)
S12 (exercis* or strengthen* or stretch* or train* or physiotherapy or physical therap*) 
(249,334)
S13 S11 OR S12 (249,543)
S14 PT clinical trial (75,963)
S15 (MH “Clinical Trials+”) (174,859)
S16 TI clinical trial* OR AB clinical trial* (41,307)
S17 TI ( (single blind* or double blind*) ) OR AB ( (single blind* or double blind*) ) 
(19,881)
S18 TI random* OR AB random* (136,297)
S19 S14 OR S15 OR S16 OR S17 OR S18 (255,533)
S20 S10 AND S13 AND S19 (147)
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AmED (Ovid Online)
1 Patellofemoral pain syndrome/ (58)
2 Patella/ or Knee/ or Knee Joint/ (4479)
3 Pain/ or Arthralgia/ (10265)
4 2 and 3 (631)
5 anterior knee pain.tw. (128)
6 ((patell* or femoropatell* or femoro-patell* or retropatell*) adj2 (pain or syn-
drome or dysfunction)).tw. (449)
7 ((lateral compression or lateral facet or lateral pressure or odd facet) adj2 syn-
drome).tw. (1)
8 ((chondromalac* or chondropath* or chondrosis) adj2 (knee*1 or patell* or femo-
ropatell* or femoro-patell* or retropatell*)).tw. (29)
9 or/1,4-8 (905)
10 Randomized controlled trial.pt. (2931)
11 Controlled clinical trial.pt. (70)
12 Randomized Controlled Trials/ (1658)
13 Random Allocation/ (311)
14 Double-Blind Method/ (506)
15 or/10-14 (5218)
16 exp Animals/ not Humans/ (7553)
17 15 not 16 (5189)
18 Clinical trial.pt. (1160)
19 exp Clinical trials/ (3368)
20 (clinic* adj25 trial*).tw. (5872)
21 ((singl* or doubl* or trebl* or tripl*) adj (mask* or blind*)).tw. (2343)
22 Placebos/ (547)
23 placebo*.tw. (2655)
24 random*.tw. (14183)
25 exp Research design/ (17924)
26 (latin adj square).tw. (24)
27 or/18-26 (31604)
28 27 not 16 (31059)
29 28 not 17 (26011)
30 9 and 29 (174)
124 Chapter 2
Appendix 2 Summary of finding tables
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 d
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 m
ea
n 
w
or
se
 
pa
in
)6
Fo
llo
w
-u
p:
 1
2 
m
on
th
s
Th
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ra
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 d
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⊝
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 p
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 m
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l p
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ra
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 m
on
th
s
Th
e 
m
ea
n 
di
ffe
re
nc
e 
in
 fu
nc
tio
na
l a
bi
lit
y 
(s
ho
rt
-t
er
m
) i
n 
th
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w
as
 a
n 
es
tim
at
ed
 1
2.
21
 h
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; C
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 c
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t d
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 p
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 m
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ra
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se
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r c
on
fid
en
ce
 in
 th
e 
es
tim
at
e 
of
 e
ffe
ct
 a
nd
 is
 li
ke
ly
 to
 c
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at
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ra
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th
us
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ul
at
ed
 
M
D
s.
2 T
he
 b
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r t
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ra
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t o
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r t
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l f
or
 ri
sk
 o
f b
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r b
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l f
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is
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l f
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4 D
at
a 
w
er
e 
fr
om
 V
A
S 
(0
 to
 1
0)
 a
nd
 th
e 
M
cG
ill
 p
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M
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 d
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 d
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 d
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r t
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l f
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f b
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 re
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r b
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l f
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l f
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r t
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ro
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 o
f t
he
 s
tu
di
es
.
13
In
 o
ur
 a
ss
es
sm
en
t o
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r t
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f b
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e 
an
 im
po
rt
an
t i
m
pa
ct
 o
n 
ou
r c
on
fid
en
ce
 in
 th
e 
es
tim
at
e 
of
 e
ffe
ct
 a
nd
 is
 li
ke
ly
 to
 c
ha
ng
e 
th
e 
es
tim
at
e.
Ve
ry
 lo
w
 q
ua
lit
y:
 W
e 
ar
e 
ve
ry
 u
nc
er
ta
in
 a
bo
ut
 th
e 
es
tim
at
e.
Fo
ot
no
te
s
1 T
he
 b
as
is
 fo
r t
he
 a
ss
um
ed
 ri
sk
 is
 th
e 
ra
ng
e 
of
 th
e 
co
nt
ro
l g
ro
up
 ri
sk
 o
f t
he
 s
tu
di
es
.
2 In
 o
ur
 a
ss
es
sm
en
t o
f t
he
 q
ua
lit
y 
of
 th
e 
ev
id
en
ce
 fo
r t
hi
s 
ou
tc
om
e,
 w
e 
do
w
ng
ra
de
d 
on
e 
le
ve
l f
or
 ri
sk
 o
f b
ia
s 
(r
el
at
in
g 
to
 la
ck
 o
f a
ss
es
so
r b
lin
di
ng
), 
on
e 
le
ve
l f
or
 im
pr
ec
i-
si
on
 (s
m
al
l s
am
pl
e 
si
ze
) a
nd
 o
ne
 le
ve
l f
or
 in
co
ns
is
te
nc
y 
(h
et
er
og
en
ei
ty
: P
 v
al
ue
 =
 0
.0
8;
 I2
 =
 6
7%
).
3 In
 o
ur
 a
ss
es
sm
en
t o
f t
he
 q
ua
lit
y 
of
 th
e 
ev
id
en
ce
 fo
r t
hi
s 
ou
tc
om
e,
 w
e 
do
w
ng
ra
de
d 
on
e 
le
ve
l f
or
 ri
sk
 o
f b
ia
s 
(re
la
tin
g 
to
 la
ck
 o
f a
ss
es
so
r b
lin
di
ng
) a
nd
 tw
o 
le
ve
ls
 fo
r s
er
i-
ou
s 
im
pr
ec
is
io
n 
(s
m
al
l s
am
pl
e 
si
ze
).
4 In
 o
ur
 a
ss
es
sm
en
t o
f t
he
 q
ua
lit
y 
of
 th
e 
ev
id
en
ce
 fo
r t
hi
s 
ou
tc
om
e,
 w
e 
do
w
ng
ra
de
d 
on
e 
le
ve
l f
or
 ri
sk
 o
f b
ia
s 
(r
el
at
in
g 
to
 la
ck
 o
f a
ss
es
so
r b
lin
di
ng
), 
on
e 
le
ve
l f
or
 im
pr
ec
i-
si
on
 (s
m
al
l s
am
pl
e 
si
ze
) a
nd
 o
ne
 fo
r i
nc
on
si
st
en
cy
 (h
et
er
og
en
ei
ty
: P
 v
al
ue
 =
 0
.0
6;
 I2
 =
 7
1%
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Su
m
m
ar
y 
of
 fi
nd
in
gs
 ta
bl
e 
fo
r c
om
pa
ri
so
n 
3d
I. 
Ta
rg
et
 o
f e
xe
rc
is
e:
 h
ip
 +
 k
ne
e 
ve
rs
us
 k
ne
e 
ex
er
ci
se
s 
fo
r t
re
at
in
g 
pa
te
llo
fe
m
or
al
 p
ai
n 
sy
nd
ro
m
e
Pa
ti
en
t o
r p
op
ul
at
io
n:
 p
at
ie
nt
s 
w
ith
 p
at
el
lo
fe
m
or
al
 p
ai
n 
sy
nd
ro
m
e 
(s
ym
pt
om
s 
> 
1 
m
on
th
 (3
 s
tu
di
es
); 
sy
m
pt
om
s 
> 
2 
m
on
th
s 
(1
 s
tu
dy
); 
sy
m
pt
om
s 
> 
3 
m
on
th
s 
(2
 s
tu
di
es
); 
no
t 
st
at
ed
 (1
 s
tu
dy
))
Se
tt
in
gs
: v
ar
io
us
: o
rt
ho
pa
ed
ic
 c
lin
ic
s, 
re
ha
bi
lit
at
io
n 
se
rv
ic
e,
 p
hy
si
ot
he
ra
py
 p
ra
ct
ic
es
/c
lin
ic
s
In
te
rv
en
ti
on
: h
ip
 +
 k
ne
e 
ex
er
ci
se
s
Co
m
pa
ri
so
n:
 k
ne
e 
ex
er
ci
se
s
O
ut
co
m
es
Ill
us
tr
at
iv
e 
co
m
pa
ra
ti
ve
 ri
sk
s*
 (9
5%
 C
I)
Re
la
ti
ve
 e
ff
ec
t
(9
5%
 C
I)
N
o 
of
 
pa
rt
ic
ip
an
ts
(s
tu
di
es
)
Q
ua
lit
y 
of
 th
e 
ev
id
en
ce
(G
RA
D
E)
Co
m
m
en
ts
A
ss
um
ed
 ri
sk
Co
rr
es
po
nd
in
g 
ri
sk
kn
ee
 e
xe
rc
is
es
H
ip
 +
 k
ne
e 
ex
er
ci
se
s
Pa
in
 d
ur
in
g 
ac
ti
vi
ty
 
(s
ho
rt
-t
er
m
)
Sc
al
e 
(0
 to
 1
0;
 h
ig
he
r 
sc
or
es
 m
ea
n 
w
or
se
 
pa
in
)1
Fo
llo
w
-u
p 
ra
ng
e:
 4
 
w
ee
ks
 to
 3
 m
on
th
s
Th
e 
m
ea
n 
pa
in
 in
 th
e 
kn
ee
 e
xe
rc
is
es
 g
ro
up
 
ra
ng
ed
 fr
om
 2
.0
 to
 5
.0
 
po
in
ts
2
Th
e 
m
ea
n 
pa
in
 d
ur
in
g 
ac
tiv
ity
 in
 th
e 
hi
p 
+ 
kn
ee
 e
xe
rc
is
e 
gr
ou
p 
w
as
 2
.0
2 
lo
w
er
 (3
.8
0 
lo
w
er
 to
 0
.6
0 
hi
gh
er
)
M
D
 -2
.0
2
(-3
.8
0 
to
 -0
.6
0)
10
4
(3
 s
tu
di
es
)
⊕
⊝
⊝
⊝
ve
ry
 lo
w
3
U
su
al
 p
ai
n 
(s
ho
rt
-
te
rm
)
VA
S 
(0
 to
 1
0;
 h
ig
he
r 
sc
or
es
 m
ea
n 
w
or
se
 
pa
in
)
Fo
llo
w
-u
p:
 4
 to
 6
 
w
ee
ks
Th
e 
m
ea
n 
pa
in
 in
 th
e 
kn
ee
 e
xe
rc
is
es
 g
ro
up
 
ra
ng
ed
 fr
om
 4
.0
 to
 4
.8
 
po
in
ts
2
Th
e 
m
ea
n 
us
ua
l p
ai
n 
in
 
th
e 
hi
p 
+ 
kn
ee
 e
xe
rc
is
e 
gr
ou
p 
w
as
 1
.7
7 
lo
w
er
 
(2
.7
8 
to
 0
.7
6 
lo
w
er
)
M
D
 -1
.7
7
(-2
.7
8 
to
 -0
.7
6)
46 (2
 s
tu
di
es
)
⊕
⊝
⊝
⊝
ve
ry
 lo
w
4
Pa
in
 d
ur
in
g 
ac
ti
vi
ty
 
(lo
ng
-t
er
m
)
N
PR
S 
(0
 to
 1
0;
 h
ig
he
r 
sc
or
es
 m
ea
n 
w
or
se
 
pa
in
)
Fo
llo
w
-u
p:
 1
2 
m
on
th
s
Th
e 
m
ea
n 
pa
in
 in
 th
e 
kn
ee
 e
xe
rc
is
es
 g
ro
up
 
w
as
 6
.4
 p
oi
nt
s2
Th
e 
m
ea
n 
pa
in
 d
ur
in
g 
ac
tiv
ity
 in
 th
e 
kn
ee
 +
 
hi
p 
ex
er
ci
se
 g
ro
up
 w
as
 
3.
90
 lo
w
er
 (4
.4
6 
to
 3
.3
4 
lo
w
er
)
M
D
 -3
.9
0
(-4
.4
6 
to
 -3
.3
4)
49 (1
 s
tu
dy
)
⊕
⊝
⊝
⊝
ve
ry
 lo
w
5
U
su
al
 p
ai
n 
(lo
ng
-
te
rm
)
Se
e 
co
m
m
en
t
Se
e 
co
m
m
en
t
N
ot
 e
st
im
ab
le
-
Se
e 
co
m
m
en
t
N
ot
 m
ea
su
re
d 
in
 a
ny
 o
f t
he
 7
 s
tu
di
es
 
m
ak
in
g 
th
is
 c
om
pa
ris
on
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Su
m
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 fi
nd
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 ta
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e 
fo
r c
om
pa
ri
so
n 
3d
I. 
(c
on
tin
ue
d)
O
ut
co
m
es
Ill
us
tr
at
iv
e 
co
m
pa
ra
ti
ve
 ri
sk
s*
 (9
5%
 C
I)
Re
la
ti
ve
 e
ff
ec
t
(9
5%
 C
I)
N
o 
of
 
pa
rt
ic
ip
an
ts
(s
tu
di
es
)
Q
ua
lit
y 
of
 th
e 
ev
id
en
ce
(G
RA
D
E)
Co
m
m
en
ts
A
ss
um
ed
 ri
sk
Co
rr
es
po
nd
in
g 
ri
sk
kn
ee
 e
xe
rc
is
es
H
ip
 +
 k
ne
e 
ex
er
ci
se
s
Fu
nc
ti
on
al
 a
bi
lit
y 
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ho
rt
-t
er
m
)
Sc
al
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(0
 to
 1
00
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hi
gh
er
 s
co
re
s 
m
ea
n 
be
tt
er
 fu
nc
ti
on
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Fo
llo
w
-u
p 
ra
ng
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w
ee
ks
 to
 3
 m
on
th
s
Th
e 
m
ea
n 
di
ffe
re
nc
e 
in
 fu
nc
tio
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lit
y 
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ho
rt
-t
er
m
) i
n 
th
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hi
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kn
ee
 e
xe
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is
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gr
ou
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w
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st
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de
vi
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lo
w
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hi
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D
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17
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tu
di
es
)
⊕
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⊝
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ve
ry
 lo
w
7
In
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rd
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 in
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rp
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t t
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se
 re
su
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 in
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 th
e 
A
KP
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 w
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 v
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SD
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w
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er
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lo
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ig
he
r)
Fu
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al
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bi
lit
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(lo
ng
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m
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Sc
al
e 
(0
 to
 1
00
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hi
gh
er
 s
co
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m
ea
n 
be
tt
er
 fu
nc
ti
on
)8
Fo
llo
w
-u
p 
ra
ng
e:
 5
 to
 
12
 m
on
th
s
Th
e 
m
ea
n 
di
ffe
re
nc
e 
in
 
fu
nc
tio
na
l a
bi
lit
y 
(lo
ng
-
te
rm
) i
n 
th
e 
hi
p 
an
d 
kn
ee
 e
xe
rc
is
e 
gr
ou
p 
w
as
 1
.4
9 
st
an
da
rd
 
de
vi
at
io
ns
 h
ig
he
r
(0
.1
7 
lo
w
er
 to
 3
.1
5 
hi
gh
er
)
SM
D
 1
.4
9
(-0
.1
7 
to
 3
.1
5)
78 (2
 s
tu
di
es
)
⊕
⊝
⊝
⊝
ve
ry
 lo
w
9
In
 o
rd
er
 to
 in
te
rp
re
t t
he
se
 re
su
lts
 in
 
te
rm
s 
of
 th
e 
A
KP
S,
 w
e 
sc
al
ed
 v
al
ue
s 
to
 0
 to
 1
00
 a
nd
 m
ul
tip
lie
d 
th
e 
SM
D
 b
y 
th
e 
m
ed
ia
n 
SD
 o
f t
he
 A
KP
S 
(1
1.
1)
Th
e 
m
ea
n 
fu
nc
tio
na
l a
bi
lit
y 
(s
ho
rt
-
te
rm
) i
n 
th
e 
hi
p 
+ 
kn
ee
 e
xe
rc
is
es
 
gr
ou
p 
w
as
 a
n 
es
tim
at
ed
 1
6.
54
 h
ig
he
r
(1
.8
9 
lo
w
er
 to
 3
4.
97
 h
ig
he
r)
Re
co
ve
ry
 lo
ng
-t
er
m
N
um
be
r o
f p
at
ie
nt
s 
at
 le
as
t m
od
er
at
el
y 
be
tt
er
Fo
llo
w
-u
p:
 5
 m
on
th
s
68
8 
pe
r 1
00
02
92
2 
pe
r 1
00
0
(6
40
 to
 1
00
0)
RR
 1
.3
4
(0
.9
3 
to
 1
.9
4)
29 (1
 s
tu
dy
)
⊕
⊝
⊝
⊝
ve
ry
 lo
w
10
Th
es
e 
da
ta
 e
qu
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e 
to
 2
34
 m
or
e 
(9
5%
 
CI
 4
8 
fe
w
er
 to
 3
12
 m
or
e)
 p
ar
tic
ip
an
ts
 
pe
r 1
00
0 
w
ho
 w
ou
ld
 h
av
e 
re
co
ve
re
d 
in
 th
e 
lo
ng
 te
rm
 a
s 
a 
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su
lt 
of
 h
ip
 a
nd
 
kn
ee
 e
xe
rc
is
e
*T
he
 b
as
is
 fo
r t
he
 a
ss
um
ed
 ri
sk
 is
 p
ro
vi
de
d 
in
 th
e 
fo
ot
no
te
s. 
Th
e 
co
rr
es
po
nd
in
g 
ris
k 
(a
nd
 it
s 
95
%
 c
on
fid
en
ce
 in
te
rv
al
) i
s 
ba
se
d 
on
 th
e 
as
su
m
ed
 ri
sk
 in
 th
e 
co
m
pa
ris
on
 g
ro
up
 a
nd
 
th
e 
re
la
tiv
e 
eff
ec
t o
f t
he
 in
te
rv
en
tio
n 
(a
nd
 it
s 
95
%
 C
I).
A
KP
S:
 A
nt
er
io
r K
ne
e 
Pa
in
 S
co
re
; C
I: 
co
nfi
de
nc
e 
in
te
rv
al
; M
D
: m
ea
n 
di
ffe
re
nc
e;
 N
PR
S:
 n
um
er
ic
al
 p
ai
n 
ra
tin
g 
sc
or
e;
 R
R:
 ri
sk
 ra
tio
; S
M
D
: s
ta
nd
ar
di
se
d 
m
ea
n 
di
ffe
re
nc
e;
 V
A
S:
 v
is
ua
l 
an
al
og
ue
 s
ca
le
/s
co
re
G
RA
D
E 
W
or
ki
ng
 G
ro
up
 g
ra
de
s 
of
 e
vi
de
nc
e
H
ig
h 
qu
al
ity
: F
ur
th
er
 re
se
ar
ch
 is
 v
er
y 
un
lik
el
y 
to
 c
ha
ng
e 
ou
r c
on
fid
en
ce
 in
 th
e 
es
tim
at
e 
of
 e
ffe
ct
.
M
od
er
at
e 
qu
al
ity
: F
ur
th
er
 re
se
ar
ch
 is
 li
ke
ly
 to
 h
av
e 
an
 im
po
rt
an
t i
m
pa
ct
 o
n 
ou
r c
on
fid
en
ce
 in
 th
e 
es
tim
at
e 
of
 e
ffe
ct
 a
nd
 m
ay
 c
ha
ng
e 
th
e 
es
tim
at
e.
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Lo
w
 q
ua
lit
y:
 F
ur
th
er
 re
se
ar
ch
 is
 v
er
y 
lik
el
y 
to
 h
av
e 
an
 im
po
rt
an
t i
m
pa
ct
 o
n 
ou
r c
on
fid
en
ce
 in
 th
e 
es
tim
at
e 
of
 e
ffe
ct
 a
nd
 is
 li
ke
ly
 to
 c
ha
ng
e 
th
e 
es
tim
at
e.
Ve
ry
 lo
w
 q
ua
lit
y:
 W
e 
ar
e 
ve
ry
 u
nc
er
ta
in
 a
bo
ut
 th
e 
es
tim
at
e.
Fo
ot
no
te
s
1 D
at
a 
w
er
e 
fr
om
 V
A
S 
(0
 to
 1
0)
 a
nd
 N
PR
S 
(0
 to
 1
0)
. W
e 
sc
al
ed
 v
al
ue
s 
to
 0
 to
 1
0 
(h
ig
he
r i
s 
w
or
se
). 
Th
es
e 
m
ea
su
re
s 
ar
e 
co
m
pa
ra
bl
e 
an
d 
th
us
 w
e 
ca
lc
ul
at
ed
 M
D
s.
2 T
he
 b
as
is
 fo
r t
he
 a
ss
um
ed
 ri
sk
 is
 th
e 
ra
ng
e 
of
 th
e 
co
nt
ro
l g
ro
up
 ri
sk
 o
f t
he
 s
tu
di
es
.
3 In
 o
ur
 a
ss
es
sm
en
t o
f t
he
 q
ua
lit
y 
of
 th
e 
ev
id
en
ce
 fo
r t
hi
s 
ou
tc
om
e,
 w
e 
do
w
ng
ra
de
d 
on
e 
le
ve
l f
or
 ri
sk
 o
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ia
s 
(r
el
at
in
g 
to
 la
ck
 o
f a
ss
es
so
r b
lin
di
ng
), 
on
e 
le
ve
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or
 im
pr
ec
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si
on
 (w
id
e 
co
nfi
de
nc
e 
in
te
rv
al
s 
an
d 
sm
al
l s
am
pl
e 
si
ze
) a
nd
 o
ne
 le
ve
l f
or
 s
er
io
us
 in
co
ns
is
te
nc
y 
(h
et
er
og
en
ei
ty
: P
 v
al
ue
 =
 0
.0
04
, I
2  =
 8
2%
).
4 In
 o
ur
 a
ss
es
sm
en
t o
f t
he
 q
ua
lit
y 
of
 th
e 
ev
id
en
ce
 fo
r t
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s 
ou
tc
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do
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ng
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id
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e 
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l s
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ze
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5 In
 o
ur
 a
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es
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en
t o
f t
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 q
ua
lit
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 th
e 
ev
id
en
ce
 fo
r t
hi
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ou
tc
om
e,
 w
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do
w
ng
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de
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on
e 
le
ve
l f
or
 ri
sk
 o
f b
ia
s 
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la
tin
g 
to
 la
ck
 o
f a
ss
es
so
r b
lin
di
ng
) a
nd
 tw
o 
le
ve
ls
 fo
r s
er
i-
ou
s 
im
pr
ec
is
io
n.
6 D
at
a 
w
er
e 
fr
om
 th
e 
lo
w
er
 e
xt
re
m
ity
 fu
nc
tio
n 
sc
al
e 
(L
EF
S)
 s
co
re
 (0
 to
 8
0)
 in
 o
ne
 s
tu
dy
, A
KP
S 
(0
 to
 1
00
) i
n 
tw
o 
st
ud
ie
s 
an
d 
Ly
sh
ol
m
 (0
 to
 1
00
) i
n 
on
e 
st
ud
y.
 W
e 
re
sc
al
ed
 
da
ta
 fr
om
 th
e 
LE
FS
 to
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 to
 1
00
.
7 In
 o
ur
 a
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t o
f t
he
 q
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 th
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et
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: P
 v
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ue
 <
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8 D
at
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w
er
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fr
om
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lo
w
er
 e
xt
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e 
(L
EF
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 o
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 W
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LE
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00
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 b
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w
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 o
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 d
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 d
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Structural abnormalities on MRI in 
patients with patellofemoral pain:  
a cross-sectional case-control study
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ABSTRACT
Background
Structural abnormalities of the patellofemoral joint might play a role in the pathogen-
esis of patellofemoral pain (PFP), a common knee problem among young and physically 
active individuals. No previous study has investigated if PFP is associated with structural 
abnormalities of the patellofemoral joint using high-resolution magnetic resonance 
imaging (MRI).
Purpose: This study aims to investigate the presence of structural abnormalities of the 
patellofemoral joint on high-resolution MRI in patients with PFP compared to healthy 
control subjects.
Study Design
Case-control study.
methods
Patients with PFP and healthy control subjects aged between 14 and 40 years under-
went high-resolution MRI at 3T. All images were scored using the Magnetic Resonance 
Imaging Osteoarthritis Knee Score (MOAKS) with the addition of specific patellofemoral 
features. Associations between PFP and the presence of structural abnormalities were 
analysed using logistic regression analyses, adjusted for age, BMI, sex and sports partici-
pation.
Results
64 patients and 70 control subjects were included. Mean age was 23.2 (6.4) year, mean 
BMI 22.9 (3.4) and 56.7% was female. Full thickness cartilage loss was not present. Minor 
patellar cartilage defects, patellar bone marrow lesions (BMLs) and high signal intensity 
of Hoffa’s fat pad were frequently seen in both patients (23%, 53% and 58% respectively) 
and control subjects (21%, 51% and 51% respectively). After adjustment for age, BMI, 
sex and sports participation, none of the structural abnormalities were statistically 
significantly associated with PFP.
Conclusions
Many structural abnormalities of the patellofemoral joint were seen on MRI in this rela-
tively young population, but none of them were associated with PFP.
Clinical Relevance: Structural abnormalities of the patellofemoral joint have been hy-
pothesized as a factor in the pathogenesis of PFP, but our findings suggest that structural 
abnormalities of the patellofemoral joint on MRI are not associated with PFP.
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INTRODUCTION
Patellofemoral pain (PFP) is a common knee condition, defined as retro or peripatellar 
pain that occurs during knee loading activities, like running, cycling, squatting, stair 
climbing and during prolonged sitting with the knees bent. PFP is particularly present 
among young and physically active individuals and may account for up to 40% of all 
knee problems seen in sports injury clinics.1-4 PFP can have a debilitating effect, because 
of the common recurrence of symptoms, tendency to chronicity and its impact on physi-
cal activity levels.5-8 A variety of treatments, such as exercise therapy and orthoses, are 
applied, but reported effects are moderate and a substantial group of patients with per-
sistent complaints remains.9-13 In order to develop better-targeted treatment modalities 
there is a need to elucidate the pathogenesis of PFP. Although there is consensus that 
the etiology of PFP is multifactorial, precise contributing factors to the pathogenesis of 
pain are still not well understood.
In the 20th century it was believed that PFP was caused by chondromalacia. However, ar-
throscopic studies clarified that PFP is not necessarily related to cartilage defects, which 
was confirmed by the MRI study of Kannus et al.4,6,14,15 Still, minor cartilage defects, such 
as signal abnormalities, fraying or fissuring, and hypertrophy, could potentially have 
been undetected up to now. Nowadays, it is possible to detect even very small cartilage 
defects with the use of high-resolution magnetic resonance imaging (MRI). In addition, 
abnormalities of the patellar retinaculum, synovial plicae, Hoffa’s fat pad and subchon-
dral bone marrow have been mentioned in literature over the past years as possible 
source of pain, but have not yet been investigated systematically in a PFP population 
with high-resolution MRI.4,16-19 Hypothetically, more abnormalities are expected to be 
present in patients with PFP.
Therefore, this study will investigate the possible association between PFP and the pres-
ence of structural abnormalities of the patellofemoral joint. Based on the degenerative 
process with aging, as seen in OA, more abnormalities were expected in adult patients. 
Therefore, differences in number of abnormalities between adolescent and adult pa-
tients were also evaluated. This may eventually lead to a better understanding of the 
pathogenesis of patellofemoral pain.
mATERIALS AND mETHODS
Study design and participants
A cross-sectional case-control study was conducted between January 2013 and Sep-
tember 2014 including patients with PFP for two months up to two years and healthy 
control subjects without any type of knee complaints. All subjects were aged between 
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14 and 40 years. Patients diagnosed with PFP were recruited by general practitioners, 
sports physicians and physiotherapists and had to fulfil the following criteria: the pres-
ence of at least three of the following symptoms: retro or peripatellar pain while walking 
up or down stairs; while squatting; while running; while cycling; while sitting with knees 
flexed for a prolonged period of time, or grinding of the patella. Patients were excluded 
if they had other defined pathological conditions of the affected knee at present such 
as patellar tendinopathy or osteoarthritis, if the onset of PFP occurred after trauma or 
if they had previous knee injuries or surgery or previous episodes of PFP more than 
two years ago. Control subjects were recruited from patients’ sports team members, 
friends or among the university (employees and students). We aimed to match control 
subjects on age, BMI, sex and activity level. Control subjects were excluded if they were 
first grade family members of patients or if they had patellofemoral pain at present or in 
the past, traumatic injury or surgery of both knees. Furthermore, all study participants 
had to have sufficient knowledge of the Dutch language and no contra-indications for 
MRI scanning with contrast administration (not used for current study purpose). Written 
informed consent was obtained from all participants (and parents/wardens in the case 
of subjects <18 years) and the study was approved by the Institutional Review Board 
(Medical Ethical Committee of Erasmus MC, protocol MEC-2012- 342).
measurements
After signing informed consent, study participants were asked to fill in an online ques-
tionnaire, including questions on demographics (age, sex, BMI), sports participation at 
the time of inclusion and before onset of pain (yes or no) and knee complaints (duration 
of complaints, pain at rest and during activity (Numerical Rating Scale (NRS) 0-10) and 
Anterior Knee Pain (AKP) score 0-10020). Subsequently, they were invited for a physical 
examination (including crepitation during squatting (present or not), palpation of the 
medial patellar facet (painful or not) and Clarke’s compression test21 (positive or nega-
tive)) and MRI scan at our university medical center. In patients, the (most) affected knee 
was selected for physical examination and MRI, or randomly chosen if both knees were 
equally painful. For control subjects, a randomly selected knee was used for both physi-
cal examination and MRI.
MRI was performed at 3 Tesla(T) (Discovery MR750, GE Healthcare, Milwaukee, WI, USA) 
with a dedicated eight-channel knee coil (Invivo Inc., Gainesville, USA). The MRI protocol 
comprised sagittal, axial and coronal fast spin echo proton density weighted sequences 
with a slice thickness of 3 mm and sagittal, axial T2 weighted sequences with fat sup-
pression with a slice thickness of 3 mm. Furthermore, a 3D high-resolution sagittal fat-
saturated spoiled gradient-echo (SPGR) sequence was acquired with a slice thickness of 
0.5 mm, a repetition time of 17 milliseconds (ms), an echo time of 5.4ms, a flip angle of 
12 degrees, a 288x192 matrix and a 15 cm field of view.
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Assessment of mRI features
All MRI scans were scored primarily by a senior resident in radiology with musculoskeletal 
subspecialisation, who was blinded for participant status, using the semi-quantitative 
Magnetic Resonance Imaging Osteoarthritis Knee Score (MOAKS). Subsequently, all 
findings were discussed with an experienced musculoskeletal radiologist, who was 
also blinded for participant status and made the final determination. The MOAKS was 
developed to evaluate articular cartilage loss in conjunction with surrounding bony and 
soft tissue abnormalities, including bone marrow lesions (BML’s), osteophytes, lesions of 
the menisci, ligaments, and tendons, joint effusion and periarticular features (i.e., ilio-
tibial band abnormalities, ganglion cysts).22 Since the MOAKS was primarily developed 
to study osteoarthritis, several additional patellofemoral joint features, possibly more 
applicable for this young population, were added (See appendix 1).16 These additional 
features included minor defects of cartilage (high signal intensity, fraying or fissuring, 
hypertrophy), medial patellar plica thickness and width, avascular necrosis, stress frac-
tures, thickening of patellar tendon, quadriceps tendon and retinaculum and high signal 
intensity of retinaculum, quadriceps tendon and fat pads (superolateral part of Hoffa’s 
fat pad, quadriceps fat pad and prefemoral fat pad according to Chhabra et al.16). High 
signal intensity was defined as an abnormally high signal intensity on T2-weighted im-
ages of a certain structure. Hypertrophy was seen as a result of cartilage swelling. Fray-
ing, a shredded appearance on MRI, is supposed to be the results of fibrillation of the 
cartilage surface. Fissuring comprises small cracks in the cartilage surface. Furthermore, 
in the MOAKS score the complete anterior femur is scored as trochlea.22 Since we fo-
cused on the patellofemoral joint, we subdivided this total anterior femur in a subregion 
which comprises solely the trochlea and a, medial and lateral condylar subregion. This 
was done for cartilage loss, and BML’s. With regard to the additional scoring of minor 
cartilage defects, only the trochlear subregion and patella were scored.
Items were clustered and dichotomized to reduce the large number of MRI features. The 
MOAKS category ‘size’ was used for dichotomizing cartilage loss and BMLs. If size was 0 
the feature was scored negative, if size>1 the feature was scored positive. Osteophytes 
were scored positive if their size was small to large and effusion if a medium to large 
amount was present Thickening and high signal intensity were clustered in case of ten-
dons or ligaments. Minor cartilage defects was scored positive if high signal intensity or 
fraying/fissuring or hypertrophy was present. Plica thickening or widening was scored 
positive in case of grade 3 for either thickness (≥3mm) or width (being sufficient to reach 
the midline in a non-distended joint) according to the grading of Boles et al.23
Statistical analysis
Statistical analyses were performed with SPSS for Windows, version 20 (SPSS Inc., 
Chicago, IL, USA). If normal distribution was present, Chi-square test for dichotomous 
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variables and independent sample t-test for continuous variables were used to compare 
differences in characteristics between patients and control subjects, but also between 
adults and adolescent patients (aged <18 years). Otherwise, a Mann-Whitney U test 
was applied. Associations between patellofemoral pain and the presence of structural 
abnormalities were analysed using logistic regression analyses. In addition, logistic re-
gression analyses were applied to test potential differences between adolescent and 
adult patients in the presence of structural abnormalities. Regression analyses were 
adjusted for the potential confounders: age, sex, BMI and sports participation. Results 
are presented as Exp(B) with 95% confidence intervals and adjusted p-values. P -values 
<0.05 were considered statistically significant.
RESULTS
Participants
64 patients (Figure 1) and 70 control subjects were included between January 2013 and 
September 2014, of which 40, equally distributed between groups, were adolescents.
Mean age was 23.2 (6.4) years, mean BMI was 22.9 (3.4) kg/m2 and 56.7% was female. A 
significant difference between PFP patients and control subjects was observed in BMI 
(higher in patient group) and percentage of sports participants (higher in the control 
group) (Table 1).
Figure 1. Flowchart of recruited patients
Structural abnormalities on MRI in patelloremoral pain 147
Compared to adult patients, function (AKP score) was significantly lower in adolescent 
patients. Bilateral knee pain and painful palpation of the medial patellar facet were 
significantly more present in adolescents compared to adult patients (Table 2).
Structural abnormalities on mRI
The results described in Table 3 are the key outcomes from the regression analyses 
based on adjusted p-values.
Table 1. Characteristics of study participants.
Patients
(N=64)
Controls
(N=70) P-value
Female sex n (%) 35 (54.7) 41 (58.6) 0.65
Age (years) Mean (SD) 23.4 (7.0) 23.1 (5.9) 0.88*
BmI (kg/m²) Mean (SD) 23.6 (3.8) 22.3 (3.0) 0.04*
Sports participants
at study inclusion n (%) 38 (59.4) 55 (78.6) 0.02 
before onset of pain n (%) 56 (87.5) n.a. 
Presence of crepitation n (%) 29 (45.3) 20 (28.6) 0.05
Painful palpation medial patellar facet n (%) 31 (48.4) 0 (0) <0.001
Positive Clarke compression test n (%) 14 (21.9) 2 (2.9) 0.001
N.A.: not applicable; *non-parametric testing
Table 2. Characteristics of PFP patient population, subdivided in adults and adolescents
Adolescents
(N=20)
Adults
(N=44) P-value
Female sex n (%) 14 (70) 21 (47.7) 0.10
Age (years) Mean (SD) 15.9 (1.2) 26.8 (5.8) <0.001*
BmI (kg/m2) Mean (SD) 20.7 (2.1) 24.9 (3.7) <0.001*
Sport participants
during study n (%) 10 (50.0) 28 (63.6) 0.30 
before onset of pain n (%) 15 (75.0) 41 (93.2) 0.04 
Duration of complaints (months) Mean (SD) 14.2 (8.2) 11.0 (6.4) 0.14*
Bilateral knee pain n (%) 14 (70.0) 19 (43.2) 0.047
Pain at rest (NRS 0-10) Mean (SD) 3.75 (2.2) 4.00 (2.6) 0.71
Pain during activity (NRS 0-10) Mean (SD) 7.15 (1.9) 6.32 (2.3) 0.17
Function (AKP Score 0-100) Mean (SD) 60.6 (10.7) 68.7 (11.7) 0.17
Presence of crepitation n (%) 4 (20.0) 11 (25.0) 0.17
Painful palpation medial patellar facet n (%) 14 (70.0) 17 (38.6) 0.02
Positive Clarke compression test n (%) 6 (30.0) 8 (18.2) 0.29
*non-parametric testing
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Table 3. Presence of structural abnormalities of the patellofemoral joint on MRI (n (%))
Patients
(N=64)
Controls
(N=70) P-value Exp (B) (95% CI)
Adjusted 
P-value
Cartilage loss; full thickness
Patella 0 (0) 0 (0) n.a. n.a. n.a. 
Femur anterior 0 (0) 0 (0) n.a. n.a. n.a. 
trochlea 0 (0) 0 (0) n.a. n.a. n.a. 
medial condyle 0 (0) 0 (0) n.a. n.a. n.a. 
lateral condyle 0 (0) 0 (0) n.a. n.a. n.a. 
Cartilage loss; partial thickness 
Patella 6 (9.4) 1 (1.4) 0.04 0.16 (0.02;1.48) 0.11 
Femur anterior 3 (4.8) 0 (0) 0.07 0.00 (0.00;n.a.) 1.00 
trochlea 1(1.6) 0 (0) 0.29 0.00 (0.00;n.a.) 1.00 
medial condyle 0 (0) 0 (0) n.a. n.a. n.a. 
lateral condyle 2 (3.2) 0 (0) 0.14 0.00 (0.00;n.a.) 1.00 
minor cartilage defects; high signal /hypertrophy/fraying
Patella 15 (23.4) 15 (21.4) 0.78 0.96 (0.39;2.36) 0.93 
Trochlea 2 (3.1) 0 (0) 0.14 0.00 (0.00;n.a.) 1.00 
Bone marrow lesions
Patella 34 (53.1) 36 (51.4) 0.84 0.96 (0.46;2.02) 0.92 
Femur anterior 5 (7.8) 8 (11.4) 0.48 0.95 (0.27;3.30) 0.94 
trochlea 3 (4.7) 2 (2.9) 0.63 0.39 (0.06;2.62) 0.33 
medial condyle 0 (0) 3 (4.3) 0.09 2.95*107 (0.00;n.a.) 1.00 
lateral condyle 0 (0) 2 (2.9) 0.17 2.66*107 (0.00;n.a.) 1.00 
Osteophytes; small to large
Patella 45 (70.3) 42 (60.0) 0.21 0.61 (0.28;1.33) 0.21 
Femur anterior 12 (18.8) 9 (12.9) 0.35 0.64 (0.24;1.72) 0.37 
Effusion; medium to large 4 (6.3) 11 (15.7) 0.08 2.36 (0.64;8.77) 0.20
meniscus
High signal 10 (22.7) 3 (6.0) 0.03 0.29 (0.07;1.17) 0.08 
maceration 0 (0) 0 (0) n.a. n.a. n.a. 
Tear 2 (3.1) 0 (0) 0.14 0.00 (0.00;n.a.) 1.00 
Cyst 1(1.6) 0 (0) 0.29 0.00 (0.00;n.a.) 1.00 
Hypertrohpy 0 (0) 0 (0) n.a. n.a. n.a. 
Extrusion; >2mm 10 (22.7) 9 (12.9) 0.65 0.74 (0.27;2.05) 0.57 
Cruciate ligament tear
ACL 1(1.6) 0 (0) 0.29 0.0 (0.00;n.a.) 0.96 
PCL 0 (0) 0 (0) n.a. n.a. n.a. 
Tendon thickening or high signal
Patellar 24 (37.5) 21(30.0) 0.36 1.10 *0.49;2.47) 0.82 
Quadriceps 10 (22.7) 8 (11.4) 0.48 0.52 (0.18;1.56) 0.24 
Retinaculum thickening or high signal
medial 0 (0) 1 (1.4) 0.34 1.5*107 (0.00;n.a.) 1.00 
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Most frequently found abnormalities in both patients and control subjects were mi-
nor cartilage defects of the patella (high signal or hypertrophy or fraying) (23.4% vs. 
21.4%), patellar BMLs (53.1% vs. 51.4%), patellar osteophytes (70.3% vs. 60.0%), high 
signal intensity of Hoffa’s fat pad superolaterally (58% vs. 51%), high signal intensity or 
thickening of the patellar tendon (37.5% vs. 30%), high signal intensity of prefemoral 
and quadriceps fat pad (70.3% vs. 65.7% and 37.5% vs. 34.3%), ganglion cyst (32.8% 
vs. 34.3%), popliteal cyst (67.2% vs. 71.4%)(Table 3). Full thickness cartilage loss of the 
patellofemoral joint was not present in this study population. Partial thickness cartilage 
loss of the patella occurred in 9% of patients and 1% of control subjects.
Osteophytes of the anterior femur occurred in 18.8% of patients and 12.9% of control 
subjects. Other structural abnormalities of the anterior femur occurred less frequently. 
For instance, partial thickness cartilage loss only occurred in three patients and not in 
control subjects. BMLs were present in five patients and eight control subjects. Minor 
cartilage defects of the trochlea were only present in two patients.
Table 3. Presence of structural abnormalities of the patellofemoral joint on MRI (n (%)) (continued)
Patients
(N=64)
Controls
(N=70) P-value Exp (B) (95% CI)
Adjusted 
P-value
Lateral 3 (4.7) 2 (2.9) 0.58 0.51 (0.06;4.67) 0.55 
Plica thickening or widening 3 (4.7) 1 (1.4) 0.27 0.16 (0.01;1.79) 0.14
Hoffa’s fat pad
Edema; moderate to severe 3 (4.7) 6 (8.6) 0.50 1.55 (0.34;7.08) 0.58 
High signal superolaterally 37 (57.8) 36 (51.4) 0.46 0.80 (0.39;1.66) 0.55 
Fat pad high signal
Prefemoral 45 (70.3) 46 (65.7) 0.57 0.85 (0.37;1.95) 0.70 
Quadriceps 24 (37.5) 24 (34.3) 0.70 0.90 (0.42;1.95) 0.80 
Pes anserinus
Bursitis 2 (3.1) 1(1.4) 0.80 n.a. n.a. 
Tendinitis 0 (0) 0 (0) n.a n.a. n.a. 
Iliotibial band high signal 1(1.6) 1 (1.4) 0.95 0.27 (0.01;10.89) 0.49
Cyst
Ganglion 21(32.8) 24 (34.3) 0.86 1.37 (0.62;3.03) 0.43 
Popliteal 43 (67.2) 50 (71.4) 0.60 1.05 (0.48;2.32) 0.90 
Bursa high signal; large
Infrapatellar 15 (23.4) 14 (20.0) 0.63 0.88 (0.36;2.14) 0.72 
Prepatellar 1 (1.6) 1 (1.4) 0.95 5.00 (0.13;187.94) 0.39 
Loose bodies 0 (0) 0 (0) n.a. n.a. n.a.
Stress fractures 0 (0) 0 (0) n.a. n.a. n.a.
Avascular necrosis 0 (0) 0 (0) n.a. n.a. n.a.
n.a.: not applicable, could not be calculated; CI: confidence interval.
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High signal intensity of the meniscus occurred in 22.7% of patients and 6.0% of control 
subjects. Meniscal extrusion occurred in 22.7% of patients and 12.9% of control subjects. 
Medial retinaculum thickening or high signal occurred only in 1 control subject. Plica 
thickening or widening occurred in three patients and one control subject. After adjust-
ment for age, BMI, sex and sports participation none of the structural abnormalities seen 
on MRI were statistical significantly associated with the presence of PFP.
Subgroup analyses of a selection of the abnormalities of the patellofemoral joint on 
MRI in the patient population comparing adult and adolescent patients revealed no 
significant differences between these patient groups (Table 4). Most frequently found 
abnormalities in both adult patients and adolescent patients were patellar BMLs (47.8% 
vs. 65%), patellar osteophytes (79.5% vs. 50%), high signal intensity of Hoffa’s fat pad 
superolaterally (58% vs. 51%) and high signal intensity or thickening of the patellar 
tendon (38.6% vs. 35%). Partial thickness cartilage loss of the patella occurred in 13.6% 
Table 4. Presence of structural abnormalities of the patellofemoral joint on MRI (n (%)) in patients, subdi-
vided in an adult and adolescent population
Adults
(N=44)
Adolescents
(N=20) P-value Exp (B) (95% CI)
Adjusted 
P-value
Bone marrow lesions
Patella 21 (47.8) 13 (65.0) 0.20 1.25*108 (0.21;7.94) 0.79 
Trochlea 3 (6.8) 0 (0) 0.23 1.3*108 (0.00;n.a.) 1.00 
Cartilage loss; partial thickness
Patella 6 (13.6) 0 (0) 0.08 6.75*107 (0.00;n.a.) 1.00 
Trochlea 1 (2.3) 0 (0) 0.50 3.0*106 (0.00;n.a.) 1.00 
minor cartilage defects; high signal/hypertrophy/ fraying
Patella 14 (31.8) 1 (5.0) 0.02 3.52 (0.23;53.97) 0.37 
Trochlea 2 (4.6) 0 (0) 0.33 5.11*107 (0.00;n.a.) 1.00 
Osteophytes; small to large
Patella 35 (79.5) 10 (50.0) 0.02 1.03 (0.15;7.20) 0.98 
Femur anterior 9 (20.5) 3 (15.0) 0.60 0.20 (0.01;3.04) 0.25 
meniscus
High signal 9 (20.5) 1 (5.0) 0.11 5.76 (0.35;96.17) 0.22 
Extrusion 5 (11.4) 5 (25.0) 0.16 0.34 (0.03;4.38) 0.41 
Thickening or high signal
Patellar 17 (38.6) 7 (35.0) 0.78 1.16 (0.15;9.02) 0.89 
Quadriceps 7 (15.9) 3 (15.0) 0.93 1.42 (0.11;17.7) 0.79 
Hoffa’s fat pad
Edema;moderate to severe 2 (4.6) 1 (5.0) 0.94 0.26 (0.00;73.7) 0.64 
High signal superolaterally 29 (65.0) 8 (40.0) 0.05 2.1 (0.31;14.2) 0.45 
n.a.: not applicable, could not be calculated; CI: confidence interval.
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of adult patients, but not in adolescents. Minor cartilage defects of the patella (high 
signal intensity or hypertrophy or fraying) were present in 31.8% of adult patients and 
5% of adolescent patients. Trochlear BMLs, partial thickness cartilage loss of the trochlea 
and minor cartilage defects of the trochlea only occurred in adults.
After adjustment for age, BMI, sex and sports participation no difference in presence of 
structural abnormalities of the patellofemoral joint on MRI was present between adult 
and adolescent patients.
DISCUSSION
The purpose of this study was to investigate if PFP was associated with structural ab-
normalities of the patellofemoral joint using high-resolution MRI, which enabled us to 
detect even small lesions. Full thickness cartilage loss of the patellofemoral joint was 
not present in this study population. Minor patellar cartilage defects, patellar BMLs, 
patellar osteophytes, high signal intensity of Hoffa’s fat pad and high signal intensity 
or thickening of the patellar tendon were frequently seen in both patients and control 
subjects. Structural abnormalities of the trochlea occurred less frequently. For partial 
thickness patellar cartilage loss and meniscal high signal intensity, both only present in 
small numbers, the difference between patients and control subjects was not statisti-
cally significant, but both of them occurred seemingly more in patients. Medial synovial 
plica and patellar retinaculum abnormalities were rarely seen in this population. Overall, 
our results indicate that the presence of structural abnormalities of the patellofemoral 
joint on MRI is not associated with patellofemoral pain.
Subgroup analyses comparing adult and adolescent patients showed consistently more 
abnormalities in adult patients. However, after adjustment for gender, BMI and sports 
no statistically significant differences were present between these groups. Additional 
analyses in the total study population also revealed no differences between adults and 
adolescents (data not presented).
It could be hypothesized that abnormalities are most likely to occur at the medial part of 
the patella, since this is the most frequent pain location in patellofemoral pain patients. 
Furthermore, pain might actually be located in a specific part of a surrounding structure, 
like the medial meniscus or superior patellar tendon. Therefore, explorative analyses 
of specific sub-regions of the patella (medial, lateral, superior and inferior), meniscus 
(medial and lateral) and patellar tendon (superior, middle, inferior) were performed. 
These analyses also showed no significant differences between patients with PFP and 
healthy control subjects (see Appendix 2). Differences in the presence of combinations 
of abnormalities were not tested due to a lack of power.
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Comparison with literature
So far, only one previous study by Kang et al. has investigated MRI findings in patients 
with PFP.24 However, they applied MRI at 1.5T, whereas in our study high resolution MRI 
at 3T was performed. Furthermore, their study consisted of male soldiers with a mean 
age of 22 years, whereas our study consisted of the general PFP population seeking 
care in primary care and even included a group of adolescents. Similar to our study, ab-
normalities of the patellofemoral joint (e.g. cysts, effusion, bone marrow signal change, 
meniscal lesions) were common in both patients and controls in the study by Kang et al. 
24 The prevalence of abnormalities on MRI in asymptomatic knees has been frequently 
reported in the literature.25-28 This raises the question if these features really contribute 
to the pathogenesis of knee pain and, if they do, which other factors need to be present 
in order to induce pain. Kang et al.24 did find a higher prevalence of abnormalities of the 
patellofemoral joint and the extensor mechanism in patients and especially a higher 
prevalence of thick medial plica in the patient group compared to the control group 
(9% vs. 0%). In our study plica thickening or widening occurred in two patients and one 
control subject only. This might be due to a difference in scoring as they scored medial 
patellar plicae thickening when 2 mm or more contrary to the 3 mm or more in our 
protocol, which we based on the study of Boles.23 Furthermore, it is important to notice 
that their population consisted of soldiers and, consequently, the physical activity level 
is assumed to be higher compared to our population.
It was apparent that sports participation was not associated with the presence of BMLs, 
cartilage defects and meniscal lesions, but only with the patellar tendon. For BMLs and 
cartilage defects these results are in contrast to previous literature stating that subjects 
with higher physical activity levels have a higher incidence of these abnormalities.29-34 
This might be due to the fact that we have dichotomized physical activity into sports 
participation or not instead of using a continuous scale for physical activity level.
Retropatellar cartilage damage has been implicated as a possible etiological factor for 
PFP for many years. In the 20th century, arthroscopic studies clarified that patellofemoral 
pain was not necessarily related to cartilage defects.4,14,15 This was confirmed in a MRI 
study by Kannus et al. who found no correlation between cartilage defects and patel-
lofemoral pain.6 Similar to these studies, our results indicate that cartilage defects are 
not associated with PFP. The current high-resolution imaging technique even allowed 
us to look at minor cartilage defects including high signal intensity, fraying/fissuring 
and hypertrophy. These were also not associated with the presence of PFP. Therefore, 
it seems that there is conclusive evidence that major or minor patellofemoral cartilage 
defects are not associated with PFP.
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Strengths and limitations
This is the first case-control study on structural abnormalities of the patellofemoral joint 
in PFP including a large group of PFP patients and comprising a group of adolescent 
patients who are often excluded in literature. To our knowledge, there has been no pre-
vious study in PFP using high-resolution MRI, which even enables detection of minimal 
structural abnormalities.
There are, however, some limitations to our study that need to be addressed. Our in-
tention was to match patients and controls on age, sex, BMI and sports participation. 
However, some differences were present concerning BMI and percentage of sports 
participants and therefore all analyses were adjusted for these confounders.
We used the MOAKS, a semi quantitative score primarily developed to study osteoar-
thritis on MRI. In order to make this score more appropriate for the relatively young 
population studied, some additional features were added. Therefore, we feel that we 
covered all potential items.
Finally, a lack of power might be the reason that we did not find an association between 
certain structural abnormalities and PFP. Although a higher percentage of partial thick-
ness patellar cartilage loss and more frequent meniscal high signal intensity were pres-
ent in PFP patients compared to control subjects, these differences were not statistically 
significant. Though, this is one of the largest case-control studies in the patellofemoral 
pain research field we lacked power due to the small numbers of abnormalities found 
in the study population. However, since these abnormalities are present in such small 
numbers, their contribution to the pathogenesis of PFP is unlikely.
CONCLUSION
A large number of structural abnormalities of the patellofemoral joint on MRI were seen 
in this relatively young population. Our results indicate that structural abnormalities of 
the patellofemoral joint on MRI are not associated with patellofemoral pain.
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APPENDIX
Appendix 1. Scoring of additional patellofemoral features on MRI
mRI feature Scoring mRI pulse sequence
Signal abnormalities of cartilage Absent/present Sagittal and axial PD and T2FS 
sequences
Hyperthrophy of cartilage Absent/present Sagittal and axial PD and T2FS 
sequences
Fraying/fissuring of cartilage Absent/present Sagittal and axial PD and T2FS 
sequences
Thickening patellar tendon Absent/present Sagittal and axial PD and T2FS 
sequences
Thickening or high signal 
quadriceps tendon
Absent/present Sagittal and axial PD and T2FS 
sequences
Thickening or high signal 
retinaculum
Absent/present Axial PD and T2FS sequences
Plica thickening 1: less than 1mm
2: less than 3mm
3: 3mm or greater
Axial PD and T2FS sequences
Plica width 1: being a small ridge
2:  being a width large enough to 
reach the trochlear cartilage of 
no joint fluid were present
3:  being sufficient to reach the 
midline in a non-distended joint
Axial PD and T2FS sequences
Signal abnormality fatpad (3x) Absent/present Sagittal and axial PD and T2FS 
sequences
Pes anserinus tendinitis Absent/present Sagittal and axial PD and T2FS 
sequences
Infrapatellar and prepatellar bursa 
high signal
Small/medium/large Sagittal and axial PD and T2FS 
sequences
Stress fracture Absent/present Sagittal, coronal and axial PD and 
T2FS sequences
PD=proton density, T2FS=T2-weighted with fat suppression.
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Appendix 2. Presence of structural abnormalities on MRI in subregions (n (%))
Patients
(N=64)
Controls
(N=70) P-value Exp (B) (95%CI)
Adjusted 
P-value
Cartilage loss; partial thickness
Patella
medial 4 (6.3) 1 (1.4) 0.14 0.25 (0.03;2.50) 0.24 
Lateral 2 (3.1) 0 (0) 0.14 0.00 (0.00;n.a.) 1.00 
Superior 2 (3.1) 0 (0) 0.14 0.00 (0.00;n.a.) 1.00 
Inferior 5 (7.8) 1 (1.4) 0.07 1.78 (0.02;1.67) 0.13 
Bone marrow lesions
Patella 
medial 26 (40.6) 23 (32.9) 0.35 0.67 (0.31;1.43) 0.30 
Lateral 22 (34.4) 24 (34.3) 0.99 1.02 (0.48;2.17) 0.96 
Superior 10 (15.6) 10 (14.3) 0.83 1.03 (0.38;2.82) 0.95 
Inferior 31 (48.4) 31 (44.3) 0.63 0.76 (0.36;1.59) 0.47 
minor cartilage defects; high signal, hypertrophy, fraying
Patella
medial 11 (17.2) 8 (11.4) 0.34 0.58 (0.19;1.74) 0.33 
Lateral 9 (14.1) 8 (11.4) 0.65 0.77 (0.26;2.24) 0.63 
Superior 11 (17.2) 13 (14.3) 0.84 1.29 (0.49;3.41) 0.61 
Inferior 13 (20.3) 7 (10.0) 0.07 0.35 (0.11;1.05) 0.06 
Osteophytes; small to large
Patella 
medial 23 (35.9) 25 (35.7) 0.98 1.05 (0.50;2.21) 0.90 
Lateral 19 (29.7) 19 (27.1) 0.74 0.78 (0.34;1.82) 0.57 
Superior 19 (29.7) 27 (38.6) 0.28 1.60 (0.73;3.52) 0.24 
Inferior 26 (40.6) 18 (25.7) 0.10 0.50 (0.23;1.10) 0.09 
meniscus
High signal 
medial 6 (9.4) 2 (2.9) 0.11 0.33 (0.06;1.78) 0.20 
Lateral 4 (6.3) 3 (4.3) 0.61 0.90 (0.17;4.86) 0.90 
Extrusion 
medial 9 (14.1) 8 (11.4) 0.65 0.70 (0.24;2.02) 0.51 
Lateral 1 (1.6) 1 (1.4) 0.95 1.34 (0.07;25.7) 0.85 
Patellar tendon thickening or high signal
Superior 6 (9.4) 5 (7.1) 0.64 1.12 (0.28;4.55) 0.87 
middle 2 (3.1) 0 (0) 0.14 0.00 (0.00;n.a.) 1.00 
Inferior 20 (31.3) 17 (24.3) 0.37 1.06 (0.46;2.44) 0.90 
n.a.: not applicable, could not be calculated; CI: confidence interval.
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ABSTRACT
Background
Retropatellar cartilage damage has been suggested as an etiological factor for patel-
lofemoral pain (PFP), a common knee condition among young and physically active 
individuals. To date, there is no conclusive evidence for an association between cartilage 
defects and PFP. Nowadays, advanced quantitative magnetic resonance imaging (MRI) 
techniques enable estimation of cartilage composition.
Purpose: To investigate differences in patellofemoral cartilage composition between 
patients with PFP and healthy control sub- jects using quantitative magnetic resonance 
imaging (MRI).
Study Design
Cross-sectional study; Level of evidence, 3.
methods
Patients with PFP and healthy control subjects underwent 3.0-T MRI including delayed gad-
olinium-enhanced MRI of cartilage and T1ρ and T2 mapping. Differences in relaxation times 
of patellofemoral cartilage were compared between groups by linear regression analyses, 
adjusted for age, body mass index, sex, sports participation, and time of image acquisition.
Results
This case-control study included 64 patients and 70 controls. The mean (6SD) age was 
23.2 6 6.4 years and the mean body mass index was 22.9 6 3.4 kg/m2; 56.7% were female. 
For delayed gadolinium-enhanced MRI of cartilage, the mean T1GD relaxation times of 
patellar (657.8 vs 669.4 ms) and femoral cartilage (661.6 vs 659.8 ms) did not significantly 
differ between pa- tients and controls. In addition, no significant difference was found in 
mean T1ρ relaxation times of patellar (46.9 vs 46.0 ms) and femoral cartilage (50.8 vs 50.2 
ms) and mean T2 relaxation times of patellar (33.2 vs 32.9 ms) and femoral cartilage (36.7 
vs 36.6 ms) between patients and controls. Analysis of prespecified medial and lateral 
subregions within the patellofemoral cartilage also revealed no significant differences.
Conclusion
There was no difference in composition of the patellofemoral cartilage, estimated with 
multiple quantitative MRI techniques, between patients with PFP and healthy control 
subjects. However, clinically relevant differences could not be ruled out for T1ρ in the 
adolescent population. Retropatellar cartilage damage has long been hypothesized as 
an important factor in the pathogenesis of PFP, but study findings suggest that dimin-
ished patellofemoral cartilage composition is not associated with PFP.
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INTRODUCTION
Patellofemoral pain (PFP) is a common knee disorder, especially among young and 
physically active individuals.1 PFP is described as retro or peripatellar pain provoked by 
specific activities, such as kneeling, stair climbing, running, cycling, squatting and pro-
longed sitting with the knees flexed. On average, the general practitioner encounters 5 
to 6 new cases of PFP per 1000 patients per year, whereas the incidence reaches 22 new 
cases per 1000 persons per year in a highly physically active population.2,3 In fact, 17% 
of all patients with a new running injury in sports medicine practices are diagnosed with 
PFP.4 Despite a variety of treatment options (eg, exercise therapy, patellar taping/brac-
ing, and foot orthoses), persistent complaints remain for a large group of patients.5-8 The 
pathogenesis of PFP must be disentangled to develop better-targeted treatment. The 
origin of PFP is considered to be multifactorial but is still largely unknown.9 Retropatellar 
cartilage damage has long been suggested as a possible etiological factor. However, to 
date, there has been no conclusive evidence on the presence of morphologic cartilage 
damage in PFP based on radiography or arthroscopy.10-13
PFP has been suggested as a precursor of patellofemoral osteoarthritis (OA).14,15 Because 
changes in cartilage composition are known to precede morphologic cartilage damage 
in OA16 and because PFP involves a young patient population with typically no morpho-
logic cartilage defects, it could be hypothesized that altered cartilage composition plays 
a role in the pathogenesis. With recent quantitative magnetic resonance imaging (MRI) 
techniques such as delayed gadolinium enhanced MRI of cartilage (dGEMRIC), T1ρ and 
T2 mapping, it is now possible to estimate cartilage composition.17
Thus far, 2 small studies have performed one of these quantitative MRI techniques to 
investigate possible differences in cartilage composition between specific PFP patient 
groups and control subjects. Significantly higher T1ρ relaxation times in patellar car-
tilage, indicating proteoglycan loss, were found in 20 patients with PFP with patellar 
maltracking compared to healthy controls.18 However, in this study and in another study 
of female patients with PFP, the patellar cartilage of cases and control subjects demon-
strated no differences in T2 relaxation time, an estimate of collagen content and network 
integrity.18,19 To our knowledge, multiparametric quantitative MRI, including dGEMRIC 
(considered the best validated method for glycosaminoglycan quantification17), has not 
been applied before in a large PFP patient population without prior selection of sub-
groups (e.g. maltracking, female sex, professional athletes). Therefore, this study aimed 
to investigate differences in patellofemoral cartilage composition between patients 
with PFP and control subjects, estimated with multiple quantitative MRI techniques, 
which may eventually lead to a better understanding of the pathogenesis of PFP.
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mATERIAL AND mETHODS
Study design and participants
This cross sectional case-control study was conducted between January 2013 and Sep-
tember 2014 and included a healthy control group and patients with PFP with minimum 
symptom duration of two months to a maximum of two years and. All participants were 
aged between 14 and 40 years. Patients who visited their general practitioner, physio-
therapist or sports physician were included if they were diagnosed with PFP based on 
the presence of at least 3 of the following symptoms: crepitus or pain while stair climb-
ing, squatting, running, cycling, or sitting for a prolonged period with the knee flexed. 
Patients were excluded if they currently had a defined pathological knee condition of 
the affected knee (eg, osteoarthritis or patellar tendinopathy), previous surgery or injury 
of the affected knee, or previous episodes of PFP more than two years ago or if onset of 
PFP occurred after trauma. Control subjects consisted of team members, friends or col-
leagues of the included patients with PFP. We aimed to match control subjects on age, 
Body Mass Index (BMI), sex and activity level. Control subjects were excluded if they had 
current or past PFP, if they previously had a traumatic injury or surgery on both knees or 
if they were first-grade family members of patients. Other exclusion criteria for all study 
participants were contraindications for MRI with contrast and insufficient knowledge of 
the Dutch language. The Medical Ethics Committee of Erasmus MC approved this study 
(protocol MEC-2012- 342), and informed consent was accordingly obtained from all 
participants.
measurements
All participants completed a questionnaire that included questions on demographics 
(BMI, age, and sex), sports participation (yes or no) and knee complaints (duration of 
complaints, pain at rest and during activity using a numerical rating scale of 0-10 and 
the anterior knee pain scale of 0-10020). Participants were subsequently invited to visit 
our university medical center for MRI and a physical examination, which included an 
assessment of crepitation during squatting (present or not), palpation of the medial 
facet (painful or not), and administration of the Clarke compression test21 (positive or 
negative). In patients, the more affected knee was selected for physical examination and 
MRI, or randomly chosen if both knees were equally painful. For control subjects, a ran-
domly selected knee was used for both physical examination and MRI. All participants 
underwent 3.0-T MRI (Discovery MR750, GE Healthcare) with a dedicated eight-channel 
knee coil (Invivo Inc.).
The MRI protocol comprised the following 5 sequences: a 3-dimensional (3D) high 
resolution sagittal spoiled gradient echo (SPGR) sequence, a 3D high resolution sagittal 
fat-saturated SPGR sequence, a 3D sagittal inversion recovery non-fat-saturated SPGR 
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sequence for dGEMRIC22, a 3D sagittal fast spin-echo (FSE) T1ρ mapping sequence23 and 
a 3D sagittal FSE T2 mapping sequence24 (Table 1).
dGEMRIC was only conducted in adult participants (aged ≥18 years) because it requires 
the administration of contrast agent. dGEMRIC, expressed as T1GD relaxation time, uses 
the inverse relation between a negatively charged contrast agent and the amount of 
glycosaminoglycan in cartilage.25 This means that in the case of less glycosaminoglycan, 
more contrast agent is able to penetrate the cartilage, resulting in a lower T1GD relaxation 
time. T1ρ mapping, expressed as T1ρ relaxation time, is proposed to be a noncontrast-
enhanced alternative for dGEMRIC, in which higher T1ρ values indicate less glycosami-
noglycan.17 T2 mapping, expressed as T2 relaxation time, is regarded as the best method 
to estimate collagen content of cartilage; higher T2 times indicate lower collagen con-
tent.17 After acquisition of the high-resolution SPGR and T1ρ and T2 mapping sequences, 
a double dose (0.2 mmol/kg) of gadopentate dimeglumine (Magnevist®, Bayer Schering 
AG) based on the participants’ weight was injected intravenously according to the T1GD 
mapping protocol.26 All adult participants were then asked to cycle for 10 minutes on 
a home trainer to enhance distribution of contrast throughout the knee joint. T1GD was 
acquired 120 minutes after contrast administration.
mRI analysis
For all quantitative MRI techniques, the regions of interest (ROIs) consisted of the 
cartilage of the whole patella and the trochlear portion of the femoral cartilage. The 
border between trochlea and weightbearing femoral cartilage was defined by drawing 
a line tangentially to the anterior aspect of the proximal tibia on the sagittal image 
until it intersected the femoral surface.27 An experienced observer, who was blinded for 
participant status, manually delineated the patellar and femoral cartilage on the high-
resolution SPGR scan with Matlab software (R2011a, The MathWorks) (Figure 1).
Previously published in-house developed software (Software for Post-processing and 
Registration of Cartilage of the Knee [SPARCK]) was used for image postprocessing to 
calculate relaxation times.28 SPARCK was applied for postprocessing in studying knee 
osteoarthritis previously.29-31 Automated image registration, using open source registra-
tion software (Elastix32, http://elastix.isi.uu.nl), was applied to compensate for subject 
motion within and between sequences. The T1GD, T1ρ and T2 sequences each consist of 5 
images, which are acquired using different inversion times, spin lock times or echo times 
respectively. These images were co-registered before the relaxation time per voxel was 
computed. The T1GD, T1ρ and T2 sequences were also registered to the high-resolution 
SPGR images in which the ROIs were annotated. This had the advantage that ROIs only 
needed to be annotated once and a comparison between the same ROIs for all MRI 
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sequences was possible. After registration, the relaxation time per voxel in the ROI was 
estimated using a maximum likelihood fit and a mean relaxation time per ROI was calcu-
lated. Possibly included cortical bone pixels in the ROI were automatically removed by 
a participant-specific set bone-cartilage threshold. Because voxels at tissue boundaries 
could influence the mean relaxation time, a weighted mean relaxation time was calcu-
lated using the reciprocal of the uncertainty of the fit (ie, voxels for which the estimated 
relaxation time was more uncertain had less influence on the mean). All slices of each 
cartilage ROI were averaged. For each participant, 2 averaged weighted mean relaxation 
times (1 for patellar and 1 for femoral cartilage) were obtained per sequence. In addition, 
weighted mean relaxation times of prespecified medial and lateral subregions within 
the patellar and femoral cartilage ROI were calculated. Medial and lateral subregions 
comprised 3 central slices through the medial and lateral region, respectively. Weighted 
T1GD relaxation times were corrected for the participant’s BMI as proposed by Tiderius 
et al.33
Figure 1. Representation of the 
regions of interest of the patellar 
and femoral cartilage on a high-
resolution image
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Statistical analysis
Differences in characteristics between patients and control subjects, as well as between 
adult and adolescent patients (aged <18 years), were tested with independent sample 
t-tests and chi-square tests if normal distribution was present. Otherwise, a Mann-
Whitney U test was applied. Differences in patellar and femoral cartilage composition 
between patients and controls, as well as within adult and adolescent (aged <18 years) 
subgroups, were analyzed with linear regression analyses adjusted for age, sex, BMI, 
sports participation and time of image acquisition (morning or afternoon/evening). P < 
.05 was considered statistically significant. All analyses were performed with SPSS 20.0 
(SPSS Inc).
RESULTS
Participants
Between January 2013 and September 2014, 64 patients and 70 control subjects were 
included in this study; 40 participants (equally distributed between groups) were ado-
lescents (Figure 2). The mean age was 23.2 ± 6.4 years, mean BMI was 22.9 ± 3.4 kg/m2 
and 56.7% of the participants were female.
A significant difference between patients with PFP and control subjects was observed 
in BMI (higher in patient group) and percentage of sports participants (higher in the 
control group) (Table 2).
Figure 2. Flowchart of recruited patients
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Compared with adult patients, bilateral knee pain was more common in adolescents 
and the mean duration of complaints longer (Table 3). Function (assessed with the ante-
rior knee pain scale) was significantly lower in adolescent patients compared with adult 
patients. Bilateral complaints and painful palpation of medial facet were significantly 
more prevalent in adolescents.
Table 2. Characteristics of study participants.
Patients
(N=64)
Controls
(N=70) P Value
Female sex 35 (54.7) 41 (58.6) .65
Age (years) 23.4 ± 7.0 23.1 ±5.9 .88
BmI (kg/m²) 23.6 ±3.8 22.3 ± 3.0 .04
Sports participants .02
During inclusion 38 (59.1) 55 (78.6) 
Before onset of pain 56 (87.5) n.a.
Presence of crepitation 29 (45.3) 20 (28.6) .05
Painful palpation medial facet 31 (48.4) 0 (0) <.001
Positive Clarke compression test 14 (21.9) 2 (2.9) .001
Data are reported as n (%) or means ± SD. n.a., not applicable.
Table 3. Characteristics of the Adult and Adolescent Patient Populations With PFP.
Adolescents
(N=20)
Adults
(N=44) P Value
Female sex 14 (70) 21 (47.7) .10
Age (years) 15.9 ± 1.2 26.8 ± 5.8 <.001
BmI (kg/m2) 20.7 ± 2.1 24.9 ± 3.7 <.001
Sport participants
During inclusion 10 (50.0) 28 (63.6) .30 
Before onset of pain 15 (75.0) 41 (93.2) .04 
Duration of complaints (months) 14.2 ± 8.2 11.0 ± 6.4 .14
Bilateral knee pain 14 (70) 19 (43.2) .05
Numerical rating scale score
Pain at rest 3.75 ± 2.2 4.00 ± 2.6 .71 
Pain during activity 7.15 ± 1.9 6.32 ± 2.3 .17 
Anterior knee pain scale score (function) 60.6 ± 10.7 68.7 ± 11.7 .01
Presence of crepitation 6 (30.0) 23 (52.3) .10
Painful palpation medial facet 14 (70.0) 17 (38.6) .02
Positive Clarke compression test 6 (30) 8 (18.2) .29
Data are reported as n (%) or means ± SD.
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Quantitative mR imaging
T1ρ and T2 mapping was conducted in all participants. Acquisition of T2 mapping failed 
in 1 patient and 1 control subject and acquisition of T1ρ mapping was not conducted 
in 12 patients and 6 control subjects because this sequence was not yet available at the 
beginning of the study. dGEMRIC was only conducted in adult participants and failed 
in 2 patients. Failure was caused by several reasons including technical, logistic and 
contrast administration issues.
For dGEMRIC, mean T1GD relaxation times of patellar (657.8 vs 669.4 ms) and femoral 
cartilage (661.6 vs 659.8 ms) did not significantly differ between patients and controls 
(Table 4). In addition, no significant differences were observed in mean T1ρ relaxation 
times of patellar (46.9 vs 46.0 ms) and femoral cartilage (50.8 vs 50.2 ms) and mean 
Table 4. Weighted mean relaxation times of patellar and femoral cartilage
Patients Controls
mean difference
(95% CI) P Value
dGEmRIC(T1GD)
No. of participants (n=42) (n=50)
patella 657.79 ± 83.69 669.44 ± 55.06 -11.65 (-40.58 to 17.28) .52
medial 670.57 ± 85.94 675.36 ± 58.71 -4.80 (-34.90 to 25.31) .82 
lateral 662.33 ± 95.31 683.40 ± 59.02 -21.07 (-53.37 to 11.24) .25 
femur 661.59 ± 63.80 659.81 ± 66.21 1.77 (-25.30 to 28.85) .83
medial 691.32 ± 75.14 675.29 ± 73.64 16.03 (-14.88 to 46.94) .30 
lateral 655.40 ± 72.05 668.97 ± 76.00 -13.57 (-44.40 to 17.29) .50 
T1ρ
No. of participants (n=52) (n=64)
patella 46.92 ± 4.00 46.00 ± 4.44 0.92 (-0.66 to 2.49) .51
medial 45.25 ± 4.89 45.00 ± 4.66 0.24 (-1.52 to 2.00) .87 
lateral 47.55 ± 4.86 46.07 ± 6.42 1.49 (-0.65 to 3.62) .54 
femur 50.75 ± 3.47 50.15 ± 3.99 0.60 (-0.79 to 2.00) .46
medial 49.92 ± 4.05 49.82 ± 4.48 0.10 (-1.19 to 1.69) .75 
lateral 52.78 ± 4.61 51.47 ± 5.58 1.31 (-0.60 to 3.22) .44 
T2
No. of participants (n=63) (n=69)
patella 33.19 ± 2.85 32.88 ± 2.54 0.31 (-0.62 to 1.24) .26
medial 32.01 ± 2.84 32.01 ± 2.94 <0.01 (-0.99 to 1.00) .69 
lateral 33.43 ± 4.02 32.77 ± 2.94 0.66 (-0.54 to 1.87) .18 
femur 36.66 ± 2.50 36.64 ± 2.36 0.01 (-0.83 to 0.85) >.99 
medial 35.79 ± 2.47 35.92 ± 2.66 -0.13 (-1.02 to 0.75) .70 
lateral 37.79 ± 3.16 38.08 ± 2.61 -0.28 (-1.28 to 0.71) .77 
Data are reported as means ± SD unless indicated otherwise. Times are given in milliseconds. CI: confidence 
interval
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T2 relaxation times of patellar (33.2 vs 32.9 ms) and femoral cartilage (36.7 vs 36.6 ms) 
between patients and control subjects. Analysis of the medial and lateral subregions 
within the patellar and femoral cartilage also did not reveal significant differences be-
tween the study groups.
No significant differences were found in relaxation times of patellar and femoral carti-
lage between patients and control subjects within the adolescent and adult subgroups 
(see the Appendix, available online at http://ajsm .sagepub.com/supplemental).
DISCUSSION
This study aimed to investigate whether there was a difference in patellofemoral carti-
lage composition, estimated with a multiparametric quantitative MRI protocol, between 
patients with PFP and healthy control subjects. Our results showed no significant dif-
ferences in relaxation times between patients and control subjects in all sequences for 
both patellar and femoral cartilage. Subdividing the study population in adolescents 
and adults and analyzing prespecified medial and lateral subregions within the patellar 
and femoral cartilage also revealed no significant differences.
Comparison with literature
Thus far, only 2 other studies have investigated differences in cartilage composition esti-
mated with quantitative MRI between patients with PFP and controls.18,19 T1ρ relaxation 
times of patellar cartilage in PFP patients in our study were slightly higher compared 
to values obtained by Thuillier et al. (46.6 vs 44.6 ms).18 However, T2 relaxation time of 
patellar cartilage in patients with PFP were comparable between our study and the 
study of Farrokhi et al. (33.2 vs 32.5 ms), but lower than those of Thuillier et al. (36.9 
ms).18,19 Similar to our results, no significant differences were found in T2 relaxation 
times between PFP patients and control subjects in both previous studies.18,19 We were 
able to confirm these findings, indicating that there is a normal amount of collagen in 
patellar cartilage of patients with PFP. In OA, loss of glycosaminoglycans precedes loss of 
collagen.34 Therefore, dGEMRIC and T1ρ are proposed to be more sensitive than T2 map-
ping for detecting very early changes in cartilage composition, which are more likely to 
be seen in a young PFP population.35 In contrast with our findings, Thuillier et al.18 did 
report higher T1ρ relaxation times in patients with PFP with patellar maltracking (indi-
cating glycosaminoglycan loss) of the lateral facet of the patella.18 However, their patient 
population consisted of an older and very specific group of PFP patients with patellar 
maltracking, whereas our study included a younger more representative PFP population 
without prior selection of specific subgroups (ie, maltracking females or athletes only). 
Furthermore, adjustment for confounders was lacking in the study by Thuillier et al.18 
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However, this seems essential because it has been shown that for instance dGEMRIC is 
influenced by physical activity and T2 mapping by age and physical activity level.36-38 
Our analyses indeed showed that associations between dGEMRIC, T1ρ and T2 mapping 
and specific confounders (age, sex, BMI, sports participation and time of image acquisi-
tion) were present in our multivariate adjusted model.
Although no significant differences were found between our study groups, it was appar-
ent that T1ρ relaxation times were consistently higher in the adolescent patient popula-
tion compared with the adolescent control subjects. The largest mean difference was 
seen in the lateral subregion of both the patellar and femoral cartilage. On the basis of 
the 95%CI intervals of the mean differences we cannot rule out clinically relevant differ-
ences, regarded as an effect size of ≥0.5. Therefore, the absence of significant differences 
might be caused by a lack of power. The relatively higher T1ρ relaxation times seen in 
the lateral part of the patella were also reported in a previous study in patients with PFP 
and maltracking.18 However, on the basis of our results and because no other literature 
is available on adolescents, we cannot conclude that the presence of PFP in adolescents 
is associated with a change in cartilage content.
Retropatellar cartilage damage has long been implicated as a possible etiological factor 
for PFP and PFP has been suggested as a precursor of patellofemoral OA.14,15 Because de-
terioration of cartilage composition is known to precede morphologic cartilage defects 
in OA, differences in cartilage composition were expected to be found between a young 
PFP patient population and healthy control subjects. However, no significant differences 
were found between the study groups. Because clinically relevant differences could 
not be ruled out for T1ρ in the adolescent population, future research might focus on 
conducting T1ρ in a large cohort of adolescents with PFP.
Strengths and limitations
This is the first case-control study on cartilage composition in PFP that includes a large 
group of patients with PFP comprising adolescents. To our knowledge, there has been 
no previous study in PFP using multiparametric quantitative MRI, including dGEMRIC., 
which is considered the best validated quantitative MRI technique to estimate glycos-
aminoglycan content.17 Moreover, in contrast with previous studies, we examined both 
the trochlear and patellar cartilage, which has not been done previously.
There are, however, some limitations of our study that must be addressed. First, we aimed 
to match patients and controls on age, sex, BMI and sports participation. However, some 
differences were observed in BMI and percentage of sports participants. Therefore, all 
analyses were adjusted for these confounders. Second, acquisition of T1ρ mapping was 
not conducted in 12 patients and 6 control subjects because this sequence was not yet 
available at the beginning of the study. We do not expect this to have influenced our 
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conclusions, because the baseline characteristics of these participants did not differ 
from the participants in which the T1ρ acquisition succeeded.
In this study, we primarily focused on the cartilage composition as a possible etiological 
factor of PFP. Future approaches of our group will focus on the use of MRI to identify 
other potential relevant etiological factors of PFP, including structural abnormalities (eg, 
subchondral bone marrow lesions, joint effusion or fat pad abnormalities) and vascular 
problems (eg, local tissue ischemia or venous outflow obstruction.
CONCLUSION
Our results indicate that there is no difference in composition of the patellofemoral 
cartilage, estimated with multiple quantitative MRI techniques, between patients with 
PFP and healthy control subjects. However, clinically relevant differences could not be 
ruled out for T1ρ in the adolescent population.
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APPENDIX
Appendix 1. Weighted mean T1ρ relaxation times of patellar and femoral cartilage for adolescent and adult 
population.
Patients Controls
mean difference
(95% CI) P Value
Adolescents (n= 17) (n=19)
patella 46.17 ± 3.50 43.78 ± 4.50 2.39 (-0.36 to 5.15) .34
medial 44.35 ± 4.96 42.46 ± 4.13 1.89 (-1.19 to 4.97) .60 
lateral 46.93 ± 5.42 43.83 ± 6.85 3.10 (-1.12 to 7.32) .45 
femur 50.49 ± 3.33 48.80 ± 3.67 1.69 (-0.69 to 4.08) .29
medial 49.82 ± 4.31 49.10 ± 4.34 0.72 (-2.22 to 3.65) .63 
lateral 52.29 ± 4.16 49.46 ± 5.82 2.83 (-0.64 to 6.29) .21 
Adults (n=35) (n=45)
patella 47.28 ± 4.24 46.94 ± 4.12 0.34 (-1.53 to 2.21) .94
medial 45.69 ± 4.85 46.08 ± 4.48 -0.40 (-2.48 to 1.69) .58 
lateral 47.86 ± 4.61 47.01 ± 6.06 0.85 (-1.61 to 3.30) .82 
femur 50.88 ± 3.57 50.72 ± 4.03 0.16 (-1.56 to 1.88) .70
medial 49.97 ± 3.98 50.12 ± 4.55 -0.15 (-2.09 to 1.78) .75 
lateral 53.02 ± 4.86 52.32 ± 5.31 0.70 (-1.60 to 3.00) .66 
Data are reported as means ± SD unless indicated otherwise. Times are given in milliseconds. CI: confidence 
interval
Cartilage composition in patellofemoral pain 175
Appendix 2. Weighted mean T2 relaxation times of patellar and femoral cartilage for adolescent and adult 
population.
Patients Controls
mean difference
(95% CI) P Value
Adolescents (n= 20) (n=20)
patella 33.42 ± 2.73 33.00 ± 2.33 0.42 (-1.20 to 2.04) .46
medial 32.59 ± 3.15 32.19 ± 2.80 0.39 (-1.51 to 2.30) .90 
lateral 33.79 ± 3.40 33.25 ± 2.72 0.54 (-1.43 to 2.51) .26 
femur 37.31 ± 2.55 37.13 ± 2.68 0.19 (-1.49 to 1.86) .99
medial 36.65 ± 2.18 36.27 ± 3.17 0.38 (-1.37 to 2.12) .86 
lateral 38.78 ± 3.30 38.80 ± 2.75 -0.02 (-1.97 to 1.92) .87 
Adults (n=43) (n=49)
patella 33.08 ± 2.93 32.83 ± 2.64 0.25 (-0.90 to 1.41) .58
medial 31.74 ± 2.68 31.93 ± 3.01 -0.19 (-1.38 to 1.00) .96 
lateral 33.26 ± 4.31 32.57 ± 3.03 0.69 (-0.84 to 2.22) .42 
femur 36.35 ± 2.45 36.45 ± 2.22 -0.10 (-1.06 to 0.87) .63
medial 35.39 ± 2.52 35.78 ± 2.44 -0.39 (-1.42 to 0.64) .31 
lateral 37.34 ± 3.02 37.78 ± 2.52 -0.44 (-1.59 to 0.70) .43 
Data are reported as means ± SD unless indicated otherwise. Times are given in milliseconds. CI: confidence 
interval
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Dynamic contrast-enhanced MR 
imaging of the patellar bone: how to 
quantify perfusion
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ABSTRACT
Purpose
Since no established analysis method for dynamic contrast enhanced (DCE)-MRI in the 
patella exists, our purpose was to identify the optimal combination of pharmacokinetic 
model and arterial input function (AIF) for quantitative analysis of blood perfusion in the 
patellar bone using DCE-MRI.
method
This method design study used a random subset of five control subjects from an IRB 
approved case-control study into patellofemoral pain. We systematically investigated 
the reproducibility of pharmacokinetic parameters for all combinations of Orton and 
Parker AIF models with Tofts, Extended Tofts (ETofts), and Brix pharmacokinetic models. 
We evaluated if the AIF should use literature parameters, be subject specific, or be group 
specific. Model selection was based on the goodness-of-fit and the coefficient of varia-
tion of the pharmacokinetic parameters.
Results
The vascular component in the ETofts model could not reliably be recovered and the 
Brix model parameters showed high variability. A subject specific AIF performed worse 
than a group specific AIF, but better than an AIF with literature parameters. The best 
reproducibility and goodness-of-fit were obtained by combining Tofts’ pharmacokinetic 
model with the group specific Parker AIF.
Conclusions
We identified several good combinations of pharmacokinetic model and AIF for quanti-
tative analysis of perfusion in the patellar bone. The recommended combination is Tofts 
pharmacokinetic model combined with a group specific Parker AIF model.
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INTRODUCTION
Research suggests that altered blood perfusion of the patellar bone may play a role in 
the pathogenesis of patellofemoral pain (PFP), a common knee complaint1–8. Blood per-
fusion can be visualized and analyzed quantitatively using dynamic contrast-enhanced 
magnetic resonance imaging (DCE-MRI)9. Despite the well-described use of DCE-MRI for 
a variety of indications such as tumors and cerebral stroke10,11, only a limited number of 
publications address DCE-MRI in bone12–16, and none specifically in the patella. DCE-MRI 
in bone has been limited due to the sparse vascularization of bone and the typical low 
contrast enhancement compared to surrounding tissues12,16. The mobility of the patella 
poses an additional specific challenge.
Signal intensity changes in the DCE-MRI time series are due to the contrast medium 
entering the tissue through feeding arteries, residing in the extravascular space, and 
subsequent draining. This process can be studied semi-quantitatively using measures 
like time-to-peak, or quantitatively by fitting a pharmacokinetic model to the DCE-MRI 
data to extract truly quantitative measures of perfusion9. Quantitative DCE-MRI requires 
choosing one of multiple proposed arterial input functions (AIFs) and one of the pharma-
cokinetic models that together are able to describe the dynamic contrast concentration. 
Selection of appropriate models is especially relevant for low signal intensity regions 
since a too complex model (too many degrees of freedom)will be influenced stronger 
by acquisition noise and, hence, is less sensitive to between-group or between-subject 
differences in perfusion. Moreover, a model that cannot describe the DCE-MRI signal 
with sufficient accuracy may fail to detect relevant changes in perfusion. Although 
quantitative DCE-MRI has been performed in several bones9, no thorough evaluation of 
the optimal combination of AIF and pharmacokinetic model has been presented.
The aim of this study was to identify the optimal combination of pharmacokinetic model 
and AIF for quantitative analysis of perfusion in the patellar bone using DCE-MRI. As 
potentially appropriate AIF models we selected three models by Orton17 and several pa-
rametrizations of Parker’s model18. As pharmacokinetic models we selected the models 
of Brix, Tofts, and the extended model of Tofts19. The optimal combination of models will 
be used in studies investigating possible perfusion alterations in PFP20.
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mATERIALS AND mETHODS
DCE-mRI acquisition
This method design study used a random subset of five control subjects from an IRB 
approved case-control study into patellofemoral pain20. All subjects provided written 
informed consent. A 3T-MRI scanner (Discovery MR750, GE Healthcare, Milwaukee, USA) 
with a dedicated 8-channel knee coil (Invivo Inc., Gainesville, USA) was used.
DCE-MRI was acquired by a time-resolved imaging of contrast kinetics (TRICKS) se-
quence with anterior-posterior (AP) frequency encoding direction to avoid pulsation 
artifacts of the popliteal artery into the region of interest. MRI parameters were: in-plane 
pixel resolution 15mm, slice thickness 5mm, field of view 380 × 380 × 70mm, acquisition 
matrix 256 × 128, 14 sagittal slices, 70% sampling in the phase direction, TE = 1.7MS, 
TR = 9.3MS, FA = 300. The DCE-MRI protocol consisted of 35 phases of 10.30s ± 0.07s 
(constant within subject). Intravenous contrast administration of 0.2mmol/kg gadopen-
tetate dimeglumine (Magnevist, Bayer, Berlin, Germany), at a rate of 2ml/s, was started 
after the first phase. Additionally, a non-fat-suppressed 3D SPGR sequence with in-plane 
resolution of 0.3mm × 0.3mm and 5mm slices was acquired before contrast administra-
tion for delineation of the patellar bone marrow.
motion compensation
Image driven motion compensation was applied, based on a technique developed for 
T1 mapping in femoral and tibial articular cartilage21. A registration mask was drawn 
around the patella in the 3D SPGR image. Within this mask the DCE-MRI time series were 
automatically registered to the first DCE-MRI time point using a rigid transformation 
model. Subsequently, the first phase was registered to the 3D SPGR image and all DCE-
MRI scans were transformed to the grid of the high-resolution 3D SPGR. Visual inspection 
indicated successful alignment of the time series.
Quantitative DCE-mRI modelling
The dynamic DCE-MRI signal in each voxel a(t) is described by a combination of three 
models: The arterial input function (aiF), the pharmacokinetic response function (p), and 
the function that relates contrast concentration to signal intensity (s), combined as:
a(t) = sξ ((aiFΧ * pφ)(t))        [1]
where * denotes convolution and ξ, Χ, φ are model parameters.
For the aiF model we evaluated three computationally efficient models of Orton17 
(Orton1, Orton2, Orton3), five variations on Parker’s model18 with increasing degrees of 
freedom (Parker-L, Parker-A, Parker-S, Parker-E, Parker-T), as well as a ‘dummy’ triangle 
shaped AIF function. The aiF parameters Χ were estimated from a manually outlined 
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arterial region, either from a single subject (subject specific) or from the entire group of 
subjects (group specific), or obtained from literature (literature based).
For the pharmacokinetic model p we evaluate Brix, Tofts, and Extended Tofts (ETofts) 
models19,22. The Brix model has ah, Kep, and kel as parameters φ, while Tofts model has Ktrans 
and kep as φ, and ETofts adds vp to it; each model additionally includes a delay parameter.
For s we used a standard model suitable for the SPGR based sequence with one free 
parameter ξ = s0.
Appendices A.1-A.3 provide more details on the models and Appendix A.4 provides 
details on the maximum likelihood estimation method used to recover ξ, Χ, and φ.
Technical validation on phantom data
To validate the model fitting method, a simulated dataset from a DCE-MRI anthropomor-
phic digital reference phantom was used23. All AIF models were fitted on selected arte-
rial voxels and evaluated with the R-square value. Subsequently, these AIFs were used to 
analyze the provided volume-of-interest (VOI) with ETofts; this VOI contained the tumor 
of which the perfusion was simulated. Accuracy of the pharmacokinetic parameters was 
measured by the median absolute difference (MAD) between the estimated and ground 
truth parameters of the ETofts model in the VOI and compared to the median ground 
truth value.
Comparative evaluation of AIF models
The AIF models were fitted to the voxels in an ROI drawn in the center of the popliteal 
artery, approximately at the level of the center of the patella. This artery was the largest 
artery in the field of view and could easily be identified in all subjects. Fit quality was 
evaluated by Akaike’s information criterion (AIC)24,25:
aiC = 2 k + n 1n(ssr)       [2]
where k is the number of parameters in the model (for all subjects), n is the number of 
samples to which the model is fitted, and ssr is the sum of squared residuals (measure-
ments minus values predicted by the fitted model). AIC provides an objective way to 
compare models with different complexities. Since the voxels from which the AIF is esti-
mated are selected from a small region, they have substantial spatial correlation, which 
reduces the effective number of degrees of freedom. To avoid a biased model selection 
due to these correlations, we evaluated the AIC on one randomly selected voxel within 
the arterial ROI of each subject, and we report the mean and standard deviation of the 
AIC over 1000 random selections.
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Comparative evaluation of pharmacokinetic models
Each combination of AIF and pharmacokinetic model was fitted to the DCE-MRI data. For 
each pharmacokinetic parameter we computed its weighted mean over a VOI consisting 
of the patellar bone marrow, drawn by an experienced observer (RH). As weights we used 
1/CrLb where CrLb is the Cramér-Rao lower bound at each voxel, which is a measure of 
fit uncertainty (see appendix A.4). In this way, we suppress the influence of voxels with 
an unreliable fit. The mean and coefficient of variation (Cv = standard deviation / |mean|) 
across subjects were computed to investigate reproducibility. The residual (=√ssr)) was 
computed to evaluate goodness-of-fit.
RESULTS
Technical validation on phantom data
On the phantom data, the Parker-T model fitted best to the arterial signal with an R-
square value of 0.9994, whereas Parker-E and Orton3 had R-square of 0.9983 and 0.9870, 
respectively. Orton3 fitted best among the Orton models. See Table 1 for the MAD of 
Ktrans, kep, and vp inside the VOI. Parker-T had the lowest MAD for Ktrans and vp.
Table 1. Median absolute difference (MAD) of ETofts parameters in the VOI of the phantom experiment for 
the different AIF models. Median ground truth values are given in the bottom row.
Ktrans(1/min) kep(1/min) vp(fraction)
Literature based
Triangle 0.1986 0.345 0.0155
Orton1 0.0696 0.459 0.0111
Orton2 0.0672 0.466 0.0059
Orton3 0.0081 0.446 0.0074
Parker 0.0133 0.468 0.0079
subject specific
Triangle 0.5461 0.387 0.0379
Orton1 0.0696 0.459 0.0111
Orton2 0.0695 0.032 0.0126
Orton3 0.0293 0.043 0.0107
Parker-A 0.0118 0.082 0.0092
Parker-S 0.0059 0.070 0.0047
Parker-E 0.0096 0.085 0.0058
Parker-T 0.0079 0.086 0.0011
median ground truth 0.0701 0.418 0.0138
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Comparative evaluation of AIF models
Figure 1 shows the AIFs that were estimated by the different models. There were substan-
tial differences between AIFs when estimated for each subject individually, especially 
for the models Orton2, Orton3, and Parker-A. The substantial differences in contrast 
concentration in the tail of the curve were observed to be correlated to under/over es-
timation of the baseline signal intensity ξ. For subject specific Parker-E and Parker-T, the 
first-pass contrast concentration differed substantially from the group specific first-pass 
and the first-pass as provided by the literature based AIFs. The group specific Parker-T 
was also substantially different from the literature based Parker model.
Table 2 shows the mean and standard deviation of the AIC value of the AIF fits over the 
1000 random selections of one voxel per subject. Note that in Equation 2, n=175 (35 
time points × 1 randomly selected voxel ×5 subjects) and k varies between 10 (literature 
based AIF; only estimating delay and ξ per subject) and 60 (subject specific Parker-T). 
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Figure 1. Literature based, subject specific, and group specific arterial contrast concentration, from left 
to right, top to bottom: Literature, Orton1, Orton2, Orton3, Parker-A, Parker-S, Parker-E, Parker-T. In each 
figure, the group specific estimate is shown by the black bold line
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The AIC of Parker-E and Parker-T were much lower than the AIC of the Orton models. All 
models substantially improved over the triangle AIF.
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Figure 1. (continued) Literature based, subject specific, and group specific arterial contrast concentration, 
from left to right, top to bottom: Literature, Orton1, Orton2, Orton3, Parker-A, Parker-S, Parker-E, Parker-T. In 
each figure, the group specific estimate is shown by the black bold line
Table 2. The mean (sd) of the AIC of AIF fits. Lower values indicate a better model fit.
Literature Subject Group
triangle 1180.3 (14.9) 846.9 (15.0) 843.8 (14.0)
Orton1 776.1 (25.7) 581.2 (23.0) 777.7 (23.3)
Orton2 613.7 (26.0) 141.5 (17.0) 236.1 (38.2)
Orton3 512.4 (14.9) 202.3 (14.0) 268.3 (32.2)
Parker-L 528.0 (14.6)
Parker-A 174.7 (19.4) 259.7 (34.5)
Parker-S 154.1 (23.4) 240.6 (40.9)
Parker-E 61.9 (32.9) 204.0 (46.9)
Parker-T 69.2 (35.1) 200.6 (48.6)
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Comparative evaluation of pharmacokinetic models
Table 3 and Table 4 show the mean and CV across subjects of the pharmacokinetic param-
eters, as well as the residual norm, for all combinations of AIF and pharmacokinetic models.
Substantial variations in parameter values for different AIF models were observed (Table 
3). The residual of ETofts was not substantially lower than the residual of Tofts, which 
indicates that, in our patellar VOI, inclusion of the vascular component did not lead to 
a better fit. For most AIF models, the residual of the Brix model was approximately 10% 
lower than the residual of Tofts and ETofts. The residual norm did not vary substantially 
across AIF models, except for the `dummy’ Triangle AIF and the literature based AIFs 
combined with the ETofts model, which resulted in much higher residual norm.
Table 3. For each AIF and pharmacokinetic model this table shows the mean over the five subjects of each 
parameter and the residual. Delay is in min; Ktrans, kep, kel in 1/min; vp is a fraction; ah is in 1/min2; residual 
norm is in arbitrary unit but it can be compared across all model combinations.
Tofts ExtendedTofts Brix Residual
Ktrans kep Ktrans kep vp AH kep kel Tofts ETofts Brix
Literature based
Triangle 0.097 -0.147 0.084 -0.138 0 0.132 0.022 0.441 0.113 0.382 0.070
Orton1 0.035 0.138 0.028 0.140 -0.004 0.060 0.262 1.367 0.079 0.147 0.069
Orton2 0.037 0.155 0.029 0.153 -0.005 0.064 0.281 1.377 0.077 0.135 0.069
Orton3 0.021 0.166 0.016 0.162 -0.001 0.036 0.213 1.342 0.076 0.077 0.069
Parker 0.022 0.153 0.015 0.147 -0.002 0.038 0.318 0.931 0.077 0.147 0.069
subject specific
Triangle 0.850 -0.212 0.833 -0.210 -0.064 0.918 -0.084 0.388 0.135 0.135 0.116
Orton1 0.052 0.254 0.039 0.225 0.009 0.083 0.246 1.890 0.071 0.070 0.073
Orton2 0.018 0.133 0.013 0.047 -0.001 0.030 0.253 1.272 0.079 0.074 0.070
Orton3 0.007 0.091 0.004 0.090 -0.001 0.011 0.166 1.379 0.081 0.082 0.068
Parker-A 0.011 0.130 0.008 0.098 -0.001 0.018 0.286 1.090 0.079 0.080 0.069
Parker-S 0.021 0.198 0.015 0.192 -0.002 0.036 0.254 0.991 0.073 0.079 0.069
Parker-E 0.020 0.179 0.014 0.174 -0.002 0.033 0.226 1.650 0.074 0.075 0.068
Parker-T 0.019 0.174 0.014 0.171 -0.002 0.032 0.399 1.358 0.074 0.075 0.068
Group specific
Triangle 0.819 -0.188 0.795 -0.186 -0.053 0.898 -0.003 0.279 0.123 0.123 0.107
Orton1 0.035 0.138 0.028 0.140 -0.004 0.060 0.250 1.425 0.079 0.147 0.069
Orton2 0.023 0.225 0.017 0.214 -0.002 0.039 0.304 1.607 0.073 0.073 0.069
Orton3 0.005 0.058 0.004 0.057 0 0.007 0.151 0.812 0.084 0.085 0.068
Parker-A 0.008 0.119 0.006 0.115 -0.001 0.013 0.180 1.459 0.078 0.077 0.068
Parker-S 0.021 0.184 0.018 0.174 -0.003 0.036 0.278 1.393 0.076 0.080 0.069
Parker-E 0.019 0.171 0.016 0.164 -0.003 0.031 0.227 1.149 0.075 0.077 0.069
Parker-T 0.019 0.184 0.016 0.178 -0.001 0.031 0.221 1.393 0.074 0.074 0.069
186 Chapter 5
Table 4 shows that the pharmacokinetic parameters estimated with subject specific AIF 
models had an increased CV compared to pharmacokinetic parameters estimated with 
literature based and group specific AIF models. For most combinations there were only 
small differences in CV of the parameters between literature based and group specific AIF 
models. The exceptions were kep of Tofts and ETofts with Orton3, vp of ETofts with Orton2, 
and kep and kel of Brix with Orton2 and Orton3, which were mostly found to have a higher 
CV for the group specific AIF. When comparing the CV of the different models we noted 
that the CV for Tofts’ model was substantially lower than the CV for the other models. 
Especially the CV of Ktrans was substantially larger in ETofts than Tofts. For ETofts, the CV 
of vp was very high demonstrating that the vascular component could not be precisely 
recovered, as was also indicated by the unrealistic (small) negative vp (Table 3). The CV of 
the Brix model parameters was, overall, higher than the CV of the Tofts model parameters.
Table 4. For each AIF and each parameter of the pharmacokinetic models this table shows the CV (%) over 
the five subjects. The three right-most columns show the CV of the residual.
Tofts ExtendedTofts Brix Residual
Ktrans kep Ktrans kep vp AH kep kel Tofts ETofts Brix
Literature based
Triangle 23.1 18.0 24.4 18.5 165.7 23.5 546.4 79.5 20.6 34.0 14.9
Orton1 24.2 29.3 40.3 26.8 54.1 29.4 43.0 60.7 16.4 31.1 15.9
Orton2 24.2 26.9 39.5 26.3 58.2 32.6 62.6 57.6 16.1 33.1 15.8
Orton3 24.3 25.4 34.1 25.4 117.6 31.2 25.4 54.0 16.1 16.3 16.2
Parker 24.2 27.2 36.0 27.8 113.5 30.0 45.2 74.6 16.0 42.6 16.1
subject specific
Triangle 18.2 8.4 19.9 8.0 47.2 7.7 63.7 68.4 25.4 25.3 25.5
Orton1 34.3 30.9 43.6 26.7 83.7 33.8 31.3 48.1 16.0 15.7 16.6
Orton2 57.0 159.5 64.9 799.2 227.1 61.3 26.7 65.7 30.7 20.4 16.1
Orton3 44.6 56.4 38.4 57.1 80.8 45.5 36.0 36.1 16.4 16.5 16.7
Parker-A 55.7 60.6 48.7 115.1 228.9 63.2 52.8 72.5 18.5 16.6 16.2
Parker-S 24.5 37.6 40.7 40.1 102.7 30.6 47.2 70.2 17.5 19.5 15.9
Parker-E 28.0 22.6 32.2 25.0 172.2 32.4 24.3 20.9 15.9 16.2 15.8
Parker-T 30.5 27.1 31.7 28.7 155.1 34.6 69.1 45.9 15.9 16.4 15.8
Group specific
Triangle 16.9 17.6 19.6 17.3 58.1 7.9 3371.7 68.4 23.1 23.0 22.8
Orton1 24.2 29.3 40.3 26.8 54.4 29.4 38.1 58.2 16.4 31.1 15.9
Orton2 24.4 20.3 44.6 21.2 162.4 31.3 40.8 31.7 16.0 16.4 15.8
Orton3 24.0 60.8 36.7 61.8 84.2 28.4 57.0 70.0 17.6 17.9 16.5
Parker-A 24.2 32.6 36.6 35.3 96.5 29.7 34.0 33.8 16.7 17.1 16.4
Parker-S 24.2 23.5 40.2 23.9 77.0 30.1 53.9 47.1 16.3 14.6 16.1
Parker-E 24.2 24.9 40.6 24.8 81.9 30.8 32.3 61.2 15.8 14.9 15.4
Parker-T 24.4 23.5 36.7 24.0 140.5 31.6 24.3 53.9 15.7 16.1 15.5
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DISCUSSION
This paper presents the first systematic comparative evaluation of AIF and pharmaco-
kinetic models for quantitatively analyzing patellar perfusion with DCE-MRI. Below, we 
derive several recommendations based on our experimental results, and discuss limita-
tions and impact.
First, the evaluation on digital phantom data shows that the proposed fitting method 
can accurately recover pharmacokinetic parameters when a correct AIF model is used. 
Although this phantom dataset simulates tumor perfusion, which is different from patel-
lar perfusion, the comparison with the ground truth confirms the technical validity of 
the proposed fitting methods.
Orton or Parker?
As indicated by the AIC scores (Table 2), Triangle and Orton1 do not model the arterial 
signal well. For the Parker model, the increase in complexity from Parker-A to Parker-E 
is supported by the measured imaging data, since Parker-E leads to substantially im-
proved arterial fits, reflected by lower AIC. This indicates that our addition of a persisting 
contrast concentration to the Parker-E model was justified. Overall, in terms of AIC, most 
competitive models are Orton2, Parker-E and Parker-T.
Subject specific, group specific, or literature based?
The AIC score shows substantially improved arterial fits of the subject and group specific 
AIFs compared to the literature based AIF (Table 2). Moreover, the literature based AIFs 
lead to high residuals when used in combination with the ETofts pharmacokinetic model 
(Table 3). Based on these results, we recommend against using a literature based AIF.
Since the large intersubject variability in the shape of the first-pass contrast concentra-
tion for subject specific AIF modelling with Parker-E and Parker-T, and to a lesser extent 
with Orton2 and Orton3, cannot be explained biologically, the group specific AIF is 
preferred for these models, despite the higher AIC value that was seen in Table 2. This 
is additionally supported by the fact that the CV of the pharmacokinetic parameters 
(Table 4) is lower for the group specific AIF than for the subject specific AIF, which also 
suggests that intersubject variation in true AIF is small compared to the variance of the 
single subject estimate. Hence, we recommend to use a group specific AIF, as it leads to 
highest reproducibility of the pharmacokinetic parameters.
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Tofts, ETofts, or Brix?
Comparing pharmacokinetic models, the CV typically is lowest for Tofts (Table 4). This is 
probably due to the larger number of parameters in ETofts and Brix. The larger number 
of parameters in Brix probably also explains the lower residual compared to Tofts. As all 
three pharmacokinetic models explain a similar fraction of the DCE-MRI signal, we ex-
pect that group differences, e.g. between cases and controls, in perfusion cause similar 
relative changes in parameter values. This implies that the model with the smallest CV 
(Tofts) will likely be more sensitive to detect group differences than the other models 
(ETofts, Brix).
Limitations and impact
We chose to aggregate the voxelwise pharmacokinetic measures by computing a 
weighted mean over the patella VOI. Any spatial heterogeneity within the patella is thus 
averaged out. Hence, it should be noted that using these measures to study group dif-
ferences implicitly assumes non-localized physiological changes in the patella.
As no in-vivo ground truth values for pharmacokinetic parameters are available, we could 
not base model selection on closeness to ground truth and this implies that reliable 
absolute quantification of perfusion values currently cannot be claimed. As in Schmid 
et al.26, we used a statistical analysis method to trade off model complexity against 
goodness-of-fit, in order to guide model selection. Note that, compared to Schmid et al., 
we evaluated a wider range of models, both for AIF and for pharmacokinetic model, and 
applied it to patellar DCE-MRI data.
The substantial differences in pharmacokinetic parameters obtained with different AIFs 
emphasize the relevance of choosing a good AIF model. Severe bias in parameters could 
occur with a suboptimal AIF. The small differences observed among the best candidates 
indicate that potentially other combinations can be best for acquisitions with different 
settings and/or in different body parts; even for other bones. Hence, our proposed 
framework for evaluating perfusion is an important contribution in itself. It allowed 
identification of a few combinations of AIF models and pharmacokinetic models that 
performed well on all aspects: AIC score and biological credibility of the AIF, CV of phar-
macokinetic parameters, and goodness-of-fit in the patella VOI.
Overall recommendation
Although Orton2 combined with Tofts’ model seems to slightly improve reproducibility 
and goodness-of-fit in this dataset, we consider the lower AIC score of Parker-T as well as 
the improved biological credibility of that AIF to be more important. Together with the 
accuracy of this combination on phantom data, this gives good confidence that group 
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specific Parker-T combined with Tofts’ model is suitable to identify patellar perfusion 
abnormalities.
The observed values of the CV indicate that with a consistently used combination of 
models, reproducibility is sufficient to allow identification of group differences in perfu-
sion with reasonably sized groups; e.g. approx. 40 subjects per group allow identifica-
tion of group differences of 10% in Ktrans or kep at a significance level of p < 0.05 with 75% 
power.
CONCLUSION
We conclude that the most suitable choice of models for the analyzed patellar DCE-MRI 
data is Parker’s arterial input model where all parameters of Parker’s model are estimated 
from arterial voxels of the full group of subjects, combined with Tofts’ pharmacokinetic 
model. This combination will be used in a large study on patellar perfusion in patients 
with PFP20.
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APPENDIX
A.1 DCE-mRI models – Arterial input function
In the next subsections the different AIF models used in the evaluations are described.
Triangle
To investigate if the arterial input needs to be modelled at all, we investigate the perfor-
mance of a triangle function as dummy reference AIF:
aiFΧ(t) = a/w
⎧
⎨
⎩
1 − |t|/w |t|≤w
0 |t|>w
with Χ = [a, w] and using a = 1 and w = tr as `literature’ value.
Orton
We investigated the three AIF models of Orton17. These AIF models can be convolved 
analytically for often used pharmacokinetic models. When this analytical convolution 
is used, the computational performance might be better than for other models where 
a numerical approximation of the convolution should be employed. Even though the 
Orton models can be convolved analytically, our implementation relied, for all models, on 
numerical convolutions to ease testing and implementation in this investigative research.
Specifically, the Orton model 1 (Orton1) is given by:
aiFΧ(t) = 
⎧
⎨
⎩
ab exp(−tμb) + aG exp(−tμG) t > 0
0 t ≤ 0
with Χ = [ab, μb, aG, μG] and as literature values17: ab = 9.32 mM, aG = 1.06 mM, μb = 12.0 
min-1, μG = 0.169-1.
The Orton model 2 (Orton2) is given by:
aiFΧ(t) = 
⎧
⎨
⎩
t ab exp(−t μb) + aG(exp(−t μG) − exp(−t μb)) t > 0
0 t ≤ 0
with Χ = [ab, μb, aG, μG] and as literature values17: ab = 323 mM min-1, aG = 1.07 mM, μb = 
20.2 min-1, μG = 0.172-1.
Orton model 3 (Orton3) is given by:
aiFΧ(t) =
⎧
⎨
⎩
ab (1− cos(−t μb) + abaGƒ(t, μG) 0 < t ≤ tb
abaGƒ(tb, μG)exp(−(t −tb)μG) t > tb
0 t ≤ 0
with
tb = 2∏/μb, ƒ(t, μG) = 
1
−1/(μ2G    +μ2b  )(μG cos(t μb) + μb sin(t μb) − μG exp(−tμG)),μG(1−exp(−tμG))
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Χ = [ab, μb, aG, μG] and as literature values17: μb = 22.8 min-1, μG =0.171 min-1, ab = 2.84 mM, 
aG = 1.36 min-1.
Parker
The AIF model of Parker et al.18 is a general function for describing the arterial impulse 
response. It models the first pass and second pass of the bolus separately, followed by 
an exponential decay. As will be motivated below, we slightly extended this model to:
aiFΧ(t) = 
∑ 2
an exp ⎛⎝
−(t−tn)2 ⎞
⎠ +
α exp(−βt) + γ
n=1 σn√2π 2σ2n 1 + exp(−s(t − τ))
1 − hct
where an, tn, and σn are scaling constants, centers, and widths of two Gaussians; α, β, 
and γ are the amplitude, decay constant, and asymptote of the exponential tail; and s 
and τ are the width and center of the sigmoid that is used as soft step function for the 
exponential tail, respectively. Our extension is the introduction of γ as we observed that 
a mono-exponential decay did not accurately describe the decay. The literature values 
that we used are18: a1 = 0.809 mM min, a2 = 0.330 mM min, t1 = 0.17046 min, t2 = 0.365 
min, σ1 = 0.0563 min, σ2 = 0.132 min, α = 1.050 mM, β = 0.1685 min-1, γ = 0 mM, s = 38.078 
min-1, τ = 0.483 min, hct = 0.42.
Since this model contains many parameters, some of which are hard to identify due to 
the relatively low temporal resolution in our dataset, we also tested restricting some 
parameters to the literature values18. In this work, the following restricted models were 
used, where all parameters not in Χ are taken from the literature with values given above.
Parker-L : All values from Literature.
Parker-A : Χ = [a1, a2, α] ; Estimate only the Amplitude parameters.
Parker-S : Χ = [a1, a2, σ1, σ2, α, β]; In addition to Parker-A also estimate the Scale parameters.
Parker-E : Χ = [a1, a2, σ1, σ2, α, β, γ]; Extend Parker-S by including γ.
Parker-T :Χ = [a1, a2, t1, t2, σ1, σ2, α, β, γ, s]; In addition to Parker-E add Timing tn and s 
to estimate all parameters except τ. Note that including τ would lead to a degenerate 
model as we estimate a delay per subject (see A.4) and also estimate all other timing 
parameters (tn).
The optimization of Χ of the Parker AIF models was nested, such that the result of each of 
the listed restricted Parker models was used as initialization for the next.
A.2 DCE-mRI models - Pharmacokinetics
Three different pharmacokinetic models were compared: Tofts, Extended Tofts, and 
Brix19,22. The extension in the Extended Tofts model is the inclusion of a vascular compo-
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nent. While obviously in actual tissues there is a vascular component, the addition of an 
extra parameter may make the fitting less robust. Especially, since only in a few frames 
around the first pass there is a substantial difference between the Tofts and Extended 
Tofts model. The pharmacokinetic impulse of the Extended Tofts model is given by
pφ(t) = vpδt,0 + 
Ktrans exp(−t kep)
1 + exp( − t )∆t
where φ = [Ktrans, kep, vp]. The vascular volume fraction vp is defined as zero in the Tofts 
model. Thus, for the Tofts model φ = [Ktrans, kep].
The pharmacokinetic impulse response model of Brix19,22 is given by:
pφ(t) = 
⎧
⎨
⎩
− ah 
exp(−t kep) − exp(−t kel)
kep  − kel  t > 0
0  t ≤ 0
with φ = [ah, kep, kel].
A.3 DCE-mRI models - Contrast concentration to signal
The gadolinium-based contrast medium gadopentetate dimeglumine (Magnevist; Bayer, 
Berlin, Germany) that we used predominantly shortens the T1 (spin-lattice) relaxation 
time. Hence, as commonly done, we used a T1 sensitive SPGR based TRICKS sequence18,19 
which can be modelled with the symbols defined below as (modification of 27)
sξ(c) = s0
1 − E10cos α 1 − e1(c)
1 − e10 1 − e1(c) cos α
with ξ = [s0], e10 = exp(−tr r1), e1(c) = exp(−tr (r1 + c rcontrast)). This model has s0, the signal 
intensity without contrast agent present, as parameter to ease estimation and interpre-
tation. According to Tofts et al.19, the relaxivities of tissue and contrast medium can be 
assumed to be additive. To infer the contrast concentration, the t1 = 1/r1 value of the 
tissues of interest without contrast agent should be known. Our protocol did not include 
a non-contrast-enhanced quantitative T1 scan due to acquisition time considerations. 
However, the native T1 value was expected to be constant across subjects, and at least 
to not be strongly correlated with PFP as T1 itself is not known to be a biomarker for PFP. 
Hence, using a fixed T1 value for all subjects was considered appropriate. For blood we 
used T1 = 1664 ms, which is given as best estimate at normal hematocrit values in Lu et 
al.28. For bone and patella we used T1 = 288 ms as given in Han et al.29. Based on Rohrer et 
al.30 we used rcontrast = 4.3 liter/(mM sec) as relaxivity of the contrast agent.
A.4 DCE-mRI model fitting
Using the models defined in the appendices above, the signal intensity predicting 
model a(t) (Equation 1) was fitted with a Maximum Likelihood estimation procedure to 
the magnitude MR images i:
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ξˆ, φˆ, σˆ = argmaxΣt 1np(i(t), a(t), σ) [3]ξ, φ, σ
where p is the likelihood function of the Rice distributed measurements i(t), which are 
assumed to be independent. Note that the voxel location Χ is not shown for convenience 
of notation. The optimization uses MRI fitting tools31 and was performed in two stages. 
In the first stage a Halton sequence based ‘grid’ search was performed with 1000 points. 
In the second stage, the six best matches of the first stage were refined by a local nonlin-
ear optimization with lower and upper bound constraints on the individual parameters 
(fmincon in MATLAB 2011b, MathWorks with the active-set algorithm). The final result 
was the best match after optimization. The range for the initial grid and the constraints 
applied during nonlinear optimization are given in Table 5. The constraints applied dur-
ing optimization were chosen based on the range that was assumed to be identifiable 
by the acquisition that was performed, while the ranges used for initialization were 
determined by encompassing the observed range of values. The fitting tools used are 
provided online on the website fitmri.bigr.nl.
The parameters of the AIF, Χ, were estimated from, in each subject, a manually drawn 
(small) ROI in a part of an artery that by visual inspection did not contain imaging arti-
facts. The estimation procedure, which was similar to equation 3, recovered the subject 
specific as well as the group specific Χ by using a delay per subject as pharmacokinetic 
model and summing the log likelihood over all voxels in the arterial ROIs. As the arterial 
SNR was sufficiently high in all cases, the likelihood function p was replaced with a Gauss-
ian distribution in this estimation. For the subject specific AIF the fit was performed for 
each subject individually, while for the group specific AIF the selected arterial voxels in 
all subjects were combined into a single fit.
Maximum Likelihood estimation additionally allows evaluating the Cramér-Rao lower 
bound (CRLB)32. This is a lower bound for the variance of the parameters θˆ due to the 
noise in the acquisition (σ) for any unbiased estimation procedure. Even though it is 
a lower bound, the Maximum Likelihood estimator was observed to almost reach this 
bound in simulation experiments. Hence, the CRLB was used in the evaluation of the 
weighted mean of the pharmacokinetic parameters over the patellar bone marrow VOI.
Table 5. Parameters, units and constraints applied during estimation.
parameter
all Tofts and ETofts Brix
delay Ktrans kep vp AH kep kel
unit min (min)-1 (min)-1 (fraction) min-2 (min)-1 (min)-1
lower bound optimization 0 -0.1 -1 -0.1 -0.2 -1 0
lower bound initialization 0.17 -0.01 -0.2 -0.001 -0.05 -0.2 0.2
upper bound initialization 2.50 0.5 0.5 0.001 0.25 0.8 4
upper bound optimization 5 1 3 0.2 1 3 10
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Chapter 6
Blood perfusion of patellar bone 
measured by dynamic contrast-
enhanced MRI in patients with 
patellofemoral pain: a case-control 
study.
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ABSTRACT
Background/Aim
Patellofemoral pain (PFP) is a common knee complaint with unknown pathophysiology. 
Vascular problems, like bone ischemia or increased intraosseous hydrostatic pressure 
due to venous outflow obstruction, might play a role in PFP. Dynamic contrast-enhanced 
magnetic resonance imaging (DCE-MRI) enables quantitative measurement of patellar 
bone blood perfusion. This case-control study aims to investigate differences in DCE-
MRI perfusion parameters between patients with PFP and healthy control subjects.
methods
Patients diagnosed with PFP and healthy controls underwent MRI at 3T including DCE-
MRI. Quantitative MR perfusion parameters (i.e. kep, ktrans) of manually segmented patel-
lar bone were derived from motion-compensated DCE MRI-data by fitting Tofts’ model 
to the measured data in each voxel. Differences in perfusion parameters of patellar bone 
were compared between groups by linear regression analyses, adjusted for age, body 
mass index (BMI), gender, and sports participation.
Results
35 adult patients and 44 adult controls were included. Mean age was 26.1 (SD 5.0), mean 
BMI was 24.1(SD 3.4)kg/m2 and 49% was female. Mean kep was 0.189(SD 0.147)min-1 for 
patients and 0.154(SD 0.114)min-1 for controls(Table 2). Mean ktrans was 0.019(SD 0.015)
min-1 for patients and 0.014(SD 0.009)min-1 for controls. Both perfusion parameters were 
not significantly different between groups. However, a significant difference in variance 
between populations was observed for ktrans.
Conclusions
In contrast to expected, higher values of patellar bone perfusion parameters were found 
in patients with PFP compared to healthy control subjects, but these differences were 
not statistically significant. This result, and the observed significant difference in ktrans 
variance warrant further research.
Patellar bone blood perfusion in patellofemoral pain 199
INTRODUCTION
Patellofemoral pain (PFP) is a common knee complaint, which occurs especially in young 
physically active individuals.1 PFP is characterized by retro or peripatellar pain during 
kneeling, stair climbing, running, cycling, squatting and prolonged sitting with the 
knees flexed. A substantial percentage of patients experiences persistent symptoms, 
despite a variety of treatments.2-6 The pathophysiology of PFP is largely unknown. An 
increasing body of research suggests that vascular problems might play a role in patel-
lofemoral pain.7-13 In 1978, Lemperg and Arnoldi reported an elevated intraosseous 
hydrostatic pressure in the femur and tibia of patients with aching rest pain of the knee 
without osteoarthritis.12 They were the first to describe the intraosseous engorgement-
pain syndrome, characterized by reduced venous outflow from bone marrow, elevated 
intraosseous hydrostatic pressure and rest pain. More recently, Ho et al. demonstrated 
an elevated patellar water content, suggestive of venous engorgement on MRI in rec-
reational runners with PFP.11 Increased intraosseous hydrostatic pressure is proposed to 
induce pain by activating nociceptors in the subchondral bone.14 Another proposed vas-
cular source of pain is local bone tissue ischemia, which could be induced by increased 
intraosseous pressure due to impaired venous outflow, or by impaired arterial blood 
inflow. Local bone tissue ischemia might be particularly important in PFP patients with 
pain during prolonged sitting, since Naslund et al. showed a reduced pulsatile patellar 
blood flow on photoplethysmography in flexed knees.10
Visualization and quantitative analysis of blood perfusion is possible with dynamic 
contrast-enhanced magnetic resonance imaging (DCE-MRI).15 DCE-MRI is routinely 
applied in clinical practice for a variety of indications such as tumor and cerebral 
stroke imaging.16,17 However, there have only been a limited number of studies on the 
application of DCE-MRI for bone using a quantitative approach, due to the relatively 
poor vascularization of bone and the typical low contrast enhancement compared to 
surrounding tissues.18-22 To our knowledge, DCE-MRI has neither been applied in the 
patellar bone nor in patients with PFP before.
Therefore, the purpose of this study was to investigate differences in blood perfusion of 
the patellar bone, measured with quantitative DCE-MRI, between patients with PFP and 
control subjects. This may lead to a better understanding of the pathophysiology of PFP. 
Lower values of patellar bone perfusion parameters, suggestive for local tissue ischemia 
or venous outflow obstruction, are expected to be found in patients with PFP compared 
to healthy control subjects.
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mATERIAL AND mETHODS
Study design and participants
For the current study purpose, patients aged 18-40 years with PFP and healthy control 
subjects were included between January 2013 and September 2014. Patients with PFP 
for two months to two years diagnosed by their general practitioner, physiotherapist 
or sports physician, based on the presence of at least three of the following symptoms: 
crepitus or, retro or peripatellar pain during stair climbing, squatting, running, cycling, 
or sitting for a prolonged period with flexed knees were included. Exclusion criteria 
were: previous PFP episodes more than two years ago, onset after trauma, defined 
pathological condition of the affected knee at present, or previous surgery or injury of 
the affected knee. Healthy controls were recruited from patients’ sports team members, 
friends, or colleagues. We aimed to match patient and controls on age, gender, body 
mass index (BMI), and activity level. Exclusion criteria for controls were: present or past 
PFP, surgery or traumatic injury of both knees, or first degree relatedness with patients. 
Other exclusion criteria were: contra-indications for contrast-enhanced MRI and insuf-
ficient knowledge of the Dutch language. Written informed consent was obtained and 
this study was approved by our Institutional Review Board.
measurements
Participants completed a questionnaire on demographics, sports participation (yes/no) 
and knee complaints (duration, bilateral pain, Anterior Knee Pain Scale (AKP) 0-10023) and 
underwent 3 Tesla MRI (Discovery MR750, GE Healthcare) using a dedicated 8-channel 
knee coil (Invivo Inc., Gainesville, USA) at our institution. The (most) symptomatic knee 
of PFP patients was selected, or randomly chosen if both knees were equally painful 
or if both were asymptomatic (controls). The MRI protocol consisted of routine clinical 
proton density and T2-weighted fat-saturated sequences in three orthogonal planes, 
and a 3D spoiled gradient-echo (SPGR) sequence with in-plane resolution of 0.29 mm. 
In adult subjects, DCE-MRI was acquired, consisting of a sagittal, anterior-posterior 
frequency-encoded, fat suppressed 3D SPGR sequence, 35 phases of 10 seconds with 
intravenous contrast administration (0.2 mmol/kg Magnevist (Bayer)) at 2 ml/s starting 
after the first phase. Other parameters were: field of view 38x38cm, acquisition matrix 
of 256x128, zero filled to 256x256, in-plane resolution 1.5 mm, slice thickness 5 mm 
without interslice gap.
Image analysis
DCE-MRI measures the amount of contrast enhancement, based on signal intensity, over 
time in a specific volume of interest (VOI) as a measure of blood perfusion15. This can be 
visualized by a time-intensity curve, enabling qualitative analysis on an individual basis. 
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By voxelwise fi tting of a pharmacokinetic model, which takes into account the diff er-
ences in time required for the contrast agent to reach each voxel, quantitative perfusion 
parameters, ktrans and kep, can be calculated. Quantitative analysis enables comparison 
on group level.15 Tofts’ model24 combined with a group-wise arterial input function 
(AIF) was applied, since this combination best fi tted our data in a pilot study.25 Over the 
entire dataset, the residual was close to the acquisition noise level. This model uses the 
AIF from the popliteal artery and assumes one tissue compartment and one vascular 
compartment (Figure 1).24
Ktrans refl ects the volume transfer constant into the tissue compartment while kep de-
scribes the rate constant back to the vascular component. Low ktrans values might indicate 
local tissue ischemia, while low kep values are suggestive for venous outfl ow obstruction. 
The VOI, consisting of the patellar bone marrow (Figure 2), was manually delineated on 
the 3D SPGR non-fat saturated MR images with Matlab (R2011a, The MathWorks) by an 
experienced blinded observer.
In-house developed software was used to correct for patient motion during MRI 
acquisition.26-29 Perfusion parameters were calculated voxel-wise and weighted by the 
reciprocal Cramér-Rao-Lower-Bound (indicating fi t uncertainty) obtained by using a 
Maximum-Likelihood (ML) estimator during fi tting.30 Weighted mean and median kep 
and ktrans were calculated for all participants.
Statistical analysis
Independent sample t-tests and chi-square tests, or Mann-Whitney U test if distribu-
tion was not normal, were applied to investigate diff erences in baseline characteristics 
between groups. Diff erences in perfusion parameters (kep and ktrans) were compared 
between groups by linear regression analyses, adjusted for age, gender, BMI, and sports 
participation. Logarithmic transformations of weighted mean and median ktrans were 
performed to acquire normal distributions. Due to the presence of negative values, 
median kep was not transformed logarithmically, but tested non-parametrically with 
Vascular 
compartment 
Tissue 
compartment 
Ktrans 
Kep 
Figure 1. Schematic representation of Tofts’ pharmacokinetic model
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a Mann-Whitney U test. Diff erences in variance of perfusion parameters were tested 
with Levene’s test. Explorative analyses were conducted to investigate diff erences in 
perfusion parameters between participants with and without sitting pain. Item 8 of 
the AKP score was used to defi ne sitting pain. Two categories were formed from fi ve 
possible responses: (i) no sitting pain (“no diffi  culty” or “pain after exercise”); and (ii) sit-
ting pain (“constant pain”, “pain forces to extend the knees temporarily”, or “unable”). We 
calculated mean, standard deviation (SD), and mean diff erences with 95% confi dence 
intervals. P-values < 0.05 were considered to be statistically signifi cant. All analyses were 
performed with SPSS 20.0 (SPSS Inc).
RESULTS
Participants
35 adults PFP patients and 44 adult control subjects were included in this analysis, since 
DCE-MRI data were only acquired in adult participants. Mean age was 26.1 (range 18-40, 
SD 5.0) years, mean BMI was 24.1 (SD 3.4) kg/m2 and 49% was female. The BMI was 
signifi cantly higher in the patient group (Table 1). Patients reported a mean duration 
of complaints of 11.2 months and 45.7% reported bilateral pain. Mean AKP score of 
patients was 68.6 and 77.1% of the patients, reported the presence of sitting pain.
Figure 2. Single slice of the VOI of 
the patellar bone marrow
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DCE-mR imaging
Figure 3 shows the normalized mean time-intensity curves for patients and controls. To 
facilitate comparison, time-intensity curves were synchronized in order to compensate 
for diff erences in contrast arrival time. Per subject, the mean of the synchronized time-
intensity curve was computed over the VOI. Subsequently, these were normalized and 
the group mean and confi dence interval were computed. The curve of the patient group 
appeared to have a slightly larger amplitude compared to controls. The rest of the shape 
of the curve was not noticeably diff erent between groups. Confi dence intervals of the 
curves showed an overlap over the entire trajectory.
Table 1. Characteristics of study participants
Patients
(N=35)
Controls
(N=44) P-value
Female gender n (%) 18 (51.4) 21 (47.7) 0.74
Age (years) Mean (SD) 26.4 (5.6) 25.9 (4.6) 0.53
BmI (kg/m²) Mean (SD) 25.1 (3.8) 23.3 (2.8) 0.01
Sports participants 0.39
during inclusion n (%) 24 (68.6) 34 (77.3) 
before onset of pain n (%) 32 (91.4) n.a. 
Duration of complaints Mean (SD) 11.2 (6.3) n.a. n.a.
Bilateral pain n (%) 16 (45.7) n.a. n.a.
AkP score Mean (SD) 68.6 (11.0) n.a. n.a.
Sitting pain n (%) 27 (77.1) 0 (0) n.a.
n.a.: not applicable
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Figure 3. Normalized mean synchronized time intensity curves and corresponding confi dence intervals for 
patients and controls
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Quantitative analysis demonstrated a group mean of weighted mean ktrans of 0.017 (SD 
0.014)min-1 for patients and 0.013 (SD 0.008)min-1 for control subjects. The group mean 
of the weighted mean kep was 0.19 (SD 0.16)min-1 for patients and 0.14 (SD 0.14)min-1 for 
control subjects (Table 2). Mean and median of both quantitative perfusion parameters 
were not statistically signifi cantly diff erent between patients and control subjects (Table 
2) A signifi cant diff erence in variance of weighted mean ktran was observed between 
populations (p=0.007) (Figure 4).
Explorative analyses with respect to sitting pain showed no signifi cant diff erences be-
tween patients with and without pain during sitting (data not presented).
DISCUSSION
This case-control study showed higher values of quantitative MRI derived perfusion 
parameters in patellar bone in PFP patients compared to healthy control subjects, but 
Table 2. Group mean and standard deviation of weighted mean over VOI for kep and ktrans (min-1) and group 
mean and standard deviation of median over VOI kep and ktrans of patellar bone in patients and controls.
Patients
(N=35)
Controls
(N=44) mean diff erence (95% CI)
Adjusted 
p-value
ktrans (min-1)
mean 0.017 (0.014) 0.013 (0.008) 0.0039 (-0.0013 ; 0.0091) 0.32
median 0.029 (0.028) 0.023 (0.030) 0.0052 (-0.0078 ; 0.018) 0.47
kep (min-1)
mean 0.19 (0.16) 0.14 (0.14) 0.046 (-0.021 ; 0.11) 0.24
median 0.19 (0.23) 0.11 (0.16) 0.069 (-0.017 ; 0.15)  0.15* 
CI: confi dence interval; *non-parametric testing
Figure 4. Distribution of weighted mean ktrans (left plot) and kep (right plot) (min-1) subdivided in patients 
and controls
Patellar bone blood perfusion in patellofemoral pain 205
these differences were not statistically significant. The observed trend toward higher 
blood flow in PFP patients is contrary to what was expected, since lower values, sugges-
tive for local tissue ischemia or venous outflow obstruction, were presumed to be found. 
Interestingly, a larger variance of ktrans, comprising higher ktrans values, was observed in 
patients compared to controls. The reason behind this needs to be elucidated, but it may 
suggest that a subgroup with higher ktrans. values is present in the patient population.
To our knowledge, only one previous study has evaluated blood perfusion of bone of 
the knee joint using a quantitative DCE-MRI approach. Seah et al. applied quantitative 
DCE-MRI in knee osteoarthritis patients and found no association between perfusion 
of tibial bone marrow lesions and pain.18 Their results, however, cannot be directly 
compared to ours, since a different pharmacokinetic model was used. Although the ap-
plication of an appropriate pharmacokinetic model is crucial for the accurate calculation 
of quantitative DCE-MRI parameters, there is no consensus in literature regarding the 
recommended model in bone. In a pilot study comparing Brix’ 31, Tofts’ 24, and extended 
Tofts’ models, Tofts’ model was identified as best model to fit DCE data of patellar bone.25 
To our knowledge, two other studies used Tofts’ model in an osseous structure of the 
lower extremity. Breault et al. showed femoral kep values ranging between 3.48-3.85 
min-1 21, whereas Budzik et al. showed a ktrans of 0.06 min-1 and a kep of 0.8 min-1 for femoral 
red bone marrow.22 The discrepancy between these values and ours is likely explained 
by the fact that femur and patella have different blood perfusion. Values obtained in our 
study are relatively closer to those reported by Budzik et al. than to those of Breault et 
al., which may indicate that use of an AIF measured from the data, as was done in our 
study and by Budzik et al., is more accurate than an a priori assumed model as applied 
by Breault et al.
Explorative analyses of one hypothetic subgroup revealed no significant differences in 
blood perfusion of the patellar bone between patients with and without sitting pain. In 
order to study the phenomenon of sitting pain further, an interesting prospect would be 
to acquire DCE-MRI in an open MRI scanner with the knee flexed, particularly since some 
PFP patients especially experience pain during knee flexion and Naslund et al. reported 
a decreased pulsatile patellar blood flow in patients with flexed knees.10
Strengths of our study are that were able to include a large number of patients with 
PFP and evaluate them with quantitative DCE-MRI, which had not been done previously 
for the patella and in the context of PFP. Furthermore, in contrast to previous studies 
in other pathologies or bones, we first conducted a pilot study to determine the phar-
macokinetic model best suited for our DCE-MRI data.25 There are also some limitations 
that need to be addressed. First, although we aimed to match patients and controls on 
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age, gender, BMI, and sports participation, differences were observed in BMI. Therefore, 
all analyses were adjusted for these confounders. Second, median kep was tested non-
parametrically and thus adjustment for confounders was not possible. However, as all 
confounders in the regression analysis of median kep were not statistically significant 
and had low regression coefficients, we believe that the Mann-Whitney U test was used 
appropriately. Third, analyses showed a high spatial heterogeneity of patellar blood 
perfusion. Since the fit of the pharmacokinetic model, and therefore the uncertainty 
derived weight, is dependent on the degree of blood perfusion (better perfused areas 
have a better fit), we decided to additionally calculate the medians of both perfusion pa-
rameters to avoid underweighting of less-perfused areas. Finally, the large inter-subject 
variability, possibly caused by measurement variability or normal tissue heterogeneity, 
makes it difficult to detect significant differences. It is important to notice that DCE-MRI 
of bone is still an emerging field of research and poses important challenges due to the 
relatively poor vascularization of bone compared to other tissues. Unfortunately, repro-
ducibility of quantitative DCE-MRI parameters could not be studied due to the nature 
of our method, which involves the burden of contrast administration. Consequently, we 
were not able to disentangle measurement variability and normal tissue heterogeneity.
In conclusion, in contrast to expected, higher values of patellar bone perfusion param-
eters, measured with quantitative DCE-MRI, were found in PFP patients compared to 
healthy control subjects, but these differences were not statistically significant. This 
result, and the observed significant difference in ktrans variance warrant further research.
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ABSTRACT
Patellofemoral pain syndrome (PFPS), characterized by peri- and retropatellar pain, is a 
common disorder in young, active people. The etiology is unclear; however, quadriceps 
strength seems to be a contributing factor, and sensitization might play a role. The study 
purpose is determining the inter-rater reliability of handheld dynamometry to test both 
quadriceps strength and pressure pain threshold (PPT), a measure for sensitization, 
in patients with PFPS. This cross-sectional case-control study comprises 3 quadriceps 
strength and one PPT measurements performed by 2 independent investigators in 
22 PFPS patients and 16 matched controls. Inter-rater reliability was analyzed using 
intraclass correlation coefficients (ICC) and Bland-Altman plots. Inter-rater reliability of 
quadriceps strength testing was fair to good in PFPS patients (ICC= 0.72) and controls 
(ICC=0.63). Bland-Altman plots showed an increased difference between assessors 
when average quadriceps strength values exceeded 250N. Inter-rater reliability of PPT 
was excellent in patients (ICC=0.79) and fair to good in controls (ICC=0.52). Handheld 
dynamometry seems to be a reliable method to test both quadriceps strength and PPT 
in PFPS patients. Inter-rater reliability was higher in PFPS patients compared to control 
subjects. With regard to quadriceps testing, a higher variance between assessors occurs 
when quadriceps strength increases.
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INTRODUCTION
Patellofemoral pain syndrome (PFPS) is a common diagnosis, especially in young and 
physically active people.1-3 PFPS is characterized by diffuse peri and retropatellar pain 
provoked by climbing or descending stairs, squatting, running and prolonged sitting 
with the knees flexed. Other symptoms are crepitus and a feeling of giving way.3-5 De-
spite adequate treatment PFPS often becomes a recurring or chronic problem.6,7 The 
etiology of PFPS is still unknown.4,8 Quadriceps strength seems to play an important 
role. Less knee extension strength is associated with PFPS9 and lower knee extension 
peak torque is a possible risk factor for PFPS.10 Furthermore, new insights indicate that 
pain in chronic sports injuries like PFPS might be neuropathic.11,12 The profiles of sensory 
dysfunction show that central sensitization may play a role in PFPS.13,14 If so, treatment 
options focusing on peripheral and/or central sensitization should be considered. To 
measure quadriceps strength and possible sensitization in patients with PFPS, reliable 
measurement methods are needed. Especially for clinical practice, it would be very 
practical to use one device for both tests.
A handheld dynamometer (HHD) is often used to assess muscle strength, because it is a 
convenient and relatively inexpensive method.15 The inter-rater reliability of quadriceps 
strength testing with HDD shows conflicting results and has not yet been tested in 
patients with PFPS.16-20 To test sensitization, the pressure pain threshold (PPT) test can 
be used. The use of a handheld dynamometer with algometry tip for the PPT test has 
proven to have good inter-rater reliability in various populations, but also has not yet 
been tested in patients with PFPS.21-25
The aim of this study is therefore to investigate the inter-rater reliability of handheld 
dynamometry for quadriceps strength and PPT testing in patients with PFPS.
mATERIALS AND mETHODS
Study design
This reliability study was conducted within a cross-sectional case-control study on the 
aetiology of PFPS, and was executed according to the medical ethical regulations of the 
University Medical Center Rotterdam (MEC-2012-342) and ethical standards in sports 
and exercise science research.26 Patients, aged between 14 and 40 years, consulting 
their sport physician, general practitioner or physiotherapist were eligible to participate. 
Inclusion criteria comprised present PFPS for two months until two years, based on the 
presence of at least three of the following symptoms: pain during climbing or descend-
ing stairs, squatting, running and prolonged sitting with the knees flexed of time or 
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grinding of the patella. Patients were excluded if they had defined pathological knee 
conditions, onset after trauma, previous knee injuries or surgery.
Control subjects were recruited from patients’ sports teams, family or friends and 
matched by age, gender, BMI and sports participation. They were excluded if they had 
a history of knee injury or were first grade family members of patients. All participants 
were informed about the study and signed an informed consent. In case of minors, 
parents or guardians additionally signed an informed consent.
Test protocol
All subjects filled in a questionnaire including demographics (age, gender, height, 
weight), sports participation, duration of complaints, bilateral complaints, pain intensity 
during rest and activity (0 to 10 numeric rating scale). 2 independent investigators as-
sessed quadriceps strength and the PPT in a clinical examination room at the Erasmus 
MC with approximately 30 minutes in between both assessments. Assessors were 
blinded for each other’s results. A randomization list, using a random number generator 
in blocks of 4 without stratification, was used to determine the assessor order. Assessor 
1 was a medical student (height 158cm, weight 45kg); assessor 2 was a medical doctor 
(height 175cm, weight 78kg). To make sure both assessors conducted testing in the 
same manner, the protocol was practiced with the HHD on multiple healthy subjects 
under supervision of an experienced tester.
Quadriceps strength
Quadriceps strength was measured using a HHD (Biometrics MicroFET 2, Almere, The 
Netherlands). The subject was seated on the edge of the examination table with the 
knees in 90 degrees flexion and hands in the lap (Fig. 1a). The dynamometer was placed 
above the malleoli on the ventral side of the leg. In order to familiarize the subject with 
the desired movement, the subject was asked to apply force by extending the knee 
actively, while the assessor fixated the leg. Thereafter, the test was done with the same 
procedure, but this time the subject was asked to apply maximum force. The isometric 
maximum voluntary contraction (MVC) lasted approximately 5 seconds. Maximum 
force was read from the display of the dynamometer and noted in Newtons (N), the 
International System of Units derived unit of force. One Newton is the force needed to 
accelerate 1 kilogram of mass at the rate of 1 meter per second squared. If the subject 
was able to break through the assessor’ strength, the measurement was labelled inad-
equate. Quadriceps strength testing was conducted 3 times. The mean of the highest 2 
values was used for analysis.27
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Pressure pain threshold
To determine the PPT the same HHD was used after attaching a metal tip of 1cm2. The 
PPT was measured with the subject supine on the examination table. In order to place 
the algometry tip, subjects with PFPS were asked to point out the most painful location 
on the knee. When this was behind the patella the algometer was placed on the center 
of the patella. In control subjects, the algometer was placed on the medial patellar facet, 
since this is often regarded as the most painful location in PFPS patients (Fig. 1b). The 
assessor slowly increased pressure until the subject indicated that it became painful. 
Maximum applied force was read from the display of the dynamometer in N/cm2. Asses-
sors placed the algometer on the same location.
To prevent tissue damage a cut-off  value of 70N/cm2 was defi ned. N/cm2 is the amount 
of force per square centimeter, which is the surface of our algometry tip. A recent study 
used a cut-off  value of 45N/cm2 for patellar tendon21 Since a tendon is more vulner-
able, we increased the cut-off  value to 70N/cm2 (also based on a small test trial among 
students). The measurements of both assessors were excluded from the analyses when 
either one of the assessors reached the cut-off  value of 70N/cm2 in a subject. For both 
the strength and algometry measurements, both legs were tested and analyzed in con-
trol subjects while in patients only the (most) aff ected leg was included.
Statistical analysis
Statistical analyses were performed with SPSS for Windows, version 20. To compare 
subject characteristics, a non-parametric chi squared test for dichotomous variables 
and Mann Whitney U test for continuous variables were used. To determine the inter-
rater reliability, a 2 way mixed model of the intraclass correlation coeffi  cient (ICC) was 
used on absolute agreement between assessors 1 and 2. The measurements of both 
A B
Figure 1. Measuring methods a) Quadriceps strength b) Pressure pain threshold
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assessors were excluded from the analyses when either one of the assessors reported 
an inadequate measurement. For both tests, ICCs in patients were calculated using the 
values of the (most) affected knee. Reliability was considered excellent for ICCs higher 
than 0.75, fair to good for values from 0.40-0.75 and poor for values less than 0.40.28 
Bland-Altman plots were made to visualize the limits of agreement.
RESULTS
All eligible patients and control subjects seen between February 1 and May 17, 2013 
were included for the present study, resulting in a total study sample of 38 subjects: 
22 PFPS patients and 16 control subjects. The mean age of the study population was 
22.2(6.0) years, BMI 23.6(4.5) and 68% was female. On average, patients had knee pain 
for 12 months and 55% had bilateral complaints. Patients and control subjects were only 
significantly different in percentage of sports participants (Table 1).
Quadriceps strength
Strength measurements of 2 patient knees and 14 control knees were inadequate for 
assessor 1, compared to 1 patient knee for assessor 2. Therefore, 20 patient knees and 18 
control knees were analyzed. Mean quadriceps strength of patients measured by asses-
sor 1 was 198(39)N, compared to 206(52)N for assessor 2 (Table 2). The ICC of the strength 
measurements in patients shows fair to good agreement (ICC 0.72). Mean quadriceps 
strength in control subjects was 239(32)N in assessor 1, compared to 270.9(54.9)N in 
Table 1. Characteristics of the study population (n=38)
Patients 
(N=22)
Control subjects
(N=16) P-value
Age in years mean (SD) 22.0 (5.8) 22.5 (6.5) 0.97
Female gender n (%) 16 (72.7) 10 (62.5) 0.50
BmI mean (SD) 23.9 (4.8) 23.3 (4.2) 0.83
Sport participants n (%) 12 (54.5) 13 (81.3) 0.09
Duration of knee pain in months mean (SD) 12.0 (6.5) n.a n.a
Bilateral knee pain n (%) 12. (54.5) n.a. n.a.
Pain score in rest (NRS 0-10) mean (SD) 4.7 (2.3) n.a n.a
Pain score during activity (NRS 0-10) mean (SD) 7.1 (1.9) n.a. n.a.
Recruiting physician
Sport physician n (%) 10 (45.5%) n.a. n.a.
General practitioner n (%) 10 (45.5%) n.a. n.a.
Physiotherapist n (%) 2 (9.1%) n.a. n.a.
BMI= body mass index; SD= standard deviation; NRS= numeric rating scale; n.a.= not applicable
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assessor 2. The ICC of strength measurements in control subjects shows fair to good 
agreement (ICC 0.63).
The Bland-Altman plot shows on average lower assessed values for assessor 1 compared 
to assessor 2 (MD 7.9N (95% CI 59.9; -75.7) and 31.9N (95% CI 27.1 to -90.9N), in PFPS pa-
tients and in control subjects, respectively. (Fig. 2). Furthermore, the Bland-Altman plot 
shows an increased difference between assessors when average quadriceps strength 
values exceed 250N.
Pressure pain threshold
For analysis, 1 PFPS patient was excluded, because the most painful place differed 
between assessors. In 12 knees of control subjects, the cut-off value of 70N/cm2 was 
reached; in 9 of these knees, the cut-off value was reached by both assessors. Therefore 
a total of 21 knees of PFPS patients and 20 knees of control subjects were eligible for 
analysis.
Mean PPT of patients assessed by assessor 1 was 32.6(12.4)N/cm2, compared to 
35.4(11.1)N/cm2 in assessor 2 (Table 3). The ICC of the PPT shows excellent agreement 
Table 2. Descriptive statistics and ICC’s of HHD quadriceps strength measurements in Newtons
Group
Assessor 1 Assessor 2
ICC (95% CI)mean (SD) Range mean (SD) Range
Patients
(20 knees)
198.4 (39.7) 91.4 – 267.6 206.3 (52.1) 101.9 – 301.4 0.72 (0.43 – 0.88)
Control subjects
(18 knees)
239.0 (32.2) 161.9 – 271.2 270.9 (54.9) 166.2 – 367.2 0.63 (-0.01 – 0.87)
SD= standard deviation; ICC= intraclass correlation coëfficient; CI= confidence interval
Figure 2. Bland-Altman plots of dynamometry in patients (left plot) and control subjects (right plot). The 
solid black line shows the mean difference between assessor 1 and assessor 2. The black dotted lines show 
the 95% CI = mean difference ± 1.96 x SD. All values are in Newtons
218 Chapter 7
(0.79) in PFPS patients. In control subjects, the mean PPT was 34.2(10.1) N/cm2 in asses-
sor 1, compared to 40.2(9.7)N/cm2 in assessor 2. The ICC shows a fair to good agreement 
(0.52) in this group. The Bland-Altman plot of the PPT shows that on average assessor 1 
measured lower values compared to assessor 2 in PFPS patients (MD 2.8N/cm2 (95%CI 
11.5 to -17.2N/cm2) and in control subjects (5.9N/cm2 (95% CI 11.3 to -23.2N/cm2)). (Fig. 
3)
DISCUSSION
The use of a HHD to test quadriceps strength has a fair to good inter-rater reliability in 
patients with PFPS (ICC 0.72) and control subjects (ICC 0.63). The use of a HHD to test 
the PPT has an excellent inter-rater reliability in patients with PFPS (ICC 0.79). In control 
subjects the inter-rater reliability of the PPT test is fair to good (ICC 0.52).
Inter-rater reliability of quadriceps strength testing was lower compared to other stud-
ies with the same test protocol (ICCs 0.80 to 0.85).16,18 However, samples in these studies 
Table 3. Descriptive statistics and ICC’s of HHD pressure pain threshold measurements in Newton/cm2
Group
Assessor 1 Assessor 2
ICC (95% CI)mean (SD) Range mean (SD) Range
Patients
(21 knees)
32.6 (12.4) 14.2 – 61.3 35.4 (11.1) 20.9 – 61.3 0.79 (0.53 – 0.91)
Control subjects
(20 knees)
34.2 (10.1) 19.1 – 60.0 40.2 (9.7) 25.8 – 60.5 0.52 (0.09 – 0.78)
SD= standard deviation; ICC= intraclass correlation coëfficient; CI= confidence interval
Figure 3. Bland-Altman plots of PPT testing in patients (left plot) and control subjects (right plot). The solid 
black line shows the mean difference between assessor 1 and assessor 2. The black dotted lines show the 
95% CI = mean difference ± 1.96 x SD. All values are in Newtons/cm
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consisted of patients with advanced cancer or elderly and consequently maximum 
strength assessed in these groups was considerably lower; 200 and 218N respectively, 
compared to the current study.16,18 Higher values of quadriceps strength cause larger 
variability in measurements (Fig. 2a and Fig. 2b), which seem to result in lower ICCs and 
wider 95% confidence intervals. When the mean quadriceps strength was higher than 
250N the difference between both assessors increased rapidly, with assessor 2 achiev-
ing much higher values. In total, there were 2 PFPS patients and 7 control subjects (14 
knees), in which assessor 1 was not able to retain quadriceps strength; for assessor 2, this 
involved only 1 PFPS patient (2 knees). Since assessor 1 had a lower weight and height, 
it can be assumed that assessor 2 was weaker compared to assessor 1. This might imply 
that tester physics plays a role in the inter-rater reliability of HHD use to test quadriceps 
strength in stronger individuals. The influence of the tester’ physics on the inter-rater re-
liability of HHD use in quadriceps strength has also been reported by other authors.16,17 
To avoid the influence of tester physics, other authors used a fixed HHD, especially in a 
healthy athletic population, yielding perfect inter-rater reliability of quadriceps strength 
testing with an ICC of 0.96.29 However, to use the fixed HDD additional equipment is 
necessary, which compromises the feasibility of the HHD in clinical practice. Further-
more, it is questionable whether it has any clinical implication for PFPS patients, because 
in patient knees most quadriceps strength measurements were adequate and did not 
exceed 250N, as could be seen in the Bland Altman plot (Fig. 2a).
The inter-rater reliability of the PPT test in PFPS patients is comparable with the inter-
rater reliability of biceps brachii testing in healthy volunteers (ICC 0.74-0.78)25 and is 
slightly lower compared to the PPT of myofacial trigger points (ICC 0.82-0.86).24 How-
ever, the reliability found in this study is markedly lower compared to the reliability of 
the PPT in patients with patella tendinopathy (ICC 0.93)21 This might be explained by the 
fact that the assessors in the tendinopathy study were more experienced or by the low 
mean PPT value since higher pressure is harder to apply and might account for more 
variability between assessors. Furthermore, it is not clear whether they have used ICC’s 
on consistency or on absolute agreement. ICC’s on consistency tend to be higher than 
those on absolute agreement.30
Strengths and limitations
The most important strength is that the study sample represents the population of PFPS 
patients. Furthermore, the lack of external fixture and use of straps makes these results 
more generalizable to clinical practice in which use of extra equipment is not feasible.
A limitation might be the use of one trial for the PPT. Previous studies have shown that 
the inter-rater reliability is higher when the mean of multiple trials or the value of a 
second or third trial is used for analysis.24,25 We chose not to perform multiple trials on 
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the painful location, as it would be an extra burden for the participants. Therefore the 
ICC found in this study for the PPT test could have been slightly underestimated.
Furthermore, studies suggest standardizing the rate of pressure increase per second. 
However, when higher pressure needs to be applied, it is harder to gradually increase 
the pressure using a standardized rate.23,24 This might in part account for bigger vari-
ability in the differences of measurements between both assessors.
Conclusions
Handheld dynamometry seems to be a reliable method to test both quadriceps strength 
and the PPT in PFPS patients. Compared to controls, the inter-rater reliability for both 
tests was higher in PFPS patients. Further research on the inter-rater reliability of HHD 
used to test quadriceps strength and the PPT is needed.
Practical implications
The HHD is a small, portable and relatively inexpensive device. It offers a fast, reliable 
and easy-to-use method for testing quadriceps strength and the PPT in clinical practice 
in PFPS patients.
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ABSTRACT
Study Design
Case-control study
Objectives
To investigate differences in pressure pain threshold (PPT) between patients with patel-
lofemoral pain (PFP) and healthy control subjects and study associations between PPT 
and patients characteristics.
Background
PFP is a common knee complaint among active adolescents with unknown pathogen-
esis. It has been suggested that repeated overload might sensitize nociceptors causing 
local hyperalgesia. This might also lead to an altered central pain processing. The PPT 
can be measured to identify pressure hyperalgesia,
methods
Patients with PFP (n=64) and healthy controls (n=70) were included. Demographics, 
pain (numerical rating score) and function (anterior knee pain score) were obtained by 
questionnaire. The PPT was measured with a handheld dynamometer with algometry 
tip at the most painful spot of the affected knee (medial facet in controls), same spot 
contralateral knee and at the contralateral forearm. Differences between groups were 
tested with linear regression analyses adjusted for age, gender, BMI and sports participa-
tion.
Results
Patients had significantly lower PPTs compared to controls at all locations (β affected 
knee -13.98(-18.62;-9.33); β contralateral knee -6.91(-11.84;-1.97); β arm -7.57(-12.07;-
3.07)). A significant interaction effect was found between participant status and female 
for the PPT at the contralateral arm (β -9.95, 95%CI -18.74;-1.16). Female gender was 
significantly associated with a lower PPT in the patient population.
Conclusion
Local, distal and generalized pressure hyperalgesia, suggesting alterations in both pe-
ripheral and central pain mechanisms, were present in patients with PFP. Females with 
PFP were most likely to suffer from generalized hyperalgesia.
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INTRODUCTION
Patellofemoral pain (PFP) is a common knee complaint among active adolescents and 
young adults.1 It is characterized by peri-patellar and retro-patellar pain, mainly during 
activities as prolonged sitting, kneeling, squating, walking up and down the stairs or 
repetitive activities as running and biking.
The exact origin of PFP is still unknown.2 The current theory is that PFP originates from 
excessive patellofemoral contact stress due to high loading and/or maltracking of the 
patella. Dye et al. suggested in 2005 that this may result in a symptomatic loss of tis-
sue homeostasis.3 Next to this structural approach, he suggested the presence of an 
altered pain mechanism, by stating that once loss of tissue homeostasis was initiated, 
it may persist indefinitely.3 Previous studies by Jensen et al. indicated that aberrations 
of the nervous system leading to altered pain perception might play a role in chronic 
PFP.4,5 More recently two studies demonstrated the presence of pressure hyperalgesia, 
an increased response to a pain provoking mechanical stimulus, in PFP using the pain 
pressure threshold (PPT).6,7 Rathleff et al. were the first to demonstrate lower local and 
distal PPTs in female adolescent PFP patients compared to controls.6 In a small group of 
female adult patients Noehren et al. demonstrated that an increase in both localized and 
centralized pain sensitivity in PFP is related to movement mechanics.7 These lowered 
PPTs found in females PFP patients may have implications for treatment strategies. This 
is further strengthened by the fact that female adolescents with PFP deeming them-
selves to be recovered showed a greater improvement in PPT compared to adolescents 
who had not recovered following treatment. This indicates that it is possible to change 
PPTs as a consequence of treatment.8
So it appears that female PFP patients seem to have pressure hyperalgesia. Though it 
is up to now unclear whether this is also present in the general PFP population, includ-
ing both male and female patients. Additionally, there is emerging evidence that pain 
processes are age dependent9 and a difference between adult and adolescent patients 
with PFP is suggested.10 Furthermore, more knowledge on associations between patient 
characteristics and PPT is essential in order to develop better-targeted treatment strate-
gies.
Therefore, the aim of the present study was investigate differences in PPTs between PFP 
patients and matched control subjects, to analyze potential differences between adult 
PFP and adolescent PFP patients and to explore patient characteristics associated with 
altered PPTs.
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mETHODS
Study design and participants
This cross-sectional case-control study was performed between January 2013 and Sep-
tember 2014. Patients aged between 14 and 40 years, with PFP for at least two months 
and for a maximum of two years were compared to a healthy control group without 
knee complaints.
Patients diagnosed with PFP were included by their general practitioner, physiotherapist 
or sports physician during consultation. All patients diagnosed with PFP had to fulfill 
the following criteria: the presence of at least three of the following symptoms: pain 
complaints while stair climbing; while squatting; while running; while cycling; while sit-
ting for a prolonged period with the knee flexed, or crepitus. Exclusion criteria included 
a defined pathological knee condition at the affected knee, such as osteoarthritis or 
patellar tendinopathy, previous surgery or injury of the affected knee, previous episodes 
of PFP more than two years ago or onset of PFP after trauma. Control subjects were 
recruited by sports team members, friends or colleagues of the patients. We aimed to 
match the control subjects to the patient group on age, BMI, gender and activity level. 
Subjects suffering knee pain or a history of PFP, subjects with traumatic injury or knee 
surgery and first grade family members were excluded as control subjects. All subjects 
with contra-indications for MR scanning with contrast administration (for other study 
purposes) or insufficient knowledge of the Dutch language were excluded. Approval 
for the study was given by the Institutional Review Board (Medical Ethical Committee 
of Erasmus MC, protocol no. MEC-2012-342) and, accordingly, informed consent was 
obtained from all participants and if participants were aged < 18 years, their parents 
additionally gave informed consent.
measurements
After signing informed consent, all subjects were asked to fill in a questionnaire and 
were additionally invited for a physical examination at the Erasmus MC in Rotterdam.
The questionnaire included questions on demographics (gender, age, weight and height 
to calculate BMI), sports participation (yes/no) and type of complaints (bilateral (yes/
no), duration of complaints in months, more pain in cold environment (yes/no), function 
(AKP scale)11 and pain intensity on a numeric rating scale (NRS) from 0 to 10 at rest and 
during activity).19 During physical examination the presence of neuropathic pain was 
assessed with the DN412, widespread pain was assessed according to the tenderpoints 
index and according to the Manchester definition of chronic widespread pain with a 
mannequin.13 Subsequently, crepitation during squatting (present or not), palpation of 
the medial patellar facet (painful or not) and the Clarke compression test (positive or 
negative) were assessed.
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Pain pressure threshold
The PPT was determined by a handheld dynamometer (HHD) with a special algometry 
tip of 1cm2 (Biometrics MicroFET 2, Almere, The Netherlands). We showed earlier that this 
is a reliable method to test PPT in PFP patients.14 The PPT measurement was performed 
by one assessor (RvdH). Subjects were lying supine on the examination table and the al-
gometry tip was placed at the most painful location on the knee in the patients with PFP. 
If this place was located behind the patella (i.e. retropatellar pain), the algometer was 
placed on the center of the patella. PPT testing in patients was performed on the same 
site of the contra-lateral knee and dorsolateral mid-shaft of the contralateral forearm. In 
control subjects PPT testing was done on the medial facet of both knees, since the me-
dial patellar facet is often regarded as the most painful location in PFP, and dorsolateral 
mid-shaft of the contralateral forearm. Once the algometry tip was placed, pressure was 
slowly increased until the subjects indicated that it became painful. Maximum applied 
force was read from the display of the dynamometer in N/cm2 and consequently pain 
severity was assessed using the 0-10 NRS. We applied a cut-off of 70N/cm2 to prevent 
possible tissue damage.
Statistical analysis
Differences in characteristics between patients and control subjects and between adult 
and adolescent patients (aged < 18 years) were tested with independent sample t-test 
(continuous variables) and chi-square (categorical variables) tests if normal distribution 
was present. Otherwise the Wilcoxon test was applied.
Differences in PPT and experienced pain at threshold between patients and control 
subjects, and in predefined subgroups divided by age status (adult vs. adolescent) 
and gender were analyzed using a linear regression model with adjustment for age, 
gender (not in gender subgroup analyses), BMI and sport participation. If differences 
were present in these subgroup analyses, effect modification was tested by adding the 
relevant interaction term to the primary comparison of patients and control subjects. 
The association between patient characteristics and the PPT in a subgroup of patients 
was assessed using a multivariable linear regression model, entering all variables at 
once. Results are presented in mean differences and Betas (β) with accompanying 95% 
confidence intervals (95%CI). P-values <0.05 were considered statistically significant.
RESULTS
Participants
The study population consisted of 64 patients with PFP and 70 healthy control subjects 
(Figure 1). Both groups comprised 20 adolescents. The mean age of the patient group 
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was 23.4 (SD 7.0), mean BMI was 23.6 (SD 3.8)kg/m2 and 54.7% of the participants were 
female. Patients had a significantly higher BMI, participated less frequently in sport and 
had a lower AKP function score compared to healthy control subjects (Table 1).
Compared to adolescent PFP patients, the adult PFP patients had a significantly higher 
BMI and less frequently reported bilateral complaints (Table 2). Compared to male pa-
tients, female patients were significantly younger, had a longer duration of complaints 
and reported bilateral complaints more frequently.
Pain measures
Significantly lower PPTs were observed in patients compared to healthy control subjects 
(P<0.001) at all three locations (Table 3). Beta’s were -13.98(-18.62;-9.33) in the affected 
knee, -6.91(-11.84;-1.97)) in the contralateral knee and -7.57(-12.07;-3.07) in the contra-
lateral arm. In addition, reported pain intensity scores at threshold were significantly 
higher in PFP patients compared to healthy controls indicating that patients experienced 
significantly more pain when pain was felt.
Subgroup analyses by age status demonstrated a significant lower PPT at the affected 
knee in both adolescent and adult patients compared to their control groups (Table 
4). Concerning the contralateral knee and contralateral arm, a significant difference 
between patients and controls was present only in adults, in which adult patients had 
lower PPTs compared to adult control subjects.
Subgroup analyses by gender showed significantly lower PPTs at the affected knee were 
present in male and female patients compared to their control groups (Table 4). Con-
cerning the contralateral knee and contralateral arm, a significant difference between 
patients and controls was present only in females, in which female patients had lower 
PPTs compared to male control subjects. Further analysis showed a significant interaction 
Figure 1. Flow diagram of patients.
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effect between participant status and female with respect to the PPT at the contralateral 
arm (β -9.95, 95%CI -18.74;-1.16). Generalized widespread pain according to either the 
Manchester coding or the tenderpoints index was not present in the study population. 
Neuropathic pain according to the DN4, was present in 12.5% (n=8) of patients.
The multivariable linear regression model demonstrated a significant association be-
tween female gender and lower PPTs at the affected knee (β -8.20, 95%CI -16.36;-0.04), 
contralateral knee (β-11.10, 95%CI -20.40;-1.79) and the contralateral arm (β -18.94, 
95%CI -25.85;-12.02) (Table 5). Furthermore, sports participation was significantly as-
sociated with lower PPTs in the contralateral arm (β-7.62, 95%CI -13.75;-1.48).
Table 3. Pain pressure thresholds (algometry) for patients and control subjects
Patients
N=64
Controls
N=70
mean difference
(95%CI)
B
(95%CI)*
Adjusted 
p-value*
Affected knee (N/cm2) 38.5 (15.3) 50.7 (14.6) -12.2 (-17.33;-7.14) -13.98 (-18.62;-9.33) <0.001
Pain (NRS 0-10) 4.7 (2.0) 2.9 (2.1) 1.80 (1.10;2.50) 1.88 (1.15;2.61) <0.001
Contralateral knee (N/cm2) 44.9 (16.2) 49.6 (14.7) -4.7 (-10.05;0.52) -6.91 (-11.84;-1.97) 0.006
Pain (NRS 0-10) 4.0 (2.4) 2.9 (2.2) 1.01 (0.23;1.79) 1.22 (0.42;2.02) 0.003
Contralateral arm (N/cm2) 49.6 (13.9) 55.2 (14.6) -5.65 (-10.53;-0.78) -7.57 (-12.07;-3.07) 0.001
Pain (NRS 0-10) 3.7 (2.4) 2.3 (2.1) 1.34 (0.56;2.12) 1.60 (0.81;2.38) <0.001
* adjusted for age, gender, BMI and, sport participation; CI: confidence interval
Table 4. Pain pressure thresholds (algometry) for patients and control subjects subdivided based on age 
and based on gender.
Patients Controls
mean difference
(95%CI)
B
(95%CI)*
Adjusted 
p-value*
Adolescents n=20 n=20
Affected knee (N/cm2) 30.2 (10.1) 46.1 (13.9) -15.86 (-23.64;-8.08) -15.22 (-23.89;-6.64) <0.01
Contralateral knee (N/cm2) 40.7 (16.9) 45.1 (13.7) -4.38 (-14.21;5.45) -5.85 (-15.68;3.98) 0.24
Contralateral arm (N/cm2) 46.6 (14.8) 52.3 (15.3) -5.75 (-15.38;3.89) -6.72 (-14.96;1.52) 0.11
Adults n=44 n=50
Affected knee (N/cm2) 42.3 (15.8) 52.6 (14.5) -10.34 (-16.56;-4.13) -13.08 (-18.85;-7.30) <0.001
Contralateral knee (N/cm2) 46.7 (15.7) 51.4 (14.8) -4.69 (-10.96;1.57) -7.73 (-13.63;-1.82) 0.01
Contralateral arm (N/cm2) 51.0 (13.4) 56.4 (14.3) -5.45 (-11.14;0.24) -7.62 (-13.09;-2.14) <0.01
male n=29 n=29
Affected knee (N/cm2) 47.1 (16.7) 55.3 (14.7) -8.19 (-16.46;0.088) -11.28 (-19.41;-3.14) <0.01
Contralateral knee (N/cm2) 54.0 (14.3) 54.3 (14.3) -0.30 (-7.84;7.24) -2.85 (-10.62;4.91) 0.47
Contralateral arm (N/cm2) 59.5 (11.4) 59.9 (13.4) -0.49 (-7.04;6.06) -2.07 (-8.81;4.68) 0.54
Female n=35 n=41
Affected knee (N/cm2) 31.4 (9.3) 47.5 (13.7) -16.15 (-21.45;10.85) -16.77 (-22.57;-10.99) <0.001
Contralateral knee (N/cm2) 37.2 (13.7) 46.3 (14.2) -9.04 (-15.44;-2.64) -9.32 (-16.16;-2.49) <0.01
Contralateral arm (N/cm2) 41.4 (9.9) 51.9 (14.6) -10.50 (-16.15;-4.85) -10.36 (-16.60;-4.11) <0.01
*adjusted for age, gender, BMI and sport participation (no adjustment for gender in the second part of the 
table); CI: confidence interval
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DISCUSSION
The purpose of this study was to investigate whether there is a difference in PPT between 
patients with PFP and healthy control subjects. Our results showed that PFP patients 
had significant lower PPT’s compared to healthy controls on all three locations, sug-
gesting the presence of local, distal and generalized pressure hyperalgesia. Subgroup 
analyses for both age and gender status revealed that PPTs at the contralateral knee and 
arm were only significantly lower in adult patients and female patients. Female gender 
was identified as effect modifier with respect to the PPT at the contralateral arm. Mul-
tivariable analyses of patient characteristics showed a significant association of female 
gender with a lower PPT.
Our finding that PFP patients had significant lower PPTs compared to healthy controls is 
in line with recent studies.6,7 Rathleff et al. demonstrates lower local and distal pressure 
hyperalgesia in female adolescent PFP patients compared to controls.6 Noehren et al. 
showed an increase in both localized and centralized pain sensitivity in a small group of 
female adult patients with PFP compared to controls.7 Both studies focused on women 
only, probably because the incidence of PFP is seemingly higher in females.15 In the pres-
ent case-control study also male PFP patients were included. Significant lower PPTs at 
the affected knee were present in both male and female patients. However, PPTs at the 
contralateral knee and contralateral arm were only significantly lower in female patients 
and adult patients. It would be expected that a difference in prevalence of bilateral 
complaints among subgroups would influence the difference in PPT of the contralateral 
knee, but not the contralateral arm. Therefore, the presence of bilateral complaints was 
added to the model for the contralateral knee and indeed differences between sub-
groups for the contralateral knee were no longer significantly different.
The fact that no significant differences between patients and control subjects in PPTs at 
the contralateral knee and arm were found in the adolescent subgroup is presumably 
due to a lack of power. PPTs at the contralateral knee and arm were consistently lower in 
adolescent patients compared to adolescent controls, and based on the 95%CI intervals 
of the mean differences clinically relevant differences, regarded as an effect size of ≥0.5, 
cannot be ruled out.
Female gender was identified as effect modifier for the contralateral arm and was signifi-
cantly associated with lower PPTs in the patient population. This indicates that general-
ized hyperalgesia, indicative for an altered central pain perception, is predominantly 
present in female patients. In a recent study, Rathleff et al. also indicated that PFP might 
have a central component.16 Other symptoms indicative for a central component, such 
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as generalized widespread pain and neuropathic pain, were not explicitly present in our 
study. Noehren et al did find hypoesthesia, depicted as an elevated threshold to detect 
light touch over the center of their patella. Furthermore, a recent study by Rathleff et al. 
showed an impaired conditioned pain modulation, indicative for a central component, 
in female adolescents with chronic PFP.7,16 Moreover, the profile of the sensory dysfunc-
tions in the study of Jensen et al. also indicates an involvement of the central nervous 
system.4 Differences in findings between our study and the other two could be due to 
the use of different measures. Since a central component could be targeted with pain 
modifying drugs, more research focusing on the presence of a central component in 
PFP would be worthwhile.17 Further research is also warranted, considering the dose-
response and the effect of additional patient-education, because, Rathleff et al. showed 
the ability of exercise therapy to alter PPTs and demonstrated that recovered female 
patients with PFP have larger reduction in localized pressure hyperalgesia compared to 
non-recovered females.8
Strengths and limitations
To our knowledge, this is the first case-control study focusing on the presence of altered 
pain processing in both adults and adolescents, and males and females. Furthermore, 
associations between PPT and patient characteristics have also not been studied previ-
ously. In order to develop better-targeted treatment strategies, more knowledge on 
association between patient characteristics and PPT is essential.
Since we placed the dynamometer on the most painful spot on the knee in patients 
it was not feasible to blind the assessor. Though a previous study showed a good reli-
ability for PPT testing between the current assessor and an independent assessor in a 
subgroup of the study population.14
We intended to match the patients and their controls on age, gender, BMI and sports 
participation. However, some differences were present concerning BMI and percentage 
of sports participants and therefore all analyses were adjusted for these confounders.
It is off course not possible to test the PPT at the most painful spot, when no pain is 
experienced. Therefore, the medial patellar facet was chosen. This seems justified, since 
most patients indeed pointed the medial facet to be the most painful location. In order 
to be sure that placement of the algometer on different surfaces (patellar bone or peri-
patellar soft tissue) would not have influenced our results, PPT location was added to 
the multivariate analyses. However, no association between PPT and algometry at the 
patellar bone location was present.
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CONCLUSION
In conclusion, our results show that patients with PFP have local, distal and generalized 
pressure hyperalgesia. Females with PFP were most likely to suffer from generalized 
hyperalgesia.
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DISCUSSION
Patellofemoral pain (PFP) is a common knee complaint, especially among physically 
active young individuals.1 Unfortunately, PFP is no trivial self-limiting disorder.2-8 A large 
percentage of patients have persistent symptoms, despite a variety of treatment mo-
dalities.9-13 The pathogenesis and treatment modalities of PFP are widely debated, but 
no consensus on treatment modalities has been reached and the pathogenesis is still 
largely unknown.14 This thesis includes a systematic review on one of these treatment 
modalities and a cross-sectional case-control study that aimed to contribute to a better 
understanding of the pathogenesis of PFP.
Exercise therapy
Most patients with PFP are treated conservatively with exercise therapy. In order to as-
sess the effectiveness of exercise therapy in patients with PFP chapter II comprises a 
systematic literature review including multiple comparisons of exercise therapy, like ex-
ercise therapy versus a control strategy (no treatment, placebo or waiting list controls), 
a combination of knee and hip exercises versus quadriceps exercises alone and closed 
kinetic chain exercises versus open kinetic chain exercises. This review found very low 
quality but consistent evidence that exercise therapy for PFP may result in a clinically im-
portant reduction of pain and improvement of function, as well as enhancing long-term 
recovery. In addition, there is very low quality evidence that a combination of knee and 
hip exercises may be more effective in reducing pain than knee exercises alone. The lat-
ter corresponds with a recent review of Lack et al. that demonstrates the effectiveness of 
proximal muscle rehabilitation in PFP.15 However, the best form of exercise therapy, and 
whether it would be effective in all patients with PFP is still unknown. Comprehensive 
studies to identify subgroups of patients who would benefit more from a specific ap-
proach are therefore necessary. Some previous studies did focus on certain hypothetic 
subgroups, like females, sedentary patients or patients with maltracking.16-19 Fukuda 
et al. only included sedentary females, in which sedentary was defined as not having 
practiced physical activity (aerobic and strengthening exercises) any day of the week for 
at least 6 months previously.16 Their study showed both an effect in pain reduction at 
short and long term and improvement of function at long term in favor of hip and knee 
exercises compared to knee exercises alone.16 The effect on pain during activity at short 
term was notably larger compared to effects on pain or function in other studies of the 
same comparison that included people who did not engage regular in sports activity20, a 
general PFP population21,22, or recreational athletes.23 This implies that a larger improve-
ment in pain during activity at short term seems to be achieved in less active patients 
by applying a combination of exercises for hip and knee muscles. The reason behind 
this might lay in an overall less developed musculature and core-stability in sedentary 
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patients in comparison to the general population or to recreational athletes. Another 
possible explanation for such a big improvement might be the presence of a systemic 
effect. This systemic effect could be anti-inflammatory as demonstrated for exercise 
interventions in knee osteoarthritis.24 Supposedly, the systemic effect would be larger 
when more or larger muscle groups are targeted with exercise therapy and would also 
be larger in patients that are not used to physical exposure at all. However, this has not 
yet been studied in PFP. In sedentary females, a systemic effect could also be based on 
pain modulation of processing, since altered central pain processing is predominantly 
present in female patients with PFP (chapter VIII) and exercise therapy seems to be able 
to diminish pressure hyperalgesia.25 Therefore, further research into this hypothetic 
working mechanism is needed.
Another study in a subgroup of patients with untreated PFP of over two months in dura-
tion provides evidence that a high-intensity medical exercise therapy program (MET) is 
more effective than a low intensity exercise program in reducing usual pain and improv-
ing functional ability.18,19 Even at long-term, an effect of MET appears to be present.18 
MET is a concept in physiotherapy where the exercises are constructed according to 
both open and closed kinetic chain, with variable loads and ranges of motion to enable 
the patients to perform highly repetitive (≥30 repetitions) exercises without increasing 
pain.19 It is suggested that such a graded activity program may modulate fear-avoidance 
beliefs, and improve coping and self-efficacy.19 The question, however, is if this fairly 
large effect would also apply to the general PFP population. It is important to notice 
that the study population has not engaged in treatment despite a long mean duration 
of symptoms of 3.6 years in the intervention group and 2.9 years in the control group. 
Therefore, it might be a specific subgroup especially struggling with fear-avoidance 
beliefs or with an altered pain perception. Nevertheless, MET seems to be effective, but 
this is just a single study and therefore further research is warranted.
Recently, Barton et al. proposed a best practice guideline for effective PFP manage-
ment after combining the findings from six high quality systematic reviews with expert 
opinions.26 A tailored multimodal intervention program, complemented with patient 
education and activity modification would be the key.26 To achieve individual tailored 
treatment, the first aim would be to classify clinical subgroups. In 2005, Witvrouw et al. 
proposed a clinical classification system based on consensus reached by the European 
Rehabilitation Panel and clinical experience. Their aim was to develop a specific non-op-
erative treatment protocol for each individual with PFP, by guiding the clinician through 
clinical examination.27 Recently, Selfe et al. used a series of low cost simple clinical tests 
to identify possible subgroups and showed that three subgroups of patients with PFP 
may exist.28 The ‘strong’ subgroup had the highest mean hip abductor strength, high-
est mean quadriceps strength and greatest rectus femoris length. Most patients in this 
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group were male and had a lower body mass index, a higher level of physical activity, 
lower pain scores and better function. The ‘weak and tighter’ group had low mean hip 
abductor and quadriceps strength and less flexibility. This subgroup had a higher BMI, 
worse function and a trend towards low physical activity and longer symptom duration 
was present. The ‘weak and pronated foot’ subgroup was based on the results of the 
foot posture index and had greater patellar mobility. This group was younger and had 
the shortest symptom duration. The findings of Selfe et al. do seem to coincide with the 
findings of the studies that included specific subgroups, as stated above.16,18,19 In these 
studies, the effect of exercise therapy in inactive patients or patients with a longer dura-
tion of symptoms, which would fall in the ‘weak and tighter’ group, was larger compared 
to the effect in studies with active patients or athletes. This makes sense, since the ‘weak 
and tighter’ group has low mean hip abductor and quadriceps strength, and would 
therefore benefit more from exercise therapy. Contrary to this, active patients would fit 
in the ‘strong’ subgroup, which already has high mean strength scores. Therefore, it is 
highly unlikely that strength based exercise training would improve pain and functional 
outcome measures in the ‘strong’ subgroup. Still, the question remains whether an im-
provement in strength would lead to an improvement in pain and function. The next 
phase would be to study if targeted interventions for these subgroups do improve pain 
and functional outcomes.
Pathogenesis
Up till now, the pathogenesis of PFP is still unknown. The current hypothesis is that 
high loading conditions of the patellofemoral joint induce PFP by disturbing tissue 
homeostasis.14,29 Loss of tissue homeostasis may, once initiated, persist indefinitely.29 
Multiple pathophysiologic mechanisms of knee pain that might also apply to PFP have 
been proposed in literature.30-48 This thesis (chapter III to VIII) focused on three of these 
mechanisms, which will be discussed in more detail in the next paragraphs, using a 
broad range of advanced MRI techniques.
Structural joint tissue abnormalities
Although multiple arthroscopic studies and a MRI study showed that PFP is not neces-
sarily related to cartilage defects, the term ‘retropatellar chondropathy’ is still used to 
characterize PFP.3,30,49,50 Furthermore, abnormalities of patellar retinaculum, synovial 
plicae, Hoffa’s fat pad and subchondral bone marrow had long been mentioned in lit-
erature as possible origin of pain, but had not yet been investigated systematically in a 
PFP population.30-33,51 Therefore, Chapter III of this thesis investigated the association 
between structural abnormalities of patellofemoral joint tissues on MRI and PFP using 3 
Tesla high-field MRI with high spatial resolution (Figure 1).
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Our studies showed that neither full or partial thickness cartilage defects nor minor 
cartilage defects were associated with PFP. Together with the previous studies3,30,49,50, 
there seems to be conclusive evidence to state that patellofemoral cartilage damage 
is not associated with PFP. Therefore, ‘retropatellar chondropathy’ and ‘chondromalacia 
patellae’ are incorrect synonyms for PFP and from now on should not be used anymore. 
Furthermore, our study showed that structural abnormalities on MRI of patellar retinacu-
lum and plica, such as increased thickness or high signal intensity, were not associated 
with PFP. These abnormalities were, in fact, rarely seen in this population.
Other abnormalities, such as minor patellar cartilage defects, patellar bone marrow 
lesions (BMLs), and a high signal intensity of fat pads, were frequently seen in both 
patients with PFP and healthy control subjects. This might indicate that other factors 
need to be present to induce pain in patients. It could be hypothesized that the location 
of the abnormality might distinguish between patient and controls. However, additional 
analyses of sub-regions (medial or lateral patella, medial or lateral meniscus, superior 
or inferior part of patellar tendon) also revealed no significant differences between 
patients with PFP and healthy control subjects. Another theory might be that certain 
combinations of abnormalities need to be present to induce PFP. A logical combination, 
that of both trochlear and patellar abnormalities, could not be tested, because trochlear 
abnormalities were only present in very small numbers. Nevertheless, this does imply 
that the contribution of this combination to the pathophysiology of PFP is unlikely. 
Figure 1. 3D high-resolution sagittal 
fat-saturated spoiled gradient-echo of 
a control subjects’ knee.
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There are currently no other anticipated combinations based on literature and we lacked 
power to study all possible combinations.
Apparently, a large percentage of healthy control subjects had abnormalities of the 
patellofemoral joint on MRI. A high prevalence of abnormalities in asymptomatic 
knees of adults has also been shown by other studies.52-58 Even more remarkable was 
the presence of patellar BMLs in 65% of adolescent control subjects and the presence 
of patellar osteophytes in 45%, and a high signal intensity in Hoffa’s fat pad in 50% 
of these healthy adolescents. This stirs the question whether certain MRI findings are 
physiological instead of pathological. With respect to osteophytes, this phenomenon 
has already been discussed in osteoarthritis research and a Delphi process has been 
undertaken.59 However, the definition of a ‘definite osteophyte’ was not yet delineated 
and requires further validation. Thus, the question remains whether small osteophytes 
as seen in our case-control study are actually osteophytes as seen in osteoarthritis or 
just normal bone-cartilage transitions. In this thesis, the MOAKS MRI score was used, 
which distinguishes between medium size osteophytes (grade 2) and small osteophytes 
(grade 1).60 A large percentage of our study population had osteophytes, however only 
few participants had medium size osteophytes. The presence of small osteophytes in 
healthy control subjects, and even in the healthy adolescent population, suggests that 
this may be a physiologic finding. Hart et al. investigated the natural history of a K&L 
grade 1 osteophyte.61 The radiographic Kellgren and Lawrence (K&L) score distinguishes 
between definite osteophytes, classified as grade 2, and possible osteophytic lipping, 
classified as grade 1.62 Hart et al. found that ‘doubtful’ osteophytes are significantly re-
lated to later life radiographic knee OA, and concluded that K&L grade 1 osteophyte can-
not be ignored or classified as normal.61 Whether this also applies to small osteophytes 
on MRI is unknown up to know.
Another interesting finding was the high percentage of patellar BMLs in both patients 
and control subjects, even in the adolescent population. Over the past decade, BMLs 
have received more attention in the field of OA research, because it has been suggested 
that bone rather than cartilage may be the initiating site of pathophysiological events 
in OA and that BMLs are related to pain.63-66 But, if BMLs are related to pain, how come 
that such a large percentage of healthy control subjects have BMLs? The answer might 
be that other factors need to be present to induce pain or that BMLs in healthy control 
subjects are a different type of BML than the ones in patients experiencing pain. The 
importance of identifying different entities of subchondral BMLs has previously been 
emphasized by Roemer et al.67 It would be interesting to investigate if a specific type, 
volume, location of BMLs, or concurrent abnormality is associated with PFP. In the current 
study, the distribution of BMLs is comparable between patients and control subjects, 
with a 5 times higher percentage of BMLs in the patella compared to the anterior femur 
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in both groups. With respect to BML’ size, additional analyses to the studies presented 
in this thesis showed that only 3 patients had a larger sized patellar BML according to 
the MOAKS classification and none of the control subjects. One specific type of BML 
that might exist is an activity related BML. The association between physical activity and 
BMLs is controversial. A review by Lim et al. found limited evidence for an association be-
tween physical activity and BMLs.68 More recently, Antony et al. studied this association 
in young adults and found no association overall.58 However, when dividing physical 
activity into moderate and vigorous, a protective association was found in their study for 
moderate activity and a deleterious association for vigorous.58 In our study, activity was 
not associated with the presence of BMLs, however activity was dichotomized and level 
of activity was not taken into consideration.
It has been shown that BMLs with different content exists in osteoarthritic knees.69 Fur-
thermore, Lee et al. demonstrated more blood going and a failure to “wash out” in BMLs 
compared to normal bone, which can be interpreted as stasis or outflow obstruction.70 
Both stasis and an altered content might hypothetically lead to a higher intraosseous 
pressure, another hypothetic pathophysiologic mechanism for PFP. With advanced 
imaging techniques, like DCE-MRI and ultrashort echo time (UTE) MRI it should be 
possible to study these features in the future. Failure to “wash out” can be measured 
with DCE-MRI. In the current study DCE-MRI was not yet specifically to BMLs, but only 
applied to the patellar bone marrow. UTE-MRI can characterize BML content by imaging 
the structure of trabecular bone.71 Additionally, UTE can image the osteochondral junc-
tion72,73. This osteochondral junction has received increasing attention over the years as 
possible factor in OA pathophysiology.74,75
The current case-control study demonstrated that cartilage defects on MRI are not 
associated with PFP. However, in OA compositional alterations are known to precede 
morphological alterations of cartilage 76 and PFP has been suggested as a precursor 
for osteoarthritis.77,78 Nowadays, it is possible to study cartilage composition with ad-
vanced MRI techniques. These quantitative MRI techniques for cartilage, such as delayed 
gadolinium enhanced MRI of cartilage (dGEMRIC), T1ρ and T2 mapping, quantitatively 
measure cartilage composition by measuring its structural components, like glycosami-
noglycan and collagen.79 Therefore, chapter IV of this thesis focused on the association 
between PFP and patellofemoral cartilage composition. Previously published in-house 
developed software (Software for Post-processing and Registration of Cartilage of the 
Knee: SPARCK) was optimized for the patellofemoral joint and used to calculate cartilage 
composition (Figure 2).80-83
One of the strengths of SPARCK is automated image registration, which compensates for 
subject motion within and between sequences. Thereby, facilitating the use of the same 
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region of interest (ROI) for all sequences. Another strength is the automatic removal of 
possible included cortical bone pixels in the ROI based on a participant-specific bone-
cartilage threshold. Furthermore, a weighted mean relaxation was calculated using the 
reciprocal of the uncertainty of the fit. This is of importance as more uncertain voxels, for 
instance at tissue boundaries, could influence the mean relaxation time. By calculating a 
weighted mean, voxels for which the estimated relaxation time was more uncertain had 
less influence on the mean.
The study population comprised a relatively young population of patients with PFP and 
therefore early changes in cartilage composition were expected more frequently than 
morphologic defects. However, no significant differences were found in patellofemoral 
cartilage composition between patients and control subjects for all applied MRI se-
quences. Since, based on finite elements analysis studies43,84, the highest patellofemoral 
joint stresses are observed on the lateral side of the patellofemoral joint, it could be 
hypothesized that differences are specifically present in the lateral part of the cartilage. 
On the other hand, less pressure on the medial side of the joint, theoretically, could 
also lead to deterioration of cartilage due to insufficient loading. Therefore, additional 
analyses of pre-specified medial and lateral subregions within the patellar and femoral 
cartilage were done, but also revealed no significant differences between groups.
Based on the degenerative process with aging, as seen in OA, a diminished cartilage 
composition would rather be expected in adult patients than in adolescent patients. 
Therefore, additional analysis focused on differences between patients and controls 
subdivided in an adult and adolescent age group. This was only done for T1ρ mapping 
and T2 mapping, because T1GD mapping was not acquired in minors due to contrast 
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Figure 2. Color overlays of a 
T1-map of the patellofemo-
ral joint of a control subject. 
Lower T1GD relaxation times 
in milliseconds, shown in 
black, depict less GAG con-
tent.
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administration restrictions. A recent in-vivo validation study demonstrated that T1ρ-
mapping is no substitute for dGEMRIC, thus we lack a GAG measure for the adolescent 
population. 85 Nevertheless, this study also indicated that T1ρ-mapping is still suitable 
for measuring early compositional changes of cartilage by measuring water content or 
a combination of composites of the cartilage extracellular matrix instead.85 Analyses 
within age groups showed no significant differences, but clinically relevant differ-
ences could not be ruled out for T1ρ-mapping in the adolescent population. Based on 
the degenerative process with aging, mentioned earlier, it is illogical that differences 
would occur in the adolescent age group and not in the adult age group. The absence 
of a possible clinical relevant difference between patients and controls at the adult age 
implies that the possible clinical relevant differences at the adolescent age are transient. 
Furthermore, T1ρ-mapping values of adolescent patients are actually quite comparable 
to T1ρ-mapping values of adult patients and controls. Therefore, it is highly unlikely that 
these possible clinically relevant differences in cartilage composition at the adolescent 
age contribute to the pathogenesis of PFP.
This does not alter the fact that the difference at the adolescent age is interesting and 
presumes there needs to be another factor that influences cartilage composition in 
a different degree in adolescent patients and controls. In the current study we have 
adjusted our analyses for BMI, age, sex, sports participation and time of image acquisi-
tion, but more confounders may exist. Moreover, the influence of certain confounders 
may be more profound in specific age groups. For instance, the influence of activity 
level might be more profound. Sports participation was significantly associated with 
multiple variables of cartilage composition. Although analyses were adjusted for sports 
participation, they were not adjusted for the actual level of activity. Anther confounder, 
closely related to activity level, would be muscle strength. Kumar et al. recently dem-
onstrated a relation between cartilage relaxation times and muscle mass anatomical 
cross-sectional area, which is strongly correlated to strength measures.86 To date, there 
is still much unknown with respect to factors influencing cartilage composition and in 
what degree, especially in adolescents. Therefore, future research should focus on fac-
tors influencing cartilage composition instead of conducting T1ρ-mapping in a larger 
cohort of adolescent patients.
Based on the absence of morphologic cartilage defects on MRI and the absence of a 
diminished cartilage composition in PFP, it is unlikely that PFP is a precursor to patel-
lofemoral OA. It is however important to notice that the cross-sectional design of this 
study only facilitates investigation of associations and not of cause and effect.
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Patellar bone ischemia
Local bone tissue ischemia, induced by impaired arterial blood inflow or by increased 
intraosseous pressure due to impaired venous outflow, is suggested to be a pathophysi-
ologic mechanism of PFP.34-38 Blood perfusion can be measured with dynamic contrast-
enhanced MRI (DCE-MRI). DCE-MRI measures the amount of contrast, equivalent to the 
amount of blood, getting into and out of a preselected region over a time period. The 
most innovative, but also the most challenging, part of this thesis was applying quanti-
tative DCE-MRI in patellar bone. To our knowledge, this has not been done before and 
rendered serious acquisition and post-processing challenges due to the sparse vascu-
larization of bone and the typical low contrast enhancement compared to surrounding 
tissues. Since, there is no consensus on the optimal acquisition and pharmacokinetic 
models for the patellar bone, chapter V of this thesis focused on the development of 
a method to apply DCE-MRI in patellar bone. For DCE-MRI, native T1 values are needed 
to convert signal intensity to contrast concentration. However, due to acquisition time 
restrictions when conducting dGEMRIC and DCE-MRI in one session, acquiring a native 
T1 map was not feasible. Nevertheless, native T1 values among subjects were expected 
to be similar or at least not strongly correlated with PFP, because T1 itself is not known 
to be a biomarker for PFP. Therefore, native T1 values were based on literature. SPARCK, 
previously used to study patellofemoral cartilage composition, was optimized for patel-
lar bone blood perfusion.80-83 Because the optimal combination of arterial input function 
(AIF) model and pharmacokinetic model for the patellar bone is unknown, all possible 
combinations of pharmacokinetic models and AIF models were tested. A surprising 
finding was that Tofts’ model was likely to be more sensitive to detect group differences 
than Brix’ model87, since Brix’ model has been applied in previous studies in bones of 
the lower extremity (femur, tibia).70,88,89 With respect to the other two pharmacokinetic 
models that were tested, there were hardly any obvious differences between Tofts’90 and 
extended Tofts’ model. Tofts’ model appeared to perform consistently better and best 
fitted our data combined with a population average AIF based on the model of Parker91. 
Over the entire dataset, the residual was close to the acquisition noise level. Therefore, 
this combination was implemented in our method and used to study differences in 
patellar bone blood perfusion in our study population in chapter VI (Figure 3).
Low ktrans and low kep values were expected to be found in patients with PFP, suggestive 
for local tissue ischemia and venous outflow obstruction, respectively. However, higher 
but non-significant, values of ktrans and kep were found in patients with PFP compared to 
healthy control subjects. Furthermore, a statistically significant larger variance of ktrans 
was observed in patients compared to controls. These results suggest that a subgroup 
with higher ktrans. values in the patient population might be present. Higher values cor-
respond with hyperperfusion; more blood going into the patellar bone marrow. Hyper-
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vascularization could be a possible explanation for hyperperfusion. It is hypothesized by 
Sanchis-alfonso et al. that episodes of ischemia, possibly due to vascular torsion during 
sitting, could trigger hypervascularization of the patellar retinaculum in patients with 
patellofemoral pain due to malalignment as a result of increased vascular endothelial 
growth factor release.92 The same could apply to the subchondral bone of patients with 
sitting pain and therefore higher perfusion values would be expected in this subgroup. 
However, explorative analyses in our study revealed no significant differences in blood 
perfusion of the patellar bone between patients with and without sitting pain. Never-
theless, possible differences could be undetected due to a lack of discriminating power, 
because 77% of patients in our study population reported sitting pain. More recently 
we showed in an international dataset that 50% of patients with PFP had sitting pain 
(unpublished data) and it would thus be possible to discriminate between patients with 
and without sitting pain. Therefore, future research might focus on a bigger cohort of 
PFP patients. Furthermore, a future prospect might be acquiring DCE-MRI in an open 
MRI scanner in patients with sitting pain with their knee in different degrees of knee 
flexion. Particularly since Naslund et al. reported a decreased pulsatile patellar blood 
flow in patients with PFP during knee flexion.93 Although, this might give insight in the 
pathophysiologic mechanism of sitting pain, it would not clarify why patients experience 
pain during activities without knee flexion. If the same underlying mechanism would ac-
count for pain with and without flexed knees, than this mechanism can be investigated 
without the knees flexed, as was done in our study. Another perspective on ischemia-
induced changes proposed by Sanchis-alfonso et al. is perivascular hyperinnervation 
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Figure 3. Color overlays of 
a ktrans map of the patellar 
bone marrow of a control 
subject. Higher ktrans values 
(min-1), shown in red, de-
pict more blood going into 
the patellar bone marrow.
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as a result of increased neural growth factor production.94 It would be logical that this 
perivascular hyperinnervation would lead to hyperalgesia, a finding predominantly 
present in females (chapter VIII). Therefore, it could be hypothesized that perfusion pa-
rameters are higher in female patients compared to male patients. However, additional 
analyses to those presented in this thesis revealed no significant differences in perfusion 
parameters between female and male patients.
A more suitable explanation for hyperperfusion would be the presence of BMLs. As 
mentioned before, Lee et al. demonstrated more blood going in and a failure to “wash 
out”, which can be interpreted as stasis or outflow obstruction, in BMLs compared to 
normal bone in adult patients with OA or avascular necrosis with painful bone marrow 
edema.70 Analyses, additional to this thesis, indicate that patients with patellar BMLs 
have higher values of both perfusion parameters. Moreover, patients with a larger sized 
patellar BML seemed to have higher perfusion values than patients with smaller sized 
BMLs. However, these larger sized BMLs were only present in three patients. Accumu-
lation of fluid in a BML may lead to an increased intraosseous pressure, which might 
induce pain. Increased intraosseous pressure is one of the hypothetic pathophysiologic 
mechanisms for PFP that was not further studied in the current thesis. More recently, 
Ho et al. showed elevated patellar water content, indicative for an increased intraosse-
ous pressure, resulting from repetitive patellofemoral joint overloading in recreational 
runners with PFP compared to control subjects.37 Thus, more research regarding the 
possibility of an increased intraosseous pressure in PFP is warranted using advanced 
MRI techniques, such as DCE-MRI and the recently developed chemical-shift-encoded 
water-fat protocol.37
During the development of the DCE-MRI method that was applied in the case-control 
study new challenges arose. Spatial heterogeneity of patellar blood perfusion appeared 
to be high. To avoid underweighting of less-perfused areas in the region of interest, 
unweighted medians of both perfusion parameters were calculated additionally. 
Furthermore, a large inter-subject variability was present. A large inter-subject variabil-
ity makes it difficult to detect significant differences. We were not able to distinguish 
between two possible causes of this large inter-subject variability, i.e. measurement 
variability or normal tissue heterogeneity, since no reproducibility study was done due 
to the contrast burden. Reproducibility, as well as clinical relevant differences of patellar 
bone perfusion parameters need further investigation to be sure no clinical relevant dif-
ferences will be missed in future research. Overall, enhancing temporal resolution would 
also be preferable, but the dynamic nature of the DCE experiment limits simultaneous 
improvement of temporal and spatial resolution. For now, we can conclude that we are 
the first who have applied a tailored DCE-MRI acquisition protocol and post-processing 
tool to the patellar bone of patients with PFP and healthy control subjects that success-
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fully extracted the dynamic contrast enhancement from the MRI data, and thus can be 
used to study patellar bone blood perfusion.
Altered pain perception
Next to this structural approach, an altered pain mechanism might also contribute to 
PFP. One of the symptoms of an altered pain perception is hyperalgesia, an increased 
sensitivity to pain. The current hypothesis is that repeated overload sensitizes local 
nociceptors, which causes local hyperalgesia. The presence of pressure hyperalgesia can 
be assessed with the pressure pain threshold (PPT). Chapter VII showed that handheld 
dynamometry with algometry tip is a reliable method to assess the PPT in both patients 
with PFP and control subjects, wherein the inter-rater reliability was higher in patients. 
Subsequently, differences in PPT between patients with PFP and healthy control subjects 
were tested in chapter VIII. PPTs were significantly lower in patients with PFP compared 
to controls at the affected knee, the contralateral knee and the contralateral arm, in-
dicative for local, distal and generalized pressure hyperalgesia, respectively. Subgroup 
analyses for both age and gender status demonstrated significantly lower PPTs at the 
contralateral knee and arm in adult patients and female patients only. Considering age 
status, PPTs at the contralateral knee and arm were consistently lower in adolescent pa-
tients compared to adolescent controls, and based on the 95%CI intervals of the mean 
differences clinically relevant differences, regarded as an effect size of ≥0.5, cannot be 
ruled out. Though, no significant interaction effects were found between participant sta-
tus and age status. Considering female gender, a significant interaction effect between 
participant status and female with respect to the PPT at the contralateral arm (β -9.95, 
95%CI -18.74;-1.16) was identified and multivariable analyses of patient characteristics 
showed a significant association of female gender with a lower PPT. Thus, an altered 
central pain perception, based on the presence of generalized pressure hyperalgesia, is 
predominantly present in female patients. Recent studies also showed results indicative 
for a central component in females with PFP.95-97 Because a central component could be 
targeted with specific exercise therapy or even pain modifying drugs, more research 
focusing on the presence of a central component in PFP would be worthwhile.98 To 
our knowledge, it is unknown why central pain processing is only altered in females. A 
logical explanation would be hormones, though female patients in the present study 
indicated that pain was not associated with their hormonal cycle.
Furthermore, it has been demonstrated that exercise therapy is able to alter PPTs, but 
more research is needed considering the dose-response and the effect of additional 
patient-education.25 Moreover, insight needs to be gained with regard to patient char-
acteristics associated with altered pain perception and with regard to the working 
mechanism(s) and the time it takes to alter pain perception. If this would be known, 
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therapy could be targeted and patients could be properly educated in an early stage to 
prevent an altered pain perception.
methodological strengths and challenges
To our knowledge this is the largest case-control study using innovative quantitative 
MRI sequences to study the pathophysiology of PFP.
A representative sample of the population comprising both adults and adolescents 
patients with PFP and control subjects was included. Patients with PFP were referred for 
inclusion by their general practitioner, physiotherapist or sports physician. The diagnosis 
PFP had to be based on the presence of at least three of the following symptoms: crepi-
tus, and/or retro or peripatellar pain during stair climbing, squatting, running, cycling, or 
during sitting for a prolonged period with the knees flexed. These inclusion criteria were 
based on standards from international literature. Exclusion criteria comprised: a current 
knee pathology of the affected knee (e.g. osteoarthritis or patellar tendinopathy), or 
previous surgery or injury of the affected knee, or previous episodes of PFP more than 
two years ago, or onset of PFP after trauma. Because the diagnosis of PFP might be 
challenging, all caregivers were thoroughly informed, and the necessity to exclude other 
pathology, especially patellar tendinopathy, was emphasized. No pre-determined set 
of physical sets was applied during patients’ inclusion, since sensitivity and specificity 
of physical tests, such as the Clarke compression test, are disputable.99,100 The strength 
of this study is that we included a representative group of patients with PFP without 
prior selection of hypothetic subgroups of patients (e.g. maltracking, female gender, 
professional athletes). It is highly anticipated that different subgroups in PFP exist. 
However, to date, clear subgroups have not been identified in a systematic manner and 
due to our sample size it was not possible to test all hypothetic subgroups. Therefore, we 
decided only to perform additional analysis in patients with sitting pain with regard to 
blood perfusion and to investigate the effect of gender with respect to pain perception. 
Furthermore, additional analyses were done for different patient age groups: adults and 
adolescents. The inclusion of adolescents, 20 patients with PFP and 20 control subjects, 
aged 14-18 years, is a big strength, because many studies excluded this group. There is 
a lack of information in adolescents, for instance considering the presence of structural 
abnormalities. This is striking, because PFP is especially prevalent in young individuals.8 
Moreover, it has recently been suggested that adolescent patients with PFP might differ 
from adult patients with PFP based on a different success-rate despite providing similar 
exercise treatment and having similar exercise compliance.101
Symptom duration of the current study patient population was 2 months to 2 years. 
It could be hypothesized that patients with longer symptom duration have a differ-
ent pathophysiology compared to patients with shorter symptom duration. However, 
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univariate analyses, additional to this thesis, showed that symptom duration was not 
significantly associated with cartilage relaxation times, perfusion parameters, or pain 
pressure thresholds. Of all recruited patients, 15% were excluded because their symptom 
duration was more than 2 years or they have had previous episodes of PFP more than 2 
years ago. Thus, overall, the majority of referred patients was included, and for now there 
is no evidence to suggest that patients with longer symptom duration have a different 
pathophysiology compared to patients with shorter symptom duration. Nevertheless, 
a follow-up study is currently conducted in order to investigate if clinical and imaging 
baseline characteristics of recovered and chronic patients differ.
There is still a missing link between the presence of pathology and biomechanical/
kinematic factors that might predispose to PFP. The current hypothesis on PFP patho-
genesis is that high loading conditions of the patellofemoral joint lead to a disturbed 
tissue homeostasis.14,29 Therefore, conducting both advanced imaging techniques to 
study tissue homeostasis together with methods to assess biomechanics/kinemat-
ics need to be aspired. It was not feasible to additionally assess biomechanics and/
or kinematics for the current study, because advanced imaging techniques are rather 
time-consuming. This should be a future prospect when advanced imaging protocols 
are less time-consuming or when pathophysiology of PFP has already been clarified and 
thus a subset of imaging techniques could be chosen. It is important, though, to keep 
in mind that in cross-sectional studies it would still be unknown if the biomechanical 
and/or kinematic values were the same before onset of PFP and/or if these values would 
actually induce pathophysiology. Thus, longitudinal studies will be needed in the future. 
For now, emphasis should first be placed on identifying possible origins of pain and, 
from a radiology prospect, on improving imaging methods to do so, as was done in this 
thesis. If possible origins of pain are identified in the future, it would be of high value 
if these could be linked to certain predisposing biomechanics and/or kinematics that 
could be targeted in clinical practice.
Clinical implications
Exercise therapy is more effective compared to a control strategy. It is still unknown 
which type of exercise therapy is the most effective and whether this effect is present 
in all patients with PFP. However, hip and knee exercises seem to be more effective than 
knee exercises alone. This implies that exercise therapy, including hip and knee exercises 
should be prescribed to patients with PFP. Furthermore, the possibility of an altered 
pain perception should be kept in mind when treating patients with PFP, especially 
female patients. The PPT, an indication for an altered pain perception, could easily be 
assessed in clinical practice with handheld dynamometry. However, to our knowledge 
reference values and cut-off points are unknown and would need to be established first. 
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Furthermore, treatment options in case of an altered pain perception still need further 
investigation, but at this stage it may be worthwhile to give the patient more insight into 
his/her condition. For now, a graded activity program, such as high intensity, pain free 
exercises, could be given if alterations in pain perception seem to be present, because 
it is known that this may modulate fear-avoidance beliefs, and improve coping and self-
efficacy.19
For now, the pathophysiology of PFP is still a black box. Nevertheless, according to the 
results of this thesis one pathophysiologic mechanism can be ruled out. Structural ab-
normalities, visible on conventional MRI or a diminished cartilage composition, are not 
associated with PFP. Therefore, conventional MRI should not be acquired to diagnose 
patients with PFP and ‘chondromalacia patellae’ and ‘retropatellar chondropathy’ should 
not be used as synonyms for PFP anymore.
Furthermore, based on the results of this thesis, there is no evidence to suggest that 
PFP pathophysiology differs between adolescent and adult patients. Both groups are 
comparable concerning the amount of structural abnormalities, cartilage composition 
and pain perception. Unfortunately, patellar bone blood perfusion could not be studied 
in adolescents, because we were not allowed to administer contrast to minors.
Future research
The next step in research would be combining the separate MR outcomes with clinical 
features and patient characteristics, for instance to further investigate if BMLs or other 
structural abnormalities coincide with higher perfusion parameters in patients. There are 
far more questions to be answered and combining all data to identify subgroups is even 
more aspiring, but unfortunately the current study lacks power to do so. In the future, 
conducting larger studies or pooling data, which enables application of statistics such 
as latent class growth analysis, would facilitate identifying potential subgroups. Thanks 
to rapid advancement in computational tools for analyzing large sets of data, precision 
medicine by phenotyping through (quantitative) imaging biomarkers combined with 
clinical features is also a realistic future perspective and genomic data can already be 
extracted from blood samples conducted in the current study.
The observed trend towards higher blood flow in PFP patients and the larger variance of 
ktrans in patients warrants further research. Therefore, for PFP research, emphasis should 
rather be placed on DCE-MRI instead of quantitative MRI of cartilage. Standardization of 
our DCE-MRI method is necessary and reproducibility needs to be investigated. Whether 
or not clinical relevant differences could be detected with the current measurement 
variability indicates if further optimization of the DCE-MRI acquisition protocol is neces-
sary. However, enhancing temporal resolution would be a serious challenge due to the 
dynamic nature of the DCE experiment. Another challenge would be acquiring DCE-MRI 
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for all knee tissues at once. Recently, DCE-MRI has been applied to measure synovi-
tis.102,103 Synovitis, a sign of inflammation, is linked to knee pain in multiple studies33,46,47 
and thus also a hypothetic pathophysiologic mechanism for PFF (Figure 1). It has been 
shown that the presence of inflammatory cytokines, such as IL-6 and TNFα, is associated 
with radiographic osteoarthritis and knee cartilage loss.104,105 Because cartilage loss is 
not present in PFP and PFP is considered to be transient in contrast to OA, the presence 
of inflammatory cytokines is not the first to be expected in patients with PFP. How-
ever, it is not implausible that excessive patellofemoral stress induces certain biological 
cascade pathways including the release of inflammatory cytokines or growth factors. 
Maybe, the processes induced by the release of cytokines and growth factors can still 
be counterbalanced in transient PFP, whereas in OA the body’s repair mechanism is not 
able to achieve this anymore. Synovitis, as sign of inflammation, can be measured with 
contrast-enhanced T1106,107 and more recently DCE-MRI has been applied for the same 
purpose.102,103 Both sequences were acquired in the current study and will be used to 
investigate synovitis in a later stadium. Furthermore, serological inflammatory markers 
can be measured in the blood samples, which were also acquired in the current study.
At the same time, it should be kept in mind for future research that multiple pathways 
likely coincide. For instance, both vascular and neural growth factors as well as inflam-
matory cytokines could be present inducing hypervascularisation, inflammation and 
hyperinnervation, wherein the latter could lead to an altered pain perception.
With respect to treatment, emphasis should be placed on identification of potential clini-
cal subgroups and elucidating working mechanism of these therapies. As mentioned 
before, the latter will probably coincide with the aim to unravel the pathophysiology of 
PFP, because the link between the presence of pathology and biomechanical/kinematic 
factors that might predispose to PFP is still missing. Next to biomechanical/kinematic 
factors, differences in patellofemoral bone shape can hypothetically lead to excessive 
patellofemoral contact stress and therefore also needs to be studied. This approach is 
currently implemented in our department, where 3D patellofemoral bone shape will 
be compared between patients with PFP patients with OA and control subjects using 
statistical shape analysis.108,109
Besides this structural approach, more knowledge is essential on the role of altered pain 
mechanisms in patients with PFP. According to Noehren et al. localized and centralized 
pain sensitivity are related to movement mechanics. Furthermore, Rathleff et al. dem-
onstrated that exercise therapy seems to be able to diminish pressure hyperalgesia.25 
However, the dose-response is still unknown, as is the effect of additional patient-
education. The presence of altered central pain processing mechanism also warrants 
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further research, since these might be targeted by specific exercise therapy or even by 
pain modifying drugs in the future.98
Conclusions
This thesis focused on assessing the effectiveness of exercise therapy in patients with 
PFP and on unraveling the pathophysiology of PFP. The main conclusions can be sum-
marized as follows:
o Exercise therapy is more effective than a control strategy (no treatment, placebo or 
waiting list controls). It is still unknown which type of exercise therapy is the most 
effective and whether this effect is present in all patients with PFP. However, a com-
bination of hip and knee exercises seems to be more effective than knee exercises 
alone. Therefore, exercise therapy including knee and hip exercises should be pre-
scribed to all patients with PFP.
o Structural joint abnormalities of the patellofemoral joint on MRI, such as bone mar-
row lesions, plica lesions, and patellar retinaculum lesions, are not associated with 
the presence of PFP. It is the question whether certain structural abnormalities are 
‘pathologic’ or rather ‘physiologic’. Retropatellar cartilage damage, both morphologic 
and compositional, is also not associated with PFP.
o Our tailored DCE-MRI protocol and postprocessing tool successfully extracted quan-
titative dynamic contrast enhancement metrics from the MRI data, and thus can be 
used to study patellar blood perfusion. In contrast to expected, higher, but non-
significant values of patellar bone perfusion parameters, indicating hyperperfusion, 
were found in patients with PFP compared to healthy control subjects. Furthermore, 
a difference in ktrans variance was observed. Both findings warrant further research.
o Handheld dynamometry is a reliable method to assess both the PPT and quadriceps 
strength in patients with PFP in clinical practice. Especially female patients with PFP 
showed generalized pressure hyperalgesia. No differences were found between 
adolescent and adult patients with PFP. Further research on the role of altered pain 
mechanisms in patients with PFP is warranted.
o Two other hypothetic pathophysiologic mechanisms, increased intraossesous pres-
sure and inflammation, were not studied in the current thesis.
Figure 4 displays the current knowledge on hypothetic pathophysiologic mechanisms 
of PFP. Although mechanisms are presented as separate boxes, it is not unlikely that 
some of them coincide, as mentioned previously.
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Figure 4. Hypothetic pathophysiologic mechanisms of patellofemoral pain
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The aim of this thesis was to assess the effects of exercise therapy aimed at reducing 
knee pain and improving knee function in patients with patellofemoral pain (PFP). Fur-
thermore, this thesis aimed to contribute to a better understanding of the pathogenesis 
of PFP by focusing on the association between PFP and structural abnormalities, patellar 
bone ischemia and altered pain perception using broad range of advanced magnetic 
resonance imaging (MRI) techniques.
The objective of chapter II was to assess the effects of exercise therapy aimed at reducing 
knee pain and improving knee function for people with PFP. We searched the Cochrane 
Bone, Joint and Muscle Trauma Group Specialised Register (May 2014), the Cochrane 
Central Register of Controlled Trials (2014, Issue 4), MEDLINE (1946 to May 2014), EMBASE 
(1980 to 2014 Week 20), PEDro (to June 2014), CINAHL (1982 to May 2014) and AMED 
(1985 to May 2014), trial registers (to June 2014) and conference abstracts. Randomised 
and quasi-randomised trials evaluating the effect of exercise therapy on pain, function 
and recovery in adolescents and adults with PFP. We included comparisons of exercise 
therapy versus control (e.g. no treatment) or versus another non-surgical therapy; or of 
different exercises or exercise programmes. Two review authors independently selected 
trials based on pre-defined inclusion criteria, extracted data and assessed risk of bias. 
Where appropriate, we pooled data using either fixed-effect or random-effects meth-
ods. We selected the following seven outcomes for summarising the available evidence: 
pain during activity (short-term: ≤ 3 months); usual pain (short-term); pain during 
activity (long-term: > 3 months); usual pain (long-term); functional ability (short-term); 
functional ability (long-term); and recovery (long-term).
In total, 31 heterogeneous trials including 1690 participants with PFP are included in 
this review. There was considerable between-study variation in patient characteristics 
(e.g. activity level) and diagnostic criteria for study inclusion (e.g. minimum duration of 
symptoms) and exercise therapy. Eight trials, six of which were quasi-randomised, were 
at high risk of selection bias. We assessed most trials as being at high risk of performance 
bias and detection bias, which resulted from lack of blinding. The included studies, some 
of which contributed to more than one comparison, provided evidence for the following 
comparisons: exercise therapy versus control (10 trials); exercise therapy versus other 
conservative interventions (e.g. taping; eight trials evaluating different interventions); 
and different exercises or exercise programmes. The latter group comprised: supervised 
versus home exercises (two trials); closed kinetic chain (KC) versus open KC exercises 
(four trials); variants of closed KC exercises (two trials making different comparisons); 
other comparisons of other types of KC or miscellaneous exercises (five trials evaluating 
different interventions); hip and knee versus knee exercises (seven trials); hip versus knee 
exercises (two studies); and high- versus low-intensity exercises (one study). There were 
no trials testing exercise medium (land versus water) or duration of exercises. Where 
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available, the evidence for each of seven main outcomes for all comparisons was of very 
low quality, generally due to serious flaws in design and small numbers of participants. 
This means that we are very unsure about the estimates. The evidence for the two larg-
est comparisons is summarised here.
exercise versus control
Pooled data from five studies (375 participants) for pain during activity at short-term 
favoured exercise therapy: mean difference (MD) -1.46, 95%confidence interval (CI) -2.39 
to -0.54. The CI included the minimal clinically important difference (MCID) of 1.3 (scale 
0 to 10), indicating the possibility of a clinically important reduction in pain. The same 
finding applied for usual pain at short-term (two studies, 41 participants), pain during 
activity at long-term (two studies, 180 participants) and usual pain at long-term (one 
study, 94 participants). Pooled data from seven studies (483 participants) for functional 
ability at short-term also favoured exercise therapy; standardised mean difference (SMD) 
1.10, 95% CI 0.58 to 1.63. Re-expressed in terms of the Anterior Knee Pain Score (0 to 100), 
this result (estimated MD 12.21 higher, 95% CI 6.44 to 18.09 higher) included the MCID 
of 10.0, indicating the possibility of a clinically important improvement in function. The 
same finding applied for functional ability at long-term (three studies, 274 participants). 
Pooled data (two studies, 166 participants) indicated that, based on the ’recovery’ of 250 
per 1000 in the control group, 88 more (95% CI 2 fewer to 210 more) participants per 
1000 recovered in the long term (12 months) as a result of exercise therapy.
hip plus knee versus knee exercises
Pooled data from three studies (104 participants) for pain during activity at short-term 
favoured hip and knee exercise: MD -2.20, 95% CI -3.80 to -0.60; the CI included a 
clinically important effect. The same applied for usual pain at short-term (two studies, 
46 participants). One study (49 participants) found a clinically important reduction in 
pain during activity at long-term for hip and knee exercise. Although tending to favour 
hip and knee exercises, the evidence for functional ability at short-term (four studies, 
174 participants) and long-term (two studies, 78 participants) and recovery (one study, 
29 participants) did not show that either approach was superior.
In conclusion, this review has found very low quality but consistent evidence that ex-
ercise therapy for PFP may result in clinically important reduction in pain and improve-
ment in functional ability, as well as enhancing long-term recovery. However, there is 
insufficient evidence to determine the best form of exercise therapy and it is unknown 
whether this result would apply to all people with PFP. There is some very low quality 
evidence that hip plus knee exercises may be more effective in reducing pain than knee 
exercise alone. Further randomised trials are warranted but in order to optimise research 
effort and engender the large multicentre randomised trials that are required to inform 
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practice, these should be preceded by research that aims to identify priority questions 
and attain agreement and, where practical, standardisation regarding diagnostic criteria 
and measurement of outcome.
The following chapters focused on hypothetic pathophysiologic mechanisms of PFP.
A cross sectional case-control study was conducted between January 2013 and Septem-
ber 2014 and included a healthy control group and patients with PFP with minimum 
symptom duration of two months to a maximum of two years. All participants were 
aged between 14 and 40 years. Patients who visited their general practitioner, phys-
iotherapist or sports physician were included if they were diagnosed with PFP based 
on the presence of at least 3 of the following symptoms: crepitus or pain while stair 
climbing, squatting, running, cycling, or sitting for a prolonged period with the knee 
flexed. Patients were excluded if they currently had a defined pathological knee condi-
tion of the affected knee (eg, osteoarthritis or patellar tendinopathy), previous surgery 
or injury of the affected knee, or previous episodes of PFP more than two years ago or if 
onset of PFP occurred after trauma. Control subjects consisted of team members, friends 
or colleagues of the included patients with PFP. We aimed to match control subjects 
on age, Body Mass Index (BMI), sex and activity level. Control subjects were excluded if 
they had current or past PFP, if they previously had a traumatic injury or surgery on both 
knees or if they were first-grade family members of patients.
In total 64 patients and 70 control subjects were included; 40 participants (equally dis-
tributed between groups) were adolescents The mean age was 23.2 ± 6.4 years, mean 
BMI was 22.9 ± 3.4 kg/m2 and 56.7% of the participants were female. Participants were 
asked to fill in an online questionnaire, including questions on demographics (age, 
sex, BMI), sports participation at the time of inclusion and before onset of pain (yes or 
no) and knee complaints (duration of complaints, pain at rest and during activity (Nu-
merical Rating Scale (NRS) 0-10) and function (Anterior Knee Pain (AKP) score 0-100)). 
Subsequently, they were invited for a physical examination (including crepitation during 
squatting (present or not), palpation of the medial patellar facet (painful or not) and the 
Clarke compression test (positive or negative)) and 3 Tesla MRI scan at our university 
medical center. The MRI protocol comprised sagittal, axial and coronal fast spin echo 
(FSE) proton density weighted sequences, a 3 dimensional (3D) high resolution sagittal 
SPGR sequence with high spatial resolution with and without fat-saturation, a 3D sagit-
tal FSE T1ρ mapping sequence, a 3D sagittal FSE T2 mapping sequence, a 3D sagittal 
inversion recovery non-fat-saturated SPGR sequence for delayed gadolinium-enhanced 
MRI of cartilage (dGEMRIC) and a sagittal, anterior-posterior frequency-encoded, fat 
suppressed 3D SPGR sequence for dynamic contrast-enhanced (DCE)-MRI. The last two 
sequences were only acquired in adults due to the need of contrast administration.
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Chapter III aimed to investigate the presence of structural abnormalities of the patel-
lofemoral joint on high-resolution MRI in patients with PFP compared to healthy control 
subjects. No previous study has investigated if PFP is associated with structural abnor-
malities of the patellofemoral joint using high-resolution MRI. All images were scored 
using the Magnetic Resonance Imaging Osteoarthritis Knee Score with the addition of 
specific patellofemoral features. Associations between PFP and the presence of struc-
tural abnormalities were analysed using logistic regression analyses, adjusted for age, 
BMI, sex and sports participation.
Full thickness cartilage loss was not present. Minor patellar cartilage defects, patellar 
bone marrow lesions (BMLs) and high signal intensity of Hoffa’s fat pad were frequently 
seen in both patients (23%, 53% and 58% respectively) and control subjects (21%, 51% 
and 51% respectively). After adjustment for age, BMI, sex and sports participation, none 
of the structural abnormalities were statistically significantly associated with PFP.
In conclusion, structural abnormalities of the patellofemoral joint have been hypoth-
esized as a factor in the pathogenesis of PFP, but our findings suggest that structural 
abnormalities of the patellofemoral joint on MRI are not associated with PFP
Chapter IV aimed to investigate differences in patellofemoral cartilage composition 
between patients with PFP and healthy control subjects using quantitative MRI. Ret-
ropatellar cartilage damage has been suggested as an etiological factor for PFP, but, to 
date, there is no conclusive evidence for an association between cartilage defects and 
PFP. Nowadays, advanced quantitative MRI techniques enable estimation of cartilage 
composition. Differences in relaxation times of patellar and femoral cartilage were com-
pared between groups by linear regression analyses, adjusted for age, body mass index, 
sex, sports participation, and time of image acquisition. Higher T2 en T1ρ and lower T1GD 
relaxtion times mean less content.
For delayed gadolinium-enhanced MRI of cartilage, the mean T1GD relaxation times of 
patellar (657.8 vs 669.4 ms) and femoral cartilage (661.6 vs 659.8 ms) did not significantly 
differ between pa- tients and controls. In addition, no significant difference was found in 
mean T1ρ relaxation times of patellar (46.9 vs 46.0 ms) and femoral cartilage (50.8 vs 50.2 
ms) and mean T2 relaxation times of patellar (33.2 vs 32.9 ms) and femoral cartilage (36.7 
vs 36.6 ms) between patients and controls. Analysis of prespecified medial and lateral 
subregions within the patellofemoral cartilage also revealed no significant differences.
In conclusion, there was no difference in composition of the patellofemoral cartilage, 
estimated with multiple quantitative MRI techniques, between patients with PFP and 
healthy control subjects. However, clinically relevant differences could not be ruled out 
for T1ρ in the adolescent population. Retropatellar cartilage damage has long been hy-
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pothesized as an important factor in the pathogenesis of PFP, but study findings suggest 
that diminished patellofemoral cartilage composition is not associated with PFP.
Chapter V and VI focused on patellar bone tissue ischemia. Vascular problems, like 
bone ischemia or increased intraosseous hydrostatic pressure due to venous outflow 
obstruction, might play a role in PFP. DCE-MRI enables quantitative measurement of pa-
tellar bone blood perfusion. However, application of DCE-MRI for bone has been limited 
due to the sparse vascularization of bone and the typical low contrast enhancement 
compared to surrounding tissues. Therefore, our first aim was to develop a robust analy-
sis method for quantifying patellar bone blood perfusion with DCE-MRI (chapter V). 
DCE-MRI acquisition was optimized and the optimal combination of pharmacokinetic 
model and arterial input function (AIF) for quantitative analysis of blood perfusion in the 
patellar bone using DCE-MRI was identified. The method design study used a random 
subset of five control subjects. We systematically investigated the reproducibility of 
pharmacokinetic parameters for all combinations of Orton and Parker AIF models with 
Tofts, Extended Tofts (ETofts), and Brix pharmacokinetic models. We evaluated if the 
AIF should use literature parameters, be subject specific, or be group specific. Model 
selection was based on the goodness-of-fit and the coefficient of variation of the phar-
macokinetic parameters. The vascular component in the ETofts model could not reliably 
be recovered and the Brix model parameters showed high variability. A subject specific 
AIF performed worse than a group specific AIF, but better than an AIF with literature 
parameters. The best reproducibility and goodness-of-fit were obtained by combining 
Tofts’ pharmacokinetic model with the group specific Parker AIF.
In conclusion, we identified several good combinations of pharmacokinetic model 
and AIF for quantitative analysis of perfusion in the patellar bone. The recommended 
combination was Tofts pharmacokinetic model combined with group specific Parker’s 
AIF model.
This DCE-MRI method was than applied in chapter VI in our case-control study. Quan-
titative MR perfusion parameters (i.e. kep, ktrans) of manually segmented patellar bone 
were derived from motion-compensated DCE MRI-data by fitting Tofts’ model to the 
measured data in each voxel. Differences in perfusion parameters of patellar bone were 
compared between groups by linear regression analyses, adjusted for age, body mass 
index (BMI), gender, and sports participation. Lower values of patellar bone perfusion 
parameters, suggestive for local tissue ischemia or venous outflow obstruction, were 
expected in patients with PFP compared to healthy control subjects.
35 adult patients and 44 adult controls were included. Mean age was 26.1 ± 5.0, mean 
BMI was 24.1 ± 3.4 kg/m2 and 49% was female. Mean kep was 0.189 ± 0.147 min-1 for 
patients and 0.154 ± 0.114 min-1 for controls. Mean ktrans was 0.019 ± SD 0.015 min-1 for 
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patients and 0.014 ± SD 0.009 min-1 for controls. Both perfusion parameters were not 
significantly different between groups. However, a significant difference in variance 
between populations was observed for ktrans.
In conclusion, in contrast to expected, higher values of patellar bone perfusion param-
eters were found in patients with PFP compared to healthy control subjects, but these 
differences were not statistically significant. This result, and the observed difference in 
ktrans variance warrant further research.
Chapter VII and VIII focused on pain perception. It has been suggested that repeated 
overload might sensitize local nociceptors causing local hyperalgesia. This might also 
lead to an altered central processing of nociceptive information. In order to identify 
pressure hyperalgesia, the pressure pain threshold (PPT) can be measured. Therefore, 
our first aim was to determine the inter-rater reliability of handheld dynamometry to 
test PPT in patients with PFP. Quadriceps strength was also conducted, because it can 
be easily assessed with the same device. A reliability study took place in 22 PFP patients 
and 16 matched controls of the case-control study mentioned previously (Chapter 
VII). Measurements comprised three quadriceps strength and one PPT measurements 
performed by two independent investigators. Inter-rater reliability was analyzed using 
intraclass correlation coefficients (ICC) and Bland-Altman plots.
Inter-rater reliability of quadriceps strength testing was fair to good in PFP patients 
(ICC= 0.72) and controls (ICC=0.63). Bland-Altman plots showed an increased difference 
between assessors when average quadriceps strength values exceeded 250 Newton. 
Inter-rater reliability of PPT was excellent in patients (ICC=0.79) and fair to good in 
controls (ICC=0.52).
In conclusion, handheld dynamometry seems to be a reliable method to test both 
quadriceps strength and PPT in PFP patients. Inter-rater reliability was higher in PFP 
patients compared to control subjects. With regard to quadriceps testing, a higher vari-
ance between assessors occurs when average quadriceps strength values exceeded 250 
Newton.
This method was than applied in chapter VIII in a case-control study to investigate 
differences in PPT between patients with PFP and healthy control subjects and study 
associations between PPT and patients characteristics. The PPT was measured with a 
handheld dynamometer with algometry tip on three locations: most painful spot at 
the affected knee (medial facet in controls), same spot contralateral knee and at the 
contralateral forearm. Differences between groups were tested with linear regression 
analyses adjusted for age, gender, BMI and sports participation.
Patients had significantly lower PPTs compared to controls at all locations. Beta’s were 
-13.98(95%CI -18.62;-9.33) at the affected knee, -6.91(95%CI -11.84;-1.97)) at the contra-
lateral knee and -7.57(95%CI -12.07;-3.07) at the arm. A significant interaction effect was 
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found between participant status and female with respect to the PPT at the contralateral 
arm. (β -9.95, 95%CI -18.74;-1.16). Female gender was significantly associated with a 
lower PPT in the patient population.
In conclusion, local, distal and generalized pressure hyperalgesia, suggesting alterations 
in both peripheral and central pain mechanisms, were present in patients with PFP. 
Females with PFP were most likely to suffer from generalized hyperalgesia.
Chapter IX discusses the main findings and places them in a wider prospective. Meth-
odological strengths and challengers are discussed. Furthermore, clinical implications 
and future research prospectives are given.
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Het doel van dit proefschrift was het vaststellen van de effectiviteit van oefentherapie 
gericht op vermindering van kniepijn en verbetering van de kniefunctie in patiënten 
met patellofemorale pijn (PFP). Ook beoogde dit proefschrift om bij te dragen aan een 
beter begrip van de pathogenese van PFP door middel van het bestuderen van associ-
aties tussen PFP en structurele afwijkingen, ischemie van het bot van de patella en een 
veranderde pijnperceptie. Dit werd gedaan met een grote selectie aan geavanceerde 
beeldvormende technieken gebaseerd op magnetische resonantie (MRI).
Hoofdstuk II beschrijft een systematisch literatuuronderzoek naar de effectiviteit van 
oefentherapie gericht op vermindering van kniepijn en verbetering van de knie functie 
in patiënten met PFP. We doorzochten daarvoor verschillende databases o.a. van de Co-
chrane Bone, Joint and Muscle Trauma Group (Mei 2014) en Cochrane Central Controlled 
Trials. Gerandomiseerde en quasi-gerandomiseerde studies, die het effect van oefen-
therapie op pijn, functie en herstel in adolescenten en volwassenen met PFP hadden 
onderzocht werden geincludeerd. De studies deden dit door middel van vergelijkingen 
van oefentherapie versus een controle strategie (bijv. geen behandeling) of versus een 
andere niet-operatieve therapie, en vergelijkingen van verschillende oefeningen of oe-
fenprogramma’s, werden geïncludeerd. We selecteerden de volgende zeven uitkomsten 
om het beschikbare bewijs in samen te vatten: pijn tijdens activiteit (korte termijn: ≤ 
3 maanden), dagelijkse pijn (korte termijn), pijn tijdens activiteit (lange termijn: > 3 
maanden), dagelijkse pijn (lange termijn), fysiek functioneren (korte termijn), fysiek 
functioneren (lange termijn) en herstel (lange termijn).
In totaal, zijn er 31 studies met in totaal 1196 patiënten met PFP geïncludeerd. Er was 
sprake van een behoorlijke variatie in patiënt karakteristieken (bijv. in activiteiten ni-
veau en diagnostische criteria voor inclusie in de studie (bijv. minimale klachtenduur)) 
en in de soort oefentherapie tussen studies. De geïncludeerde studies, waarbij som-
mige bijdroegen aan meer dan een vergelijking, verschaften bewijs voor de volgende 
vergelijkingen: oefentherapie versus controle strategie, oefentherapie versus andere 
conservatieve interventies (bijv. tapen), en verschillende oefeningen of oefenpro-
gramma’s. De laatste groep bevatte gesuperviseerde oefeningen versus oefeningen 
thuis, gesloten kinetische keten oefeningen versus open kinetische keten oefeningen, 
varianten van gesloten kinetische keten oefeningen, andere vergelijkingen of andere 
types van gesloten keten oefeningen of ander soort oefeningen, heup- en knie oefenin-
gen versus knie oefeningen, heup versus knie oefeningen en hoge intensiteit- versus 
lage intensiteit oefeningen. Het bewijs voor alle zeven belangrijkste uitkomsten was van 
erg lage kwaliteit. Dit kwam vooral door serieuze gebreken in de studie opzet, zoals 
bijvoorbeeld het niet blinderen van patiënten en behandelaars voor de behandeling 
waarin de patiënt geplaatst was, en door het kleine aantal deelnemers in de studies. 
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Dit betekent dat de validiteit van de uitkomsten discutabel is. Het bewijs voor de twee 
grootste vergelijkingen hebben we samengevat in de volgende paragrafen.
Oefentherapie versus controle strategie:
Samengevoegde data van vijf studies voor pijn tijdens activiteit op de korte termijn 
toont aan dat oefentherapie meer leidt tot een afname van pijn dan een controle stra-
tegie; gemiddeld verschil van -1.46, 95% betrouwbaarheids interval (BI) -2.39 tot -0.54. 
Dit verschil is klinisch relevant. Hetzelfde was het geval bij dagelijkse pijn op de korte 
termijn, pijn tijdens activiteit op de lange termijn en dagelijkse pijn op de lange termijn. 
Samengevoegde data van zeven studies toont aan dat voor fysiek functioneren op de 
korte termijn oefentherapie meer leidt tot een verbetering in functie; met een gestan-
daardiseerd gemiddeld verschil van 1.10, 95% BI 0.58 tot 1.63. Uitgedrukt in de ‘Anterior 
Knee Pain Score’ (schaal 0 tot 100) was het gemiddelde verschil 12.21 (95% BI 6.44 tot 
18.09). Dit is klnisch relevant. Dezelfde bevinding werd gedaan voor fysiek functioneren 
op de lange termijn. Samengevoegde data van twee studies liet ook zien dat, gebaseerd 
op een herstel van 250 per 1000 in de controle groep, er 88 (95% BI 2 minder tot 210 
meer) meer deelnemers per 1000 op de lange termijn (12 maanden) herstelden in de 
oefentherapie groep.
Heup- en knie oefeningen versus knie oefeningen:
Samengevoegde data van drie studies voor pijn tijdens activiteit op de korte termijn 
gaf een voorkeur aan heup- en knie oefeningen versus alleen knie oefeningen, met een 
gemiddel verschil van -2.20 (95% BI -3.80 tot -0.60). Dit verschil is klinisch relevant effect. 
Hetzelfde is van toepassing op dagelijkse pijn op de korte termijn. Een studie vond een 
klinisch relevante afname in pijn tijdens activiteit op de lange termijn voor heup- en 
knie oefeningen. Ook al neigde het bewijs voor fysiek functioneren op de korte termijn 
, lange termijn en herstel naar heup- en knie oefeningen, toch was geen van beide 
aanpakken superieur aan de ander.
Concluderend geeft dit systematische literatuuronderzoek bewijs van erg lage, maar 
wel consistente kwaliteit, dat oefentherapie in patiënten met PFP kan resulteren in een 
klinische relevante afname in pijn en verbetering van de knie functie, als ook in meer 
herstel op lange termijn. Er is echter onvoldoende bewijs om vast te kunnen stellen 
welke vorm van oefentherapie de beste is en of dit resultaat op alle patiënten met 
PFP van toepassing is. Er is ook bewijs, zij het van erg lage kwaliteit, dat heup- en knie 
oefeningen effectiever zouden zijn in het verminderen van pijn dan knie oefeningen 
alleen. Meer gerandomiseerde studies zijn nodig. Maar om onderzoeksinspanningen te 
optimaliseren, moet er eerst onderzoek worden gedaan naar de belangrijkste vragen en 
overeenstemming bereikt worden wat betreft diagnostische criteria en uitkomstmaten.
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De volgende hoofstukken richtten zich op het ontrafelen van de pathofysiologische 
mechanismen van PFP. Een cross-sectionele case-controle studie heeft plaatsgevonden 
van Januari 2013 tot September 2014. Hierbij werden een gezonde controle groep en 
patiënten met PFP met een klachtenduur tussen de twee maanden en twee jaar geïn-
cludeerd. Alle patiënten waren tussen de 14 en 40 jaar oud. Patiënten die hun huisarts, 
fysiotherapeut of sportarts bezochten, werden geïncludeerd als ze gediagnosticeerd 
werden met PFP gebaseerd op drie van de volgende symptomen: crepitatie (kraken 
van het gewricht bij buigen) of pijn bij traplopen, hurken, rennen, fietsen of langdurig 
met de knieën gebogen zitten. Patiënten werden geëxcludeerd als ze momenteel reeds 
vastgestelde pathologie van de aangedane knie hadden (zoals artrose of patellotendi-
nopathy), als ze een eerdere operatie of blessure aan de aangedane knie hadden gehad, 
als ze meerdere episodes van PFP meer dan twee jaar geleden hadden gehad of als 
PFP was ontstaan na een trauma. Controlepersonen waren teamgenoten, vrienden of 
collega’s van de geïncludeerde patiënten met PFP.
In totaal zijn er 64 patiënten en 70 controlepersonen geïncludeerd, waarbij 40 deel-
nemers (evenredig verdeeld over de groepen) adolescenten waren. De gemiddelde 
leeftijd was 23.2 ± 6.4 jaar, het gemiddelde BMI was 22.9 ± 3.4 kg/m2 en 56.7% van 
de deelnemers was vrouw. Deelnemers werd gevraagd om een online vragenlijst in te 
vullen betreffende demografische gegevens (leeftijd, geslacht, BMI), sportdeelname 
tijdens inclusie en voordat de pijn begon (ja of nee) en knieklachten (duur, pijn tijdens 
rust en tijdens activiteit (Numerical Rating Scale (NRS) 0-10) en functie (Anterior Knee 
Pain (AKP) score 0-100)). Daarna werden ze uitgenodigd voor een lichamelijk onderzoek 
(met o.a. crepitatie tijdens hurken (aanwezig of niet), palpatie van het mediale patellaire 
facet (pijnlijk of niet) en de Clark compressie test (positief of negatief )) en een 3 Tesla 
MRI scan in het Erasmus universitair medisch centrum. Het MRI protocol bevatte proton 
density sequenties, hoge resolutie sequenties, quantitatieve sequenties voor het meten 
van kraakbeen (T1GD (delayed gadolinium-enhanced MRI of cartilage (dGEMRIC)), T2 en 
T1ρ) en een quantitatieve sequentie om de doorbloeding te meten (dynamic contrast-
enhanced (DCE)-MRI) De laatste twee sequenties zijn alleen gemaakt in volwassen, 
omdat hierbij contrast toegediend moest worden.
In hoofdstuk III wordt de aanwezigheid van structurele afwijkingen van het patellofe-
morale gewricht op hoge-resolutie MRI tussen patiënten met PFP en gezonde controle-
personen vergeleken. Geen enkele eerdere studie heeft onderzocht of PFP geassocieerd 
is met structurele afwijkingen van het patellofemorale gewricht met behulp van hoge-
resolutie MRI. Alle beelden werden gescoord volgens de Magnetic Resonance Imaging 
Osteoarthritis Knee Score, waarbij er enkele specifieke patellofemorale items werden 
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toegevoegd. Associaties tussen PFP en de aanwezigheid van structurele afwijkingen 
werden getest met logistische regressie analyses, welke geadjusteerd werden voor 
leeftijd, BMI, geslacht en sportdeelname.
Volledige dikte kraakbeenverlies was niet aanwezig. Kleine patellaire kraakbeendefecten, 
patellaire beenmerglesies (BMLs) en een hoge signaalintensiteit van Hoffa’s vetlichaam 
werd veelvuldig waargenomen, zowel in patiënten (23%, 53% en 58% respectievelijk) 
als controlepersonen (21%, 51% en 51% respectievelijk). Na adjustering voor leeftijd, 
BMI, geslacht en sportdeelname, was geen van de structurele afwijkingen statistisch 
significant geassocieerd met PFP.
Concluderend is het verondersteld dat structurele afwijkingen van het patellofemorale 
gewricht bijdragen aan de pathogenese van PFP, maar onze resultaten suggereren dat 
structurele MRI afwijkingen van het patellofemorale gewricht niet geassocieerd zijn met 
PFP.
In hoofdstuk IV worden verschillen in patellofemorale kraakbeen-samenstelling tussen 
patiënten met PFP en gezonde controlepersonen onderzocht met behulp van kwan-
titatieve MRI technieken. Retropatellaire kraakbeenschade wordt verondersteld een 
etiologische factor voor PFP te zijn, maar tot op heden is er niet afdoende bewijs voor 
een associatie tussen PFP en kraakbeendefecten. Met behulp van geavanceerde, kwan-
titatieve MRI technieken (T1GD, T2 en T1ρ) is het tegenwoordig mogelijk om de kraak-
beensamenstelling te bepalen. Verschillen in relaxatietijden van patellair en femoraal 
kraakbeen werden vergeleken tussen de groepen met lineaire regressie analyses, welke 
waren geadjusteerd voor leeftijd, BMI, geslacht, sportdeelname en het tijdstip waarop 
de MRI scan gemaakt was. Een hogere T2 en T1ρ en lagere T1GD relaxatietijd betekent 
minder bestanddelen in het kraabeen en het dus minder stevig, gezond kraakbeen.
De gemiddelde T1GD relaxatie tijd van het patellaire kraakbeen (657.8 vs 669.4 ms) en 
van het femorale kraakbeen (661.6 vs 659.8 ms) was niet significant verschillend tus-
sen patiënten en controles. Ook was er geen significant verschil in de gemiddelde T1ρ 
relaxatietijden van patellair- (46.9 vs 46.0 ms) en femoraal kraakbeen (50.8 vs 50.2 ms) en 
de gemiddelde T2 relaxatietijden van patellair- (33.2 vs 32.9 ms) en femoraal kraakbeen 
(36.7 vs 36.6 ms) tussen patiënten en controles.
Analyses van vooraf gedefinieerde mediale en laterale subregio’s binnen het patellofe-
morale kraakbeen lieten ook geen significante verschillen zien.
Concluderend was er geen verschil in patellofemorale kraakbeensamenstelling, bepaald 
met multiple kwantitatieve MRI technieken, tussen patiënten met PFP en gezonde con-
trolepersonen. Voor T1ρ in de adolescenten kunnen klinisch relevante verschillen echter 
niet worden uitgesloten. Het is lang verondersteld dat retropatellaire kraakbeenschade 
een belangrijke factor is in de pathogenese van PFP, maar onze resultaten suggereren 
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dat een verminderde patellofemorale kraakbeensamenstelling niet geassocieerd is met 
PFP.
Hoofdstuk V en VI richtten zich op ischemie, een verminderde doorbloeding, van het 
bot van de patella. Vasculaire problemen, zoals ischemie van het bot van de patella of 
een verhoogde inta-ossale druk in de patella door een veneuze afvloeiingsobstructie, 
kunnen een rol spelen in PFP. Met DCE-MRI is het mogelijk om de doorbloeding, de 
perfusie, van het patella bot te meten. Vanwege de lage vascularisatie van bot en lage 
signaalintensiteit ten opzichte van omliggende weefsels is DCE-MRI in bot nog weinig 
toegepast. Daarom, was ons eerste doel om een robuuste analyse methode te ontwik-
kelen waarmee we de perfusie van het patella bot met DCE-MRI kunnen kwantificeren 
(hoofdstuk V). De acquisitie van DCE-MRI is eerst geoptimaliseerd en daarna hebben 
we de optimale combinatie van farmacokinetisch model en arteriële input functie (AIF) 
onderzocht. De studie om de methode te ontwikkelen, bevatte vijf random controleper-
sonen. In deze studie werd de reproduceerbaarheid van de farmacokinetische parame-
ters onderzocht voor alle combinaties van AIF, zoals voorgesteld door Orton en Parker, 
in combinatie met het farmacokinetische model van Tofts, Extended Tofts en Brix. We 
evalueerden of de AIF gebaseerd moest zijn op literatuur parameters, of geschat moest 
worden per subject of over de gehele groep. Voor elke combinatie van modellen, wer-
den de variatiecoëfficiënt, als maat van reproduceerbaarheid van de geschatte perfusie 
parameters, en de goodness of fit onderzocht.
De vasculaire component in het Extended Tofts model kon niet betrouwbaar worden 
verkregen en het model van Brix had een hoge variabiliteit. Een op het subject geba-
seerde AIF was minder goed dan de groep-specifieke AIF, maar beter dan de op litera-
tuur parameters gebaseerde AIF. De beste reproduceerbaarheid en goodness of fit werd 
verkregen door Tofts farmacokinetisch model te combineren met de groep-specifieke 
Parker AIF.
Concluderend werden verschillende goede combinaties van farmacokinetisch model en 
AIF voor de kwantitatieve analyse van doorbloeding van patella bot geïdentificeerd. De 
uiteindelijk aangeraden combinatie was Tofts farmacokinetisch model gecombineerd 
met de groeps-specifieke Parker AIF.
Deze DCE-MRI methode werd vervolgens toegepast in hoofdstuk VI in onze case-
controle studie. Kwantitatieve MRI perfusie parameters (kep, ktrans) van manueel geseg-
menteerd patella bot werden verkregen uit beweging gecompenseerd DCE-MRI data 
waarop Tofts’ model gefit was op voxel niveau. Verschillen in perfusie parameters van 
patella bot tussen de groepen werden vergeleken met lineaire regressie analyses, welke 
geadjusteerd waren voor leeftijd, BMI, geslacht en sportdeelname. Lagere perfusie waar-
den, suggestief voor ischemie van het bot van de patellar of een veneuze afvloeiingsob-
structie, werden verwacht in patiënten met PFP vergeleken met controlepersonen.
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In totaal weren 35 volwassen patiënten en 44 volwassen controlepersonen geïnclu-
deerd. De gemiddelde leeftijd was 26.1 ± SD 5.0 jaar, het gemiddelde BMI was 24.1 ± 3.4 
kg/m2 en 49% was vrouw. De gemiddelde kep was 0.189 ± 0.147 min-1 in patiënten en 
0.154 ± 0.114 min-1 in controlepersonen. De gemiddelde ktrans was 0.019 ± 0.015 min-1 in 
patiënten en 0.014 ± 0.009 min-1 in controlepersonen. Beide perfusieparameters waren 
niet significant verschillend tussen de groepen. Een significant verschil in variantie tus-
sen de populaties was echter aanwezig.
Concluderend werden er, in tegenstelling tot verwacht, hogere waarden gevonden voor 
de perfusieparameters van het patellabot in patiënten met PFP in vergelijking met ge-
zonde controlepersonen, maar deze verschillen waren niet statistisch significant. Gezien 
dit resultaat en het gevonden verschil in variantie in ktrans is verder onderzoek nodig.
Hoofdstuk VII en VIII richtten zich op pijnperceptie. Het wordt gesuggereerd dat locale 
nociceptors gesensitiseerd kunnen worden door herhaalde overbelasting. Dit resulteert 
in hyperalgesie en kan ook leiden tot een verstoorde centrale pijnverwerking. Druk 
hyperalgesie kan gemeten worden met de pressure pain threshold (PPT). Daarom was 
ons eerste doel om de betrouwbaarheid vast te stellen wanneer de PPT wordt gemeten 
in patiënten met PFP met een dynamometer die met de hand wordt vastgehouden 
door verschillende onderzoekers. De kracht van de quadriceps spier werd gelijktijdig 
gemeten, omdat dat eenvoudig kan met hetzelfde apparaat. Deze betrouwbaarheids-
studie vond plaats in 22 patiënten en 16 controlepersonen van de eerder genoemde 
case-controle studie (Hoofdstuk VII). De kracht van de quadriceps spier werd drie keer 
gemeten en de PPT een keer door twee onafhankelijke onderzoekers. De betrouwbaar-
heid tussen deze onderzoekers werd geanalyseerd met intraclass correlation coefficients 
(ICC) en Bland-Altman plots.
De betrouwbaarheid tussen onderzoekers voor het meten van de quadriceps kracht was 
redelijk tot goed in patiënten (ICC= 0.72) en controlepersonen (ICC=0.63). De Bland-
Altman plots lieten een toename in het verschil tussen onderzoekers zien wanneer de 
gemiddelde quadriceps kracht meer dan 250 Newton bedroeg. De betrouwbaarheid 
tussen onderzoekers voor de PPT was uitstekend in patiënten (ICC=0.79) en redelijk tot 
goed in controlepersonen (ICC=0.52).
Concluderend, is met de hand toegepaste dynamometrie een betrouwbare methode 
om zowel de quadriceps kracht als de PPT in patiënten met PFP te meten. De betrouw-
baarheid tussen onderzoekers was hoger in patiënten dan in controlepersonen. Wat 
het meten van de quadriceps kracht betreft, bleek dat er een groter verschil tussen 
onderzoekers optrad wanneer de gemiddelde quadriceps kracht meer dan 250 Newton 
bedroeg.
Deze methode is vervolgens toegepast in hoofdstuk VIII in de case-controle studie om 
verschillen in PPT tussen patiënten met PFP en gezonde controlepersonen te onder-
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zoeken en om te bestuderen welke patiënt karakteristieken geassocieerd zijn met PFP. 
De PPT is gemeten met de dynamometer met speciale algometrie opzetstuk op drie 
locaties: meest pijnlijke plek op de aangedane knie (mediale facet bij controleperso-
nen), dezelfde plek op de contralaterale knie en een plek op de contralaterale onderarm. 
Verschillen tussen groepen werden getest met lineaire regressie analyses, welke waren 
geadjusteerd voor leeftijd, BMI, geslacht en sportdeelname.
Patiënten hadden een lagere PPT vergeleken met controlepersonen voor alle locaties; 
aangedane knie β -13.98 (95% BI -18.62;-9.33), contralaterale knie β -6.91 (95% BI -11.84;-
1.97)) arm β -7.57 (95% BI -12.07;-3.07). Er werd een significant interactie effect gevon-
den tussen deelnemers status (patiënt of controle) en vrouw zijn wat betreft de PPT van 
de contralaterale arm (β -9.95, 95%BI -18.74;-1.16). Vrouwelijk geslacht was significant 
geassocieerd met een lagere PPT.
Concluderend waren lokale, distale en gegeneraliseerde druk hyperalgesie, suggestief 
voor zowel perifere- als centrale pijnmechanismes, aanwezig in patiënten met PFP. 
Vooral vrouwen met PFP hadden gegeneraliseerde druk hyperalgesie.
Hoofstuk IX geeft een overzicht en beschouwing van de belangrijkste bevindingen. 
Methodologische sterke punten en uitdagingen worden bediscussieerd. Verder, worden 
implicaties voor de kliniek uiteengezet en aanbevelingen gedaan voor verder onder-
zoek.
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Aan alles komt een einde, maar gelukkig komt er ook altijd weer een nieuw begin, zoals 
bij mij de opleiding tot radioloog/nucleair geneeskundige. Hopelijk lukt het om dit in de 
toekomst te combineren met onderzoek in wat voor vorm dan ook, zodat samenwerkin-
gen kunnen worden voortgezet of nieuwe samenwerkingen kunnen worden aangegaan. 
Voor nu wil ik in ieder geval iedereen die mij de afgelopen jaren geholpen, geïnspireerd 
of geprikkeld heeft of op enige andere manier heeft bijgestaan, zeer hartelijk bedanken.
De inclusie is iets uitgelopen, maar ik ben er trots op dat we met vereende krachten tot 
dit deelnemersaantal hebben kunnen komen. Daarom wil ik graag als eerste alle patiën-
ten bedanken voor hun deelname. Ik hoop dat we in de toekomst de pathofysiologie van 
patellofemorale pijn verder kunnen ontrafelen en uiteindelijk tot betere behandelingen 
kunnen komen. Natuurlijk wil ik ook de zorgverleners die de moeite hebben genomen 
om deze patiënten naar mij door te verwijzen hartelijk bedanken. Sportarts Maarten 
Verschure wil ik hierbij nog extra noemen vanwege het grote aantal deelnemers dat 
hij doorverwezen heeft, hartstikke bedankt voor je grote bijdrage! Ook alle collega’s, 
vrienden, kennissen die als controlepersoon hebben deelgenomen, bedankt!
Mijn copromotor, Marienke, bedankt voor de goede begeleiding de afgelopen jaren! Als 
er iemand is die mij heeft geprikkeld om het beste uit mezelf te halen was jij het wel, ook 
al was het ook regelmatig zo dat ik juist afgeremd moest worden (maar desalniettemin is 
dat pijn stuk toch nog in dit boekje gekomen ;) ). Naast dat ik veel van je heb geleerd op 
wetenschappelijk gebied, waardeer ik het zeer dat jij mij hebt mee gegeven hoe tot een 
betere werk-privé balans te komen. Jij bent voor mij een mooi voorbeeld dat de drang 
naar een sportief en avontuurlijk leven zeer zeker te combineren is met een drukke, 
maar intellectueel uitdagende baan. Op een verdere samenwerking in de toekomst!
Mijn copromotor, Edwin, waar moet ik beginnen… Naast dat ik jouw secure begeleiding 
tijdens mijn promotie zeer fijn vond, ben jij ook diegene die mijn enthousiasme voor 
de radiologie verder aangewakkerd heeft. Je hebt gezorgd dat ik een kans kreeg om 
te laten zien dat ik de opleiding waardig ben met als gevolg dat ik aangenomen werd. 
Ik bewonder enorm hoe je al jouw taken combineert en toch zo rustig, vriendelijk en 
toegankelijk blijft. Daarnaast kijk ik op tegen je enorme vakinhoudelijke kennis. Ik hoop 
in de toekomst nog veel van je te leren!
Mijn promotor, Sita, bedankt voor de inspirerende gesprekken. Ook al moest ik de hoe-
veelheid (nieuwe) ideeën meestal eerst even laten bezinken, heb ik deze input wel als 
zeer waardevol ervaren. Verder wist je, zoals het de professor betaamt, altijd nog wel de 
vinger te leggen op belangrijke punten die nog wat beter benadrukt konden worden.
Beste prof. Krestin, bedankt voor de altijd waardevolle reacties op mijn stukken. Ik vind 
uw staat van dienst bewonderenswaardig en waardeer het daarom zeer dat u toch elke 
keer zo snel op mijn stukken reageerde.
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Beste overige commissieleden, hartelijk dank dat u wilt plaatsnemen in mijn commissie. 
Ik kijk er naar uit om met u van gedachten te wisselen.
Thanks patellofemoral research community for the inspiring discussions and social 
gatherings at the research retreats! With such a motivated group of people, I am sure we 
will tackle patellofemoral pain eventually.
Dan wil ik graag een aantal mensen bedanken die mijn interesse in radiologisch onder-
zoek van het bewegingsapparaat gewekt hebben en mij in meer of mindere mate ge-
holpen hebben tijdens mijn eerste stappen op onderzoeksgebied. Dr. Heijboer, bedankt 
voor de interessante discussies over cam-impingement, al kwamen we toch ook wel vaak 
uiteindelijk uit bij de wielersport, wat natuurlijk ook een heel interessant onderwerp is. 
Dr. Ginai, bedankt voor het wekken van mijn interesse voor de radiologie toen ik nog 
student was, ook al had ik toen nog helemaal niet door hoe goed het vak bij mij paste. 
Ook bedankt voor de wijze woorden wat betreft de uiteindelijke keuze om hier in op-
leiding te gaan. Prof. Verhaar, bedankt voor de zeer snelle en klinisch relevante reacties 
op mijn stukken. Patellofemorale pijn is een onderwerp dat ons beiden aanspreekt, wat 
leidde tot interessante discussies over o.a. weker kraakbeen en of er bij vrouwen niet 
nog een ander proces speelt. Dank daarvoor. Prof. Weinans, beste Harrie, bedankt voor 
het vertrouwen in mij toen ik als student bij je kwam voor keuze-onderzoek en zelfs mee 
mocht naar de OARSI in Rome om mijn eerste podiumpresentatie te houden. Ook al is 
dat toen niet uitgemond in een promotie, vind ik het leuk dat het cirkeltje nu wel rond is 
met jou als commissielid. Erwin, dit laatste geldt natuurlijk ook voor jou, ook al is het niet 
als commissielid, maar als collega op de 19e het laatste jaar. Bedankt voor de inwijding 
in de active shape modeling en het delen van je uitgebreide statistische kennis.
Beste Peter, bedankt voor je sportgeneeskundige blik op mijn stukken. Ook al ligt mijn 
toekomst toch niet in de sportgeneeskunde, is de kans aanzienlijk dat we elkaar weer 
tegen zullen komen in de kliniek of op het sportcongres(, als ik tenminste voor de mus-
culoskeletale radiologie kies).
Mijn voorganger, Jasper, ik wil je bedanken voor de tijd die je hebt genomen om mij 
wegwijs te maken in de kwantitatieve MR imaging technieken voor kraakbeen en het 
zelf maken van MRI scans. Door de tijd en energie die jij reeds had gestoken in het 
mede-ontwikkelen van de Software for Post-processing And Registration of Cartilage of 
the Knee (SPARCK) software om de MRI beelden te analyseren, is het voor mij mogelijk 
geweest om dit over de jaren verder uit te breiden. Ik vind het mooi dat we beiden nu 
in opleiding zijn in het Erasmus, ik tot radioloog en jij al wat verder op weg tot orthope-
disch chirurg. Mogelijk kan dit in de toekomst leiden tot verdere samenwerking.
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Over SPARCK gesproken…., ik wil mijn collega’s van de BIGR (Biomedical imaging group 
Rotterdam) zeker noemen, want zonder hen was mijn proefschrift niet in deze vorm 
tot stand gekomen. Voor jullie allen geldt dat ik hoop dat we de samenwerking in de 
toekomst kunnen voortzetten! Esther, samen met Jasper heb jij SPARCK ontwikkeld 
en samen hebben we dit verder uitgebreid tot een zeer uitgebreid (misschien iets te 
uitgebreid) pakket. Bedankt dat je altijd klaar stond om te helpen, terwijl je dit eigenlijk 
gewoon naast je eigen promotietraject deed. Dirk, zonder jou geen kwantitatieve DCE 
in mijn boekje. Onze samenwerking heeft zich over de jaren steeds verder ontwikkeld 
waarbij we elkaar nu volgens mij mooi aanvullen wat betreft medische kennis en tech-
nische toepassingen. Na vier jaar moeilijke DCE discussies, heeft dit uiteindelijk geresul-
teerd in twee mooie stukken. Bedankt dat je de tijd hebt genomen om samen met mij 
kwantitatieve DCE-MRI van de knieschijf mogelijk te maken. Daarnaast wil ik je bedanken 
voor de handige en vaak tijdbesparende oplossingen, die je voor me programmeerde, 
waaruit onder andere ook de voorkant van mijn boekje is voortgekomen! Felicia Lopes, 
thanks for your help considering the development of the DCE-MRI post-processing tool, 
all the best! Stefan, bedankt voor je altijd zeer grondige reactie op mijn stukken. Ook al 
verloor ik in het begin soms de moed bij de vaak zeer vele kleine aanpassingen, ben ik 
je daar toch ook zeer dankbaar voor (want ik hou er zelf eigenlijk ook wel van als het tot 
op de puntkomma correct is). Daarnaast vond ik onze gesprekken zeer inspirerend; jij 
maakte de abstracte technische materie begrijpelijk en ik vertaalde het vervolgens naar 
wat klinisch relevant was. Ik denk dat deze manier van samenwerken zeer waardevol is 
om in deze zich technisch zeer snel ontwikkelende wereld tot klinische relevante toe-
passingen te komen. Joost en Bas, wat fijn dat jullie de DCE verder voortzetten, succes 
met respectievelijk het afronden en het opstarten van jullie onderzoek!
Janneke, ik vind jouw bijdrage aan het morfologische artikel naast je opleiding bewon-
derenswaardig. Bedankt voor het zo secuur scoren van alle proefpersonen en succes 
met het afronden van je opleiding en natuurlijk ons osteofytartikel!
Gyula, though we could not prolong our collaboration, I would like to thank you for 
developing my acquisition protocol together with Jasper. Mika, jij was mijn trouble-
shoot wat betreft de MRI scanner. Als de scanner om de een of andere reden weer eens 
gereset moest worden, lukte het jou (meestal) om de onderzoek software weer tijdig 
draaiende te hebben, bedankt! Als we het dan over troubleshooten hebben, wil ik ook 
graag de groep radiologische laboranten noemen, die me altijd welwillend waren als er 
wat speelde op K7. Ditzelfde geldt voor diegenen die de infusen prikten bij mijn patiën-
ten. Door de hoeveelheid taken die ik moest doen in korte tijd, was het zeer waardevol 
dat dit mij uit handen werd genomen. Verder was het zo dat het scannen altijd met 
zijn tweeën plaats diende te vinden en er gelukkig over de jaren altijd wel een student 
geneeskunde, die zijn/haar afstudeeronderzoek op de afdeling Huisartsgeneeskunde 
deed of een collega wilde helpen. Hartelijk dank daarvoor en in het bijzonder Kevin van 
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Leeuwen, die veelvuldig heeft geholpen. Ook wil ik de studenten die hun afstudeeron-
derzoek bij mij hebben gedaan, Tessa Vollebregt, Pieter Vissers, Melek Ekinci, bedanken 
voor hun bijdrage en heel veel succes wensen in de toekomst! Collega’s van het trial 
bureau, bedankt voor alle logistieke hulp! Ton, bedankt voor mijn mooie anatomische 
plaatje! Jolanda, ik vind je een zeer prettige leidinggevende, die altijd geïnteresseerd is 
in hoe het gaat, bedankt.
Ook de onderzoekers van de Radiologie en aanverwante afdelingen wil ik bedanken. 
Lotte en Hazel, bedankt voor de gezelligheid tijdens de RSNA en tijdens het koffie 
drinken erna. Succes met jullie promoties! Ghassan, Rebecca, Rozanna bedankt  voor 
het naar me luisteren als ik (weer eens) stoom af kwam blazen bij problemen met de 
inclusie of met de registratie van mijn MRI beelden. En natuurlijk bedankt voor de 
kleurtips voor mijn voorkant, Rebecca en Rozanna. Ook al bestuderen jullie de hersenen 
en ik de knie, is het is toch fijn dat in ieder geval het kleurenprofiel van de doorbloeding 
overeenkomt! Succes met het afronden van jullie eigen promotie of met jullie postdoc 
werkzaamheden!
Tja waar te beginnen bij mijn collega’s van de Huisartsgeneeskunde. Lang samengevat: 
aan alles komt uiteindelijk een einde, maar in het kader van het vasthouden van de 
positiviteit gedurende het project kan je beter elke dag bewegen (al ga ik liever moun-
tainbiken dan dat ik ruim 600 treden ga traplopen, Toke); kan je beter dan niet gelijk 
ook maar even voor de marathon gaan als je toch bezig bent, toch Caroline? (al vind ik 
het knap dat je hem uitgelopen hebt); kan je beter met de Lankhorst groep een wijntje 
drinken (hooguit twee) i.p.v. een Cochrane review schrijven; kan je beter zoveel mogelijk 
volcano’s rolls tegelijk bestellen als je met Nynke en Alyt sushi gaat eten ook al vindt de 
chef-kok dat niet leuk; kan je denk ik beter buiten voetballen dan binnen met Marienke 
en Winifred; kan je beter je mascara horizontaal aanbrengen dan verticaal aldus Adinda; 
kan je als vrouw beter een draagmoeder regelen dan zelf zwanger worden volgens 
Joost; kan je beter een uur van tevoren al je onderzoek deelnemers voor de vierde keer 
bellen zodat je zeker weet dat ze komen i.p.v. met een tas die net zo groot is als jijzelf 
voor niks de stad door te fietsen, toch Kelly?; kan je beter de giraffe zelf wederom terug 
gaan halen i.p.v. wachten tot Josje hem komt brengen; kan je beter een Marieke op de 
kamer hebben, want die is altijd zo lief en behulpzaam; kan je beter naar voorbeeld 
van Wendy voor internationale samenwerkingen zorgen zodat je er even tussenuit kan. 
Bedankt voor de gezelligheid de afgelopen jaren, het was me een waar genoegen.
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Dan toch ook alvast een bedankje aan de mensen, die deel uitmaken van mijn nieuwe 
uitdaging:
Prof. Krestin, ik ben u zeer dankbaar dat ik in opleiding mocht komen, nadat ik u eerst 
had bevestigd dat ik inderdaad besef dat er meer is dan musculoskeletaal onderzoek 
binnen de radiologie. Ik ben ondertussen vol enthousiasme gestart met de opleiding 
met all opties nog open!
Winnifred, hartelijk dank dat je me de kans gaf om een dag bij je thorax foto’s te komen 
verslaan in het kader van mijn overweging om voor de opleiding te solliciteren. Helemaal 
bedankt dat ik vervolgens versneld het sollicitatieproces mocht doorlopen. Ook al blijf 
jij zeggen dat ik dat zelf hebt bereikt, is het ook wel heel fijn dat er dan iemand is die zich 
voor je inzet en het mogelijk maakt. Bedankt ook voor je nuchtere blik en pragmatische 
aanpak toen ik je op dag zeven van mijn opleiding kwam vertellen dat ik vijf weken in 
bovenarms gips moest, het leven gaat inderdaad door, ook tijdens je opleiding. Ik kijk er 
naar uit om nog veel van je te leren de komende jaren.
Desiree, bedankt voor de hartelijke ontvangst tijdens mijn eerste week van de opleiding! 
Graag wil ook de overige medewerkers van het secretariaat bedanken voor hun hulp, 
zowel tijdens mijn onderzoek als ook tijdens de start van mijn opleiding.
Nieuwe collega AIOS, hartelijk dank voor de warme ontvangst bij de start van mijn 
opleiding. Gerald en Ruben wil ik dan graag nog even apart noemen voor de tijd die ze 
gestoken hebben in het mij wegwijs maken wat betreft alles wat geregeld moet worden 
en belangrijk is om te weten.
Mijn fietsvrienden, Dirtyhill Syndicate leden, over mijn promotie hebben we het niet zo 
vaak gehad, maar het is juist prima om ook echt afleiding te hebben door samen met 
de mountainbike erop uit te trekken. Al vereist het wat aanpassingsvermogen als enige 
vrouw tussen de mannen, kijk ik al uit naar ons volgende avontuur (als ik tenminste op 
tijd uit dit bovenarmgips ben)!
Mijn ‘fiets’ vriendinnetje, Vivian, bedankt voor je betrokkenheid en de altijd hartelijke 
ontvangst bij jullie thuis. Het begon allemaal alweer 10 jaar geleden met een downhill 
clinic in Winterberg, jaren later kwamen we elkaar weer tegen en werden we zelfs team-
genootjes. De laatste jaren wisselen we elkaar af op het reservebankje, maar er komt een 
tijd dat we toch echt samen Lac Blanc onveilig zullen maken!
Mijn ‘oudere broer’ Johan, we kennen elkaar al 30 jaar en hebben dus een hoop meege-
maakt. Ook al zien we elkaar de laatste tijd wat minder, kan ik denk ik wel zeggen dat we 
elkaar altijd steunen and nothing else matters. Moke en vooral de Staat waren weer als 
vanouds een feestje en dus een mooie afleiding tijdens het schrijven van mijn algemene 
discussie. Op nog meer gedenkwaardige avonden!
Mieke, wat lief dat je me op kwam zoeken met die maffe Binkie op de momenten dat 
het nodig was. Jij bent iemand die heel begaan is en goed aanvoelt wat de ander nodig 
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heeft. Dat vind ik echt mooi aan je! Die mountainbike toertocht komt er echt nog wel 
van en anders verzinnen we gewoon iets anders, zoals skydiven of motorrijden ofzo….
Mijn schoonfamilie, Jan, Coby, Monique, Onno en Eline, bedankt voor jullie interesse in 
mijn proefschrift en de gezellige familie samenkomsten. Hier zien jullie nu eindelijk wat 
ik al die tijd heb gedaan. Jan en Coby, ook bedankt voor het veelvuldige aanbieden van 
hulp om mij op die manier iets uit handen te nemen.
Mijn paranimfen, Alyt en Kristel, ik vind het heel fijn dat jullie deze taak op jullie wilden 
nemen. Jullie hebben mij de afgelopen jaren al bijgestaan tijdens lastige periodes, 
dus ik zie mijn verdediging helemaal zitten met jullie achter me. Alyt, jij bent me reeds 
voorgegaan met promoveren en hebt een mooi voorbeeld gegeven van hoe het moet. 
We hebben elkaar goed gevonden qua sportieve drang en ambitie. Al zitten we wat 
het eerste betreft nu beiden op het reservebankje, zit het gelukkig met het tweede wel 
goed en is het mooi om te zien dat je als postdoc je onderzoek kan voortzetten. Het is 
fijn dat je begrijpt hoe vervelend het is om je ei niet kwijt te kunnen met sporten, maar 
goed dat je me helpt relativeren en dat we ons ook prima kunnen vermaken met hele 
leuke onsportieve dingen, zoals de Sneekweek en de Swan market. Kristel, jij zal me 
zeker opvolgen wat promoveren betreft. Ook al werken je muizen of de mensen erom-
heen niet altijd mee, toch zet je door, ook in het weekend. Het heeft me zeker geholpen 
om mijn perikelen wat betreft planningen die misliepen door onvoorziene zaken met je 
te delen. Verder waren onze uitstapjes helemaal mooi, ook al liepen die soms ook een 
beetje anders dan gepland: kano’s die omslaan waardoor ik bijna verzuip en Basel was 
misschien ook een beetje te, maar wel memorabel.
Dan natuurlijk mijn familie. Opaatje, bedankt voor de steun, dat je maar 100 mag worden! 
Maritte en Katelijne, mijn twee superslimme en ambitieuze zusjes. Alhoewel zusjes… 
eigenlijk zijn jullie nu toch echt wel volwassen (en dienen jullie je daar dus ook naar te 
gedragen he). Bedankt voor de afleiding tijdens de gezellige zussenavonden, die we alle 
drie hard nodig hebben, want jullie zijn ook hard bezig met je verdere ontwikkeling. 
Maritte, ik hoop dat er spoedig iemand op je pad komt die je kwaliteiten ziet en je de 
kans zal geven om je verder te ontwikkelen tot gezondheidszorgpsycholoog. Katelijne, 
veel succes met het afronden van je coschappen. En als je weer eens te maken hebt met 
een doorgedraaide dokter tijdens zijn/haar spreekuur, bedenk dan dat je je altijd nog 
kan bedenken en toch radioloog kan worden. Dat zijn tenminste heel normale mensen 
;) Ik ben trots op jullie! Mijn ouders, Alfred en Hanneke, jullie zijn erg belangrijk voor 
me. Bedankt voor de onvoorwaardelijke steun en het vertrouwen in mijn kunnen. Pap, 
bedankt voor het ook altijd belichten van de zakelijke kant van het verhaal in lastige si-
tuaties. Dit kan je natuurlijk heel goed door je ervaring als rector. Door omstandigheden 
hebben we de laatste tijd wat minder gefietst, maar laten we dat weer snel oppakken, 
want ik vind dat erg leuk om samen te doen ter ontspanning (en momenteel ga ik toch 
niet hard ;) ). Mam, de elfde stelling is voor jou. Wat heb jij een sterke geest, wat heb ik 
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onnoemelijk veel steun aan jou gehad en wat leer ik veel van je. Jouw droom was om 
professor te worden, totdat je lichaam je in de steek liet na mijn geboorte. Of ik ooit een 
professorschap aan je kan opdragen weet ik nog niet, maar dit proefschrift draag ik in 
ieder geval aan jou op!
Lieve Dennis, je bent me heel dierbaar. Wat is het een fijn en geruststellend gevoel dat 
jij er altijd bent om me bij te staan. En het is helemaal fijn en super leuk dat jij er altijd 
bent om het leven mee te vieren of we nou gaan mountainbiken, naar een concert van 
Machine Head gaan of tapas gaan eten in Spanje. Op nog vele jaren samen!
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